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Y-box-binding protein 1 (YB-1) is a biomarker that is predictive of poor prog-
nosis in cancer. Various molecular functions of YB-1 in cancer have been proposed,
including the transcriptional regulation of gene expression. YB-1 also binds to RNA
transcripts to influence gene expression.
In the present study, the status of YB-1 as a biomarker was confirmed by im-
munohistochemistry using two antibodies against YB-1. However, the prognostic
sensitivity of these two antibodies differed. The observed difference in antibody
affinity was most likely due to the tertiary structure or protein-protein interactions
(PPI) associated with various functions of YB-1 in situ.
To gain further insights into the molecular functions and potential mechanisms
of YB-1 in cancer biology the state of phosphorylation of YB-1 and the PPI were
investigated in the cytoplasm and nucleus of two cancer cell lines. The YB-1 from
the cytoplasm and nucleus of the cell lines was extensively phosphorylated. These
experiments identified >250 proteins. These binding partners confirmed the multi-
functionality of YB-1 as the proteins that co-purify with YB-1 participate in glycol-
ysis, RNA splicing, RNA stabilization, translation, mitochondrial localisation, and
chromosomal association. These data suggest that the bulk of YB-1 function may
be explained by non-transcriptional mechanisms.
Mechanisms of drug resistance were also investigated. Depleting YB-1, using
siRNA duplexes, reduced MDA-MB231 cell growth and increased cell death. The
loss of YB-1 sensitised MDA-MB231 cells to cisplatin exposure by increasing cell
death. Cisplatin exposure altered the distribution of YB-1 protein to perinuclear
spots and to foci in the nucleus of many cells.
The molecular basis of YB-1 mediated cisplatin resistance was analysed by exam-
ining the alterations of YB-1 PPI during cisplatin exposure using co-immunoprecipitation
of YB-1 binding partners and mass spectrometry-based protein identification. Quan-
titative analyses of the co-immunoprecipitated proteins from MDA-MB231 cells in-
dicated that a subset of the proteins, such as TRIM28 and FAM120A, increased
markedly after 48 and 96 hours of cisplatin exposure. The chromosomal proteins
that interacted with YB-1 were disproportionately affected by cisplatin exposure.
The importance of FAM120A, TRIM28, and C1QBP, three YB-1 binding part-
ners identified here, during cisplatin exposure was studied. The subcellular distri-
bution of FAM120A was most similar that of YB-1 in MDA-MB231 cells. Depleting
YB-1 or FAM120A, but not TRIM28 or C1QBP, sensitised MDA-MB231 cells to
cisplatin exposure. Depleting YB-1 alongside either FAM120A or C1QBP partially
restored the growth of MDA-MB231 cells. YB-1 does not appear to participate in
the repair of double-strand DNA breaks during cisplatin exposure as depleting YB-1
had no effect on the number of γH2AX foci that formed during cisplatin exposure.
This is the first report that integrates findings of protein-binding partners, state
of phosphorylation, and subcellular localisation of endogenous YB-1 to understand
the complex functions of YB-1. These results confirm the importance of RNA bind-
ing to the molecular function of YB-1. The interaction of YB-1 with FAM120A, a
novel finding, increases during cisplatin exposure and both proteins together, via an
unknown molecular pathway, confer cisplatin resistance to breast cancer cells.
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Chapter 1
YB-1 a multifunctional protein: a
review
1.1 Biology of cancer
Biological systems are self-maintaining and very complex. In general, complex mul-
ticellular organisms, such as vertebrates, begin as a single cell that was the result of
the fusion of one oocyte and one spermatozoan. Many divisions are required before
this cell, and its daughter cells, can form a mature organism that is ready to re-
produce. While dividing, these cells must also differentiate to create the specialised
cell-types and tissues that the organism will require to function. Furthermore, the
fully-grown organism will need to replace cells as they die. The process described
above is known as homeostasis (reviewed in Pellettieri & Sánchez Alvarado 2007).
The systems that guide the growth, differentiation, and maintenance of homeostasis
in eukaryotes are robust (Yan et al. 2010). Many molecular pathways are involved
in homeostasis but three main functions are central to its maintenance; cell dif-
ferentiation, cell survival (this includes cell division and cell death), and genome
maintenance (Vogelstein et al. 2013).
Perturbation of the mechanisms that maintain homeostasis can lead to unregu-
lated cell division and clusters of cells, known as tumours, may form if the errantly
dividing cells are not removed. In general, tumours that remain within their tissue of
origin are known as benign tumours. Cancerous tumours arise when a group of cells
with uncontrolled cell division also have the potential to grow into and penetrate
other tissues.
At the cellular level, the genome, encoded using deoxyribonucleic acid (DNA),
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contains the primary code for the components of the homeostatic systems. Cancer is
predominantly thought to be caused by alterations to the genome, which are known
as mutations, and the cells in most cancers contain multiple mutations (Knudson
1986, Renan 1993, Vogelstein et al. 2013). Mechanisms that act at the organism
and tissue levels, such as inflammation via the immune system, are also important
to the development of cancer (reviewed in Hanahan & Weinberg 2011). However,
the primary focus of this thesis is on events at or below the cellular level.
Tumour suppressor genes encode proteins are critical to maintaining homeostasis.
The ability of tumour suppressors to monitor for loss of homeostasis is frequently
modified or lost in cancer cells. Many tumour suppressors control the transition of
cells through key points in mitosis, known as cell cycle checkpoints, to ensure that
only normal cells may complete mitosis (Sager 1989, Hanahan & Weinberg 2000).
The p53 tumor suppressor is encoded by the Cellular tumor antigen p53 (TP53 ) gene
which is mutated in ∼50% of cancers (Braithwaite et al. 2005, Levine & Oren 2009,
Bieging et al. 2014). p53 exercises control over the stress response of cells through
an ability to control the cell cycle and to direct DNA damage response signalling
(Figure 1.1). p53 can induce cell cycle arrest, senescence, or apoptosis. Mutations
to p53 reduce or remove its capabilities in cancer cells to induce cell cycle arrest,
senescence, or apoptosis (Braithwaite et al. 2005, Levine & Oren 2009). In addition
to controlling cell death, many tumour suppressors, like p53, may also be tied to
metabolic processes that allow cancerous cells to survive in rapidly growing tumours
(Levine & Puzio-Kuter 2010). Retinoblastoma-associated protein (RB) is another
tumour suppressor with a key role in controlling the cell cycle (Figure 1.1). RB can
inhibit mitosis at the transition of cells from the gap 1 (G1) phase, which consists
of cells that have completed mitosis, to S-phase, where cells begin to synthesise
a copy of their genome (Classon & Harlow 2002, Manning & Dyson 2012). This
regulatory role is supported by the ability of RB to negatively regulate the E2F-
family transcription factors, as some of these transcription factors can positively
regulate the cell cycle (Classon & Harlow 2002, Manning & Dyson 2012). Cyclin-
dependent kinase inhibitor 2A (CDKN2A, also known as p16INK4A which is used
throughout) is another tumour suppressor gene which also inhibits the transition
of cells from G1/S through its ability to inhibit cyclin-dependant kinases which
inactivate RB (Figure 1.1; Liggett & Sidransky 1998, Rayess et al. 2012). Genome
instability, which further weakens or removes homeostatic mechanisms, can be a
consequence of the loss of TP53 or RB gene functions (Rausch et al. 2012, Manning
& Dyson 2012). Breast cancer type 1 susceptibility protein (BRCA1 ) is involved in
2
Figure 1.1: Tumour suppressor genes control the passage of cells through the cell cycle.
Gap 1 (G1) is followed by the synthesis of DNA (S), gap 2 (G2), and then mitosis (M).
Cells can exit the cell cycle (G0) or die.
monitoring for DNA integrity. BRCA1 can also influence mitosis, specifically during
the S-phase, the following gap 2 (G2) phase, and through to mitosis checkpoint (M;
Figure 1.1; Roy et al. 2012). Mutation of BRCA1, or the related BRCA2 gene,
accounts for most inheritable cases of breast and ovarian cancer. Therefore, tumour
suppressor proteins generally monitor for modification of the genome and have the
ability to control cell fate by inhibiting their division or initiating cell death.
Other genes and their protein products can also promote the features of can-
cerous cells. These genes and proteins, known as oncogenes and oncoproteins re-
spectively, promote cancer development and maintenance through gain-of-function
mutations or overexpression (reviewed in Shortt & Johnstone 2012). Like tumour
suppressors, many oncogenes encode proteins that influence cell division and cell
death. In general, their deregulation or mutation leads to the promotion of cell
division, inhibition of cell death, or senescence (Vita & Henriksson 2006, Shortt &
Johnstone 2012). The Myc proto-oncogene (MYC ) is an oncogene that functions as
a transcription factor for many genes that promote mitosis (Vita & Henriksson 2006).
A number of oncogenes transduce mitogenic signals from the extracellular environ-
ment through their positions as critical parts of cell-surface receptors. Two proteins
that exemplify this class of oncogene are the Receptor tyrosine-protein kinase erbB-2
(ERBB2, also known as HER-2; Moasser 2007) and epidermal growth factor receptor
(EGFR, also known as HER-1 or Receptor tyrosine-protein kinase erbB-1; Ciardiello
& Tortora 2008). These proteins become deregulated in cancers and begin to provide
mitogenic signals irrespective of the presence of their ligands. The four Ras family
genes, HRAS, NRAS, KRAS4A and KRAS4B, are another group of oncogenes that
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respond to extracellular signals to activate kinase signalling pathways to support mi-
tosis and cell survival (Schubbert et al. 2007). Mutation or deregulation of ras genes
leads to constitutive activation of the ras signalling pathway, the key downstream
targets of the ras genes are the Ras-Raf-mitogen-activated and extracellular-signal
regulated kinase (MEK) extracellular signal-regulated kinase (ERK) pathway. The
overlap in function between tumour suppressors and oncogenes reflects the impor-
tance of this redundancy of function to maintaining homeostasis and it explains why
multiple modifications are required for cancer to form (Hanahan & Weinberg 2000).
In addition to unregulated cell division, many aggressive cancers possess, or
have the potential to gain, the ability to spread from their tissue of origin to other
areas of the body (reviewed in Weigelt et al. 2005). This process is known as
metastasis and it accounts for up to 90% of cancer deaths (Hanahan & Weinberg
2011). Metastatic cancers possess the ability to move through tissues. However, the
epithelial cells, from which many cancers arise, have limited capacity to move as
they adhere tightly to adjacent cells (Hanahan & Weinberg 2011). The acquisition
of metastatic capability is correlated with the acquisition of mesenchymal markers
in a process known as epithelial-mesenchymal transition (Kalluri 2009, Singh &
Settleman 2010). Mesenchymal cells are elongated, polarised, and move more easily
through tissues than epithelial cells. The difference in the mobility of epithelial
and mesenchymal cells is in part explained by the types of connections that they
maintain with other cells. The connections between epithelial cells are stronger than
those between the more mobile mesenchymal cells, with an epithelial cell marker,
E-cadherin, indicating strong connections between cells (Hanahan & Weinberg 2000,
Singh & Settleman 2010). N-cadherin and vimentin are often used as markers of a
mesenchymal phenotype that is more invasive with a greater potential to metastasise
(Hanahan & Weinberg 2000, Singh & Settleman 2010). Other proteins that are
present in some invasive and metastatic cancers can degrade the extracellular matrix,
such as those from the matrix metalloproteinase family (Weigelt et al. 2005).
This brief review attempts to summarise the key processes in cancer. These
processes are the loss of homeostasis, the inactivation of tumour suppressors, and,
the activation of oncogenes. The hallmarks of cancer provides a more complete
framework for understanding the development of cancer (Hanahan & Weinberg 2000,
Hanahan & Weinberg 2011). Therefore, these fundamental processes are important
to the research that is reported in this thesis.
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1.2 Biology of breast cancer
The focus of this thesis is a protein called Nuclease-sensitive element-binding protein
1 (P67809; also known as Y-box-binding protein 1) (YB-1) and YB-1 is discussed
extensively in the rest of this literature review. A number of the chapters deal
specifically with the function and importance of YB-1 in breast cancer. Therefore,
further information about breast cancer is included in this introduction to provide
an expanded example of cancer.
Within the breast, the mammary glands are specialised structures that produce
milk during lactation. The breast ducts and lobules, of which the mammary gland
is comprised, are the source of the majority of breast cancers (Figure 1.2.A Li
et al. 2003a, Weigelt et al. 2008). Ductal carcinoma in situ and lobular carcinoma
in situ are comprised of abnormal cells that are confined completely within their
tissue of origin (Figure 1.2.B: Ward et al. 2015). Lobular carcinoma in situ is
considered to be a neoplasia rather than a cancer. However, the diagnosis includes
an increased risk of breast cancer. Ductal carcinoma in situ are more common
than lobular carcinoma in situ and there is potential for ductal carcinoma in situ to
become invasive. Around 90% of diagnosed breast cancers are invasive, which means
that they are not confined to the breast ducts or lobules (Li et al. 2003a, Weigelt
et al. 2008). Of this 90%, approximately 70% are ductal carcinomas, 10% lobular
carcinomas, 6% mixed ductal and lobular carcinoma, and 15% lobular and mixed
ductal-lobular carcinoma (Li et al. 2003a). In addition to the classification relating
to the tissue of origin, breast cancers are also classified based on histological markers
for the rate of proliferation. Grade I indicates low levels of proliferation and grade
III represents high levels of proliferation.
Molecular information is also important to breast cancer classification as the
molecular sub-type of breast cancers has a significant bearing on which treatments
are appropriate. Three broad groups of breast cancer have been identified in the
literature; luminal, HER2-positive (ERBB2 ), and basal-like breast cancers (Figure
1.2.B; Perou et al. 2000, Blows et al. 2010). In luminal breast cancers, either or both
of the estrogen receptor (ER) and the progesterone receptor (PR) are present and
these receptors transduce growth signals to support tumour growth (ER-ve/PR-ve;
Blows et al. 2010). HER2-positive breast cancers are those with an amplification of
the ERBB2 gene, which is also known as HER-2. ERBB2 promotes cell division
and inhibits cell death, and ERBB2 amplification leads to the overexpression of
the ERBB2 protein which supports the growth of tumours. HER2-positive breast
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Figure 1.2: Breast cancers have differing pathological and molecular features. A, the
mammary gland is the primary unit of breast tissue. B, breast tumours are characterised
by their tissue of origin, mitotic potential and their molecular subtype. Reproduced from
Blows et al. (2010).
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cancers account for 15 - 25% of all breast cancers (Pauletti et al. 1996, Ross &
Fletcher 1998). Another sub-class is luminal 2, which comprises any luminal cancers
that are either positive for ERBB2 or exhibit elevated proliferation (grade III).
Basal-like cancers do not express estrogen or progesterone receptors and they lack
amplification of the ERBB2 gene. Basal-like cancers are categorised according to
expression of basal and myoepithelial cell markers; Epidermal growth factor receptor
(EGFR) and cytokeratins 5 and 6 (Perou et al. 2000, Nielsen et al. 2004, Carey et al.
2006). Another sub-type is referred to as (triple-negative breast cancer (TNBC);
Blows et al. 2010). TNBCs do not express estrogen or progesterone receptors and
do not over-express ERBB2 (Figure 1.2.B). Therefore, many TNBCs are also part
of the basal-like molecular subtype, although some TNBC tumours are excluded
due to their lack of basal cell markers. TNBC tumours account for 15 - 20% of all
breast cancers and this group includes cancers with mutations to BRCA1 (Griffiths
& Olin 2012, Shah et al. 2012).
The breast cancer subtypes influence which treatment options are appropri-
ate. Many treatments are given in combination, either concurrently or sequentially.
There are two primary methods of treatment for invasive breast cancers and ductal
carcinoma in situs. The first is the surgical removal of tumour tissue, or the whole
breast and lymph nodes. The second is the use of radiation to destroy the cancer
cells. A variety of chemotherapy drugs are often used in combination with one an-
other (summarised in Table 1 of Mauri et al. 2005). Treatments that target critical
aspects of the molecular subtypes are used in addition to chemotherapeutic drugs.
Targeted treatments for patients with luminal cancers include agents that aim to
reduce the availability of estrogen within the body or to inhibit the response of
cells to estrogen (Horwitz & McGuire 1975, Mauri et al. 2006, Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) et al. 2015). Where the ERBB2 is over-
expressed, targeted treatments interfere with ERBB2 signalling to slow the growth,
or kill, these cancer cells (reviewed in Foulkes et al. 2010).
TNBC and basal-like sub-types currently lack targeted treatments. Both sub-
types are also aggressive as they contribute disproportionately to breast cancer cases
that progress to metastatic disease and also to breast cancer deaths (Dent et al. 2007,
Foulkes et al. 2010, Griffiths & Olin 2012). However, this aggression may be transient
and survival rates improve in cases where initial chemotherapeutic treatment results
in complete pathologic response. Molecular sub-typing of TNBCs highlights the
presence of TNBC subtypes that are sensitive to different drugs (Lehmann et al.
2011). However, surgical resection and a variety of chemotherapeutic agents remain
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the primary treatments for TNBC (André & Zielinski 2012, Griffiths & Olin 2012).
1.3 YB-1 is overexpressed in cancer
The research presented in this thesis focuses on the YB-1 protein which is encoded
by the Y-box binding protein 1 (Entrez Gene: 4904) (YBX1 ) gene. The published
reports contain contradictions relating to which tissues contain YBX1 mRNA and
YB-1 protein; some studies suggest that YB-1 is largely, or entirely, absent in normal
tissue (Bargou et al. 1997, Dahl et al. 2009, Janz et al. 2002). Irrespective of this
ambiguity in normal tissues, a primary reason for researching YB-1 is that many
studies indicate that the functions of YB-1 are significant in cancer. Elevated levels
of YB-1, or of YBX1 mRNA, have been identified in a wide range of cancers. YB-1
levels are elevated in colorectal cancer (Shibao et al. 1999, Jürchott et al. 2010, Yan
et al. 2014), non-small cell lung carcinoma (Gu et al. 2001, Shibahara et al. 2001,
Gessner et al. 2004), adenocarcinoma (Shibahara et al. 2001), synovial sarcoma
(Oda et al. 2003), androgen resistant prostate cancers (Giménez-Bonafé et al. 2004),
ovarian cancer (Kamura et al. 1999, Huang et al. 2004a, Basaki et al. 2007) and
breast cancer (Bargou et al. 1997, Lee et al. 2008, Woolley et al. 2011, Stratford
et al. 2012, Reipas et al. 2013). Furthermore, YB-1 levels are positively correlated
with cancer aggression and negatively correlated with disease-free or recurrence-free
survival (Janz et al. 2002, Habibi et al. 2008, Dahl et al. 2009, Lasham et al. 2012).
In addition to overexpression, the subcellular localisation of YB-1 appears to
be important (Kamura et al. 1999). For example, an immunohistochemistry (IHC)
study reported that YB-1 was not present in normal breast tissue but found clear
evidence of both nuclear and cytoplasmic staining in tumour tissues (Janz et al.
2002). This study also found that elevated levels of YB-1 were associated with
tumour progression. Increased levels of YB-1 in the nuclei of tumour cells is also
correlated with lymph node metastasis in patients with non-small cell carcinoma
(Gessner et al. 2004, Shibahara et al. 2001). Furthermore, nuclear YB-1 staining is
also associated with increased expression of Multidrug resistance protein 1 (MDR-1)
in patients with poor prognosis (Bargou et al. 1997, Dahl et al. 2009). The ATP-
binding cassette, sub-family B [MDR/TAP], member 1 (also known as multidrug
resistance gene 1/MDR1) (ABCB1 ) gene encodes an ATP-dependant drug efflux
pump that is responsible for drug resistance in many cancer cells (Modok et al. 2006).
Other reports rarely detect YB-1 in the nucleus however, increased levels of YB-1 in
the cytoplasm have still been associated with poor patient prognosis (Wu et al. 2006).
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Therefore, the distribution of YB-1 in cancer cells varies from study to study even
among those that have examined the same cancer type.
To summarise, the accumulated evidence supports the conclusions that YB-1 is
elevated in a wide range of cancers and that elevated YB-1 is linked to aggressive
cancers. These results confirm that YB-1 is an oncoprotein (Astanehe et al. 2009,
Cohen et al. 2010).
1.4 The functions of YB-1 in cancer
The functional significance of the elevation of YB-1 in cancer cells does not appear to
be singular. Rather, the elevation of YB-1 in a range of cancers has been attributed
to the participation of YB-1 in multiple functions in cancer cells. The following
sub-sections outline these functions. The molecular mechanisms that allow YB-1 to
participate in these functions are provided at a later stage in the review.
1.4.1 YB-1 promotes the early stages of cancer development
A number of studies implicate YB-1 in the early development of breast cancers
through the ability to promote genome stability. Overexpressing the YB-1 homo-
logue in murine mammary tissue leads to the development of breast carcinomas
(Bergmann et al. 2005). The breast carcinomas appear to develop because YB-1 in-
creases mitosis rates and the presence of cells with two nuclei indicates that mitotic
checkpoints are being breached. Bergmann et al. (2005) conclude that the breast
carcinomas are caused by genetic instability that was the result of mitotic failure
and the amplification of centrosomes. Centrosomes are a structure that mediates
the partitioning of genetic material during the M-phase of mitosis.
More recent work has affirmed that YB-1 also directly promotes genetic instabil-
ity in human cells. The overexpression of YB-1 in human breast epithelial cells also
leads to centrosome amplification and aneuploidy (Davies et al. 2011). Subsequent
work from the same authors confirms that YB-1 promotes genetic instability and
they propose that YB-1 is a driver of tumour initiating stem cells (Davies et al. 2014).
Other research supports a link between YB-1 and genetic instability. In DT40 cells, a
chicken B cell line (Baba & Humphries 1984), disrupting one allele of the chicken YB-
1 homologue (Chk-YB-1b) led to genetic abnormalities (Swamynathan et al. 2002).
However, this work is difficult to interpret as it correlates the depletion of YB-1 with
genetic abnormalities. The differing cellular context may explain the difference from
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results in murine and human cells, or it could be an example of the goldilocks effect,
where too much or too little of an allele is suboptimal (Cohen et al. 2004, Boothby
& Williams 2012).
Not all research supports the role of YB-1 in the development of cancer. Overex-
pression of YB-1 blocks the oncogenic transformation of chicken embryo fibroblasts
by phosphatidylinositol 3-kinase (PI3K) or RAC-alpha serine/threonine-protein ki-
nase (AKT) (Bader et al. 2003, Bader & Vogt 2008). Furthermore, the AKT in these
cells remained functional, indicating that YB-1 does not inactivate AKT. These ob-
servations remain difficult to link to other work on YB-1.
In summary, YB-1 may contribute to genetic instability. Increased prolifera-
tion accompanies this genetic instability and the ability of YB-1 to promote the
proliferation of cancer cells is a fundamental function of YB-1.
1.4.2 Role of YB-1 in mitosis
Many studies have shown that YB-1 promotes cell division (mitosis; Ladomery &
Sommerville 1995) and YB-1 is correlated with elevated rates of mitosis in cancer
cells (Sabath et al. 1990). Furthermore, overexpression of YB-1 stimulates tumour
growth in cultured breast cells (Sutherland et al. 2005) and also in non-small cell
lung carcinomas (Harada et al. 2014). The ability of the murine YB-1 homologue
to increase proliferation indicates that this function of YB-1 is conserved in other
species (discussed above; Bergmann et al. 2005). Furthermore, the expression of
YBX1 mRNA is positively correlated with an E2F1 cell proliferation signature in
breast cancer tumours (Lasham et al. 2012). Confirmation of a functional link
between YB-1, mitosis, and the E2F-transcription factors comes from observations
that depleting YB-1 in various cell lines perturbs transcripts from the E2F1 pathway
while also inhibiting mitosis and tumour formation in a mouse xenograft model
(Lasham et al. 2012). Therefore, the ability of YB-1 to promote mitosis has been
confirmed by studies showing that overexpression of YB-1 has a positive effect on
mitosis and that depletion of YB-1 has a negative effect.
The literature includes conflicting reports relating to the point of the cell cycle
that is promoted by YB-1. However, recent work appears to provide some clarifi-
cation. A number of studies have found that depleting YB-1 arrests tumour cells
in G11 of the cell cycle (Figure 1.3; Shiota et al. 2008a, Basaki et al. 2010, Yu
et al. 2010, Kawaguchi et al. 2015). Overexpression of YB-1 has the opposite effect,
in that it increases the number of cells that are in G2 and undergoing mitosis (Davies
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Figure 1.3: YB-1 can promote the passage of cells through the cell cycle at the G1-S
boundary and during mitosis (M).
et al. 2011). YB-1 has been proposed to promote the progress of cells through G1/S
by repressing the expression of p16INK4A (Figure 1.3; Basaki et al. 2010, Yu
et al. 2010, Kotake et al. 2013).
YB-1 also appears to participate in the maturation of the centrosomal micro-
tubule array during mitosis (Figure 1.3; Davies et al. 2011, Kawaguchi et al. 2015).
Depleting YB-1 disrupts the organisation of microtubules in relation to the centro-
some during telophase which in turn, leads to defects in the reformation of the
nuclear membrane (Kawaguchi et al. 2015). Despite the microtubule abnormali-
ties, cells lacking YB-1 have been shown to pass through the G2/M checkpoint and
then accumulate in G1. It has been proposed that spindle assembly occurring via
a chromatin-mediated pathway allows the cells to complete mitosis, and the defects
in the resulting nuclear envelope then hold the cells in G1 (Kawaguchi et al. 2015).
Kawaguchi et al. (2015) found no indication of aneuploidy.
In other species YB-1 also appears to be linked to mitosis. Disruption of one
allelle of the chicken YB-1 homologue slowed the growth of DT40 cells via an appar-
ent blockade of G2/M of the cell cycle (Swamynathan et al. 2002). In this study the
disruption of a single allele had no effect on the levels of YBX1 mRNA or YB-1 and
the effects were proposed to be due to the remaining disrupted allele. Support for
this hypothesis comes from a study of the N-terminus of the rat YB-1 homologue.
Khandelwal et al. (2009) observed that the N-terminus fragment slowed the growth
of rat hepatoma cells via an apparent blockade of the G2/M of cell cycle. The N-
terminus fragment, located in the cytoplasm of the cells, was proposed to block the
G2/M cell cycle checkpoint by sequestering cyclin D1 (Khandelwal et al. 2009).
Therefore, YB-1 promotes the proliferation of a variety of cells. The ability to
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promote mitosis may explain the contributions of YB-1 to the growth of tumours.
It is however, important to note that YB-1 can also promote the survival of cells
(Lasham et al. 2000, Capowski et al. 2001, Lu et al. 2005) and this may be a critical
feature of tumour development (Hanahan & Weinberg 2000). The ability of YB-1
to promote mitosis by facilitating passage through cell cycle checkpoints appears to
explain in part, the role of YB-1 in genetic instability.
1.4.3 YB-1 promotes drug resistance
The ability of YB-1 to promote the survival of cells became evident through research
into the role of YB-1 in the cellular response to a number of stressors. The overex-
pression of YB-1 has been correlated with drug resistance in a number of different
cancers, including breast cancers (Janz et al. 2002, Huang et al. 2005), synovial
sarcomas (Oda et al. 2003), and in a murine melanoma model (Zaidi et al. 2015).
Furthermore, YB-1 has been implicated in the resistance of a number of cancers
to specific compounds. For example, elevated levels of YB-1 are present in recur-
rent breast cancers that were treated with anthracycline, a drug that blocks DNA
replication (Huang et al. 2005).
The overexpression of YB-1 in cancers also correlates with other proteins that
are known to promote drug resistance. The overexpression or nuclear localisation
of YB-1 has been correlated with MDR-1 expression or activity in prostate cancer
(Giménez-Bonafé et al. 2004), ovarian cancer (Huang et al. 2004a), colon cancer
(Vaiman et al. 2007), and lymphoma (Xu et al. 2009). However, in non-small cell
lung cancer there is no correlation between YB-1 and MDR-1 expression although
elevated expression of YB-1 does positively correlate with proliferating cell nuclear
antigen (PCNA) and DNA topoisomerase IIα (TOP2A; Gu et al. 2001). Both
PCNA and TOP2A participate in DNA repair rather than drug efflux. Another
study implicates YB-1 in the stress response through the correlation of elevated YB-
1, mutated p53, and negative patient outcomes (Gessner et al. 2004). Therefore,
analyses of clinical samples links YB-1 to drug resistance via multiple pathways.
In addition to the correlation of YB-1 with drug resistance in general, a number
of biochemical studies also confirm that YB-1 has a direct role. Depleting YB-1
sensitises cells to a range of stressors and drugs; UV irradiation (Guay et al. 2008b),
platinum compounds (Guay et al. 2008b), etoposide (Ohga et al. 1996, Ohga et al.
1998, Schittek et al. 2007, Tsofack et al. 2013), and doxorubicin (Bargou et al. 1997).
The opposite is also true as overexpression of YB-1 contributes to cisplatin resistance
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(Ohga et al. 1996, Ohga et al. 1998, Shibahara et al. 2004). YB-1 has been implicated
in a stress response to the inhibition of RNA synthesis via actinomycin D (Asakuno
et al. 1994). Depleting one allele of the mouse YB-1 homologue sensitises cells to
cisplatin and mitomycin C (Shibahara et al. 2004). YBX1 -/- mouse fibroblasts are
sensitive to oxidative stress due to high levels of the cell cycle checkpoint inhibitors
P16INK4A and p21Cip1 (Lu et al. 2005). In breast cancer, YB-1 is also implicated
in resistance to targeted therapies. YB-1 may promote resistance to antihormonal
therapies for breast cancer by stimulating TGFβ pathways (Popp et al. 2013). YB-
1 may also promote resistance to the primary therapy for HER2-positive breast
cancers, Trastuzumab (also known as Herceptin; Astanehe et al. 2012). The role
of YB-1 in the resistance to these therapies is likely to rely on the ability of YB-1
to encourage cell division despite the loss of hormonal or ERRB2 growth signals
(Figure 1.3).
YB-1 levels are correlated with resistance to a wide range of stressors, includ-
ing chemotoxic drugs and inhibitors of proliferation. The breadth of these agents
appears to favour a general mechanism for YB-1 during stress that inactivates cell
death signalling. Support for such a general mechanism comes from observations
that YB-1 can inhibit the function of p53 (Homer et al. 2005, Lasham et al. 2003) in
addition to the ability of YB-1 to promote the passage of cells through the cell cycle.
However, multiple molecular functions have been proposed to explain the activity
of YB-1 in protecting cells from stress. Many of these, such as the modulation of
drug efflux pumps and interaction with DNA repair proteins, seem to indicate that
YB-1 has multiple functions during stress.
Mechanistic explanations for the molecular role of YB-1 in the stress response are
provided later in this literature review. Furthermore, the research that is reported
in Chapters 5 - 7 focuses on the role of YB-1 during drug exposure.
1.4.4 YB-1 facilitates an invasive phenotype
YB-1 is also known to promote the metastasis of cancer cells. The correlation of ele-
vated YB-1 with aggressive tumours and survival in breast cancers was discussed in
Chapter 1.3. YB-1 levels are also positively correlated with metastasis in colorectal
cancer (Yan et al. 2014) and gastric cancers (Wu et al. 2012).
The importance of YB-1 in the development of metastatic features has been con-
firmed in cell culture experiments following YB-1 overexpression. The overexpression
of YB-1 causes cells to develop mesenchymal and metastatic features (Evdokimova
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et al. 2009a, Evdokimova et al. 2009b). YB-1 overexpression increases cell motility
in a wound healing assay, and also rates of invasion in a matrigel invasion assay
(Castellana et al. 2015). Overexpressing YB-1 in adenocarcinoma cells (MCF-7)
leads to an invasive phenotype which is attributed in part to the interaction of YB-1
with Membrane type 1 matrix metalloproteinase (MT1-MMP) at the cell mem-
brane, in structures referred to as invadopodia (Lovett et al. 2010). This interaction
appears to promote cell motility in three-dimensional culture as the addition of a
monoclonal antibody against MT1-MMP reverses the invasive phenotype. Depleting
YB-1 in an invasive breast cancer cell line with metastatic potential, MDA-MB231,
promotes an epithelial-like phenotype (Castellana et al. 2015). Indirect evidence for
the ability of YB-1 to influence cell migration and invasion comes from experiments
that show that inhibiting the activity of mammalian target of rapamycin (mTOR)
reduces the levels of YB-1 while also reducing the migration and invasion of prostate
cancer cells (PC-3) in three dimensional culture (Hsieh et al. 2012). Therefore, a
number of studies have confirmed that YB-1 can promote metastatic characteristics.
YB-1 may increase the levels of many mesenchymal cell proteins while also reduc-
ing epithelial cell proteins. YB-1 promotes the expression of the mesenchymal cell
markers (SNAI1 and TWIST) in breast cancer (Evdokimova et al. 2009a, Castellana
et al. 2015) and bone osteosarcoma cells (U2OS; Lyons et al. 2016). Overexpression
of YB-1 can also reduce the levels of the epithelial cell marker E-cadherin in breast
cancer cells (Castellana et al. 2015). Similar results were obtained from colorectal
cancers where YB-1 was inversely correlated with E-cadherin expression and pos-
itively correlated with N-cadherin and vimentin (Yan et al. 2014). There was an
inverse correlation of YB-1 with the epithelial cell marker E-cadherin in prostate
cancer cells (Khan et al. 2014).
Therefore, a number of studies have found that YB-1 correlates with metastasis
in cancers. Furthermore, the results from in vitro culture experiments confirm that
YB-1 promotes invasive behaviour and the expression of numerous protein markers
of metastatic potential.
1.4.5 Functions of YB-1 in cancer; summary
The levels of YB-1 are elevated in many cancers and the functional consequences of
this appear to include; the promotion of genomic instability, mitosis, drug resistance,
and, metastasis. Promoting chromosome instability, mitosis, and cell survival during
drug exposure, may rely on general interactions of YB-1 with cellular pathways that
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control cell survival and check-point control mechanisms (p53, p16INK4a, E2F-
family members). The role of YB-1 in promoting an invasive phenotype is less
likely to be linked to these survival and check-point control mechanisms. Instead,
it appears to rely on the ability of YB-1 to promote the expression of mesenchymal
markers and to interact with membrane receptors. The diverse functions that have
been attributed to YB-1 in cancer make it difficult to produce a cohesive model that
incorporates all of these functions in a consistent way. The following sections review
the details of the YBX1 gene. The molecular activities of YB-1 are then reviewed
as these appear to explain the functions of YB-1 in cancer.
1.5 The YBX1 gene
The YBX1 gene (Gene ID: 4904) is located on chromosome 1p34.2 (Qian et al. 1995,
Makino et al. 1996) and it codes for a multifunctional protein that is 324 amino acids
long. The YBX1 gene comprises 8 exons that span 7 introns and covers 19 kilobases
of genomic sequence (Toh et al. 1998). The processed YBX1 mRNA (GI: 109134359)
is 1561 bp in length and nucleotides 172 - 1146 encode the YB-1 protein. Ensembl
(ENSG00000065978, GRCh38.p7) indicates the potential for multiple YBX1 splice
variants but they have not been reported in the literature which instead consistently
confirms the existence of full-length YBX1 mRNA (Kudo et al. 1995, Ohga et al.
1996). However, the use of alternative transcriptional start sites can vary the length
of the 5′-untranslated region (UTR) of YBX1 mRNA without altering the protein
coding region of the transcript (Fukuda et al. 2004, Lyabin et al. 2014). Therefore,
the YBX1 gene appears to produce mRNA that codes for a single protein and if
alternative splicing occurs it is a rare event.
Human YBX1 is very similar to the homologous Y-box genes in other species
(Figure 1.4; Wolffe 1994). Furthermore, Homo sapiens possesses four YBX1
pseudogenes, located on 9p13.1, 14q23.3, 7q22.3, and 7q36.1. These were most
likely generated by gene duplication events (Toh et al. 1998) and, excepting the
pseudogene on 7q22.3 (YBX1P2), the YBX1 pseudogenes lack introns. Processed
YBX1 pseudogenes are also found in Bos Taurus (Ozer et al. 1993b), rat (Ozer
et al. 1993a), and mouse (Familari et al. 1994). None of these pseudogenes are
believed to be translated to protein but it cannot be excluded as some intronless
pseudogenes do produce protein (Rusk 2011).
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Figure 1.4: The YBX1 gene is highly conserved in vertebrates. A phylogenetic tree
showing the similarity of the sequences for YBX1 mRNA in various mammals. The phy-
logenenetic tree was produced in CLC Sequence Viewer 8.0 from an alignment of the YBX1
mRNA sequences from a range of vertebrates (gap open cost = 10; gap extension cost =
1.1, End gap cost = as any other, Alignment mode = very accurate). The phylogenetic
tree was produced using the neighbour joining algorithm with Kimura 80 as the distance
measure. Distance measures are shown below each branch.
1.6 The structure of YB-1
The high level of conservation of the YBX1 gene loci most likely relates to the
membership of YB-1 in the super-family of cold-shock domain (CSD) proteins. In
human YB-1 the CSD is encoded by amino acids 55 - 128 (Figure 1.5). Members of
the cold-shock protein superfamily possess the ability to bind RNA, single stranded
DNA (ssDNA) and double stranded DNA (dsDNA). Homologues are known to exist
in prokaryotes and in eukaryotes from plants (Chaikam & Karlson 2010) to mammals
(reviewed in Wolffe 1994, Kohno et al. 2003). Multiple regions of YB-1 have been
implicated in binding to single-stranded DNA, and the region from 15 - 77 aa is
important for binding to single-stranded nucleic acids (Kloks et al. 2002). There
are two ribonucleoprotein motifs, RNP-1 at 70 - 77 aa and RNP-2 at 84 - 87 aa,
within the CSD which also promote binding to nucleic acids (Figure 1.5; Kolluri
et al. 1992, Landsman 1992, Wang et al. 2000). Escherichia coli cold-shock proteins
consist of only the CSD. Many other eukaryotic CSD genes share amino terminus
(N-terminus) or the carboxyl terminus (C-terminus) domains that are homologous
to human YB-1 (Figure 1.5).
While the CSD is highly structured, both the N-terminus and the C-terminus of
YB-1 appear to be intrinsically unstructured (Selivanova et al. 2010). Proteins con-
taining unstructured domains are proposed to form hubs within biological networks
due to their ability to form transient structures that can interact with a large number
of other proteins (Dunker et al. 2005). Hence, the unstructured N-terminus and C-
terminus of YB-1 may, in part, explain the wide range of functions and interactions
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Figure 1.5: The protein structure of YB-1. Percentage figures are iden-
tity scores from Clustal alignments (CLUSTALO, http://www.uniprot.org/help/
sequence-alignments). Red arrows above the protein diagrams indicate the positions
of amino acid side chain acetylation and black arrows indicate the positions of amino
acid side chain phosphorylation. Red bars above the protein diagrams represent reported
structural motifs. The grey bar represents the region of YB-1 that interacts with ssDNA.
CSD = cold-shock domain; RNP = RNA recognition motif; NLS = nuclear localisation
signal; cleave = proteolytic cleavage site; CRS = cytoplasmic retention signal; S102 =
serine 102 phosphorylation site.
that have been observed from YB-1.
The N-terminus (1 - 54 aa) of YB-1 contains a high proportion of alanine and pro-
line residues and of the 3 domains on YB-1, the N-terminus has the fewest functions
attributed to it. The C-terminus of YB-1 is comprised of ∼ 30 aa stretches where
alternatively either acidic or basic amino acids predominate (Murray et al. 1992).
The C-terminus of YB-1 also confers the protein with the ability to non-specifically
bind to DNA and RNA (reviewed in Wolffe 1994, Ladomery & Sommerville 1994).
In keeping with a role in binding to RNA, the C-terminus of YB-1 is required
for YB-1 to incorporate into messenger ribonucleoprotein (mRNP)s (Matsumoto
et al. 1996) and it is also required for YB-1 to promote translational repression of
mRNA transcripts (Izumi et al. 2001). Furthermore, a cytoplasmic retention signal
is also located in the C-terminus of YB-1 (267 - 293 aa; Figure 1.5).
Cleavage of the C-terminus of YB-1 between Glu-219 and Gly-220 is proposed to
act as a signal for the N-terminus and CSD containing fragment to translocate to the
nucleus. Here YB-1 can act as a transcription factor (Stenina et al. 2001, Sorokin
et al. 2005). However, this cleavage event is not a prerequisite for the nuclear
localisation of YB-1 following genotoxic stress (Cohen et al. 2010). Furthermore,
some YB-1 antibody preparations produce a cross-reactive signal from HNRNP-A1
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which localises to the nucleus of cells following stress. A recent publication proposes
that there are two further nuclear localisation signals within YB-1 (van Roeyen et al.
2013). The C-terminus YB-1 fragment that is produced by proteasomal cleavage
localises to the nucleus of cells following genotoxic stress to block the transcriptional
activity of full-length YB-1. These conflicting reports are difficult to reconcile. With
regards to post-translational cleavage of YB-1 a single point is certain, full-length
YB-1 can translocate to the nucleus following stress (Cohen et al. 2010).
1.7 Regulation of YBX1 gene expression and YB-
1 function
1.7.1 Regulation of YBX1 transcript
Many proteins and mechanisms can regulate the levels of YBX1 mRNA and YB-1 in
cells. A number of proteins can transactivate the YBX1 gene (Figure 1.6). MYC
can transcriptionally activate the YBX1 gene in multiple myeloma cells (Bommert
et al. 2013). A feedback loop exists between these two proteins as YB-1 also regulates
the levels of MYC via the ability to promote translation of MYC mRNA (Figure
1.6.B; Cobbold et al. 2008, Cobbold et al. 2010). YB-1 and interleukin 6 (IL-6)
also appear to mutually regulate one another. In keeping with a role for YB-1 in
invasion and metastasis, the transcriptional control of the YBX1 gene in cancers can
be promoted by interleukin 6 (IL6) via the STAT3 pathway (Castellana et al. 2015).
YB-1 has also been shown to promote the production of IL-6 mRNA (Castellana
et al. 2015) Furthermore, in macrophages YB-1 binds to and promotes the secretion
of IL-6 mRNA (Kang et al. 2014). Therefore, some of the trans-acting proteins for
the YBX1 gene form regulatory loops.
E(nhancer)-boxes in the promoter of the YBX1 gene appear to be important to
the transcriptional regulation of the YBX1 gene (Figure 1.6.C; Makino et al. 1996).
The E-box sequence (CANNTG) is most commonly found as the sequence CACGTG
(Murre et al. 1989). A number of proteins interact with the E-box in the promoter
of the YBX1 gene. Following cisplatin exposure, tumor protein 73 (TP73) has been
found to aid in the recruitment of a complex of MYC and Protein max (MAX)
to the E-box upstream of YBX1 to promote transcription from the YBX1 gene
(Figure 1.6.B; Uramoto et al. 2002). Neurogenic differentiation 6 (aka MATH2)
also promotes transcription from YBX1 in the brain of post-natal mice via an E-box
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Figure 1.6: The YBX1 gene is regulated by multiple transcription factors. A, a simplified
cartoon of the YBX1 gene loci showing the E-box that is in the 5′ promoter region. B, the
MYC transcription factor binds to the E-box in the promoter of YBX1 gene to promote
the production of YBX1 mRNA and YB-1. C, the TWIST transcription factor binds to
the E-box in the promoter of YBX1 gene to promote the production of YBX1 mRNA and
YB-1.
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in the 5′ UTR of YBX1 (Ohashi et al. 2009).
Twist homolog 1 (TWIST), a transcription factor, also binds to E-boxes and a
number of studies highlight its ability to promote transcription of the YBX1 gene
(Figure 1.6.C). The initial reports link the regulation of YBX1 by TWIST to the
role of YB-1 in drug resistance by showing that TWIST can transactivate the YBX1
gene in cisplatin-resistant cell lines (Shiota et al. 2008a).
A number of proteins and interactions appear to facilitate the transactivation of
the YBX1 gene by TWIST. For example, TWIST requires acetylation by histone
acetyltransferase p300 (p300), an acetyltransferase that can regulate transcription
through chromatin remodelling, before it can function as a transcription factor for
YBX1 (Figure 1.6.C; Shiota et al. 2010a). The transactivation of the YBX1 gene
by TWIST is inhibited by programmed cell death protein 4 (PDCD), a tumour
suppressor protein with roles influencing transcription and translation, binding to
the DNA-binding domain of TWIST (Figure 1.6.C; Shiota et al. 2009). p53 can
also inhibit the ability of TWIST to transactivate the YBX1 gene (Figure 1.6.C;
Shiota et al. 2008b). Furthermore, overexpression of either YB-1 or TWIST blocks
the ability of p53 to induce cell arrest. The relationship between YB-1 and TWIST
appears to influence the function of YB-1 in cancer as a promoter of invasion and
metastasis (Shiota et al. 2010b, Iwanami et al. 2014, Song et al. 2014). This is
consistent with independent observations that TWIST also drives the formation of
invadopodia in metastatic tumour cells (Eckert et al. 2011). Furthermore, the ability
of TWIST to transactivate the YBX1 gene may impact on the role of YB-1 in drug
resistance and survival as well as in cell division (Shiota et al. 2010b).
The expression of the YBX1 gene is regulated post-transcriptionally through the
interaction of proteins with YBX1 mRNA. Some of these proteins interact with the
5′-UTR region of YBX1 mRNA (Yokoyama et al. 2003, Thoreen et al. 2012, Lyabin
et al. 2012, Zaccara et al. 2014). YB-1 functions as a developmental protein during
the maturation of haematopoeitic cells (Yokoyama et al. 2003). The expression of
YB-1 is reduced by Erythroid transcription factor (GATA1) binding to an element
in the 5′-UTR region (Yokoyama et al. 2003).
The 5′-UTR of YBX1 mRNA also allows the mTOR pathway to promote the
translation of YBX1 mRNA (Figure 1.7; Thoreen et al. 2012, Lyabin et al. 2012,
Zaccara et al. 2014, Lyabin & Ovchinnikov 2016). An oligopyrimidine motif (ATT
CTCGCT) in the 5′-UTR of mouse YBX1 mRNA subjects it to translational sup-
pression following the inhibition of the mTOR pathway (Thoreen et al. 2012). The
5′-UTR of YBX1 mRNA in humans contains a pyrimidine-rich translation element,
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also known as a TOP-like motif, which allows the mTOR pathway to promote the
translation of YBX1 mRNA (Hsieh et al. 2012, Lyabin et al. 2012). The mTOR
pathway promotes the translation of YBX1 mRNA through the ability of the mTOR
complex 1 (mTORC1) to inhibit the eukaryotic translation initiation factor 4E-
binding protein (4E-BP) which itself inhibits translational initiation by binding to
eIF4E, or other 4F-group proteins (Figure 1.7; translational initiation is reviewed in
Chapter 1.8.3.2; Thoreen et al. 2012, Hsieh et al. 2012, Lyabin et al. 2012). Lyabin
& Ovchinnikov (2016) suggest that 4E-BP and 4F-group proteins are dispensable to
the action of the mTOR pathway on YBX1 mRNA translation. Irrespective of this
suggestion, the study does confirm the ability of mTOR to promote the translation
of YBX1 mRNA. The ability of the mTOR pathway to increase levels of YB-1 may
support features of metastatic cancers (Chapter 1.4.4; Hsieh et al. 2012). During
stress, induced by doxorubicin exposure, p53 can reduce the translation of YBX1
mRNA by inhibiting the mTOR pathway (Figure 1.7; Zaccara et al. 2014). Lyabin
et al. (2012) also provides indirect support for the importance of the interaction of
YB-1 and the mTOR pathway by showing that as the confluence of both mouse
embryonic fibroblast cells (3T3) and human embryonic kidney cells (HEK293) in-
creases, mTOR signalling leads to reduced levels of YB-1 which in turn may slow cell
division (Chapter 1.4.2). Therefore, the mTOR signalling pathway can increase
levels of YB-1 by promoting the translation of YBX1 mRNA. The interaction of
mTOR pathway with YB-1 translation appears to be relevant to the functions of
YB-1 that relate to drug resistance and metastatic cancer.
In addition to regulation by other genes and proteins, YB-1 has also been found to
autoregulate the translation of YBX1 mRNA. The YBX1 promoter lacks a CAAT-
box or TATA-box in the 10 kilobases that are upstream of the gene; thus ruling out
autoregulation of YBX1 transcription via a Y-box sequence (Makino et al. 1996).
However, this same 5′ promoter sequence is composed of 70% G and C nucleotides
which could attract YB-1 binding (see Chapter 1.8.1). YB-1 negatively regulates
the translation of YBX1 mRNA via two binding elements. Translational inhibition
is caused by the binding of YB-1 to an element in the 3′ UTR of YBX1 mRNA. This
excludes polyadenylate-binding protein (PABP) from binding to and promoting the
translation of the YBX1 mRNA (Skabkina et al. 2005, Lyabin et al. 2013). The
second YB-1 binding element is in the 5′ UTR of YBX1 mRNA. This also inhibits
the translation of YBX1 mRNA although the mechanisms are unknown (Fukuda
et al. 2004). However, the YBX1 5′ UTR that was cloned by Fukuda et al. (2004) is
160bp longer than the canonical YBX1 mRNA sequence and only one of the studies
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Figure 1.7: mTORC1, from the mTOR pathway, can promote the translation of YBX1
mRNA. The TOP motif, shown above YBX1 mRNA, can also be a pyrimidine-rich trans-
lation element. 4E-BP and eIF4E may be dispensable for mTORC1 regulation of YBX1
mRNA translation.
elements lies within the commonly observed 5′ UTR (Lyabin et al. 2011). This
makes the results difficult to interpret.
YBX1 gene expression is known to be modulated by a variety of proteins. A
negative feedback loop exists whereby the translation of YBX1 mRNA can be in-
hibited by YB-1. TWIST also appears to be an important regulator of the YBX1
gene. The post-transcriptional regulation of YBX1 mRNA by the mTOR pathway
also appears to be a significant positive regulator of YBX1 gene expression.
1.7.2 Regulation of YB-1 activity
The concentration of YB-1 affects the activity of the protein. For example, the
loss of one or both YBX1 alleles sensitizes mouse fibroblasts to DNA damage from
mitomycin C and cisplatin; this shows that YBX1 is haploinsufficient (Shibahara
et al. 2004, Lu et al. 2005). Therefore, it appears possible that mechanisms that alter
the concentration of YB-1 molecules in the cell, impact indirectly on the activity(s)
of YB-1 at the molecular level. The apparent shift in YB-1 function that occurs when
levels of YB-1 increase may be driven by changes in the rate of post-translational
modification (PTM) on YB-1 as competition for kinases may alter the PTM of
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YB-1 This shift could also be n effect of the alteration of YB-1:RNA ratios in
RNP complexes (see Chapter 1.8.3.2). Some PTMs such as the acetylation of
S2 and K81 have unknown effects on YB-1 function (Choudhary et al. 2009, Gauci
et al. 2009). Similarly, a single study indicates that following DNA damage, YB-
1 may become poly(ADP-ribosyl)ated by poly(ADP-ribose)polymerase 1 (PARP1;
Alemasova et al. 2015). However, as discussed below, various PTMs have known
effects on YB-1 function.
1.7.2.1 Regulation of YB-1 activity; phosphorylation
Phosphorylation is the addition of a phosphate group (HPO3) mainly to serine,
threonine or tyrosine residues by a kinase. Phosphorylation is a common post-
translational modification that can alter protein function (Rubin & Rosen 1975).
YB-1 has many potential phosphorylation sites. Most of these are conserved in the
YB-1 homologues in other species, supporting the idea that they are important to
YB-1 function (Figure 1.5 and Table 1.1).
Table 1.1: The YB-1 residues that have been shown to be phosphorylated in human
samples are conserved in other species.
Human Rabbit Rat Mouse Chicken Xenopus
S2 y y y y y
T7 y y y y y
S102 y S100 S100 S99 S80
Y158 y Y156 Y156 Y155 Y136
Y162 y S160 S160 S159 Y140
S165 y S163 S163 S162 -
S167 y S165 S165 S164 S145
S174 y S172 S172 -
S176 y S174 S174 - S152
S313 y S311 S311 T310 T292
S314 y S312 S312 S311 S293
“y” indicates that the residue bears the same exact position in the protein as the human
YB-1 residue. “-” indicates that the residue is not present in the protein. Abbreviations;
S = serine, T = threonine, Y = tyrosine.
High-throughput studies have revealed that many serine and threonine residues
on YB-1 are commonly phosphorylated. These studies show that YB-1 is phospho-
rylated at residues spanning the length of the protein across a range of cell types
and growth conditions (S2, T7, S102, Y158, Y162, S165, S167, S174, S176, S313,
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and S314; Molina et al. 2007, Sugiyama et al. 2007, Dephoure et al. 2008, Kyono
et al. 2008, Ruse et al. 2008, Sui et al. 2008, Tsai et al. 2008, Brill et al. 2009, Gauci
et al. 2009, Nagano et al. 2009, Van Hoof et al. 2009, Han et al. 2010, Olsen
et al. 2010). Phosphorylation of the residues from S165 to S176 and of S314 has
been detected by a minimum of 8 studies for each site, indicating that these modi-
fications are common. However, S102 (Pan et al. 2009, Brill et al. 2009) and S313
(Gauci et al. 2009, Olsen et al. 2010) have only been detected by two studies respec-
tively. This disparity may indicate that YB-1 sequences containing phosphorylation
at S102 or S313 are difficult to detect using the method of liquid chromatography-
coupled tandem mass spectrometry (LC-MS/MS) or, that it is rare for YB-1 to be
phosphorylated at these residues. The former appears to be most likely for YB-1
peptides that are phosphorylated at S102 as the phosphorylation of S102 has been
confirmed by numerous biochemical studies (discussed below).
There is limited information regarding the functional consequences of YB-1 being
phosphorylated at most of the known sites. However, phosphorylation in general
has been shown to influence the activity of YB-1. For example, phosphorylation of
the Xenopus YB-1 homologue affects its ability to bind to nucleic acids (Tafuri &
Wolffe 1993, Murray et al. 1991, Kick et al. 1987) and phosphorylated rabbit YB-1 is
incorporated into free and polysomal mRNPs in ribosome-free rabbit reticulocytes
(Minich et al. 1993). YB-1 requires phosphorylation by Mitogen-activated protein
kinase 1 (MAPK1, also known as ERK2) and Glycogen synthase kinase-3 beta
(GSK3β) to bind to single-stranded DNA in the hypoxia responsive region that is
downstream of the Vascular endothelial growth factor (VEGF ) gene. This binding
also inhibits the transcription of VEGF (Coles et al. 2005). These studies indicate
that phosphorylation enhances the ability of YB-1 to bind to nucleic acids. The
phosphorylated YB-1 residues and the kinases involved remain unidentified.
The functional significance of phosphorylation at two specific sites on YB-1
has been described. Prabhu et al. (2015) found that treating HEK293 cells with
Interleukin-1 beta (IL-1β) leads to the phosphorylation of ectopically expressed
YB-1 at S165. It should be noted that the authors have failed to fully annotate
the MS/MS spectra (T. Kleffmann, personal communication). Examination of the
MS/MS spectra for the fragment ions that indicate the presence of HPO3, or a loss of
H3PO4, on an amino acid side chain shows that the MS/MS spectra comes from two
peptides each with a single phosphorylation, one at S165 and the other at S167 (see
Supplementary A.1 - A.1.1 for notes on MS/MS fragmentation and the analysis
of phosphorylated peptides). Prabhu et al. (2015) found that the phosphorylation
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of YB-1 at S165 is necessary for NF-κB activation which in turn is likely to facilitate
the development of colon tumours. Therefore, the function of phosphorylation at
S165 seems to impact on the ability of YB-1 to promote the early stages of cancer
development (Prabhu et al. 2015).
The phosphorylation of S102 on YB-1 appears to be an important marker of the
activity of YB-1 in cancer cells. It is thought to influence the ability of YB-1 to
bind to nucleic acids as S102 resides within the CSD and, as such, this region is
involved in DNA binding (Wu et al. 2006). Phosphorylation of YB-1 at S102 has
been observed in breast cancer cells (Sutherland et al. 2005, Evdokimova et al. 2006b,
Bader & Vogt 2008, Law et al. 2010, Toulany et al. 2011), monocytes (Alidousty
et al. 2014), and the granulosa cells that surround ovaries (Donaubauer & Hunzicker-
Dunn 2016). Furthermore, phosphorylation of YB-1 at S102 has been correlated with
aggression and metastasis in melanomas (Sinnberg et al. 2012) and with epithelial
to mesenchymal transition in prostate cancer cells (Khan et al. 2014). Therefore,
phosphorylation of YB-1 at S102 appears to be common in a wide range of cancers
and it is also important to YB-1 function.
Multiple kinases can phosphorylate YB-1 at S102. Expression of AKT is cor-
related with YB-1 in breast tumours and AKT can phosphorylate S102 of YB-1
(Sutherland et al. 2005, Evdokimova et al. 2006b, To et al. 2007). p90 ribosomal
S6 kinase (RSK) also phosphorylates YB-1 at S102, and it appears to do so with
a greater efficiency than AKT (Stratford et al. 2008, Aronchik et al. 2014). Fur-
thermore, a point mutation of the K-ras gene at codon 13 (Hollestelle et al. 2007),
which activates the PI3K/AKT pathway and is common in some cancer, leads to
constitutive phosphorylation of YB-1 at S102 (Toulany et al. 2011). The phosphory-
lation of YB-1 at S102 was increased in granulosa cells following exposure to follicle
stimulating hormone (FSH) via the ERK/RSK-2 signaling pathway (Donaubauer
& Hunzicker-Dunn 2016). The authors showed that RSK-2 does not phosphorylate
S102 but it inhibits the activity of a phosphatase, Serine/threonine-protein phos-
phatase PP1-beta catalytic subunit (PP1β), that dephosphorylates S102 on YB-1
(Donaubauer & Hunzicker-Dunn 2016). YB-1 is also phosphorylated in monocytic
cells where it promotes maturation to macrophages by binding to the promoter of C-
C motif chemokine 5 (CCL5, also known as regulated upon activation, normal T cell
expressed and secreted [RANTES]). Calcineurin acts as a phosphatase and removes
the phospo-group from S102 of YB-1 late in the process of macrophage maturation
(Raffetseder et al. 2012, Alidousty et al. 2014). Therefore, the phosphorylation of
YB-1 at S102 appears to be regulated via multiple kinases and phosphatases.
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Multiple alterations to the function of YB-1 have been linked to its phospho-
rylation at S102. The phosphorylation of YB-1 at S102 appears to play a role in
mitosis. However, phosphorylation of YB-1 at S102 has no significant effect on mito-
sis in adherent cells. Instead, it promotes the growth of a range of cells in soft-agar
(Anchorage independant growth; Sutherland et al. 2005, Aronchik et al. 2014). A
decoy that partially prevents the phosphorylation of S102 without lowering cellular
levels of YB-1 protein inhibits the growth of cancer cells and also sensitises them to
trastuzumab, a monoclonal antibody that inhibits the HER2 receptor from activat-
ing the MAPK and the PI3k/AKT pathways (Law et al. 2010). Depleting YB-1 or
inhibiting the phosphorylation of YB-1 at S102 reduces the expression of HER-2 and
EGFR in breast cancer cells (Sutherland et al. 2005, Wu et al. 2006, Law et al. 2010).
Furthermore, the role of YB-1 in promoting cytokinesis failure in normal breast ep-
ithelial cells (HUMEC) is reliant on phosphorylation of S102 and only YB-1 that
is phosphorylated at S102 localises to the centrosomes (Davies et al. 2011, Davies
et al. 2014, Kawaguchi et al. 2015). Currently, it is unclear how phosphorylation of
YB-1 at S102 links the promotion of anchorage independent growth with cytokinesis
failure.
The phosphorylation of YB-1 at S102 is also important to DNA damage response
signalling. YB-1 that is phosphorylated at S102 promotes the survival of cells fol-
lowing UV irradiation, most likely due to the involvement of this phosphorylated
form of YB-1 in the repair of double-stranded DNA breaks (Toulany et al. 2011).
Increased levels of phosphorylated YB-1 were also observed in the renal and inflam-
matory cells of a murine model for acute peritonitis (Hanssen et al. 2013). The
phosphorylation of YB-1 at S102 is also required for Follicle stimulating hormone
exposure to increase the levels of a range of mRNA transcripts involved in steroido-
genesis (Donaubauer & Hunzicker-Dunn 2016). The effects of phosphorylation of
YB-1 at S102 appear to be important to the function of YB-1 but the research
presents a paradox as phosphorylation at S102 is critical to DNA binding but also
critical to the interaction of YB-1 with the mircotubules of the centrosome that are
specifically separate from DNA.
Summary
To date the effects of phosphorylations of YB-1 at two sites (S102 and S165) have
been studied. Phosphorylation of YB-1 at both of these sites leads to significant
changes in the function of YB-1.
Other serine, threonine, and tyrosine residues in YB-1 appear to be phosphory-
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lated in a number of cell types (reviewed above). These phosphorylation sites are
conserved in a range of YB-1 homologues in vertebrates (Table 1.1). Therefore,
phosphorylation of YB-1 at these sites is conserved across a range of cell types and
also between species. This infers that any alterations to the function of YB-1 that
result from these phosphorylations are also likely to be conserved across a range of
cell-types and between species. Currently, the effects of phosphorylation at these
sites on the functions of YB-1 are uncharacterised. Furthermore, few studies have
focused on the systematic characterisation of the phosphorylation states of YB-1.
The work presented in Chapter 4 provides a systematic survey of YB-1 phosphory-
lation in two cancer cell lines. The elucidation of the prevalence of phosphorylation
at other YB-1 residues should be a priority given their potential to also confer mul-
tifunctionality to YB-1. Multiple phosphorylation of YB-1 at S102 and another site
may explain the paradoxical alterations of YB-1 function that are currently ascribed
solely to the phosphorylation of YB-1 at S102.
1.7.2.2 Regulation of YB-1 activity; ubiquitin and the proteasome.
YB-1 has been shown to be subject to regulation by ubiquitination and the protea-
some (discussed in Chapter 1.6; Stenina et al. 2000, Stenina et al. 2001, Sorokin
et al. 2005, Lutz et al. 2006, Chibi et al. 2008, van Roeyen et al. 2013). The interac-
tion of YB-1 with the proteasome appears to be regulated at various levels. RBBP6
(retinoblastoma binding protein 6), a putative E3 ubiquitin ligase, binds to and
ubiquitinates the C-terminus of YB-1 leading to its degradation by the proteasome
(Chibi et al. 2008). The N-terminus of YB-1 can also be polyubiquitinated by F-box
33 prior to its proteasomal degradation (Lutz et al. 2006). The conditions under
which these two proteins ubiquitinate YB-1 are not fully characterised.
The ability of proteasomal cleavage of YB-1 to modify the function of YB-1 was
discussed in Chapter 1.6. The proteasomal cleavage of YB-1 between Glu-219 and
Gly-220 may lead to the truncated protein accumulating in the nucleus (Sorokin
et al. 2005). However, this mechanism is not evident in human cancer cell lines
(Cohen et al. 2010). Thrombin has also been shown to cleave YB-1 in endothelial
cells and this cleaved YB-1 is also transcriptionally active (Stenina et al. 2000).
Furthermore, thrombin treatment of epithelial cells appears to inhibit the ability
of YB-1 to bind to mRNA (Stenina et al. 2001). Thrombin cleaves purified YB-
1 protein via a non-canonical site in vitro making the mechanism and relevance of
thrombin treatment difficult to interpret (unpublished data, Algie and Braithwaite).
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Therefore, the significance of the proteasomal cleavage of YB-1 is unclear as it is not
a requirement for stress induced nuclear localisation of YB-1 (Cohen et al. 2010).
The nuclear localisation of YB-1 has been discussed in Chapter 1.6. In general,
∼90% of YB-1 is located in the cytoplasm of cells where it binds to mRNA and
promotes the formation of mRNPs (Evdokimova et al. 2006a). However, studies have
observed YB-1 accumulating, or being present, in the nucleus of cells in response to
adenoviral infection (Holm et al. 2002), hyperthermia (Stein et al. 2001), and DNA
damage (Koike et al. 1997, Kamura et al. 1999). YB-1 can require p53 to translocate
to the nucleus following cellular stress (Zhang et al. 2003, Homer et al. 2005, Guay
et al. 2006). The accumulation of YB-1 in the nucleus is presumed to relate primarily
to the increased activity of YB-1 as a transcription factor. The C-terminus of YB-
1 contains a cytoplasmic retention signal (Koike et al. 1997) and, as mentioned
previously, proteasomal cleavage of the C-terminus of YB-1 causes the truncated
N-terminus plus CSD protein to accumulate in the nucleus (Sorokin et al. 2005).
Phosphorylation of S102 has also been posited as a requisite for nuclear localisation
of YB-1 in ovarian cancer (Basaki et al. 2007). YB-1 is also reported to localise
to the nucleus of cells during the G1/S phases of mitosis (Jurchott et al. 2003).
Therefore, the subcellular localisation of YB-1 appears to be dynamic, with the
YB-1 localising throughout the cell depending on its function.
1.8 Mechanisms of YB-1 activity
YB-1 takes part in a variety of cellular processes. Many of those processes occur
because YB-1 can promiscuously bind to nucleic acids. This section will outline
those nucleic acid binding properties and the cellular processes in which YB-1 plays
a important role.
1.8.1 Nucleic acid binding
YB-1 binds to nucleic acids in both a sequence non-specific and a sequence specific
manner (Wolffe 1994). Nucleic acid binding is integral to the ability of YB-1 to
influence the transcription of genes and the splicing, translation, and stability of
RNA transcripts. Therefore, knowledge of which nucleic acid sequences YB-1 binds
is important to understanding the function of the protein.
The study of the nucleic acid binding affinity of YB-1 is complicated by three
factors. The first is that YB-1 has a general affinity for nucleic acids (Bouvet
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et al. 1995). Furthermore, it can be difficult to assess the applicability of nucleic acid
binding studies that use YB-1 homologues from other species. However, the strong
homology of the protein in many species indicates that most homologues are likely to
share binding preferences with YB-1. Finally, the extensive phosphorylation of YB-
1 may alter the nucleic acid binding characteristics of YB-1 (Chapter 1.7.2). The
phosphorylation of YB-1 is likely to vary with the cellular context. Some studies also
use YB-1 that has been produced by bacteria and this YB-1 will lack the extensive
phosphorylation of endogenously produced YB-1 (Chapter 1.7.2).
YB-1 binds to inverted Y-boxes (CAAT-boxes) in vitro (Dorn et al. 1987, Ozer
et al. 1990). For example, YB-1 binds to the Y-boxes in the promoters of Hu-
man leukocyte antigen (HLA; also known as Major Histocompatibility complex)
class II genes (Didier et al. 1988, Rakoff-Nahoum et al. 2001). Subsequent stud-
ies have shown that YB-1 does not bind to and reduce the melting temperature
of the classic Y-box sequence (ATTG) any more aggressively than other sequences.
Instead, the alternative Y-box sites GGTC and TGGT were strongly bound by
YB-1 (Zasedateleva et al. 2002). Therefore, the general DNA and RNA binding
preferences of YB-1 are varied.
While studies of individual binding sites are informative, there have also been
attempts to deduce global rules for the interaction of YB-1 with nucleic acids. YB-
1 binds DNA sequences that are rich in pyrimidines (C/T; Kolluri et al. 1992).
It has been shown that there are two pyrimidine rich YB-1 binding sites in the
5′ UTR of the VEGF mRNA and YB-1 appears to mediate the incorporation of
polypyrimidine tract binding protein (PTB) to these complexes (Coles et al. 2004).
However, high-throughput studies indicate that YB-1 preferentially binds to ssDNA
and RNA 7-mer sequences that are enriched with guanine (Minich et al. 1993, Zase-
dateleva et al. 2002). Furthermore, a recent and exhaustive RNA-binding screen
confirms that YB-1 possesses both of the preceding preferences by showing that
YB-1 strongly binds to both pyrimidine rich and G-rich sequences. In this study,
the top 5 YB-1 binding motifs are comprised of 60% pyrimidines (C/U) without
any adenines meaning that the sequences are also enriched (40%) for guanine (Ray
et al. 2009). Another study shows that YB-1 has an affinity for GC rich sequences
(Dong et al. 2009). Endogenous rabbit YB-1 can inhibit the translation of its own
mRNA via a UCCA(G/A)CAA motif in the YBX1 mRNA (Skabkina et al. 2005).
The differences in the RNA binding motifs that have been identified in these studies
may be explained, as is noted above, by inherent differences between YB-1 homo-
logues or by the phosphorylation of YB-1 altering the nucleic acid binding prefer-
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ences of YB-1. The two high-throughput studies utilise recombinant YB-1 which
will have different PTMs to endogenous YB-1 (see Chapter 1.7.2). Furthermore,
as discussed in subsequent sections of this review, other proteins interact with YB-1
to modulate the effects of its nucleic acid binding.
YB-1 binds double-stranded DNA but possesses a higher affinity for ssDNA
(Tafuri & Wolffe 1992, Izumi et al. 2001). For example, YB-1 binds preferentially,
and in a sequence specific manner, to x-box sequences in promoters as ssDNA,
and less so to dsDNA in Y-box sequence (MacDonald et al. 1995, Zasedateleva
et al. 2002). YB-1 can also separate strands to create ssDNA in both Y-boxes and
x-boxes (MacDonald et al. 1995). The RNP-1 motif is thought to be responsible
for the ssDNA binding activities of YB-1 (Kolluri et al. 1992). The N-terminus and
C-terminus of YB-1 also contribute to the ability of YB-1 to bind RNA (Bouvet
et al. 1995).
YB-1 may recognise DNA structure, mismatched bases, and modified nucleic
acids (see Chapter 1.8.2.2 below) in addition to its sequence specific preferences
(reviewed in Swamynathan et al. 1998). YB-1 preferentially binds a ssDNA se-
quence that forms an intramolecular triplex (Horwitz et al. 1994). However, a
high-throughput screen of structured and unstructured 7-mer RNA sequences found
that the sequence specific binding of YB-1 to RNA is unaffected by tertiary RNA
structure (Ray et al. 2009). YB-1 decreases the melting temperature of dsDNA
(MacDonald et al. 1995, Zasedateleva et al. 2002). One exception to this is dsDNA
sequences containing poly-G runs; here YB-1 increases the melting temperature
(Zasedateleva et al. 2002). Furthermore, YB-1 also separates dsDNA and RNA
sequences that contain mismatches and facilitates the annealing of strands of com-
plimentary DNA and RNA (Skabkin et al. 2001, Gaudreault et al. 2004).
The involvement of YB-1 in epigenetics is implied via the ability of YB-1 to
preferrentially bind to methylated cytosines (Dürnberger et al. 2013). Notably, this
research found that YB-1 did not display enriched RNA binding. The evidence
for YB-1 participating in epigenetic processes has also come via the observation
that in renal cell carcinomas, YB-1 and Enhancer of Zeste Homolog 2 (EZH2), a
polycomb histone methyltransferase that modifies epigenetic code are positively cor-
related with one another (Wang et al. 2015a). However, Wang et al. (2015a) links
the correlation to the ability of YB-1 to promote transcription of EZH2 mRNA
rather an interaction of YB-1 and EZH2 while binding to methylated DNA.
Summary
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YB-1 has a strong general affinity for all nucleic acids. The interaction of YB-1
with RNA and DNA has been studied in multiple situations. The results show that
YB-1 has a range of preferences for nucleic acid binding which will be reviewed in a
functional context in the following sections.
1.8.2 DNA-binding protein
The ability to bind to DNA appears to be central to the functions of YB-1 in cancer
(Chapter 1.4). The nuclear localisation of YB-1 has been correlated with cancer
progression (Bargou et al. 1997, Janz et al. 2002) which has led to a focus on the
role of YB-1 in modulating transcription in cancer. This focus is reinforced by the
correlation of nuclear localisation of YB-1 and drug resistance via the transcription
of the ABCB1 gene (Bargou et al. 1997). The ability to bind DNA provides YB-1
with two mechanistic pathways to participate in cancer progression. The first is by
acting as a transcription factor and the second is participating in DNA repair. The
details of these two mechanisms are reviewed in the following sections.
1.8.2.1 Transcription factor
The ability of YB-1 to act as a transcription factor has been confirmed repeatedly;
Table 1.2 includes a subset of known YB-1 transcriptional target genes. Notably,
YB-1 can transactivate, and also repress, target genes to influence many of the func-
tions that YB-1 has in cancer (these functions are reviewed in Chapter 1.4). YB-1
is capable of acting as a transcription factor for genes containing Y-box elements in
their promoters (Spitkovsky et al. 1992, Gronostajski et al. 1984).
The ability of YB-1 to act as a transcription factor may allow it to promote drug
resistance. By binding to an inverted CCAAT-box in the ABCB1 gene promoter,
YB-1 can stimulate ABCB1 transcription during cellular stress (Asakuno et al. 1994,
Ohga et al. 1996, Ohga et al. 1998, Sengupta et al. 2011, Chattopadhyay et al. 2008).
Cofactors may be required for YB-1 to transactivate ABCB1 as acetylated human
apurinic/apyrimidinic (AP) endonuclease 1 (APE1) acts as a cofactor for YB-1
during the regulation of MDR-1 transcription (Sengupta et al. 2011).
YB-1 does not activate the transcription of ABCB1 in all contexts. Overex-
pression of YB-1 in prostate cancer cell lines has no effect on the levels of MDR-1
(Saupe et al. 2014). Furthermore, depleting YB-1 has no effect on the levels of
ABCB1 mRNA and MDR-1 or, on the survival of a human pancreatic carcinoma
cell line that is reliant on MDR-1 for resistance to the DNA-intercalculating drug
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ABCB1 x x Asakuno et al. (1994)
Fas receptor/CD95 x Lasham et al. (2000)
Thymidine kinase x Dorn et al. (1987)
Cyclin A x x Jurchott et al. (2003)
Cyclin B1 x x Jurchott et al. (2003)
DNA topoisomerase 11 α x Shibao et al. (1999)
Major vault protein x x Stein et al. (2005)
myosin light-chain 2v x x Zou & Chien (1995)
MMP2 x x x Mertens et al. (1997)
HER2 x x Sakura et al. (1988)
EGFR x x Sakura et al. (1988)
Tyrosine-protein phosphatase
non-receptor type 1
x Fukada & Tonks (2003)
MHC class II x x Didier et al. (1988)
collagen-α 1 x x Higashi et al. (2003)
GM-CSF x Diamond et al. (2001)
Daunorubicin (Kaszubiak et al. 2007). It has been postulated recently that YB-1
does not bind to the inverted CCAAT-box in vivo as there is little evidence that
YB-1 binds to Y-boxes in sequencing data from chromatin immunoprecipitation of
YB-1 (Dolfini & Mantovani 2013a, Dolfini & Mantovani 2013b). Many studies cor-
relate ABCB1 mRNA, or MDR-1, and YB-1 in cancer (Chapter 1.4.3). Therefore,
the relationship between the two appears to be important. However, it appears that
YB-1 influences the transcription of ABCB1 in specific contexts.
There are other genes that YB-1 is known to transactivate via a Y-box in their
promoter region. The ability of YB-1 to promote metastatic features may relate the
transactivation of matrix metalloproteinase 2 (MMP2 ) and the subsequent secretion
of the protein that MMP2 encodes, 72 kDa type IV collagenase (also known as
gelatinase A; Mertens et al. 2002). Exposure to ionizing radiation leads to YB-
1 promoting the transcription and secretion of MMP2, and p53 and Transcription
factor AP-2-alpha are required as cofactors (Mertens et al. 2002). The ability of YB-
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1 to transactivate the MMP2 gene has been confirmed in a variety of cell lineages
(van Roeyen et al. 2013, Schittek et al. 2007, Shinkai et al. 2016). Lovett et al. (2010)
shows that overexpressing YB-1 in MCF-7 cells promotes an invasive phenotype
which occurs because, rather than a strong transactivation of the MMP2 gene, YB-
1 overexpression leads to the presentation of 2 kDa type IV collagenase at the surface
of migrating cells. The increased levels of MMP2 promote invasive features in cells
which links to the role of YB-1 in invasion.
YB-1 also activates and represses the transcription of genes that lack Y-boxes
in their promoters. By binding to single-stranded DNA, YB-1 can repress the tran-
scription of Tumor necrosis factor receptor superfamily member 6 (CD95, also known
as the fas receptor; Lasham et al. 2000). The CD95 protein is capable of inducing
apoptosis and this inhibition may impact on the ability of YB-1 to promote apop-
tosis. Other work has shown that YB-1 may inhibit p53 from transactivating target
genes (Homer et al. 2005).
YB-1 can also transactivate genes that promote mitosis. YB-1 binds the pro-
moter of ERBB2 and EGFR in vitro (Sakura et al. 1988) and has more recently
been found to enhance the expression of both ERBB2 and EGFR mRNA (Wu
et al. 2006). YB-1 elevates the levels of other transcripts in the MAPK pathway
and poor survival of patients from colorectal cancer has been correlated with both
a MAPK pathway gene signature and YB-1 (Jürchott et al. 2010). YB-1 levels are
positively correlated with ERBB2 and EGFR expression in breast tissue (Turashvili
et al. 2011) and ER/PR negative breast tumours that include the HER-2 positive
tumours (Woolley et al. 2011).
YB-1 promotes the progress of cells through G1/S by inhibiting the expression of
cyclin-dependent kinase inhibitors, p21(Cip1) and p16(INK4A), that prevent cell cy-
cle progression and may induce senescence (Basaki et al. 2010, Yu et al. 2010, Davies
et al. 2014). YB-1 binds to a Y-box located in the promoter of the CDC6 gene,
which promotes DNA synthesis during the S-phase of the cell cycle, and the levels
of CDC6 mRNA reduced when YB-1 was depleted (Basaki et al. 2010). Depleting
YB-1 also led to decreased levels of mRNA transcripts for other genes that promote
passage through the cell cycle (cyclin D1 [CCND1 ], CDK1 and CDK2 ). In non-
small cell lung carcinomas, YB-1 may promote mitosis via transcriptional activation




YB-1 can act as a transcription factor for a number of genes with functions that are
consistent with the roles of YB-1 in cancer (Chapter 1.4). The ability of YB-1 to
act as a transcription factor is promoted as the mechanistic link to many of its func-
tions in cancer. This is one of the reasons that the nuclear localisation is considered
to be an important feature of YB-1 in cancer.
1.8.2.2 DNA repair
The importance of YB-1 to cell survival during exposure to a range of DNA dam-
aging drugs is reviewed in Chapter 1.4.3. The ability of YB-1 to bind to DNA
provides YB-1 with the opportunity to directly participate in DNA repair. YB-1 is
involved in DNA repair via a role in base excision repair, a pathway that repairs
DNA sites that are abasic, apurinic/apyrimidinic. YB-1 has a greater binding affin-
ity for depurinated DNA than for undamaged DNA (Hasegawa et al. 1991). Besides
effectively binding nucleic acid sequences containing apurinic/apyrimidinic bases,
YB-1 also preferentially binds to cisplatin, mitomycin C, and UV modified DNA
(Ohga et al. 1996, Ise et al. 1999). YB-1 has not only been implicated in the repair
of genomic DNA but also in mismatch repair in mitochondrial DNA (de Souza-Pinto
et al. 2009).
YB-1 interacts directly with damaged DNA and the C-terminus of YB-1 is
thought to help to target and recruit DNA repair proteins to damaged DNA (Ise
et al. 1999, Gaudreault et al. 2004, Skabkin et al. 2001). A number of DNA repair
proteins have been shown to interact with YB-1 during DNA repair, for example
glycosylase, Endonuclease 8-like 2 (NEIL2), DNA polymerase beta and gamma,
DNA ligase II, APE1, DNA mismatch repair protein Msh2 (MSH2), X-ray repair
cross-complementing protein 5 (XRCC5 also known as Ku80), Werner syndrome
ATP-dependent helicase (WRN), and endonuclease III (Das et al. 2007, Gaudreault
et al. 2004, Marenstein et al. 2001). PCNA is a protein that is involved in targeting
a DNA polymerase that replaces excised DNA fragments during base excision repair
(Sancar et al. 2004). PCNA interacts with the C-terminus of YB-1 both in vitro
and in vivo (Ise et al. 1999). Furthermore, YB-1 interacts with human endonuclease
III (hNTH1) following the exposure of YB-1 overexpressing cells to cisplatin or UV
which may indicate the two proteins interact to carry out base excision repair (Guay
et al. 2008b). In vitro assays show that YB-1 and APE1 stimulate the activity of
hNTH1 in base excision repair (Marenstein et al. 2003). Of particular note, in addi-
tion to APE1 participating with YB-1 during base excision repair, it also acts as a
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co-factor for YB-1 in its role as a transcription factor for ABCB1 (Chattopadhyay
et al. 2008).
Summary
YB-1 can bind to damaged DNA. YB-1 also interacts with DNA repair machinery,
in particular, the components that are involved in nucleotide excision repair or base
excision repair.
1.8.3 RNA-binding protein
While YB-1 can act as a transcription factor for a number of genes, YB-1 can also
bind to RNA. Through the ability to bind to RNA, YB-1 has been found to partici-
pate in RNA splicing, translation of RNAs, and the protection of RNAs from degra-
dation. Emerging research has also shown that YB-1 can interact with non-coding
RNAs (Blenkiron et al. 2013, Liu et al. 2015) but currently the full significance of
these interactions is unclear and as such, they will not be discussed further. Further-
more, the potential for YB-1 to accompany RNAs throughout their lifecycle makes
it very difficult to deduce the level(s) at which YB-1 regulates gene expression. It
is clear that the nuclear localisation of YB-1 that has been observed in some can-
cers, and following stress, is a prerequisite for YB-1 to act as a transcription factor.
However, while in the nucleus YB-1 may also participate in the post-transriptional
regulation of gene expression by binding to RNA to stabilise transcripts and to
participate in splicing pre-mRNA transcripts.
1.8.3.1 Splicing
RNA splicing is a multistep process that creates translatable mRNA transcripts
from the RNA gene products (pre-mRNA transcripts) that are transcribed by RNA
polymerase II (reviewed in Chen & Manley 2009). While newly transcribed RNA
contains exons, nucleic acid sequences that code for amino acids, they also contain
introns, nucleic acid sequences that do not code for amino acids. This intronic se-
quence needs to be removed (spliced) to produce a mature mRNA. Before becoming
a mature mRNA, pre-mRNAs undergo further modifications, such as the addition of
a 7-methylguanylate cap to the 5′ terminus and polyadenylation of the 3′ end. The
spliceosomal machinery comprises specialised RNA and protein complexes, small
nuclear ribonuclear particles, and other proteins that promote or inhibit splicing
via motifs and elements on immature RNAs. The spliceosome is one of the largest
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biomolecular machines in the cell (Chen & Manley 2009) and hence the assembly
and regulation of its function comprises many regulated steps. The formation of
spliceosome components on the pre-mRNA and catalysis of splicing are outside of
this review (for a review of this topic see Chen & Manley 2009).
Besides the role of the spliceosome in processing pre-mRNA to mature mRNA
transcripts, the spliceosome also contributes to protein diversity by regulating al-
ternate splicing; the inclusion or exclusion of exons from the mRNA. The primary
signals for the splicing machinery are the splice site and the branch point, these
sequence motifs are located near the 5′ and 3′ ends of intronic sequences that are
adjacent to the exons (reviewed in Chen & Manley 2009). Approximately 95% of
multi-exon containing genes are thought to be alternately spliced (Pan et al. 2008).
Co-factors interact with RNA and spliceosomal proteins to modulate the inclusion
and exclusion of RNA sequence by binding to enhancer sequences. In general, pro-
teins from the Serine-arginine family appear to promote splice-site recognition by
the spliceosome while the inhibition of splice site recognition frequently occurs via
hnRNP proteins. YB-1 interacts with a number of hnRNP proteins, for example
hnRNP-K in the nucleus of human cells (Shnyreva et al. 2000). The regulation of
splicing is also known to occur as RNA is transcribed by Polymerase II, cotran-
scriptionally, and the speed of transcription is thought to greatly affect the eventual
splicing of the RNA (Muñoz et al. 2009).
YB-1 has been detected in human prespliceosomes (also known as A complexes;
Hartmuth et al. 2002, Wolf et al. 2009) and also in spliceosomes (also known as
B complexes; Deckert et al. 2006). YB-1 and a YB-1 homologue in the midge,
Chironomus tentans, associate with newly transcribed RNA (Chansky et al. 2001,
Soop et al. 2003). These data all indicate that YB-1 associates with RNA as it
is transcribed and that YB-1 is present when pre-mRNA transcripts are processed
to mature mRNA transcripts (Figure 1.8.A). The broad RNA affinities that YB-
1 possesses may promote this early association. However, YB-1 does not interact
directly with the splicing machinery by binding to splice sites or branch points. The
role of YB-1 in splicing appears to rely predominantly on YB-1 binding to exon
sequences on pre-mRNA transcripts.
YB-1 acts as an exonic splicing enhancer by binding to, and then promoting
the inclusion of, exons (Figure 1.8.B). YB-1 has been shown to bind to exon
v4 of CD44 (Stickeler et al. 2001, Watermann et al. 2006). The binding of YB-1
to a splicing motif, known as an A/C-rich exon enhancer, in exon 4 of CD44 pre-
mRNA in vitro, enhances the inclusion of this exon (Stickeler et al. 2001, Watermann
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Figure 1.8: YB-1 influences the outcome of splicing events. A, YB-1 can bind to pre-
mRNA transcripts as they are transcribed. B, YB-1, through interactions with a number
of proteins, can act as an exonic splicing enhancer to promote the inclusion of exons during
splicing events. C, by binding to motifs in intronic regions, YB-1 and hnRNPC can act
as an exonic splicing silencers to promote the exclusion of exons during splicing.
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et al. 2006). This alternative splicing event is one of a number that have been
implicated in metastatic development of a range of cancers, including breast cancers
(Prochazka et al. 2014). YB-1 is also known to interact with splicing factors from the
Serine Arginine family, SRp30c and SRp86, and others such as PTB (Figure 1.8.B;
Raffetseder et al. 2003, Li et al. 2003b, Coles et al. 2004). This further implies that
YB-1 has a consistent role in promoting the inclusion of exons. Elevated levels of YB-
1 alter RNA splicing with and without SRp30c, indicating that YB-1 may generally
facilitate interactions of splicing factors with RNA (Raffetseder et al. 2003). Heat-
stress disrupts both the co-localisation of YB-1 with SRp30c and their promotion of
splicing. YB-1 facilitates appropriate splicing of the Neurofibromin (NF1 ) gene, a
negative regulator of the Ras-Raf-MEK-ERK signalling pathway, by binding to an
exonic splicing enhancer (ACAAC) in exon 37 of NF1 mRNA (Skoko et al. 2008).
Mutation of the first cytosine of this exonic splicing enhancer disrupts the binding of
YB-1 and leads to exon-skipping via the recruitment of hnRNP-A1 and hnRNP-A2
to the mutated NF1 mRNA. Therefore, YB-1 promotes the inclusion of exons in
pre-mRNAs.
Much of the research mentioned above used mini-gene in vitro systems to study
the influence of YB-1 on splicing. The importance of YB-1 to splicing the same
pre-mRNA transcripts in vivo was often attenuated compared to that in the mini-
gene in vitro systems. This highlights the importance sequence context to splicing
(Stickeler et al. 2001, Raffetseder et al. 2003, Skoko et al. 2008). Therefore, despite
the affinity of YB-1 for RNA cofactors appear to be critical to the ability of YB-1 to
participate in splicing. Indeed, the association of YB-1 with the C-terminus of ei-
ther translocation liposarcoma protein (TLS) or Ewings Sarcoma proto-oncoprotein
(EWS) has repeatedly been shown to influence pre-mRNA splicing (Figure 1.8.B;
Chansky et al. 2001, Rapp et al. 2002). Both TLS and EWS are prone to fusion with
other proteins. These fusion proteins do not interact with YB-1 and this disrupts the
exonic splicing enhancer activity of YB-1. The association of YB-1 and EWS with
newly transcribed MDM2 pre-mRNA also promotes its splicing to mature MDM2
mRNA (Dutertre et al. 2010). The introduction of a stressor, exposure to camp-
tothecin, disrupts the association of YB-1 and EWS and results in exon-skipping,
mis-splicing, of MDM2 mRNA (Dutertre et al. 2010). This exon-skipping allows
the deregulation of p53 driven transcription of the MDM2 gene from MDM2 pro-
tein production. This is due to the exon-skipping significantly reducing the amount
of appropriately spliced MDM2 mRNA for the duration of exposure to the stres-
sor. The removal of camptothecin restores appropriate splicing of MDM2 mRNA.
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Translation of MDM2 from these transcripts can then proceed thus allowing the
activities of p53 to be attenuated. The ability to inhibit the production of a neg-
ative regulator of p53 would promote many of the functions of YB-1 in cancer. It
is currently unclear as to how many transcripts exhibit exon-skipping when YB-1
binding is disrupted. However, Dutertre et al. (2010) found a number of other genes
where exon-skipping occurrs during camptothecin treatment and, importantly, also
following depletion of YB-1. Therefore, YB-1 may have wide-ranging function in the
promotion of exon inclusion which appears to occur in a number of cellular contexts.
YB-1 can also silence splicing by binding to specific sequences to promote exon
skipping. This function as an exonic splicing silencer requires YB-1 to interact
with other proteins (Figure 1.8.C). By binding to an exonic splicing silencer mo-
tif (TTTT) in exon 10 of the muscle specific receptor tyrosine kinase pre-mRNA,
hnRNP-C can mediate the binding of YB-1 to ”CATC/CACC” motifs that are ad-
jacent to the ”TTTT” motif. This promotes the production of mature mRNA that
lacks exon 10 (Nasrin et al. 2014). The alternatively spliced transcript is important
to the development of neuromuscular junctions in human myocytes. While the func-
tion of enhancing exon exclusion appears to conflict with the previously reported
function of YB-1 as an exonic splicing enhancer, the sequence composition of the
motifs involved are similar with high A/C content. More than 300 RNA transcripts
in the human genome contain similar motifs, TTTT adjacent to CATC or CACC
(Nasrin et al. 2014). A screen of 6% of these (24/378 candidate sequences) detected
alternative exon inclusion or exclusion in almost 40% of the candidate sites (9 out
of 24) when YB-1 or hnRNP-C was depleted with three transcripts requiring the
depletion of both hnRNP-C and YB-1 to promote alternative splicing. YB-1 over-
expression repressed splicing at a C/A-rich motifs (CACACCA; Wang et al. 2013).
Depleting YB-1 represses this effect as does depleting hnRNP-L or hnRNP-C (Wang
et al. 2013). However, the former effect is the stronger of the two.
Summary
YB-1 binds to sequences dominated by C/A to promote or suppress the splicing of
exons. This contrasts with high-throughput studies where YB-1 was found to prefer
binding to pyrimidine (C/U) and guanine rich RNA sequences (Dong et al. 2009, Ray
et al. 2009). The use of recombinant proteins or the absence of cofactor proteins,
which may alter the binding of YB-1 in the high-throughput screens, may account
for this discrepancy. Importantly, while the ability of YB-1 to influence splicing of a
small number of transcripts has been confirmed, two large screens indicate that YB-
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1 may influence the splicing of many more transcripts (Dutertre et al. 2010, Nasrin
et al. 2014).
1.8.3.2 Translation
Requiring a significant metabolic investment, the translation of mRNA transcripts
into polypeptide chains is one of the final steps in the synthesis of proteins from
genes (gene expression). As such, translation is a highly regulated process with the
regulation of translation accounting for as much as 40% of the titre of individual
proteins (Schwanhäusser et al. 2011). The uncoupling of mRNA levels from protein
levels is highly context specific. A recent study into the influence of p53 in translation
found that 70% of the genes that were differentially regulated by doxorubicin or
nutlin-3a exposure, a group that included YBX1 , displayed uncoupling of the levels
of translated proteins from mRNA levels (Zaccara et al. 2014).
Defining the complexity and steps of translation falls outside the scope of this
review. Only the steps of cap-dependent translation initiation, which YB-1 is in-
volved in, will be outlined (Figure 1.9.A; for a comprehensive review of translation
initiation see Jackson et al. 2010). The PABP family are important in translational
initiation as they bind to the 3′ poly(A) tail of mRNAs and facilitate the recruitment
of the eIF4F complex to the 7-methylguanylate cap at the 5′ end of the mRNA. The
eIF4F complex, eIF4B, or, eIF4H are required to melt secondary structures within
the 5′ UTR of the mRNA. At this point the 43S preinitiation complex can be re-
cruited to the mRNA whereupon it scans the mRNA 5′ to 3′ to locate the initiation
codon. The following steps involve the maturation of a translation ready ribo-
some and creation of a polypeptide chain from the mRNA transcript. Importantly,
translation initiation is the step that limits the production of protein from mRNA
transcripts (Jackson et al. 2010).
YB-1 is located in mRNPs, which are complexes that comprise RNA and pro-
tein, and YB-1 is known to be critical to the formation of mRNPs (Minich &
Ovchinnikov 1992, Evdokimova et al. 1995). YB-1 can inhibit or promote the trans-
lation of mRNA transcripts. Generally, when the amount of YB-1 in an mRNP is
low, translation of the mRNA transcript is promoted and when YB-1 is present in
an RNP in abundance, translation of the bound transcript is repressed (Minich &
Ovchinnikov 1992, Evdokimova et al. 1998, Pisarev et al. 2002). YB-1 is thought
to primarily promote translation initiation by increasing the efficiency of 5′ to 3′
scanning by the 43S preinitiation complex as YB-1 masks stretches of sequence that
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Figure 1.9: YB-1 influences the initiation of cap-dependent translation. A, the main
steps in the initiation of cap-dependent translation from mRNA transcripts. B, YB-1 can
improve the scanning rate of the 43s initiation complex to promote translational initiation.
C, YB-1 can inhibit translation by (i), inhibiting the binding of eIF4G at the 5′-UTR, (ii),
by blocking the binding of PABP to the poly-A tail on the 5′-UTR, or (iii), by interacting
with 5′ fragments of tRNA through an unkown mechanism. The 5′ methyl guanidine cap
(m7G) and poly-adenylated tail at the 3′ of mRNA transcripts(AAA) are shown. The
start codon is also highlighted (START).
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do not contain the initiation codon (Figure 1.9.B; Svitkin et al. 1996, Kovrigina
et al. 1996, Evdokimova et al. 1998). The general ability of YB-1 to promote trans-
lation has been verified for a small number of specific transcripts. The interaction
of YB-1 with DEAD box RNA helicase (DDX6) promotes the translation of factors
that allow self-renewal of epidermal progenitor cells (Wang et al. 2015b). YB-1
promotes the cap-independent translation of the mesenchymal cell markers SNAI1
and TWIST (Evdokimova et al. 2009a). Therefore, YB-1 appears to promote the
translation of transcripts that are involved in metastasis.
Increasing the YB-1:RNA ratio, reminiscent of that in free mRNPs, inhibits
translation from mRNA transcripts in vitro (Nekrasov et al. 2003) and in vivo
(Figure 1.9.C i; Davydova et al. 1997). The interaction of YB-1, via its C-terminus
(Izumi et al. 2001), and PABP is the primary mechanism via which YB-1 inhibits
translation (Minich & Ovchinnikov 1992, Skabkina et al. 2003, Skabkina et al. 2005,
Kedersha & Anderson 2007, Chernov et al. 2008a, Svitkin et al. 2009, Maher-Laporte
et al. 2010). The PABP family includes many homologues which most studies assume
have conserved function, however, recent studies indicate that the many members of
the PABP family possess unique functionality (Gorgoni et al. 2011). The differences
between the interaction of YB-1 and the PABP family homologues have not been
studied.
Inhibition of translation by YB-1 in free mRNPs seems to occur as YB-1 displaces
the translation initiation factor eIF4G, a component of the eIF4F complex, from
mRNA (Figure 1.9.C ii; Nekrasov et al. 2003). In rabbit reticulocyte translation
systems, YB-1 has been shown to be central to preventing translation in free mRNP
(Minich & Ovchinnikov 1992). The translational inhibition that characterised free
mRNPs remains following the removal of most proteins, other than YB-1, from the
mRNP.
YB-1 inhibits the translation of YBX1 mRNA (Chapter 1.7.1) by binding to
two elements in the transcript. The first element is in the 3′ UTR of YBX1 mRNA
(UCCA[A/G]CAA; Figure 1.9.C ii; Skabkina et al. 2005, Lyabin et al. 2011).
By binding to this element, YB-1 excludes PABP from the poly(A) tail of YBX1
mRNA. PABP can alleviate this inhibition by binding to an element (1149 - 1204
nucleotides) that overlaps with the YB-1 binding elements (Lyabin et al. 2011). YB-
1 can also bind to elements in the 5′ UTR of YBX1 mRNA to inhibit its translation
(Fukuda et al. 2004). YB-1 also influences the translation of other transcripts, such
as TGF-β mRNA which encodes a signalling protein that can promote an invasive
phenotype in cells (Singh & Settleman 2010). The 5′ UTR of the TGF-β mRNA
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contains a strong and a weak YB-1 binding site. In tubular kidney cells, YB-1 allows
translation by binding to the former while binding to the latter inhibits translation
(Fraser et al. 2008). Therefore, the regulation occurring via binding to the 5′ UTR
element likely represents an alternative mechanism by which YB-1 can influence
translation.
An alternative mechanism for YB-1 inhibiting translation relates to the interac-
tion of YB-1 with fragments from tRNAs. During or following stress, YB-1 interacts
with the 5′ fragments from tRNAs that have been cleaved by angiogenin (Ivanov
et al. 2011, Ivanov et al. 2014, Lyons et al. 2016). The interaction of YB-1 and tRNA
fragments appears to inhibit translation but the mechanism is not fully elucidated
(Figure 1.9.C iii; Ivanov et al. 2011, Lyons et al. 2016). The importance of the
interaction between YB-1, fragments of tRNAs, and translational inhibition in cells
that have undergone stress, is also currently unknown.
To date, the translational inhibition caused by YB-1 has been shown to be rele-
vant to oncogenic transformation. The chicken YB-1 homologue appears to block the
oncogenic transformation of cells by inhibiting translation of specific genes (Bader
& Vogt 2004, Bader & Vogt 2005, Bader & Vogt 2008).
In mammals, proteins containing selenocysteines function in redox reactions and
these proteins may be important in some cancers (reviewed in Lu & Holmgren 2009).
YB-1 may facilitate the inclusion of selenocysteine during translation. As such, YB-
1 has the potential to regulate a small group of 25 proteins in humans (Arnér 2010).
YB-1 interacts with glutathione peroxidase transcripts at a selenocysteine insertion
sequence in the 3′ UTR to allow UGA codons to insert selenocysteine rather than
a translation termination (Shen et al. 1998, Shen et al. 2006). The relevance of this
observation to YB-1 and its role in cancer is currently unclear.
Translation via an internal ribosome entry site (IRES), provides an alternative
mechanism to cap-dependent translation during stress and mitosis (Subkhankulova
et al. 2001, Grover et al. 2008). Research has confirmed that YB-1 can promote
translation from IRESs although our current knowledge of YB-1 interactions with
IRESs is limited to a small number of transcripts and the mechanism is yet to be
fully elucidated. However, rather than being a general mechanism for translation via
IRESs, the mechanism is sequence specific, as YB-1 does not promote translation
from all mRNA transcripts that contain IRESs (Cobbold et al. 2010).
YB-1 enhances translation via IRESs from transcripts that are consistent with
YB-1 promoting mitosis and cell survival during stress. YB-1 can promote the
translation of MYC mRNA via an IRES and a mutation that occurs within the IRES
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in multiple myeloma, further increases the ability of YB-1 to promote translation
via the mutated IRES (Cobbold et al. 2008, Cobbold et al. 2010). During hypoxia
YB-1 promotes the translation of p16INK4a mRNA by binding to an IRES in its
5′ UTR (Bisio et al. 2015). A mutation in the 5′ UTR of p16INK4a mRNA, which
is common in melanomas, reduces the binding efficiency of YB-1 with the IRES,
and this may lessen the ability of p53 and YB-1 to control senescence and cell cycle
checkpoints (Bisio et al. 2015). The presence of YB-1 in a complex with PTB during
apoptosis, activates the translation of a number of apoptotic proteins via IRESs
(King et al. 2014). The rules surrounding this interaction are yet to be elucidated
but the role for YB-1 in facilitating the apoptotic signalling cascade seems to conflict
with YB-1 inhibiting apoptosis and other cell death programs. However, the ability
of YB-1 to inhibit the initiation of apoptosis may be separate from its role in the
apoptotic signalling cascade once it has been triggered.
Phosphorylation may provide YB-1 with the ability to interact with different
aspects of the translational machinery. Phosphorylated YB-1 can bind to the 7-
methylguanylate cap at the 5′ end of mRNA but it does not inhibit cap-dependent
translation (Evdokimova et al. 2006b). However, this phosphorylated YB-1 could
still inhibit the use of an IRES on a poliovirus (Evdokimova et al. 2006b). Chicken
YB-1 that is phosphorylated at S99 also lacks the ability to inhibit cap-dependent
translation (Bader & Vogt 2008).
Summary
YB-1 can promote and inhibit the translation of mRNA transcripts. YB-1 appears
to promote translation of mRNA transcripts through two mechanisms. The first is
to improve the scanning rate of the 43S initiation complex during the initiation of
cap-dependent translation (Figure 1.9.B). The second mechanism relies on YB-1
interacting with IRESs. The ability of YB-1 to inhibit translation appears to require
multiple YB-1 molecules to bind to mRNA transcripts. This inhibits the interac-
tion of proteins that initiate cap-dependent translation (Figure 1.9.C). Therefore,
there is little evidence to suggest that protein interactions are integral to the re-
cruitment of YB-1 to mRNA transcripts during translation initiation. Instead, the
ability of YB-1 to bind to RNA (Chapter 1.8.1) appears to be central to its ability
to participate in translation.
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1.8.3.3 mRNA stability
YB-1 is likely to bind to pre-mRNA transcripts during their transcription (Chapter
1.8.3.1). YB-1 also appears to be present when mRNA transcripts are degraded. In
vitro assays indicate that YB-1 possesses endoribonuclease (Moraes et al. 2003) and
exonuclease (Izumi et al. 2001, Gaudreault et al. 2004) activities. However, these
observations are inconsistent with the vast majority of research which indicates that
YB-1 forms stable associations with RNA and DNA. This section highlights the role
of YB-1 in protecting RNA from degradation.
The ability of YB-1 to protect RNA from degradation is integrally linked to its
multiple roles in translation. The recruitment of YB-1 to mRNA transcripts leads
to mRNP formation and translational inhibition (Chapter 1.8.3.2), while also
protecting the mRNA transcripts in these translationally quiescent mRNPs from
degradation (Figure 1.10.A; Evdokimova et al. 2001, Evdokimova et al. 2006a,
Evdokimova et al. 2009a). This protection is maximal when the number of YB-1
molecules that bind to an mRNA reaches sufficient density for YB-1 to homodimerise
and form a tight structure which excludes other factors from accessing the RNA
(Skabkin et al. 2004). Therefore, when sufficient YB-1 molecules are available, YB-
1 can protect RNA from degradation though its general ability to bind RNA.
YB-1 can also protect capped-mRNA from degradation by binding to specific mo-
tifs (Figure 1.10.B; Chen et al. 2000, Capowski et al. 2001, Coles et al. 2004). YB-
1 protects Granulocyte-Macrophage Colony-Stimulating factor (GM-CSF ) mRNA
from degradation by binding to an AU-rich element in the 3′ UTR (Capowski
et al. 2001). YB-1 can also transactivate the GM-CSF gene by binding to its pro-
moter (Diamond et al. 2001). Therefore, YB-1 regulates the GM-CSF gene at
multiple levels. The ability of YB-1 to protect RNA from degradation is also high-
lighted by research showing that during hypoxia, tRNA may be cleaved to produce
fragments that can bind to YB-1. Thereby displacing YB-1 from other transcripts
which may then be at risk of degradation (Goodarzi et al. 2015).
The importance of YB-1 as a protector of mRNA is not fully defined but YB-1
has been observed to act in concert with other proteins. Nucleolin and YB-1 bind
to a response element in the 5′ UTR of IL-2 mRNA and facilitate the formation of
a mRNP complex that is stabilized in T-cells (Figure 1.10.C i; Chen et al. 2000).
YB-1 and other proteins, including hnRNP-K, protect human preprorenin mRNA
via 3′ UTR binding (Figure 1.10.C ii; Skalweit et al. 2003). YB-1, IGF2BP1, HN-
RNPU, SYNCRIP, and DHX9 associate with a coding region instability determinant
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Figure 1.10: YB-1 protects mRNA transcripts from degradation. A, many YB-1
molecules binding to a single mRNA transcript leads to a translationally silenced mRNP
that is also protected from degradation. B, YB-1, in addition to other RNA-binding pro-
teins, can protect mRNA transcripts from degradation. C, selected mRNA transcripts
that YB-1 is known to protect from degradation. i, the IL-2 mRNA transcript can be
protected from RNA degradation when YB-1 and nucleolin bind to a response element in
its 5′ UTR. ii, the pre-prorenin mRNA transcript can be protected from RNA degradation
when YB-1 and hnRNP-K bind to the 3′ UTR.
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in the MYC mRNA to hold the transcript in the non-polysomal, or translation-
ally quiescent, fraction and block translation coupled degradation of MYC mRNA
(Weidensdorfer et al. 2009). These examples show YB-1 stabilising RNA transcripts
by binding to them and aiding mRNP formation. It must be also noted that YB-1
is a component of larger cellular structures that are involved in RNA stability.
In addition to facilitating the translation of a suite of mRNA transcripts during
stress, many via IRESs, YB-1 is also a constituent of RNA and protein foci that
form in the cytoplasm of cells following stress (Figure 1.11; reviewed in Anderson
et al. 2015). Processing bodies are foci that form in the cytoplasm of mammalian
cells which are thought to degrade RNA that has been primed for degradation
(Anderson et al. 2015). Processing bodies are more frequent in the cytoplasm of cells
following stress and while YB-1 is found in processing bodies, its function within
them is currently uncharacterised (Yang & Bloch 2007, Kato et al. 2010, Bann
et al. 2014).
Stress granules also form in the cytoplasm of cells in response to stress and they
are enriched for RNA, RNA binding proteins, and proteins from translationally
stalled mRNA transcripts (Figure 1.11; Kedersha & Anderson 2007, Anderson
et al. 2015). Part of the function of stress granules appears to be the preservation of
cellular resources when translation stalls during stress. The mRNA transcripts from
the stalled ribosomes are protected from degradation while in stress granules, and
this allows translation to rapidly resume once the stress has passed. The composition
of stress granules is highly dynamic with their constituents in a constant state of flux
(Kedersha & Anderson 2007, Anderson et al. 2015, Bounedjah et al. 2014). However,
YB-1 is a consistent component of stress granules (Kedersha & Anderson 2007), and
gold-immunostaining of YB-1 in transmission electron microscopy confirms that the
density of YB-1 is elevated in stress granules compared to the rest of the cytoplasm
(Figure 1.11; Bounedjah et al. 2014). While in stress granules YB-1 appears to
have unique protein interactions (Tanaka et al. 2014). Therefore, YB-1 is aggregated
in stress granules while the remaining cytoplasmic YB-1 is more diffuse.
Despite YB-1 being a component of stress granules, an abundance of YB-1
in the cytoplasm directly inhibits the formation of stress granules (Figure 1.11;
Bounedjah et al. 2014, Tanaka et al. 2014). Stress granules form from the aggre-
gated remains of polysomes that have disassociated during stress. The presence of an
excess of YB-1 in the cytoplasm may stabilise the mRNA and proteins from disasso-
ciated polysomes so that they form mRNPs rather than stress granules (Bounedjah
et al. 2014). The role and function are currently unclear for this pool of cytosplamic
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Figure 1.11: YB-1 can promote or inhibit the formation of stress granules during stress
events.
YB-1 that does not appear to be bound to RNA.
YB-1 has also been shown to promote the formation of stress granules. It has
been suggested that YB-1 can aid in their formation by moving mRNPs along
microtubules, termed microtubule-mediated stirring, to stress granules (Chernov
et al. 2009). However, this directly contradicts the findings from Bounedjah et al.
(2014) which show that the formation of mRNPs following stress inhibits the for-
mation of stress granules. Irrespective, YB-1 appears to promote stress granule
formation by maintaining cellular levels of Ras GTPase-activating protein-binding
protein 1 (G3BP1; Figure 1.11). YB-1 promotes the translation of G3BP1 by bind-
ing to the 5′ UTR of G3BP1 mRNA (Somasekharan et al. 2015). This is critical, as
G3BP1 is thought to be the ”nucleator” protein around which stress granules form.
Depleting YB-1 in human sarcoma cells inhibits the formation of stress granules
via reductions in G3BP1 (Somasekharan et al. 2015). Therefore, in excess, YB-1
is a competitor for stress granule formation while also indirectly promoting their
formation by maintaining levels of G3BP1 around which stress granules nucleate.
The interaction of YB-1 with short RNA sequences, such as miRNA (Yuan et al.
2014) and cleaved tRNA sequences (Ivanov et al. 2011, Ivanov et al. 2014, Goodarzi
et al. 2015, Lyons et al. 2016), may also influence the formation and function of
stress granules. By binding to tRNA fragments, YB-1 appears to promote stress
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granule formation (Figure 1.11; Lyons et al. 2016). Goodarzi et al. (2015) pro-
poses that the significance of YB-1 in stress granule formation is directly influenced
by the production of stress-induced tRNA fragments. In the absence of these frag-
ments, YB-1 remains bound to transcripts that promote metastatic characteristics
during hypoxia. In contrast, the presence of stress-induced tRNA fragments dur-
ing hypoxia attract YB-1 and the metastatic transcripts are at risk of degradation
during hypoxia.
Within stress granules, a subset of mRNAs that encode critical proteins still
need to be translated. The dynamic nature of stress granules appears to allow
mRNA transcripts that are critical to cell survival to exit the stress granule so that
translation can resume (Anderson et al. 2015). YB-1 in stress granules has also been
directly implicated in facilitating the translation of heat-shock protein 70 mRNA,
which is involved in protein folding (Tanaka et al. 2014). mTORC1 is also thought
to recruit proteins to stress granules to specifically translate mRNA transcripts with
5′ terminus oligopyrimidine motifs, such as the one in YBX1 mRNA which is known
to be under control of mTORC1 signalling (Chapter 1.7.2.1). Therefore, YBX1
mRNA in stress granules is likely to be preferentially translated by translational
machinery that is activated by the mTORC1 signalling pathway.
Stress granules appear to be important to cell survival. Overexpression of 2-
oxoglutarate and Fe(II)-dependent oxygenase domain containing 1 (OGFOD), which
YB-1 associates with in stress granules, promotes the phosphorylation of eIF2α with-
out aiding in the formation of stress granules during stress (Wehner et al. 2010).
Following the removal of the stressor, overexpression of OGFOD causes phosphory-
lation of eIF2α to remain for longer and this contributes to a lag in the resumption
of cellular translational activity. The survival of cells is lowered as they recover from
stress (Wehner et al. 2010). RNA stability, particularly during stress, also appears
to be important in cancer. The expression of YB-1 and G3BP1 is highly correlated
in human sarcomas, and like YB-1, elevated G3BP1 expression correlates with poor
survival (Somasekharan et al. 2015).
Summary
YB-1 promotes RNA stability through general and specific mechanisms. The im-
portance of the ability of YB-1 to promote RNA stability has not been extensively
researched in cancer. However, the research that has been performed indicates that




The key points from this literature review are summarised as:
• Increased levels of YB-1 are correlated with aggressive cancers;
• This correlation appears to relate to four main functions of YB-1 in cancers;
1. YB-1 can drive cancer development by promoting genetic instability.
2. YB-1 promotes cell division.
3. YB-1 promotes cell survival during stress, such as chemotherapy.
4. YB-1 promotes an invasive phenotype in cancer cells.
• YB-1 can affect these functional changes in cancer cells via multiple mecha-
nisms.
The correlation of elevated YB-1 with poor patient survival has been made in a
wide range of cancers (Chapter 1.3). The functional reasons for this correlation
appear to be multiple (Chapter 1.4) as observations from clinical samples indi-
cate that YB-1 has the ability to influence events at the cellular and tumour level.
Broadly, the research has shown that YB-1 can promote the development of cancer,
the rate at which cancer cells divide, the survival of cancer cells in response to a va-
riety of stresses, and the development of invasive phenotypes in cancer cells. At the
molecular level the ability of YB-1 to bind to RNA and DNA, in a general and also a
sequence-specific manner, supplies multiple mechanisms to explain the influence of
YB-1 at the cellular and tissue level in cancer. This review attempted to summarise
the functions of YB-1, however, the ability of YB-1 to act as a transcription factor
has been widely reported. As a result, this aspect of YB-1 biology has been heavily
condensed for this review. In contrast, the activities of YB-1 that is binding RNA
have been given a greater relative focus for this review.
The contrast between the depth of reports for YB-1 as a transcription factor
and its other roles may reflect the reality of YB-1 function. An alternative, and
compelling, viewpoint, is that the importance of YB-1 as an RNA binding protein
is under-appreciated (Dolfini & Mantovani 2013a, Dolfini & Mantovani 2013b). The
primacy that transcriptional effects are given in relation to gene expression is not
limited to YB-1 research. However, recent work quantifying the concentration, pro-
duction, and stability of mRNAs and proteins for ∼5000 genes in single samples,
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found that RNA transcription and concentration predicts less than half of the varia-
tion in protein concentrations (Schwanhäusser et al. 2011, Vogel et al. 2010). These
studies also confirm that the levels of many proteins are highly uncoupled from the
levels of their mRNA transcripts. Therefore, post-transcriptional regulation of gene
expression (splicing, RNA stability, translational silencing, translation activation)
is a critical factor influencing the cellular levels of proteins. The ability of YB-1
to regulate post-transcriptional gene expression could be more important than is
currently appreciated.
In most cases, the effects of YB-1 at the cellular level may be explained by mul-
tiple molecular capabilities of YB-1. One explanation for the multiple molecular
functions of YB-1 may relate to phosphorylation of YB-1. High-throughput studies
confirm that YB-1 is phosphorylated at multiple locations in many cellular contexts
while numerous reports that focus on YB-1 highlight that, in general, phosphoryla-
tion can modulate the function of YB-1 (Chapter 1.7.2.1). However, the function
of only two of these phosphorylation sites, S102 and S165, is partially characterised
and there is currently a single article that focuses on phosphorylation of YB-1 at
S165 (Prabhu et al. 2015). The importance of phosphorylation at S102 in cancer
is supported by numerous studies. However, the phosphorylation of YB-1 at S102
has been shown to activate YB-1 as a transcription factor, as a binding factor of
microtubules that interact with the centrosome, and as a promoter of translational
initiation. Therefore, a specific function of a single YB-1 molecule which bears a
phosphorylation at S102 is unclear. The presence of phosphorylation at other sites,
in addition to S102, may more accurately explain the functional states of YB-1.
Furthermore, phosphorylation of YB-1 at these other sites is likely to modify the
function of the protein. Therefore, the functional consequences of phosphorylation
at these other sites warrants further investigation.
1.10 Thesis scope
The research that is presented in this thesis primarily focuses on YB-1 in breast
cancer or a breast cancer cell line (MDA-MB231). The chapter titles are:
• Chapter 3, Immunohistochemical analysis of YB-1 in breast tumours;
• Chapter 4, Identification of YB-1 interacting proteins in the cytoplasm and
nucleus;
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• Chapter 5, YB-1 confers resistance to genotoxic stress treatment of MDA-
MB231 cancer cells;
• Chapter 6, Identification of YB-1 interacting proteins during cisplatin expo-
sure;
• Chapter 7, Analysis of functional interactions between YB-1, FAM120A,
TRIM28, and C1QBP.
The reports that YB-1 is elevated in cancers are consistent. Chapter 3, ad-
dresses the contradictory reports regarding the presence of YB-1 in normal tissues.
It then uses IHC to examine the subcellular localisation and levels of YB-1 in can-
cerous tissues. The subcellular localisation of YB-1 in tumours is important. This
is due to the molecular functions that YB-1 is proposed to perform requiring that
YB-1 be in either the nucleus or the cytoplasm. Furthermore, the tertiary structure
and protein interactions of YB-1 appear to alter the prognostic sensitivity of IHC.
This led to an interest in the protein-protein interactions (PPI) of YB-1.
In Chapter 4 an affinity-purified antibody against YB-1 has been used to ex-
amine the PPI and phosphorylation state of endogenous YB-1 in the cytoplasm
and nucleus of cancer cell lines. This work highlights that YB-1 is phosphorylated
at multiple sites while it is in the cytoplasm and nucleus of cultured cells. The
PPI of YB-1 also provide evidence that YB-1 is likely to participate in most of the
molecular mechanisms that have been reported in this review.
The remaining chapters focus on the role of YB-1 in drug sensitivity in a breast
cancer cell line, MDA-MB231. The importance of YB-1 to MDA-MB231 cells during
exposure to chemotherapeutic drugs is researched in Chapter 5. Using the knowl-
edge gained in Chapter 5, the experiments in Chapter 6 assess how cisplatin
exposure alters the PPI of YB-1 in MDA-MB231 cells. The results confirm that the
PPI, and most likely the function, of YB-1 alters in subtle rather than coarse ways
during cisplatin exposure. Finally, Chapter 7 tests selected proteins that copurify
with YB-1 during cisplatin exposure to see whether they also influence the response





Unless otherwise stated, the cells used in this thesis were grown in DMEM me-
dia (Life Technologies) supplemented with 10% heat-inactivated and sterile-filtered
bovine foetal calf serum (Moregate, New Zealand). The cell lines were adherent and
passaged when 75 - 90% confluent using 0.25% Trypsin-Ethylenediaminetetraacetic
acid (EDTA), pH 7.2 - 8.0 (Life Technologies) for up to 5 minute (min). Growing
cells were discarded once their passage reached 22. Following retrieval from storage
in N2(l), the growing cells were maintained at 37
oC for a minimum of 4 days before
being used in experiments. The seeding ratios that were used for the A549 and
MDA-MB231 cell lines are shown in Table 2.1.
When proteins were required from cells that were being cultured, they were lifted
from the cell culture vessel using 0.25% Trypsin-EDTA for up to 5 min. A small
aliquot (30 - 50 µl) was set aside and the remainder of the cells sedimented using
centrifugation at 220 g for 5 min at room temperature. The cells in the aliquots were
counted using a haemocytometer and the sedimented cells were then resuspended
and sedimented again in 37oC phosphate-buffered saline (PBS). The cells were then
lysed in 1 × radioimmunoprecipitation assay buffer (RIPA) at a concentration of 10
000 cells per µl RIPA (Table 2.2). To allow the Benzonase to act, the DNA and
RNA was removed from the lysates via an incubation step, on ice for 30 min. The
insoluble cellular debris was removed from lysates by centrifugation at 12 000 g for
10 min at 4oC. The lysates were then frozen at -20 - -80oC or immediately used for
downstream applications.
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Table 2.1: The number of MDA-MB231 or A549 cells that were seeded for various growth
vessel formats and also for different experiment types.





























1 0.691 1.057 2.083
T175 175 121 185 364.6
T75 75 51.8 79 156.3
6-well 9.6 6.63 10.15 20
24-well 2 1.38 2.1 4.167
96-well 0.32 0.22 0.342 0.667
The columns to the right of the double lines highlight three experiment types. Proliferation
was used for the expansion of cell stocks. 50% confluence was used for experiments where
the cells were required to be ∼ 90% confluent within 48 hrs. Transfection was used
for experiments that involved the depletion of mRNA transcripts using silencing RNA
duplexes (Chapter 2.8).
2.2 Antibodies
The antibody preparations that were used are summarised in Table 2.3. Multiple
antibodies were utilised to detect YB-1 and three of these were produced in-house.
The first was an antibody, raised in rabbit, against C-terminus of YB-1 (YB1C ).
The second was an antibody, raised in rabbit, against N-terminus of YB-1 (NYB1).
The third and final antibody was antibody, raised in sheep, against N-terminus of
YB-1 (NYB1sheep). The first 12 amino acids in the N-terminal of YB-1 were used as
the immunising peptide for NYB1 and NYB1sheep (MSSEAETQQPPA). YB1
C was
raised against 299 - 313 aa of YB-1 (CDGKETKAADPPAENS). These polyclonal
antibodies were affinity-purified and their use has been validated in Cohen et al.
(2010) and Woolley et al. (2011).
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Table 2.2: Recipes for two cell lysis buffers that were used to lyse cells.
Stock 5×RIPA 5×conc. 1×RIPA Final Conc.
Standard
1 M Tris-HCl, pH 7.5 500µl 250 mM ← 50 mM
5 M NaCl 300µl 750 mM ← 150 mM
20% NP40 500µl 5% ← 1%
10% Deoxycholate 500µl 2.5% ← 0.5%
10% SDS 200µl 0.5% ← 0.1%
ultrapure H2O 8ml
Low detergent
1 M Tris-HCl, pH 7.5 500µl 50 mM
5 M NaCl 300µl 150 mM
20% NP40 250µl 0.5%
10% Deoxycholate 100µl 0.1%
ultrapure H2O 8833µl
The first listed recipe is for a standard RIPA. The Low detergent variant that is listed
was used for immunoprecipitation (IP). The 5 × RIPA was often frozen immediately af-
ter preparation and it was used once thawed or discarded. Once diluted to the working
concentration (1 × RIPA), the buffer was discarded after 12 hrs. Benzonase was added
to 1 × RIPA at a rate of 100 U per mL immediately prior to use. Complete Protease In-
hibitor EDTA-free and PhosStop were also added to 1 × RIPA following the manufacturers
reccomendations.
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Table 2.3: A list of the antibody preparations that were used for immunofluorescence
and immunoblotting.
Target Ab.Cat.No Species IF Dilution IB Dilution
NYB1 in house rabbit 1:800 1:3333
YB1C in house rabbit 1:1500
NYB1sheep in house sheep 1:333
YB1S102 C34A2 rabbit* 1:1500
YB-1 [59-Q] sc-101198 mouse* 1:250
C1qBP ab24733 mouse* 1:500 1:10000
FAM120A HPA019734 rabbit 1:80 1:500
TRIM28 A300-274A rabbit 1:1000 1:5000
γH2AX JBW301 mouse 1:800
γH2AX AB2893 rabbit 1:1000
pan H3 [A3S] 05-928 rabbit* 1:5000
β-Actin [AC-15] ab6276 mouse* 1:20000
β-Tubulin [E7] E7 mouse* 1:2000
p53S15 #9284 rabbit 1:1000
Abbreviations; * = monoclonal, IF = immunofluoresence, IB = immunoblot, in house
= affinity purified antibodies prepared in the laboratory.
2.3 Polyacrylamide gel electrophoresis and immunoblot-
ting
2.3.1 SDS-PAGE
Protein lysates were prepared in RIPA buffer (see Table 2.2). Denaturation and
reduction was carried out by the addition of denaturing loading buffer containing
dithiothreitol (DTT) and the samples were placed in boiling water for 5 min (final
concentration; 50 mM Tris-HCl, 0.1% bromophenol blue, 10% glycerol, 100 mM
DTT; modified from Weber & Osborn 1969). Sodium dodecyl sulfate Polyacry-
lamide gel electrophoresis (SDS-PAGE) gels, 15 cm long and 0.75 mm thick, were
prepared with 6% to 10% polyacyrlamide depending on the size of the proteins that
were being resolved. These SDS-PAGE gels were used to separate proteins using
electrophorsis at 125 V for approximately 2 hrs in SDS-PAGE buffer (25 mM Tris,
192 mM glycine, 0.1% SDS, pH 8.3 Laemmli 1970). The Precision Plus Protein Dual
Color Standard (Biorad) was used to monitor the migration of proteins. When re-
quired, proteins were stained in-gel by incubation for 4 - 24 hrs in 30 ml of a colloidal
coommassie G-250 stain (34% methanol, 17% [w/v] (NH4)2SO4, 3% phosphoric acid,
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0.1% coomassie G-250 [Biorad]). The gels were destained in ultrapure H2O.
2.3.2 Non-reducing SDS-PAGE
Non-reducing SDS-PAGE was undertaken as outlined in Chapter 2.3.1, however,
DTT was omitted from the loading buffer and the samples were kept on ice during
sample preparation. Non-reducing SDS-PAGE was necessary due to the presence of
reducible cross-links (for details see Figure 2.2) in lysates containing cross-linked
proteins. Samples that were not cross-linked were loaded in each gel. These sam-
ples ensured that any altered migration in cross-linked samples was due to in vitro
chemical modification with cross-linker, rather than the omission of the reducing
agent.
2.3.3 Blue-native-PAGE
Blue-native PAGE (BN-PAGE) was developed following Swamy et al. (2006). Pre-
cast 4 - 16% polyacrylamide gels and buffers were purchased from Invitrogen. Fol-
lowing optimisation, 1% digitonin and 2 units Benzonase per 100µl of lysis buffer
were included in the lysis buffer. Coomassie G-250 was added to the sample loading
buffer. The addition of Benzonase resulted in the removal of both RNA and DNA
from the lysates.
2.3.4 Immunoblotting
Proteins separated by PAGE were transferred to nitrocellulose or polyvinylidene
fluoride membrane using Towbin’s buffer (20% MeOH, 25 mM Tris, 192 mM glycine,
0.1% SDS, pH 8.3; Towbin et al. 1979, Renart et al. 1979). The successful transfer of
proteins was confirmed by incubating the membranes in Ponceau S staining solution
(0.1%(w/v) Ponceau S in 5%(v/v) acetic acid) for 5 min. The proteins were detected
using the Western Breeze kit (Life Technologies) and the chemiluminescent signal
was recorded using Medical X-Ray Film General Purpose Blue (MXB, Kodak). The
migration of proteins was confirmed using either the Precision Plus Protein Dual
Color Standard (Biorad) or MagicMark XP (Life Technologies). When YB1S102 or
shrimp alkaline phosphatase treatment (see Chapter 2.5) was used, the proteins
were transferred to nitrocellulose membrane and non-specific antibody binding was
inhibited by a blocking buffer (1% bovine serum albumin, 0.1% Tween20, 50 mM
Tris-Cl, pH 7.6, 150 mM NaCl). For these experiments, a secondary antibody that
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was conjugated to anti-horseradish peroxidase was used at 1:10 000 in 0.5% bovine
serum albumin in tris-buffered saline, pH 7.6 (TBS) with 0.1% Tween20 for 30 min.
To prepare digital images of films, a white-light transilluminator in a Gel Doc
XR Gel Documentation System provided illumination and the images were captured
using the 4 megapixal charge-coupled device camera that was provided with the Gel
Doc XR (Biorad). Densitometry was performed using Quantity One 1-D analysis
software (Biorad).
2.4 Northern blotting
Northern blotting were used to detect YBX1 mRNA. To prevent RNases from de-
grading the RNA RNase contamination was controlled by the following measures:
• All glassware and metalware was baked at 180oC for 3 hrs;
• Lids from bottles and stirring bars were treated with RNase-away (Thermo
Scientific);
• All plasticware was RNase-free;
• All solutions were prepared using Diethylpyrocarbonate-treated ultrapure H2O;
• The gel electrophoresis tank was washed with detergent, rinsed well, and
soaked in 3% H2O2 for 10 min at room temperature. Diethylpyrocarbonate-
treated water was then used to rinse the tank.
Messenger RNA was extracted from the cell lines using the Dynabeads mRNA
direct kit as per the manufacturer’s instructions (Invitrogen). The mRNA concentra-
tion was measured using a Nanodrop (Thermo-Scientific). Five-hundred nanograms
of mRNA was denatured in loading buffer (50% deionised formamide, 6% formalde-
hyde, 1*MOPS, 0.05% bromophenol blue, 1% glycerol) at 65oC for 10 minutes. The
denatured DNA was separated on a 25 × 15 cm 1% agarose denaturing RNA gel
at 120 V until the marker dye was 2 - 3 cm from the end of the gel. The mRNA
was then blotted to a positively-charged nylon membrane (Roche) overnight using
a semi-dry transfer. The mRNA cross-linked to the membrane using 120 mJ/cm2
240 nm UV.
A digoxigenin-labelled probe was synthesised using a PCR DIG probe synthesis
kit (Roche) and primers directed against 734 - 943 nucleotides of YBX1 mRNA
(5’-TATGCAGCAGACCGTAACCA-3’ and 5’-GCACAGGAGGGTTGGAATAC
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-3’). The incorporation of digoxigenin into the PCR fragment was confirmed by
the retardation of its migration compared to an unlabelled PCR fragment. This
probe binds to full-length YBX1 mRNA (ENST00000321358) as well as three other
proposed splice variants (ENST00000436427, ENST00000332220, ENST000004679
57). The probe was hybridised at 50oC in DIG easy Hyb buffer (Roche) with 1 µl
per 6 ml of buffer for 6 hrs. The DIG label was detected using a chemiluminescent
enzyme immunoassay (DIG Luminescent Detection Kit, Roche) and Medical X-
Ray Film General Purpose Blue (MXB, Kodak). To control for variance in mRNA
loading, a DIG-labelled probe was prepared against 787 - 917 nucleotides of β-
actin mRNA. The YBX1 mRNA digoxigenin-labelled probe was stripped from the
membrane using two incubations at 80oC for 60 min in 50 mM Tris-HCl, pH 7.5,
with 50% deionized formamide and 4.5% SDS. Following two 5 min incubations in
2 × Saline-Sodium Citrate buffer (pH 7.0) the membrane was then ready for a new
probe to be hybridised.
2.5 De-phosphorylation of proteins from cultured
cells
Two approaches were taken to remove phosphate groups from phosphorylated pro-
teins. The first used lysates that were prepared in 1 × RIPA (Chapter 2.1).
Shrimp alkaline phosphatase was added so that the lysates had 5000 cells per µL
and 0.25 U of shrimp alkaline phosphatase per µl (Fermentas, #EF0511; 1 × RIPA,
1 × EDTA-free Complete, 10 mM MgCl2). phosSTOP was added at a 2 × concen-
tration as required during the experiments. These lysates were incubated at room
temperature for 1 hr prior to being used for immunoblotting.
The second approach included preparing and separating protein lysates for im-
munoblotting (Chapter 2.1 and Chapter 2.3). Following the inhibition of non-
specific antibody binding, the membranes were rinsed twice for 5 min in double-
distilled H2O. The membranes were then incubated for 1 hr at room temperature
in a buffer containing 20 U per ml shrimp alkaline phosphatase (10 mM Tris-HCl
[pH 7.5 at 37oC], 10 mM MgCl2, 1 mg/ml bovine serum albumin (BSA)). The im-
munoblotting protocol resumed following a further two 5 min washes in TBS with
1% bovine serum albumin and 0.1% Tween20 (Sigma-Aldrich).
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2.6 DNA-affinity purification of YB-1
The interaction of YB-1 with DNA was investigated using a biotinylated DNA
probe (5’-Biotin-CCTCCCACCCTCCCCACCCTCCCCACCCTCCC-3’). Cells
were trypsinised, rinsed twice with phosphate-buffered saline, pH 7.4 (PBS), and
then diluted in RIPA buffer (see Table 2.2) at 1 × 104 cells per µl. The cells
were passed through a 22 gauge needle 10 times and incubated on ice for 30 min
before the debris was removed by centrifugation at 30 000 g for 20 min. Five hun-
dred microlitres of lysate was dispensed into tubes with biotinylated DNA probe
that had been dispensed at the indicated concentration and gently mixed at room
temperature for 30 min. The biotinylated probe was recovered by adding 20 µl
of streptavidin beads, which had been rinsed twice in RIPA, to each sample and
mixed at room-temperature for 1 hr. The beads were immobilised, the supernatant
removed, and the streptavidin-DNA probe conjugate was rinsed gently 4 times in
RIPA buffer. The DNA probe, and any proteins that were bound to it, were recov-
ered using two different methods. The first involved the denaturation of samples in
60 µl of denaturing sample buffer in RIPA. This was boiled for 5 min, immediately
placed on a magnet, and the supernatant, which contained the sample, was collected
in a fresh tube. The other recovery method sought to recover proteins that had in-
teracted with the DNA probe. This was carried out by digesting the probe using
1 U of benzonase per µl of RIPA buffer which was incubated at room-temperature
for 1 hr before being placed on a magnet. The supernatants were then collected in
a fresh tube and the samples stored at -20oC.
2.7 Subcellular fractionation of cultured cells
The subcellular fractionation was performed by swelling trypsinized cells in a hy-
potonic solution prior to passing them through a dounce to rupture the outer cell
membrane (Mermoud et al. 1992). Adherent cells were harvested and resuspended
in PBS. An aliquot was counted on a haemocytometer. Cells were spun at 220 g
for 5 min at 4oC, resuspended in a hypotonic buffer at a concentration of 1 × 104
cells per µl (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM, DTT,
1 × Complete EDTA-free), and incubated for 5 min at 4oC. 2 × 106 cells were
added to a dounce homogeniser (Kontes, 885300-0002, 2 ml, tight pestle; 0.013 -
0.064 mm clearance) and the dounce was applied for 20 strokes. Following the 20
strokes aliquots were then taken after every 3 strokes, placed in a haemocytometer
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and inspected on a microscope. The douncing was stopped when ∼ 95% of the cell
membranes were ruptured. The sample was removed from the dounce and spun at
220 g for 5 min at 4oC. The supernatant (cytoplasm) was removed and 12.5 µl of 5
× RIPA was added for every 50 µl cytoplasm fraction.
Contaminating cytoplasmic proteins were removed from the nuclei using cen-
trifugation through sucrose gradients. The pelleted nuclei were resuspended in 5 ml
of chilled S1 buffer (0.25 M Sucrose,10 mM MgCl2) and gently layered over 5 ml of
chilled S3 buffer (0.88 M Sucrose,10 mM MgCl2)). The nuclei were spun at 2800 g
for 10 min at 4oC. The nuclear pellet was resuspended in PBS, pelleted, and then
lysed in 1 × RIPA.
2.8 Transfecting cells with exogenous nucleic acids
Target mRNA and proteins were depleted using siRNA duplexes (Table 2.4). Table
2.4 outlines the gene targets, target sequences, suppliers, and concentration range
at which each duplex was used. The duplexes supplied by Life Technologies were
Stealth RNAi duplexes while those supplied by Dharmacon were SmartPool duplexes
that included three siRNA duplexes. Unless otherwise stated, reverse transfections
were performed with cells dispensed into tissue culture vessels in the presence of
the siRNA duplex. The siRNA duplex had been complexed with RNAiMax (Life
Technologies) transfection reagent in 5% bovine foetal calf serum media for 24 hrs.
Following this, experiments were undertaken as outlined in other sections.
Table 2.4: The specific details of the duplex RNA(s) that were used to deplete RNA and
proteins during this thesis.
Target Supplier Ab.Cat.No Sequence (5’ - 3’)
siCTRL LifeTech. N/A CCACACGAGUCUUACCAAGUUGCUU
YB-1 LifeTech. HSS166994 GGUCCUCCACGCAAUUACCAGCAAA







Abbreviations; siCTRL = non-targeting sequence.
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To express exogenous gene products, DNA plasmids were transfected into cells.
The cells were transfected when they were ∼ 80 - 85% confluent. To transfect
one well in a 6-well plate, the cells were incubated with 2 µg of plasmid DNA. The
plasmid DNA had been complexed with 5 µl Lipofectamine 2000 in bovine foetal calf
serum-free DMEM media for 24 hrs before being returned to media that contained
10% bovine foetal calf serum.
2.9 Assays for monitoring cell growth and viabil-
ity
The growth and viability of adherent cells was monitored in up to 360 wells per ex-
periment using an InuCyte FLR (Essen Biosciences). The general structure of these
experiments is summarised by Figure 2.1. Cells that had grown to a confluence of
70 - 85% in media with 10% bovine foetal calf serum were harvested and the de-
pletion of mRNA and proteins took place as outlined in Chapter 2.8. Specifically,
2,200 cells were seeded into each well of a 96-well plate; all outer wells on the 96-well
plate were filled with 200 µl PBS to minimise evaporation. After 24 hrs, the media
were changed to a standard media plus or minus any treatments that were required
for the experiment. When cell viability was also monitored, YOYO-1 Iodide dye
(Life Technologies) was added at 1 µl per 10 ml of media (discussed below; O’Clair
& Appledorn 2011). All treatments were dispensed from this pool.
Cell confluence was monitored by collecting phase-contrast images every 2 or
3 hrs for the duration of the experiment using the InuCyte FLR. Confluence was
calculated by the Confluence algorithm (v1.5), which is included with the InuCyte
FLR software. The maximal growth-rate for each well was derived from the conflu-
ence data using the grofit package (Kahm et al. 2010) in R (v3.1.1 (2014-07-10)).
Following optimisation of the parameters, the spline fitting function was used to
estimate the maximal growth-rate from maximum slope (µ) and the maximum cell
growth (A). The following settings were used for curve-fitting of the confluence data
by grofit ;
1 opt bt rt <− grofit.control(smooth.gc = 0.7, smooth.dr = 0.4, parameter
= 28, neg.nan.act = TRUE, fit.opt = ”b”, nboot.gc = 100, nboot.dr
= 100)
The DRC package in R (version 3.1.1 (2014-07-10) – ”Sock it to Me” Ritz &
Streibig 2005, Ritz et al. 2015) was used to create dose-response curves that were
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Figure 2.1: The general outline for experiments investigating the role of YB-1 in the
sensitivity of MDA-MB231 cells to various drugs. Fluorescence measurements came from
YOYO-1 Iodide, which has excitation/emission maxima at 491 nm and 509 nm, using the
fluorescence channel on the InuCyteFLR l which has an excitation of 470 nm max (450 -
490 nm) and an emission of 515 nm max (500 - 530 nm).
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created from the maximal slope data. A number of the inbuilt parametric regres-
sion models were tested including a five-parameter log-logistic dose-response model,
Weibull I, and Weibull II. The testing also included an analysis of the residuals from
each fit, a comparison of each fit to a fit from an analysis of variance, and, finally, the
amount of variation explained by each model was compared using the Akaike infor-
mation criterion (Ritz et al. 2015). When drugs were used in sufficient concentration
to reduce total cell survival to 0%, the growth measurements were scaled to the con-
trol and the top-most drug dose (µ - µmaximum drug)/(µmedia only-µmaximum drug). Each
experiment was analysed using the same models and fixed parameters. Optimisation
revealed that analysing the scaled data, and using a 2-parameter log-logistic calcu-
lation, provided the most accurate and consistent fitting to the data. The lower and
upper asymptotes for the models were set to 0 and 1 respectively, while the slope
and effective dose were calculated for each combination of siRNA duplex at each
concentration.
In experiments where cell viability was monitored, fluorescent images from an
excitation of 470 nm max (450 - 490 nm) and an emission of 515 nm max (500 -
530 nm) were obtained alongside the phase contrast images using the InuCyte FLR.
YOYO-1 Iodide is cell-impermeant and produces fluorescence when it intercalculates
with DNA from cells where the cell membrane is no longer intact.
Autofluorescence, primarily from the riboflavin in the DMEM (Essen Bioscience
2009), was evident for the first 24 hrs of each experiment, by which time the aut-
ofluorescence was bleached. Analysis of the fluorescence data began with images
taken 24 hrs after the YOYO-1 Iodide was added to the media. The fluorescence
data were extracted with the following parameters fixed; Background Intensity = 20
fluorescence arbitrary units (A.U.), Foreground Intensity 200 A.U., Manual Adjust-
ment 50 A.U. Cell viability data were originally intended to be analysed as live/dead
counts. To produce these measurements, the number of dead cells was derived from
the number of fluorescent particles at the end of the experiments. The number of
total cells was calculated from fluorescent images following the permeabilisation of
cells with Triton-X100 at the end of the experiment. However, consistent permeabil-
isation did not occur and counting fluorescent particles following permeabilisation
did not provide an accurate assessment of the total number of cells in each field of
view. In the absence of a viable end-point measurement the data from fluorescence
were reported as death index. Death index is; log-transformed[(confluence of the
fluorescent signal / confluence of the cells)].
The effects of drug exposure on cell death are reported as Relative death index.
64
This measurement is normalised two ways. The first way is similar to the death
index, as it controls for cell number by dividing YOYO-1 Iodide signal by confluence.
The second controls for the general effects of the siRNA duplex on cell viability by
normalising the measures to cells that were incubated without drugs for that siRNA
duplex and siRNA duplex concentration. Therefore, relative death index is the
measure of change in non-viable cells and it was calculated as; log-transformed +
1 ([confluence of the fluorescent signal /confluence of the cells]media - [confluence of
the fluorescent signal / confluence of the cells]cisplatin).
2.10 Immunofluorescence
To prepare a 2% Paraformaldehyde solution, 1 g of EM-grade paraformaldehyde
was dissolved into 20 ml of 65oC double-distilled water with 4 drops of 1 M NaOH.
One molar NaOH was added slowly until the paraformaldehyde was in solution and
the volume adjusted to 25 ml using double-distilled water. One hundred millilitres
of 0.2 M phosphate buffer (pH 7.3) was prepared from 23 ml 0.2 M NaH2PO4 and
77 ml of 0.2 M Na2HPO4. 25 ml of 0.2 M phosphate buffer (pH 7.3) was added
to the paraformaldehyde to give a 2% paraformaldehyde solution which was used
immediately or stored at 4oC for up to 4 days.
Cells were grown on poly-L-lysine coated coverslips in 24-well plates. Cells were
fixed using paraformaldehyde solution for 15 min at room temperature. The cells
were washed twice with ice cold PBS and at this point stored at 4 oC. Cells were
permeabilsed by incubation with 200 µl PBS containing 0.25 % Triton X-100 for 10
min and then washed, with PBS, three times for 5 min. The non-specific reaction of
the primary and secondary antibodies was reduced by a 30 min incubation in 200 µl
PBS containing 0.2% cold water fish skin gelatin (Sigma) in 1% BSA with 10% heat-
inactivated serum from the species in which the secondary antibody was raised. The
cells were then incubated at 4oC in a humidified chamber overnight with the diluted
antibody in 200 µl 1% bovine serum albumin, 0.2% cold water fish skin gelatin in
PBS. See Table 2.3 for antibody specific dilutions. Every run included controls
for each secondary antibody. The only alteration in this step was that the primary
antibody was omitted. The following morning the primary antibody solution was
decanted and the cells washed three times for 5 min using PBS plus 0.25% tween20.
The cells were incubated for 1 hr at room temperature in the dark with 200 µl
PBS that included 1:2000 of the appropriate secondary antibody, 1% BSA, 0.2%
cold-fish skin gelatin (Alexa Fluor 488, F(ab’)2 fragment of goat anti-rabbit IgG (H
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+ L) [ A11070]; Alexa Fluor 488, F(ab’)2 fragment of goat anti-mouse IgG (H + L)
[A11017]; lexaFluor 568, F(ab’)2 fragment of goat anti-mouse IgG (H + L) [A11019];
Alexa Fluor 568 donkey anti-sheep IgG (H + L) [A21099]). To visualise nuclei, the
double strand DNA binding dye Hoescht was included at 0.5 mg per ml (excita-
tion/emission maxima at 350 nm and 461 respectively; Life Technologies). The
secondary antibody solution and Hoescht was decanted and the coverslips washed
in the dark three times for 5 min in 160 µl PBS with 0.25% Tween20. The slides
were prepared by placing small dots of ProlongGold (Life Technologies), an antifade
mountant, to appropriately labelled slides. The coverslips were then recovered and
eased, cell side down, onto the dots of mountant. The slides were placed upside
down on a flat surface before being weighted to ensure that the coverslips cured flat.
For fluorescence microscopy, the slides were imaged using a Zeiss fluorescent
microscope with SPOT-RT CCD camera (Diagnostic Instruments). Confocal mi-
croscopy was performed using a Nikon C2+ Confocal Eclipse Ni-E Microscope
(Channels; 405 nM, 488 nM, 561. nM) objective; Plan Apo λ 40x. During imaging,
the control containing no primary antibody, and a selection of the slides, was used to
set exposure conditions that encompassed the intensity range for each primary anti-
body. Once the settings were set, they remained static for imaging of each channel
for that set of slides.
2.10.1 Extraction of cytoplamic proteins and RNA
Cytoplasmic proteins and mRNAs were extracted from MDA-MB231 cells using two
5 min incubations in Cytoskeleton buffer that had been pre-heated to 37oC (10 mM
Pipes, pH 7.0, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 0.7% Triton X-100,
0.3 mg/ml RNase A; Britton et al. 2013). The cells were gently washed in PBS
and fixed immediately. Fixation and immunofluorescence (IF) then proceeded as
outlined in Chapter 2.10.
2.10.2 Analysis of micrographs
The images from IF were analysed using the FIJI distribution of ImageJ (Version,
2.0.0-rc-49/1.51a; Schindelin et al. 2012). Confocal images were imported into
FIJI using the Bio-Formats library plugin (version, 5.1.10; The Open Microscopy
Environment 2016). To ensure accurate assessment of the subcellular distribution,
two-dimensional images that bisected the centre of the nucleus of the imaged cells
were created. To do this, two-dimensional images, or Z-projections, were produced
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from the maximum signal intensity of the three Z-slices where the Hoechst dye
(DNA) produced its peak signal. Fluorescence data (gray values) were displayed
using an enhanced false colour lookup table (Green hot, ImageJ). This allows better
visualisation of low intensity signals from YB-1. To provide an accurate summary of
the results, where appropriate the gray values are plotted in R (see Chapter 2.15
for details). Gamma H2A foci were counted using the pzFociez macro in ImageJ
(Znojek 2012). The macro was used in a semi-supervised fashion where, following
masking of the nuclei channel, nuclei that were too close to be separated by the
mask were removed from the analysis. The γH2AX foci in the nuclei of a minimum
of 200 cells were counted for each treatment.
2.11 Immunohistochemistry
Sections fixed in neutral-buffered-formalin and embedded in paraffin wax were pro-
cessed using a standard citrate buffer antigen-retrieval protocol. Three rabbit poly-
clonal primary antibodies were used to detect YB-1, (see above). These were di-
luted in 1%BSA in PBS as follows: NYB1; 1:1200 and YB1C ; 1:1000 and incu-
bated overnight at 4oC. Detection of the primary antibody was carried out using
the EnVisionTM+ Dual Link system (Dako) according to the manufacturers proto-
col. Specimens were counterstained in Gills haematoxylin and mounted in Entellan
(ProSciTech). Staining pattern and intensity was visualized using a Zeiss Axioplan
compound microscope, and photographed with a SPOT-RT CCD camera. Immuno-
histochemistry was the work of Dr Adele Woolley.
2.11.1 Immunohistochemistry Assessment
100 cells in each specimen were scored according to the presence and intensity of
staining. Negative staining was scored as zero, weak as one, moderate as two and
strong as three. The intensity of staining within the tumour was compared to at least
three regions of adjacent normal tissue. Identification and assessment of immuno-
histochemical staining of diagnostic breast tissue was carried out in consultation
with registered pathologists. Immunohistochemistry assessment was the work of Dr
Noelyn Hung and Dr Adele Woolley.
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2.12 Immunoprecipitation
Proteins were immunoprecipitated from cellular lysates using either protein G dyn-
abeads (Invitrogen) or Protein G Mag Sepharose (GE healthcare). Lysates were
prepared for IP at standard concentrations, the equivalent of 1 × 104 cells per µl,
or in the case of IP from nuclei, 5 × 104 cells per µl. A low detergent RIPA buffer
was used for all IP (Table 2.2). To create this buffer in 5 ml cytoplasmic prepa-
rations (Chapter 2.7), the following was added; 1 phosSTOP tablet, 55 µl 10%
deoxycholate, 137.5 µl 20% NP40, 275 µl 1M Tris-HCL, pH 7.5. The low detergent
RIPA buffer was added to nuclei pellets, passed through a 22 gauge needle 10 times,
and incubated on ice for 20 min. Debris was cleared from lysates by centrifugation
at 13 000 g for 10 min.
During these steps, the beads were prepared for use. At this point in the experi-
ment, the protein G dynabeads and Protein G Mag Sepharose protocols differ from
one another. Protein G dynabeads were immobilised on a magnet and washed three
times with 300 µl of lysis buffer. Antibody preparations were added to the lysates
and they were rotated for 1 hr at 4oC. Twenty-five µl of protein G beads were then
added for every 20 µg of antibody and incubated on a rotator for 30 min at 4oC.
The bead:antibody:YB-1 complexes were then immobilised by a magnet, the lysate
removed, and the bead:antibody:YB-1 complex was taken to the next step.
The Protein G Mag Sepharose beads were used at a concentration of 75 µl for
every 50 µg of antibody. For these IPs, the antibody and Protein G Mag Sepharose
beads were complexed together in 500 µl of low-detergent RIPA for 30 min, immo-
bilised, and then rinsed once with another 500 µl of soft buffer. The lysate was
then added to the immobilised antibody plus Protein G Mag Sepharose beads and
rotated for 1 hr at 4oC.
From this point the experiments, the protocols were the same. Samples were
washed three times in 200 µl soft buffer at 4oC. The samples were inverted gently
for mixing and carefully transferred to a new tube for the last wash. The interaction
of the antibody with the protein G beads was disrupted using competitive elution.
The peptide to which NYB1 was raised was added to each sample at a concentration
of 100-fold to nativePAGE buffer (Life Technologies) with 1% Digitonin (Sigma),
1 × phosSTOP (Roche) and 1 × complete EDTA- (Roche). The samples were
incubated at room temperature for two hrs with gentle mixing. Following this, the
supernatant was collected and stored at -80oC to await analysis.
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2.13 Mass Spectrometry
LC-MS/MS has been used to identify the proteins that copurify with immunopre-
cipitated YB-1. Identifying proteins using LC-MS/MS identification requires that
the proteins are reduced to peptides that can be efficiently retained and specifically
eluted by the liquid chomatography system that supplies the mass spectrometer with
peptides. An overview of the key elements for analysing peptides using LC-MS/MS
are reviewed in more detail in Supplementary information A.1.
2.13.1 Sample preparation
The proteins that were recovered using IP were separated using SDS-PAGE and
the gel was stained using colloidal coommassie staining (Chapter 2.3.1). Protein
bands and fractions were excised and subjected to in-gel digestion with trypsin using
a robotic workstation for automated protein digestion. The protocol for automated
in-gel digestion was based on the method of Shevchenko et al. (1996) and the eluted
peptides were dried using a centrifugal concentrator. To perform LC-MS/MS on
phosphorylated peptides, the phosphorylated peptides from the YB-1 bands were
enriched using TiO2 Mag sepharose beads (GE Healthcare).
To generate peptides from cross-linked proteins (see Chapter 2.13.5), the bands
were excised from non-reducing SDS-PAGE gels and processed manually. Peptides
were generated from proteins using trypsin but reduction was omitted. Gel pieces
were buffered by three rounds of dehydration and swelling in 80% acetonitrile and
then 50 mM NH4)HCO3 for 5 min each. Following a final dehydration step in
80% acetonitrile, the proteins were alkylated in 20 mM idoacetamide in 50 mM
NH4)HCO3 for 15 min in the dark. Two more rounds of dehydration and swelling
were followed by the addition of 200 ng of trypsin to the dehydrated gel pieces and
incubation overnight at 37oC. The following morning, another 100 ng of trypsin was
added and left at 37oC for another two hrs. The peptides were then collected by
two rounds of dehydration and rehydration in 80% acetonitrile with 0.2% formic
acid and 0.2% formic acid in ultrapure H2O for 30 min at each step. The sample
was then split with the peptides with intact cross-links, these were not reduced and
dried to a 2 - 5 µl volume in a centrifugal concentrator to await prompt analysis.
The remainder of the sample was dehydrated in 80% acetonitrile and then reduced
via a 45 min incubation at 45oC in 200 mM DTT in 50 mM ammonium bicarbonate.
200 mM idoacetamide was added and the samples incubated for a further 15 min in
the dark and at room temperature. DTT and idoacetamide were removed from the
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peptide mixtures using C18 filled zip-tips.
2.13.2 LC-MS/MS of tryptic peptides
Following tryptic digestion, the samples were re-solubilised in 1% (v/v) acetonitrile,
0.2% (v/v) formic acid in ultrapure H2O, and injected onto an Ultimate 3000 nano-
flow LC-System (Dionex Co, CA) that was in-line coupled to the nano-electrospray
source of a LTQ-Orbitrap XL hybrid mass spectrometer (Thermo Scientific, San
Jose, CA). Peptides were separated on an in-house packed emitter-tip column (75
µm ID fused silca tubing packed with C-18 material on a length of 8 - 9 cm).
The gradient for liquid chromatography was modified depending on the sample.
Generally, the gradient developed from 1% [v/v] acetonitrile, 0.2% (v/v) formic
acid to 80% (v/v) acetonitrile, 0.2% (v/v) formic acid in ultrapure H2O at a flow
rate of 400 nl/min.
Full MS (MS1) in a mass range between m/z 400 - 2000 was performed in the
Orbitrap mass analyser with a resolution of 60,000 at m/z 400 and an AGC target
of 2e5. Preview mode for FTMS master scan was enabled to generate precursor
mass lists. The strongest 5 signals, with a charge state ≥ [M + 2H]2+, were selected
for CID (collision induced dissociation)-MS/MS (MS2) in the LTQ ion trap at a
normalised collision energy of 35% using an AGC target of 1e5 and two microscans.
CID and higher-energy collisional dissociation (HCD) were used to fragment pep-
tides with intact cross-links and only precursors with a charge state ≥ [M + 4H]4+
were selected for MS2 scans. Dynamic exclusion was enabled with 2 repeat counts
during 30 second (sec)s and an exclusion period of 180 secs. The exclusion mass
width was set to 0.01.
2.13.3 Data Analysis
For protein identification, MS/MS data were searched against the Human Swiss-Prot
amino acid sequence database using the Mascot search engine (http://www.matrixscience.com)
and Sequest using Proteome Discoverer (v1.4). The search was set up for full tryp-
tic peptides with a maximum of 3 missed cleavage sites. Carboxyamidomethyl cys-
teine, oxidized methionine, deamidation (N, Q), and phosphorylation (S, T, Y) were
included as variable modifications as appropriate. The precursor mass tolerance
threshold was 10 ppm and the maximum fragment mass error 0.8 Da.
Peptides were accepted as identified if their score was above the score threshold
for the false discovery rate of 1:100, as assessed by the Percolator algorithm (Käll
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et al. 2007). Proteins were considered identified when they were assigned ≥ 2 unique
peptides above the aforementioned score threshold. To improve the accuracy of
protein identification, the peptide search files were loaded together. This makes
all peptides that were identified interacting with YB-1 available to provide more
information about which proteins were present. Information about splice variants
was removed prior to bioinformatic analyses.
Proteins that included peptides with CAMthiopropanoyl on a lysine were collated
and a database containing all potential cross-linked peptides from the proteins was
created using the xComb software (for details of cross-linking see Chapter 2.13.5
and Figure 2.2; Panchaud et al. 2010). To analyse cross-linked peptides, aliquots
of the cross-linked peptides were reduced and alkylated (see above) and subjected to
LC-MS/MS analysis. The CAMthiopropanoyl (K) modification, which corresponds
to a DSP adduct that has been reduced and alkylated, was added to the searches
(Figure 2.3).
2.13.4 Relative quantification of proteins by mass spectrom-
etry
The semi-quantitative analysis of the protein levels used the top three peptides
method (Silva et al. 2006) and was executed using Proteome Discoverer (v1.4).
When more accurate quantification was required, each sample was injected onto the
LC-MS/MS three times.
Skyline was used to create a spectral library from the Proteome Discoverer search
files (.msf) from each phosphopeptide run (c2.6; Schilling et al. 2012). Precursor
ions from MS1 scans were analysed using the workflow described by Schilling et al.
(2012). Each peak assignment was confirmed by manual inspection. Care was taken
to remove precursors ions where the peak area assessment was incorrect due to
the presence of ions from other precursors that interfered with the quantification.
Precursors where the ratio of the precursor isotopes was outside the expected range
(idotp <0.90; Schilling et al. 2012) were also removed from the analyses (isotope
peaks are reviewed in Supplementary information A.1).
2.13.5 In vivo cross-linking of proteins
Proteins were cross-linked in vivo by treating intact cells with dithiobis[succinimidyl
propionate] (DSP) or paraformaldehyde buffered in PBS. Cross-linking using DSP
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Figure 2.2: A, The interaction of dithiobis[succinimidylpropionate] (DSP) with the free
amino group (NH2) of lysine. Potential reactions of the remaining N-hydroxysuccinimide
(NHS) group of DSP following the formation of an adduct with a lysine. B, the remaining
NHS group can interact with Tris during the quenching reaction, it can be hydrolised, or
it can form a cross-link by interacting with another lysine residue. The name, chemical
formula, and monoisotopic mass of each adduct is noted below each structure.
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Figure 2.3: The disulfide bond at the centre of DSP was cleaved using DTT to separate
the cross-linked peptides. A, following reduction with DTT, the cross-links were B alky-
lated using idoacetamide. The name, chemical formula, and monoisotopic mass of each
adduct is noted below each structure.
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creates cross-links on the amino groups of lysine residues and N-termini (Figure
2.2). Cells were tripsinized, counted, and rinsed twice with PBS. Immediately prior
to its use, a 25 mM DSP solution was prepared in DMSO ([CH3]s2SO). The cells
were diluted to 10 000 cells per µl in PBS and the 25 mM DSP solution was added
to the cell suspension at a ratio of 1:25. Cross-linking took place with gentle mixing
at room-temperature for 45 min. The cells were spun and the supernatant removed.
The remaining cross-linker was then quenched by the addition of 100 mM Tris in
PBS which was added in a stoichiometry of at least 1:1 with the cross-linking reagent
and incubated at room-temperature for 10 min. This step was repeated once before
the cells were lysed at 10 000 cells per µl in RIPA, snap frozen, and placed into
-20oC. Cross-linked IP samples were concentrated using centrifugation at 15 000 g
at room temperature in a Vivaspin 500, 30 000 MWCO column (Sartorius) until
their volume was 25 µl.
To assess which peptides had interacted with DSP, the cross-linked peptides were
reduced and alkylated and subjected to LC-MS/MS (Figure 2.3; Chapter 2.13).
2.13.6 Size exclusion chromatography
Size exclusion chromatography was performed using a Thermo Finnegan Spectra
System SN4000 controller, SpectraSYSTEM Solvent Degasser, SpectraSYSTEM sol-
vent pump, and AS3000 UV6000. Cross-linked lysates were run three times through
a Vivaspin 20 100 kDa MWCO filter (GE Lifesciences) to the deadstop and then
refilled with 150 mM NaCl; 50 mM Tris-HCl (pH 8.0). The concentrated and de-
tergent depleted samples were directly loaded on a Superdex 200 10/300GL (GE
lifesciences) column at a flow-rate of 0.7 ml per min. The mobile phase was 150
mM NaCl:50 mM Tris-HCl (pH 8.0). Initial calibration of the elution range was
performed using Blue Dextran (Sigma) and vitamin B12 (Sigma). Fractions from
the sample were collected from two min before the estimated start of the elution
phase and through to completion as determined by spectroscopy. Fractions were
stored at -20oC.
2.14 Bioinformatics
The enrichment of terms amongst proteins was assessed using the functionally an-
notated clusters from Database for Annotation, Visualization, and Integrated Dis-
covery (DAVID) (version 6.7; Huang et al. 2009a, Huang et al. 2009b). The clas-
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sification stringency was set to medium. The background settings for enrichment
analyses were the human genome background which is built into DAVID. However,
in some instances the background was set to the total proteins that were identified
in immunoprecipitations of YB-1 from the work reported here. This alteration is
highlighted when reported.
Protein-protein interactions (PPI) were recovered from searches of the Exper-
iments and Databases evidence prediction methods in String (version 9.1; Snel
et al. 2000, von Mering et al. 2003, Franceschini et al. 2013, Szklarczyk et al. 2015).
The PPI networks were visualised and examined using Cytoscape (v3.1). The net-
works were arranged using the Spring-electric layout provided by the AllegroLayout
plug-in (Yoon 2015). Markov clustering (Yan et al. 2010, Yu et al. 2007) was per-
formed using a cytoscape plug-in CytoNCA (Tang et al. 2015). The enrichment of
gene ontology terms (Ashburner et al. 2000) was further assessed using the Bingo cy-
toscape plug-in (version 3.0.3; Maere et al. 2005). Bingo gene ontology enrichment
used the generic GOSlim with hypergeometric testing with benjamini and Hochberg
false discovery rate correction. The background was set to genome from the Homo
sapiens annotation file. Statistical significance was set to p ≤ 0.05.
2.15 Statistical analyses
Statistical analyses were carried out using R, version 3.1.1 (2014-07-10) – ”Sock it to
Me”. Data handling was primarily carried out using dplyr (version 0.5.0; Wickham
& Francois 2016) and reshape2 (version 1.4.1: Wickham 2007). Graphing was
performed using ggplot2 (version 2.1.0; Wickham 2009) except for heatmaps which
were created using the heatmaps() function from the gplots package (version 3.0.1;
Warnes et al. n.d.).
T-tests were performed using the R base function t.test() . Paired t-tests were
used where appropriate and this is noted. T-tests for the dose-response curves were
performed using the compPam() function within the DRC package. General linear
models, such as analysis of variance, were produced using the aov() command.
Post-hoc testing for the factors in these linear models was performed using the
TukeyHSD() command with conf.level = 0.95.
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Chapter 3
Tertiary structure and protein
interactions may influence the
prognostic sensitivity of antibodies
against YB-1
3.1 Introduction
Observations have consistently shown that the levels of YB-1 are elevated in ag-
gressive breast cancers (reviewed in Chapter 1.3). However, the subcellular lo-
calisation of YB-1 in these cancers is not reported consistently. The variable YB-1
immunostaining patterns between studies may be explained by variations in the
immunoreactivity of the antibodies that were used. Work from our laboratory has
highlighted that many YB-1 antibodies either have a low affinity for YB-1 or they
exhibit non-specific binding (Cohen et al. 2010). To date, the majority of YB-1
antibodies used in immunohistochemical studies have been generated to residues
within the N-terminus (Bargou et al. 1997, Dahl et al. 2009, Janz et al. 2002) or to
the C-terminus of YB-1 (Fujita et al. 2005, Habibi et al. 2008, Wu et al. 2006).
Variations in the immunoreactivity of YB-1 antibodies were hypothesised to
explain the conflicting reports, as well as the variable subcellular localisation of
YB-1. To test this hypothesis, the presence of YB-1 in normal breast tissues and
cancerous breast tissues was assessed using immunohistochemistry (IHC) with two
antibodies. The two affinity-purified antibodies target the N-terminus (amino acids
1-12; NYB1) or the C-terminus (amino acids 299 - 313; YB1C ) of YB-1. The
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specificity of NYB1 and YB1C to YB-1 was verified in Cohen et al. (2010). Both
NYB1 and YB1C have matching binding affinities for denatured YB-1 and recognise
a single band on immunoblots.
The work detailed in this chapter addresses the contradictory reports of YB-1
in normal tissues by assessing the presence and expression of YBX1 mRNA and
YB-1 in normal human tissues. Following this, an assessment was made of the cor-
relation of staining from NYB1 or YB1C in IHC of breast samples to prognostic
markers. The results demonstrate that both antibodies have significant prognostic
value. However, NYB1 shows more sensitivity. The biochemical reasons for the dif-
ferences between NYB1 and YB1C were explored. The protein-protein interactions,
or the secondary/tertiary structure of YB-1 in its native conformation, appear to
affect the binding of NYB1 and YB1C to YB-1. Portions of the work reported here
were included in Woolley et al. (2011).
3.2 Results
3.2.1 YBX1 mRNA and YB-1 are present in normal human
tissue and human cancer cell lines
The levels of YBX1 mRNA across a range of normal tissues were assessed to ad-
dress contradictory reports about the presence of YBX1 mRNA in normal tissues.
To carry out this assessment, the RNAseq Atlas was downloaded (Krupp et al. 2012).
Data relating to YBX1 mRNA were extracted and analysed. This analysis shows
that YBX1 mRNA is present in a wide range of normal tissues (Figure 3.1.A). The
levels of YBX1 mRNA are in the top quartile of the measured mRNA transcripts in
all tissues. To highlight how the levels of YBX1 mRNA compare with those of other
transcripts, a selection of gene products was included in the heatmap. Two of these
transcripts come from the lowest quartile of mRNA expression levels (TP53 and the
α catalytic subunit of Phosphatidylinositol 4,5-bisphosphate 3-kinase [PIK3CA])
and three are from the highest quartile of mRNA transcript measurements (Vi-
mentin [VIM ], β-actin [β-actin], and Glyceraldehyde-3-phosphate dehydrogenase
[GAPDH ]). Therefore, YBX1 mRNA is present and robustly expressed in a wide
range of normal tissues.
The presence of YBX1 mRNA in cancer cell lines of varying lineages was also
assessed using northern blotting. The northern blot confirms that YBX1 mRNA
is present in all of the cell lines that were analysed (Figure 3.1.B). Levels of
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Figure 3.1: YBX1 mRNA and YB-1 are present in a wide range of normal tissues.
A, YBX1 mRNA was detected and quantified using sequencing. The levels of highly
expressed (VIM, GAPDH, ACTB) and lowly expressed gene products (PIK3CA, TP53 )
provide a reference. B,YBX1 mRNA was also detected in 500ng of mRNA from 6 cancer
cell lines using northern blotting. C, YB-1 was also detected in the same tissues using
mass spectrometry. Sequencing data for the analysis in A were collected from RNAse-
qatlas on 16.07.2014 and are presented as log2(reads per kilobase per million). The data
for C were collected from proteomicsDB on 21.06.2014 and are presented as normalised
intensity. Grey panels indicate that the protein is not detected in this tissue. Abbrevia-
tions; VIM = vimentin, GAPDH = Glyceraldehyde-3-phosphate dehydrogenase, ACTB
= β-actin, PIK3CA = Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit
alpha isoform, TP53 = Cellular tumor antigen p53.
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YBX1 mRNA are lowest in A549 cells derived from a lung carcinoma and highest in
SkMEL-5 cells derived from melanoma. The cDNA probe that was used to detect
YBX1 mRNA should also bind to three of the four proposed YBX1 splice variants
(Chapter 2.4). In all cases, a single band is present and the alignment of these
bands with the mass ladder indicates that the signals come from full-length YBX1
mRNA. Therefore, northern blotting confirms the presence of only full-length YBX1
mRNA in a range of cancer cell lines.
To confirm that YB-1 is a feature of normal tissues, LC-MS/MS data was down-
loaded from the ProteomicsDB (Wilhelm et al. 2014). Analysis of these data con-
firms the presence of moderate to high levels of YB-1 in most of the tissues (Figure
3.1.C). This shows that the YBX1 mRNA in normal tissues is translated to its
protein YB-1 and that YB-1 is a feature of most normal tissues. In general, the
levels of YBX1 mRNA and YB-1 are concordant. However, despite adequate YBX1
mRNA levels, YB-1 was not detected in the heart and kidney tissue samples (Figure
3.1.C). This may reflect the variance that is inherent in samples from different
sources, or it could be due to a specific limitation of mass spectrometry. The lim-
itation being the ability of interfering signals to cause false negative results. The
LC-MS/MS data apply to the tissue level and lack critical information about pro-
teins at the cellular and subcellular levels. Histological techniques, such as IHC
or immunofluorescence (IF), provide information about proteins at the cellular and
subcellular levels.
The levels of YB-1 and its subcellular distribution in normal breast tissues (re-
duction mammoplasties) were assessed using IHC. Staining for YB-1 with NYB1 is
present in all of the reduction mammoplasties (Figure 3.2). The IHC confirms
that YB-1 is present in normal breast tissue. This work also highlights the variation
of YB-1 within normal breast tissue. YB-1 is present in both lobular and ductal
mammary structures. Consistently strong staining is present in columnar alterations
with prominent apical snouts and secretions; which share some features with pre-
malignant lesions, such as elevated proliferation (arrowheads in Figure 3.2.ii and
iv; Dessauvagie et al. 2007). At the subcellular level, staining for YB-1 is present
primarily in the cytoplasm of cells. There are no cells where YB-1 was only localised
to the nucleus. A small number of cells appear to have YB-1 in their nuclei but the
thickness of the tissue sections (5µm) prevents the definitive confirmation of this
nuclear signal (see insets Figure 3.2.i, iii, iv and vi).
In summary, these results confirm the presence of YB-1 in normal breast tissue.
IHC shows that YB-1 is primarily localised to the cytoplasm in normal breast tissue.
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Figure 3.2: YB-1 is detected by NYB1 in the cytoplasm and perinuclear region of normal
lobular (i, iii and v) and ductal (ii, iv and vi) breast tissue by IHC. Insets show staining at a
higher magnification. Arrowheads (panels ii and iv) depict high levels of YB-1 in columnar
alterations with prominent apical snouts and secretions. Immunohistochemistry, analysis,
and this image is the work of Adele Woolley. Scale bars 20 µM.
Furthermore, the levels of YB-1 in normal breast tissue vary between individuals as
well as within individual breast tissue samples.
3.2.2 YB-1 is elevated in breast cancer tissue
The strong YB-1 staining in IHC from some reduction mammoplasties indicates
that high levels of YB-1 do not generally signify cancer. However, YB-1 has been
reported to be elevated in breast cancer (Janz et al. 2002, Habibi et al. 2008, Dahl
et al. 2009, Lasham et al. 2012) and the signals from NYB1 and YB1C that are
detected using IHC are hypothesised to differ from that of normal tissues. IHC was
used to examine the levels and distribution of YB-1 in histological sections from
breast tumours. Two cohorts of tumours were analysed. The first cohort came
from the Dunedin Public Hospital, in New Zealand, and all of the images that are
included here are from this cohort. A second cohort of samples was supplied as
tissue microarrays by the Singapore General Hospital in Singapore. The summarise
results from this second cohort are included here. The levels of YB-1 in breast
cancer sections have been assessed using NYB1 and YB1C . Both NYB1 and YB1C
detect YB-1 in all sections and both show that YB-1 levels vary between the breast
tumour samples (Figure 3.3). Staining for YB-1 is predominantly in the cytoplasm
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Figure 3.3: Levels of YB-1 are increased in grade III breast tumours as detected by
NYB1, but not YB1C . IHC was carried out on formalin-fixed paraffin-embedded breast
tumours (n = 90) from the New Zealand cohort using two antibodies targeting different
epitopes and compared to adjacent normal tissue (insets). Staining patterns and levels of
expression are shown for each antibody. Differences in staining intensity as detected by
NYB1 were significant (p = 0.02) whereas those detected by YB1C were not (p = 0.06).
Nuclear YB-1, as detected by NYB1, was evident in < 3% of cases (arrowhead, upper
middle panel). Immunohistochemistry, analysis, and this image is the work of Adele
Woolley. Scale bars 10 µM.
of cells. Nuclear YB-1 is only detected with NYB1 and only observed in < 3% of
cases.
To formally assess the variability of YB-1 staining from NYB1 and YB1C , the
intensity of staining from cytoplasmic YB-1 was assessed on a scale of 0 (none) to 3
(high). The low number of reduction mammoplasty samples means they could not
be used as a normal breast tissue control for the levels of YB-1 (n = 10). Instead,
histological grade I (n = 32) and grade III (n=28) breast tumors were compared.
Grade II tumors have been excluded as their gene expression profile is not distinct
and appears to be a mixture of grade I and III tumours (Ignatiadis & Sotiriou 2008).
The second cohort included 42 grade I and 82 grade III tumours from the Singapore
General Hospital. Only NYB1 discerns a difference between grade I and grade III
breast tumours in the tumours from the Dunedin cohort (NYB1, p < 0.02; YB1C ,
p = 0.06; Fisher’s exact). In IHC performed with NYB1, the maximum intensity of
staining is seen in ∼ 40% of grade I tumours and ∼ 60% of grade III tumours. The
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results from the Singapore cohort show that both NYB1 and YB1C detect stronger
staining for YB-1 in grade III tumours than in grade I (grade I = 42, grade III = 82,
NYB1, χ2 = 35.95, p,0.005; YB1C , χ2 = 8.623, p,0.02). Therefore, breast tumours
with advanced histological grade are more likely to show intense staining for YB-1
and NYB1 is more sensitive to this subset of breast tumours than YB1C .
To examine in greater detail the importance of YB-1 in breast cancers, the
tumour data were further analysed based on hormone receptor status. One group
contains ER+ve/PR+ve cancers (n = 68; the significance of ER+ve/PR+ve is reviewed
in Chapter 1.2). The second grouping of ER-ve/PR-ve tumours includes aggressive
basal-like tumours and ERBB2 (HER2)+ tumours (n = 22). The results show that
NYB1 staining has an intensity of 2 or 3 in the ER-ve/PR-ve tumours and that
NYB1 staining is more likely to be elevated in the ER-ve/PR-ve tumours compared
to the ER+ve/PR+ve tumours (Figure 3.4; p,0.007; Fisher’s exact). YB1C detects
no difference in the levels of YB-1 between the two tumour subsets. In the larger
Singapore cohort, the levels of YB-1 are elevated with both NYB1 (χ2 = 40.71,
p,0.005) and YB1C (χ2 = 28.17, p,0.015).
In summary, variable levels of YB-1 are a feature of normal breast tissues (Figure
3.2). This variability is also a feature of cancerous breast tissues. However, the
highest levels of YB-1 were observed more frequently in aggressive breast cancers,
as predicted by histological grade and also by hormone receptor status. The two
antibodies used to detect YB-1 produce broadly similar staining but NYB1 is more
sensitive when detecting elevated YB-1 in aggressive breast cancers.
3.2.3 YB-1 is present in the cytoplasm and nucleus of cells
In breast tumour samples, the staining from NYB1 in the cytoplasm confirms that
the levels of YB-1 are elevated in a subset of cancers (high histological grade and/or
ER-ve/PR-ve; Chapter 3.2.2). The prognostic sensitivity of NYB1 is derived from
increased levels of YB-1 in the cytoplasm of breast cancer cells. This observation
appears to support the notion that the ability of YB-1 to influence RNA stability
and translation is important to the role of YB-1 in cancer.
The thickness of the sections that were used for IHC precludes the definitive
confirmation of how YB-1 is distributed in tumour cells. Therefore, confocal mi-
croscopy was used to gain further information about the distribution of the YB-1
that is detected by NYB1. The MDA-MB231 breast cancer cell line was chosen
for this work. MDA-MB231 cells are ER-ve/PR-ve making them a good model cell
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Figure 3.4: Levels of YB-1 are increased in ER-ve/PR-ve breast tumours as detected by
NYB1, but not YB1C . IHC was carried out on formalin-fixed paraffin-embedded tumours
(n = 90) from the New Zealand cohort using two antibodies targeting different epitopes.
Staining patterns and levels of expression are shown for representative sections for each
antibody: ER+ve/PR+ve tumours are represented in the left hand column; ER-ve/PR-ve
tumours in the central column. Differences in staining intensity, as detected by NYB1,
were significant (p,0.007) whereas those detected by YB1C were not (p = 0.08). Immuno-
histochemistry and analysis is the work of Adele Woolley. Scale bars 10 µM.
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line for the subset of breast cancers that have increased levels of YB-1 (Chapter
3.2.2). MDA-MB231 cells were grown on coverslips and fixed after 72 hours. Fol-
lowing IF labelling with NYB1, the cells were imaged using confocal microscopy. The
results highlight that YB-1 is located primarily in the cytoplasm of MDA-MB231
cells (Figure 3.5.A). The signal from cytoplasmic YB-1 is granular with prominent
YB-1 signal in the perinuclear region. This perinuclear YB-1 is shown on the profile
plots for all three cells in Figure 3.5.A. Notably, in many cells this perinuclear
aggregation of YB-1 signal is polar (Figure 3.5.A, Cell 2).
The signal from NYB1 in the nucleus of MDA-MB231 cells is low. The nuclei
of most MDA-MB231 cells contain weak punctate fluorescence. The profile plots
from cross-sections of Cell 2 and Cell 3 show the signal peaks from YB-1 in the
nuclei of these MDA-MB231 cells (Figure 3.5.A). A second pattern of YB-1 signal
is present in the nuclei of many MDA-MB231 cells. It consists of fine filaments that
often traverse most of the nucleus (Figure 3.5.A, Cell 1). This work confirms that
YB-1 is present in the cytoplasm and nuclei of MDA-MB231 cells. Furthermore,
NYB1 can detect YB-1 in both subcellular compartments.
The literature indicates that the YB-1 in the nuclei of MDA-MB231 cells can in-
teract with RNA and also with DNA (Chapter 1.8.1). To confirm that some of the
YB-1 in the nucleus of MDA-MD231 cells interacts with DNA, cytoplasmic proteins
and RNA were removed prior to fixation. Cytoplasmic proteins were extracted using
a cytoplasmic extraction buffer and the RNA was digested by RNase A (Chapter
2.10.1). IF was performed using NYB1. The results from confocal microscopy con-
firm that most of the cytoplasmic YB-1 is removed from these MDA-MB231 cells.
However, a weak fluorescent signal is still present outside the nucleus of most cells
(see profile plots for all cells in Figure 3.5.B). The polarity of this signal suggests
that it could come from the polar, perinuclear YB-1 maxima that are present in
many MDA-MB231 cells. The efficiency of the extraction for this perinuclear YB-1
may be reduced due to a membrane bound organelle, such as the golgi apparatus or
the endoplasmic reticulum, that hinders its clearance. In the absence of cytoplasmic
proteins and RNA, the signal from YB-1 within the nucleus is revealed as foci in
most MDA-MB231 nuclei (Figure 3.5.B). Furthermore, upon removal of cytoplas-
mic proteins and RNA, filaments of YB-1 were no longer observed in the nuclei of
MDA-MB231 cells. This suggests that these filaments were YB-1 associating with
RNA in the nucleus.
The results show that a small amount of cellular YB-1 is located in the nucleus of
MDA-MB231 cells. When in the nucleus, YB-1 is evident as filaments that are likely
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Figure 3.5: YB-1 is present in the cytoplasm and nucleus of MDA-MB231 cells. A,
IF signal from NYB1 in MDA-MB231 cells was assessed using confocal microscopy. B,
Cytoplasmic proteins and RNA were removed from MDA-MB231 cells and the YB-1 that
remained was assessed using confocal microscopy. All images are Z-projections of the
maximal signal from three Z-slices across the nuclei of MDA-MB231 cells. The profile
plots show the signal intensity from the line across each cell to the right of the graph.
NYB1 was labelled with AlexaFluor 488 and gray values are represented using the Green
Hot LUT (ImageJ). DNA labelled with Hoechst is represented as blue. Scale bar is 25
µM. 85
to be associated with RNA. YB-1 is also present as foci that appear to be interacting
with DNA or to be bound to RNA in bodies that are refractory to RNase. These
results broadly support those from the IHC in tumour samples where NYB1 appears
to be able to bind to YB-1 in the cytoplasm and nuclei of breast tumour cells.
3.2.4 NYB1 and YB1C detect denatured YB-1 with equal
efficiency
The results from IHC in breast cancer samples show that NYB1 possesses greater
sensitivity as a prognostic marker than YB1C . The differences between the two
antibodies in IHC may be explained by a post-translational modification of YB-1
that is both specific to YB-1 in the nucleus of cells and that also inhibits the binding
of YB1C to YB-1. There are 4 known post-translational modifications (PTMs) that
fall within the immunising peptide sequence for YB1C on YB-1 (299 - 313 aa);
acetylation on K301 and K304 (Frye et al. 2009) and phosphorylation of S313 or
S314. The acetylation of K301 and K304 have been implicated in the excretion of
YB-1 and as such, are unlikely to be an important modification for breast cancer
cells.
Phosphorylation of YB-1 at S313 or S314 was hypothesised to inhibit the bind-
ing of YB1C to YB-1. A phosphatase, shrimp alkaline phosphatase, was used to
study the influence of phosphorylation on the binding of YB1C and NYB1 to YB-1.
YB-1 is correlated with drug resistance in lung cancers (Kashihara et al. 2009). To
promote any PTM of YB-1 that relate to this role in drug resistance (Chapter
1.4.3), lysates were prepared from A549 cells that were cultured in 30 µM cisplatin
for 0, 5, or 24 hours. Immunoblotting was performed with these lysates. Prior to the
addition of primary antibodies, a portion of each blot was incubated with shrimp
alkaline phosphatase to remove phosphate groups from the blotted proteins. The
results show that shrimp alkaline phosphatase has no effect on the binding of NYB1
to YB-1 (Figure 3.6.A, NYB1; n = 3). Phosphatase appears to reduce the binding
of YB1C to YB-1 from lysates prepared from MDA-MB231 cells that have been ex-
posed to cisplatin for 5 hours (Figure 3.6.A, YB1C ). However, this effect is only
evident in the blot that is shown. A positive control was included in these exper-
iments to confirm the successful removal of phosphate groups from YB-1. YB1S102
is a monoclonal antibody that binds specifically to YB-1 that is phosphorylated at
S102. YB1S102 should cease to bind YB-1 following shrimp alkaline phosphatase
treatment. However, signal YB1S102 is not reliably detected in these experiments
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(Figure 3.6.A, YB1S102).
Shrimp alkaline phosphatase reacts with the chemiluminescent detection system
for secondary antibodies that are conjugated with the alkaline phosphatase used
for the other immunoblots in this thesis. This alkaline phosphatase-conjugated sec-
ondary antibody provides adequate signal from YB1S102 and an antibody against p53
that is phosphorylated at S15 (Figure 3.6.B, AP lanes). A horseradish peroxidase
secondary antibody was used in Figure 3.6.A and this secondary exhibits poor
signal to noise ratios on two phosphospecific antibodies that were used as positive
controls for these experiments (Figure 3.6.B, HRP lanes). The non-specific bind-
ing by YB1S102 is observed at approximately 60 kDa. The specificity of the YB1S102
antibody is confirmed by the specific depletion of only the ∼ 50 kDa band in samples
where YB-1 had been depleted (A. Braithwaite, personal communication). Titration
of the horseradish peroxidase antibody, and freshly ordered antibody and detection
reagents, did not improve the detection of either antibody. Therefore, the failure
of the YB1S102 as a positive control is due in part to the poor sensitivity of the
horseradish peroxidase detection system for YB1S102.
In the following step, shrimp alkaline phosphatase was used to remove the phos-
phate groups from YB-1 in solution, rather than from YB-1 that was immoblised on
a nitrocellulose membrane. The lysates from A549 cells that were at ∼ 75% conflu-
ence were prepared with and without phosphatase inhibitors. Once the lysates had
been cleared of cellular debris, shrimp alkaline phosphatase was added to aliquots
of each sample which were then incubated at room temperature for 1 hour prior to
being separated using SDS-PAGE. In the presence of the phosphatase inhibitors,
the intensity of the signal from YB1C is reduced in the sample that was incubated
with shrimp alkaline phosphatase (Figure 3.6.C). However, in the absence of phos-
phatase inhibitors, shrimp alkaline phosphatase has no effect. The results from this
experiment show that shrimp alkaline phosphatase does not alter the intensity of
signal from YB1S102 (Figure 3.6.C). Therefore, either YB1S102 is not specific to
YB-1 that is phosphorylated at S102 or, the shrimp alkaline phosphatase failed to
remove the phosphate group from S102.
These experiments failed to produce a consistent alteration to the binding of
YB1C to YB-1. The successful removal of phosphate groups was not confirmed in
these experiments. This was in part due to poor detection of the positive control
YB1S102 by the horseradish peroxidase secondary. Horseradish peroxidase was only
used in the immunoblots for these experiments. Therefore, the results from these
experiments are inconclusive.
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Figure 3.6: The binding of NYB1 and YB1C to YB-1 does not appear to be influenced by
phosphorylation of YB-1. A, immunoblots of lysates from A549 cells that were incubated
in 30 µM cisplatin for 0 - 24 hours. Prior to detection with primary and horseradish
peroxidase (HRP) secondary antibodies, a portion of the membrane was cut and incubated
with shrimp alkaline phosphatase to remove phosphorylations from the separated proteins.
Immunoblots were exposed to NYB1, YB1C and YB1S102. B, immunoblots of lysates from
A549 cells that were exposed to 30 µM cisplatin for 0 or 24 hours. The signal from YB1S102
and p53S15 was detected with HRP and alkaline phosphatase (AP) secondary antibodies.
Efficient loading of proteins is confirmed using ponceau S staining. C, immunoblots of two
lysates prepared from the same A549 cells but phosphatase inhibitors were only included
in one. Shrimp alkaline phosphatase was also added to an aliquot of each lysate prior to
SDS-PAGE. Abbreviations; M = marker, SAP = shrimp alkaline phosphatase, AP =
alkaline phosphatase, HRP = horseradish peroxidase.
88
An alternative approach was taken to assess whether phosphorylation of YB-1 at
S313 or S314 could inhibit the binding of YB1C to YB-1. Immunoprecipitation with
YB1C was used to test the ability of YB1C to bind YB-1 that is phosphorylated at
S313 or S314. The tyrptic peptides derived from the YB-1 that was immunoprecip-
itation with YB1C are subjected to LC-MS/MS analysis. Analysis of the data from
LC-MS/MS shows that the YB-1 recovered by YB1C produces peptides that were
phosphorylated at S314 (the work of W. Ma and V. Valova, reported in Woolley
et al. 2011). The presence of YB-1 peptides phosphorylated at S314 appears to
confirm that YB1C can bind to YB-1 that is phosphorylated at S314.
In conclusion, phosphorylation of YB-1 at S314 does not appear to affect the
binding of YB1C . This indicates that phosphorylation of YB-1 at S314 is unlikely
to be the direct cause of the difference between the two antibodies in IHC analyses
of breast tumours.
This study sought other explanations for the differing prognostic sensitivity of
YB1C and NYB1. Previous research on the function of YB-1 in breast cancer has
highlighted the importance of the ability of YB-1 to bind to DNA and act as a
transcription factor (Chapter 1.8.2.1). Therefore, it was hypothesised that NYB1
is superior to YB1C in its ability to bind to YB-1 that has an increased affinity
for DNA; an affinity that allows YB-1 to function as a transcription factor. This
hypothesis is consistent with the observation that IHC using NYB1, but not YB1C ,
detects YB-1 in the nucleus of breast cancer cells (Figure 3.3). It is also consistent
with the results from IF which confirm that YB-1 is likely to interact with DNA
(Figure 3.5).
The hypothesis has been tested by examining the ability of YB1C and NYB1
to bind to YB-1 that is captured by a single-stranded DNA probe (Chapter 2.6).
The ability of YB-1 (Cohen et al. 2010) and a YB-1 homologue (Horwitz et al. 1994)
to bind to this sequence has already been confirmed. The YB-1 that was captured
by the DNA-probe was recovered and then visualised using immunoblotting. The
results from both NYB1 and YB1C reveal that a small proportion of total cellular
YB-1 is recovered by the DNA probe as the majority of YB-1 remained in the flow-
through fraction (Figure 3.7.A, flow compared to DNA). Phosphorylation of YB-1
at S102 has been implicated in activating YB-1 as a transcription factor (Sutherland
et al. 2005, Wu et al. 2006, Davies et al. 2011). Thus, YB1S102 is the ideal positive
control to confirm the recovery of transcriptionally active YB-1. Immunoblotting
using YB1S102 indicates that YB-1 that is phosphorylated at S102 does not bind
to the DNA probe (Figure 3.7.A). The signal from YB-1 that is recovered by the
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Figure 3.7: YB1C and NYB1 both detect the YB-1 that binds to a single-stranded DNA
probe. A, a representative image showing the proportion of YB-1 that was captured from
A549 cell lysates using a DNA-affinity probe and detected on immunoblots using NYB1,
YB1C and YB1S102. B, the YB-1 that was captured by 0 - 5 µg of DNA-affinity probe.
These samples came from the experiment shown in A but they were loaded without the
flow-through fraction. The regions of the YB1S102 immunoblots where YB-1 and non-
specfic signals were observed are noted. Abbreviations; flow = flow-through fraction,
DNA = protein captured by single-stranded DNA probe.
DNA probe makes it difficult to compare the amount of recovered YB-1 when the
flow-through is loaded alongside each sample. Loading only the DNA-captured YB-
1 samples provides a clearer picture of the YB-1 that is bound to the DNA probe.
The representative immunoblots highlight the negative relationship between YB-1
recovery and the concentration of DNA probe (Figure 3.7.B). This is consistent
across all experiments (n = 4). The bead-only control purifications, where DNA
probe was not added, indicate that YB-1 has an intrinsic affinity for the streptavidin
beads that were used for these experiments (Figure 3.7.B, 0µg lane).
These experiments show that only a small amount of the YB-1 in A549 cells was
able to bind to DNA. Surprisingly, there is no support for YB-1 having an affinity
for DNA when it is phosphorylated at S102. The differences in the prognostic
sensitivity between NYB1 and YB1C do not appear to be related to the ability of
either antibody to bind to a subset of the total cellular YB-1 that has an increased
affinity for DNA.
A final approach was taken to compare the intrinsic binding properties of YB1C
and NYB1 to YB-1. The results from IF confirmed that most of the YB-1 was in
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the cytoplasm of MDA-MB231 cells but they were not quantitative. Subcellular
fractionation, followed by immunoblotting, was performed to gain quantitative data
for the distribution of YB-1 between the cytoplasm and nucleus of cells. The A549
cell line, which is derived from a lung adenocarcinoma, was used for these experi-
ments. The subcellular fractionation was performed as outlined in Chapter 2.7.
The IF experiments indicate that there is less YB-1 in the nucleus of cells than the
cytoplasm (Figure 3.5). Therefore, contamination of the nuclear fraction by YB-1
from the cytoplasm is the most likely weakness for these experiments. An antibody
to β-tubulin, which is present in cells at high levels but only in the cytoplasm, was
used to ensure that the nuclear fraction does not contain any cytoplasmic proteins.
All data presented here comes from experiments where there was no signal from
β-tubulin in the nuclear fraction (see Figure 3.8.A, left panel).
The distribution of YB-1 between the cytoplasm and nuclei of A549 cells has been
assessed using densitometry. The percentage of signal in each fraction is calculated
by dividing the density measurement for that fraction from the pooled sum of the
densities of the cytoplasmic and nuclear fractions. The results confirm that, at any
given time, most of the YB-1 in asynchronous A549 cells is in the cytoplasm (78 ±
7.6% YB-1 in the cytoplasm; Figure 3.8.A). Therefore, YB-1 is predominantly in
the cytoplasm of a wide range of cells types.
The densitometry measurements from these experiments were also used to test
for differences in the intrinsic affinity of NYB1 and YB1C for the YB-1 in the
cytoplasm and nucleus of A549 cells. The results show that there is no difference
in the affinity of NYB1 and YB1C for YB-1 from the nucleus of A549 cells (paired
t-test, t = 2.1733, df = 5, p = 0.0818; Figure 3.8.B). These experiments also show
that ∼ 20% of YB-1 is in the nucleus of these cells. Furthermore, both NYB1 and
YB1C detect YB-1 in the cytoplasm and the nucleus of cells with a similar efficiency.
In summary, the results in this section are derived from the detection of de-
natured YB-1 on immunoblots with the aim of separating a sub-species of YB-1
that would explain the increased sensitivity of NYB1 as a prognostic marker in IHC
of breast cancer (Chapter 3.2.2). Three approaches were used to separate this
hypothesised sub-species of YB-1. The results show that none of the approaches
reveal differences between NYB1 and YB1C on immunoblots. This indicates that
NYB1 and YB1C are likely to bind to denatured and reduced YB-1 with an equal
efficiency.
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Figure 3.8: NYB1 and YB1C have equal affinity for YB-1 from the cytoplasm and nucleus
of A549 cells. Immunoblot analysis of A549 cells that were separated into cytoplasmic and
nuclear fractions. A, the presence of cytoplasmic proteins was confirmed using β-tubulin
and YB-1 was detected using antibodies to NYB1 and YB1C . B, the amount of YB-1 in
the cytoplasm and nucleus of A549 cells was estimated by analysis of the density of the
signal from immunoblots (n = 8). A paired t-test found no difference in the levels of YB-1
that were detected by NYB1 and YB1C (t = 2.1733, df = 5, p = 0.0818).
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3.2.5 NYB1 and YB1C detect YB-1 in a number of multi-
protein complexes
The PPI or secondary/tertiary structure of YB-1 were hypothesised to affect the
binding of NYB1 and YB1C to YB-1. To research this hypothesis, protein lysates
from A549 cells were separated under native conditions using BN-PAGE. RNA and
DNA were removed from the lysates prior to their separation. The immunoblots from
BN-PAGE reveal that YB-1 is found in multiple complexes in A549 cells (Figure
3.9.A). Both NYB1 and YB1C bind to multiple bands containing YB-1 on these
immunoblots. However, the signals from NYB1 and YB1C are different, with the an-
tibodies binding to multi-protein complex (MPC)s with differing mobilities (Figure
3.9.A for a representative gel). Specifically, a band is detected by both NYB1 and
YB1C at ∼ 720 kDa. However, NYB1 always detects a sharp band at this mobil-
ity while the signal at ∼ 720 kDa from YB1C is diffuse. Both NYB1 and YB1C
detect different bands between 250 - 450 kDa. In this region of the gel, YB1C ex-
hibits signal (band 2) in only the cytoplasm while the signal from NYB1 is observed
in both nuclear and cytoplasmic fractions (band 3). Band 4 is most likely to be
monomeric YB-1, as denatured YB-1 runs with the same mobility (Figure 3.9.B).
Unlike the other protein species that are discussed, its appearance on immunoblots
from BN-PAGE varies between runs indicating that it may be a result of technical
variation.
The immunoblots from BN-PAGE in this section indicate that protein-protein
interactions or the secondary/tertiary structure of YB-1, is most likely to be respon-
sible for the differing performance of NYB1 and YB1C . Therefore, the differences in
the performance of NYB1 and YB1C in IHC appear to relate to variable detection
of YB-1 when it is incorporated in various MPCs and, to reflect that, NYB1 detects
a functionally distinct subset of complexes that contain YB-1.
3.3 Discussion
The data presented in this chapter confirm that:
• YB-1 is present in normal human tissues;
• Elevated levels of cytoplasmic YB-1 staining from NYB1 and YB1C in IHC
are correlated with high histological grade and ER-ve/PR-ve breast cancers;
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Figure 3.9: NYB1 and YB1C bind to multiple MPCs that are resolved in BN-PAGE.
A, following subcellular fractionation (confirmed using SDS-PAGE in Figure 3.8) lysates
from A549 cells were separated using blue-native PAGE and the separated proteins blotted
onto a membrane. YB-1 protein was detected using YB1C and NYB1. B, lysates from
A549 cells. *, indicates that prior to separation, the lysate had denaturing sample buffer
added (containing SDS and DTT) and was heated to 100oC for 5 minutes. The arrows
highlight the location of the main bands that were observed in repeated experiments.
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• The YB-1 in A549 and MDA-MB231 cells is primarily present in the cyto-
plasm;
• Denaturation and reduction resistant PTM are unlikely to affect the binding
of NYB1 and YB1C ;
• NYB1 and YB1C bind to multiple multiprotein complexes that do not entirely
overlap.
The results presented here confirm that YBX1 mRNA and YB-1 are present in
most normal adult tissues (Chapters 3.2.1 - 3.2.2). The studies that failed to
detect YB-1 in normal tissues utilise IHC (Bargou et al. 1997, Dahl et al. 2009,
Gunasekaran & Ganeshan 2014). Therefore, IHC appears to have variable success
in detecting YB-1.
The data from IHC presented in this chapter show that YB-1 is present in breast
tissue. IHC confirms the presence of YB-1 in all ductal breast tissue from reduction
mammoplasties. Notably, cytoplasmic YB-1 is present in all normal breast tissue.
The presence of YB-1 in normal breast tissue differs from previous findings (Bargou
et al. 1997, Dahl et al. 2009). Dahl et al. (2009) detected very weak staining for
YB-1 in normal breast tissue. This discrepancy appears to relate to the antibody
used in that study that does not bind to endogenous YB-1 on immunoblots. Dahl
et al. (2009) proposes that the antibody can only bind to YB-1 when it maintains
a specific conformation. Bargou et al. (1997) also reported that YB-1 was not de-
tected in normal breast tissue. This is difficult to reconcile with the results reported
here as the antibody was produced from the same epitope as NYB1. Technical con-
siderations may explain this discrepancy. Antigen retrieval, that can improve the
signal from target proteins in IHC by reversing some modifications that occur during
formalin fixation and paraffin embedding (Shi et al. 2001), and the blocking condi-
tions, which can decrease the signal from non-specific proteins, may differ between
Bargou et al. (1997) and the work presented here. The buffer conditions, duration
and temperature of the antigen retrieval steps were not reported in Bargou et al.
(1997). The discrepancy between the results that are reported here and previous
studies may also relate to the difficulty of accurately assessing the location of signal
in IHC, which is discussed in the following paragraph.
This work also aimed to determine whether IHC in breast tumours using two
antibodies, generated to either end of YB-1, would provide the same conclusions
about the value of YB-1 as a prognostic tool. Two performance characteristics
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are important in relation to the prognostic value of YB-1; the ability to detect
the levels of YB-1 and the subcellular localisation of YB-1. With the N-terminus
antibody (NYB1), the staining intensity of cytoplasmic YB-1, although variable,
tends to be highest in grade III tumours and in the more aggressive ER-ve/PR-ve
negative tumours. Other research is supportive of the importance of cytoplasmic
YB-1 staining in breast cancer (Mylona et al. 2014). These findings confirm previous
reports that were carried out with an antibody generated to the same N-terminus
epitope (Bargou et al. 1997, Dahl et al. 2009, Janz et al. 2002). Unlike these previous
reports,this study found that strong YB-1 staining in the nucleus is rare (∼ 3%
of tumours). Confocal immunofluorescence microscopy shows that NYB1 detects
punctate nuclear staining in most grade III tumours that is not discernible by IHC
(Woolley et al. 2011). The localisation and distribution of YB-1 in MDA-MB231
cells is similar to previous reports of YB-1 distribution in A549 cells (Cohen et al.
2010). Many cells exhibit staining in the cytoplasmic region directly adjacent to
the nucleus (perinuclear). Previous reports may have interpreted this increased
perinuclear intensity as nuclear staining due to the plane of section.
Cytoplasmic YB-1 detected with YB1C is also highest in grade III and ER-ve/PR-ve
negative tumours. It does not reach statistical significance in the smaller New
Zealand cohort but does show a significant difference in the Singapore cohort. How-
ever, this is of lesser magnitude than that found with NYB1 (Woolley et al. 2011). As
with NYB1, the increase in cytoplasmic staining is most notable in the perinuclear
region. These findings are in agreement with elevated YB-1 levels, that are detected
by an antibody generated to the same C-terminus peptide sequence, previously re-
ported in breast (Wu et al. 2006, Habibi et al. 2008), non-small cell lung (Shibahara
et al. 2001) and prostate cancers (Giménez-Bonafé et al. 2004). However, unlike
some of these reports, confocal immunofluorescence microscopy using this antibody
finds no evidence of nuclear YB-1 staining (Woolley et al. 2011).
Multiple studies show that increased YBX1 mRNA levels provide sufficient in-
formation to detect aggressive breast cancers by highlighting the negative correla-
tion of YBX1 mRNA with survival (Yu et al. 2010, Turashvili et al. 2011, Lasham
et al. 2012). Similar observations, including those outlined in this chapter, have
been made for YB-1. Together, these data strongly indicate that increased levels of
YB-1 in breast tumours reduce the odds of survival for people with cancer. How-
ever, the significant variance in the levels of YB-1, which is observed in IHC of both
normal breast tissue and breast tumours, highlights important issues relating to the
use of YB-1 in prognostic assessments. Highly elevated levels of YB-1 are observed
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in some normal breast epithelial cells (Figure 3.2). Therefore, the role of YB-1 in
aggressive breast cancer cells must require some changes in the function of YB-1.
The increased sensitivity of NYB1 compared to YB1C may relate to the function
of a second element of YB-1 biology that is present in cancer cells. NYB1 detects
this second element with greater sensitivity. The utility of cytoplasmic YB-1 as a
prognostic marker may highlight the importance of the functions that are undertaken
by YB-1 in the cytoplasm. However, an alternative explanation is that the high levels
of cytoplasmic YB-1 are a secondary effect of increased levels of YB-1. Increased
levels of YB-1 may allow a small amount of YB-1 to interact with DNA and influence
the transcription of target genes that promote an aggressive breast cancer phenotype.
To explain the difference between NYB1 and YB1C , a number of possibilities
have been considered. The most obvious is that the antibodies have different bind-
ing affinities to YB-1. However, the Kd of each antibody, as measured by immuno-
precipitation, is approximately 5 nM (Woolley et al. 2011), making this explanation
unlikely. Another explanation is that the fixation of clinical samples prior to IHC
renders the epitope for YB1C unavailable in YB-1 that is located in the nucleus
(Habibi et al. 2008, Wu et al. 2006). However, this also seems unlikely. YB-1
is not detected in the nucleus of cultured cells by YB1C when fixation and tis-
sue thickness is not an issue (Woolley et al. 2011). Another possibility is that the
C-terminus epitope is obscured by PTMs that are important when YB-1 is in its
native conformation. YB-1 peptides with phosphorylation to serine 314, adjacent to
the epitope for YB1C , were identified in both NYB1 and YB1C immunoprecipitated
YB-1. Therefore, phosphorylation of YB-1 on serine 314 also seems to be an unlikely
explanation.
The apparent differences in epitope availability may be explained by steric inhi-
bition caused by protein-protein interactions. When protein lysates are separated in
the absence of reducing or denaturing agents to preserve protein:protein interactions
moieties, this study shows that NYB1 and YB1C bind to YB-1 with different mo-
bilities. This suggests that NYB1 and YB1C differ in their ability to detect specific
protein complexes containing YB-1. The detection of YB-1 in the nuclear frac-
tion by YB1C in BN-PAGE contradicts the findings that YB1C is unable to detect
YB-1 in the nuclei of fixed cells (Woolley et al. 2011). This discrepancy may be ex-
plained by YB-1 binding RNA to form homodimeric YB-1:RNA complexes (Skabkin
et al. 2004). The formation of these YB-1:RNA complexes involves the CSD and the
C-terminus region (Izumi et al. 2001) and could render the epitope of YB1C inac-
cessible in YB-1 molecules that are integrated into the YB-1:RNA complexes. The
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role of the C-terminus region in forming these YB-1:RNA multimers increases as the
YB-1:mRNA ratio increases (Skabkin et al. 2004). Other unknown interactions, par-
ticularly within the spliceosome which contains many proteins (Chapter 1.8.3.1),
may also allow heterodimers to form within the spliceosome. IHC results correlate
elevated YB-1 levels with grade and negative ER-ve/PR-ve status. Therefore, the
increased sensitivity of NYB1, relative to YB1C , may be due to a reduction in the
availability of the C-terminus epitope caused by the effects of increasing YB-1:RNA
ratio on YB-1:RNA multimer formation.
3.3.1 Summary
The results from this chapter demonstrate the potential for the tertiary structure
and protein interactions of YB-1 to influence the prognostic sensitivity of antibodies
against YB-1 in IHC. Furthermore, the lack of strong nuclear localisation in IHC
highlights the potential importance of the function of YB-1 as an RNA binding
protein in aggressive breast cancers.
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Chapter 4
Identification of YB-1 interacting
proteins in the cytoplasm and
nucleus
4.1 Introduction
The ability of YB-1 to influence cell biology via a wide range of molecular mecha-
nisms, most of which require interaction with either RNA or DNA, is thought to ex-
plain the role(s) of YB-1 in cancer (Chapter 1.8). Previous reports have identified
the most prominent molecular mechanism of YB-1 in cancer as the process of bind-
ing to DNA to influence gene transcription (Chapter 1.8.2.1). The specific ability
of YB-1 to transactivate genes with CAAT boxes in their promoters is hypothesised
to be important to the function of YB-1 in cancer. However, the chromatin puri-
fied by chromatin immunoprecipitation of endogenous YB-1 (Astanehe et al. 2012)
showed no evidence that YB-1 binds to CAAT boxes (Dolfini & Mantovani 2013b).
A review that followed this observation concluded that YB-1 may act via post-
transcriptional regulation in cancer cells (Dolfini & Mantovani 2013a). It is flawed
to equate the lack of clear interaction between YB-1 and inverted y-boxes with a
lack of transcriptional effects for YB-1. However, the importance of gene regulation
at the RNA level should not be discounted.
Translation may have a dominant influence on protein abundance as only ∼
40% of the variation in protein levels was explained by mRNA abundance in murine
fibroblasts (Schwanhäusser et al. 2011). Chapter 3 also shows that most of the YB-
1 in breast cancer cells is in the cytoplasm which provides support for the importance
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of molecular mechanisms of YB-1 besides transcription. YB-1 in the cytoplasm may
influence the biology of cancer cells by binding to RNA and altering gene expression
via a number of post-transcriptional mechanisms (Chapter 1.8.3). When in the
cytoplasm, YB-1 is present in mRNPs and, as a core constituent of mRNPs, YB-1
can promote translational initiation or inhibit translation (Chapter 1.8.3.2). The
other potential function of YB-1 in the cytoplasm of cells is to stabilise mRNA
transcripts (Chapter 1.8.3.3).
Given the predominant cytoplasmic localisation of YB-1 in breast cancers (Chapter
3), the work in this chapter aims to clarify the function(s) of YB-1 in cancer cells.
Phosphorylation is likely to alter the function of YB-1 and high-throughput studies
indicate that YB-1 is phosphorylated along its length (Chapter 1.7.2.1). This work
aimed to deduce the phosphorylation state of YB-1 in cancer cells. The phosphory-
lation was hypothesised to differ depending on the subcellular localisation of YB-1.
A second hypothesis was that the function of YB-1 changes with its subcellular
localisation. This has been examined by studying the protein-protein interactions
(PPI) of YB-1 in the cytoplasm and nucleus. The work in this chapter uses NYB1 for
immunoprecipitating YB-1 in an attempt to include the interactions of the subset
of YB-1 that NYB1 detected in IHC.
4.2 Results
4.2.1 Over-expression of YB-1 is a poor strategy for study-
ing the protein interactions of YB-1
YB-1 constructs were produced to determine the suitability of using exogenously
expressed YB-1 to study the protein interactions of YB-1. A large tag protein, such
as FLAG or GST, was hypothesised to influence the structure of the intrinsically dis-
ordered domains at either end of YB-1. Altering the confirmation of these domains
may alter the function and protein interactions of the expressed YB-1. Therefore,
two constructs were produced with a small tag protein, Human influenza haemag-
glutinin (HA), at either the N-terminus (HA-YB-1) or the C-terminus (YB-1-HA;
Dr Rhodri Harfoot, St. Judes Children’s Hospital, Memphis, USA, performed the
cloning). A549 cells were transfected with the two YB-1 constructs for 72 hours
at which time lysates were produced and then separated using SDS-PAGE. The
results from immunoblotting show that YB-1 with HA at the N-terminus is poorly
expressed (Figure 4.1.A, arrow). This poor expression was due to an error which
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Figure 4.1: YB-1-HA does not behave like endogenous YB-1 on immunoblots from
BN-PAGE. A, immunoblots of protein lysates from A549 cells expressing YB-1 with HA
tags (HA-YB1 and YB1-HA) for 72 hours show the signal from NYB1 and anti-HA. B,
immunoblots from blue-native PAGE of HA YB-1 constructs that were transfected for
48 hours. The signal on the immunoblots comes from either NYB1 or from anti-HA.
Abbreviations; media = media-only cells, Trans ctrl = transfection control, <HA =
position of HA-tagged YB-1.
led to the initiator methionine being included at the start of the coding sequence
of the construct. However, YB-1 with HA at the C-terminus is detected as a fine
band above endogenous YB-1 by NYB1 (Figure 4.1.A, arrow). The presence of
YB-1-HA is further confirmed by the signal produced by anti-HA on immunoblots.
The effect of the over-expression of HA-tagged YB-1 on the multi-protein com-
plex (MPC)s that are detected by NYB1 was tested. Two wild-type HA-tagged YB-1
constructs were over-expressed for 48 hours in A549 cells. The results show that
over-expression of YB-1-HA does not greatly alter the pattern of signal produced by
NYB1 on BN-PAGE (Figure 4.1.B). However, the signal from anti-HA does not
resemble the pattern of endogenous YB-1 produced by NYB1. This result highlights
that the PPI of exogenous YB-1 are likely to differ from those of endogenous YB-
1. The PPI and phosphorylation of endogenous YB-1 became the focus of further
investigation into the PPI of YB-1.
4.2.2 The purification of endogenous YB-1 protein
The aim of this work was to identify separate fractions of YB-1 that were involved
in different cellular processes using cancer cell lines. To do so, A549 and MDA-
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MB231 cells were separated into cytoplasmic and nuclear fractions prior to the
immunoprecipitation of YB-1 using NYB1. Total YB-1 from these two cell lines
was hypothesised to be separated into functionally distinct groupings of YB-1. The
first of these groupings influences RNA stability and translation in the cytoplasm.
The second grouping was the YB-1 that influences transcription and RNA splicing
in the nuclear fraction. Cytoplasmic lysates were prepared from 5 × 107 cells at a
concentration of 1 × 104 cells per µL. Previous observations indicated that ∼ 20% of
the total cellular YB-1 resided in the nucleus of A549 and MDA-MB231 cells (refer to
Chapter 3; Figures 3.5 and 3.8). Therefore, nuclei from 5× 108 cells were used for
nuclear immunoprecipitations (n = 2 for each cell line and subcellular compartment).
Tissue culture and nuclei preparation took place in batches. Following purification,
an aliquot of nuclei was lysed and used to screen for cytoplasmic contaminants.
The remainder was snap-frozen in liquid nitrogen and stored at -80oC. Each YB-1
immunoprecipitation used 100 µg of NYB1 (outlined in Chapter 2.12).
The purified YB-1 was separated using 10% SDS-PAGE and stained using col-
loidal coommassie staining. The band in each lane with the greatest density mi-
grated at around 45 kDa, an appropriate mass to be YB-1 (Figure 4.2.A, <YB-1).
The lanes were cut from the gel, digested with trypsin, and the composition of the
tryptic peptides was analysed using LC-MS/MS (Chapter 2.13). Analysis of the
LC-MS/MS runs confirmed the purification of YB-1. The peptides assigned to YB-1
from all LC-MS/MS runs cover ∼ 90% of YB-1 sequence (Figure 4.2.B). Further-
more, the sequence coverage from individual YB-1 immunoprecipitation samples
provides coverage across most of the linear YB-1 sequence with only the N-terminus
exhibiting inconsistent coverage. This inconsistent coverage is due to a paucity of
lysine and arginine residues in this region and, as a result, trypsin creates fewer, and
longer, peptides from the N-terminus of YB-1.
The amount of YB-1 that was captured by each immunoprecipitation has been
estimated using the data from LC-MS/MS. The LC-MS/MS runs were performed to
maximise peptide identifications rather than provide quantitative data. The YB-1
bands were cut from the coommassie gel for phosphopeptide analysis which further
impairs the accuracy of estimates of YB-1 levels.
The results from the LC-MS/MS data indicated that there was 4-fold less YB-1
recovered from the nucleus of MDA-MB231 cells (peak area under the curve; 2 ×
107 arbitrary units (A.U.) and 2 × 107 A.U.) than from the cytoplasm (peak area
under the curve; 7 × 107 A.U. and 9 × 107 A.U.). In A549 cells, the loading appears
more even with the YB-1 recovered from the nuclei (peak area under the curve; 4 ×
102
Figure 4.2: YB-1 was purified from the cytoplasm and nuclei of A549 and MDA-MB231
cells using NYB1. A, representative coommassie stain of YB1 from the cytoplasm and
nuclei of A549 and MDA-MB231 cells. B, the sequence coverage from peptides for YB-
1 that were identified using LC-MS/MS. The peptide identifications from all runs (sum
total) and each replicate sample (Sample = 1 or 2) from the cytoplasm and nuclei of A549
and MDA-MB231 cells are shown.
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108 A.U. and 7 × 106 A.U.) being 80% of that from the cytoplasm (peak area under
the curve; 4 × 108 A.U. and 3 × 107 A.U.). Inter-run variation was evident between
the replicates from A549 cells. The highest values are from a pair of samples from
A549 cells that were analysed in the first YB-1 immunoprecipitation experiment.
These estimates of YB-1 levels from the LC-MS/MS are at odds with the intensity
of coomassie staining from the YB-1 bands (Figure 4.2.A). The staining intensity
of these YB-1 bands appears to be approximately equivalent, if not slightly greater
in the nuclear fractions where 10-fold more cells were used. This disparity is likely to
be due to inaccurate quantification from the LC-MS/MS as a result of the aforemen-
tioned focus on maximising peptide identifications in addition to the YB-1 peptides
that were lost during phosphopeptide enrichment.
It was hypothesised that the differing functions of YB-1 in the cytoplasm and
nucleus would lead to the YB-1 in the cytoplasm and nucleus bearing phosphoryla-
tion(s) at different sites. To assess whether the phosphorylation of YB-1 varies with
cell line and subcellular compartment, the phosphorylated peptides from each YB-1
band were enriched using TiO2 beads. The captured peptides were analysed using
LC-MS/MS.
Analysis of the MS/MS (MS2) spectra measured by LC-MS/MS indicates that
YB-1 is phosphorylated at multiple locations in both A549 and MDA-MB231 cells
(Table.4.1; notes relating to the detection of phosphorylated peptides in LC-MS/MS
are included in Supplementary figure A.1.1). The most commonly detected
phosphorylation is at S165 of YB-1. Phosphorylation of S165 is detected in the
nucleus and cytoplasm of both A549 and MDA-MB231 cells. In the cytoplasm,
phosphorylation of S165 is reliably identified by two distinct peptides that incorpo-
rate up to 4 serine residues (S165, S167, S174, and S176). There is strong evidence
that the phosphorylation is at S165 (Figure 4.3 - Figure 4.5).
A short peptide that includes S165 and S167 (NYQQNYQNSESGEK) was re-
liably detected in the LC-MS/MS runs for 3 of the 4 cytoplasmic samples (a rep-
resentative MS2 spectrum is shown in Figure 4.3 and the presence or absence of
the peptide in each sample is confirmed in Figure 4.4). The phosphorylation was
localised to S165 using fragment ions which carried the C-terminus, known as y-
series ions, which ended at S167 (y-4) and E166 (y-5) and lacked any mass shift
to indicate the presence of HPO3 (Figure 4.3). However, the C-terminal fragment
ending at S165 (y-6), was shifted by 80 Da indicating the presence of HPO3. The
spectra attributed to this peptide also had fragments from the N-terminus (b-ions)
ending at S165 (b-9) with a neutral loss of H3PO4 (representative spectra is shown
104
Table 4.1: A summary of the phosphorylated YB-1 residues that were detected here in
YB-1 from the cytoplasm and nucleus of A549 and MDA-MB231 cells.
Phosphorylation MDA-MB231 A549
cytoplasm nucleus cytoplasm nucleus
S165 + + + + + + + +
(S165 or S167)∗ + +
(S165 or S167)∗ and (S174 or S176)∗ +
S174 also S176 two + + +
S314 + + + + +
n = 2 for each cell line and subcellular compartment. Two ”+” signs indicate that this
peptide was found in both sample replicates. ∗ = the phosphorylation site could not be
localised unambiguously. two = MS2 scans indicated the presence of two peptides with
HPO3 at the indicated locations.
in Figure 4.3).
The presence of the peptide in each sample was further tested using information
about the chemical composition of the peptides and the natural abundance of heavy
stable isotopes. This information was used to predict the relative abundance of iso-
tope peaks in the MS1 scans (outlined in Chapter 2.13.4 and see Supplementary
figure A.1 for an explanation of isotope peaks in LC-MS/MS). The peaks from pep-
tides that included heavy stable isotopes were included in the analysis to improve
the accuracy of the identification of phosphorylated peptide precursors (Schilling
et al. 2012).
The MS1 scans were used to assess the levels of phosphorylated NYQQNYQNS-
ESGEK generated from YB-1 from the cytoplasm and nuclei of A549 and MDA-
MB231 cells. The results show that NYQQNYQNSESGEK was most abundant
in the two samples from the cytoplasm of MDA-MB231 cells (Figure 4.4). One
MDA-MB231 nuclear replicate sample lacks an MS2 measurement of the precursor.
However, the MS1 scan provides evidence that the peptide was present but failed
to reach the intensity threshold that was required to trigger an MS2 scan (Figure
4.4.A - B). YB-1 peptides with phosphorylated S165 were conservatively estimated
to be at least five-fold more prevalent on cytoplasmic YB-1 (Figure 4.4.B).
Longer YB-1 peptides encompassing S165 - S176 (NYQQNYQNSESGEKNE
GSESAPEGQAQQR) were also phosphorylated at S165 (Figure 4.5). In some
MS2 spectra, single and doubly-charged y-ions from C-terminal fragments ending at
E166 (Y-19) were present. This confirms that HPO3 was not present after E166.
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Figure 4.3: Immmunopurified YB-1 from A549 and MDA-MB231 cells is phosphorylated
at S165. MS2 spectra from NYQQNYQNSESGEK, a YB-1 peptide that spans serine
165 (red) and S167. MS2 spectra of representative unmodified (A, monoisotopic mass
of 1687.7074: m/z = 844.8641 of doubly charged parent ion: Mascot ion score = 60)
and phosphorylated ( B, monoisotopic mass of 1767.6737 , m/z = 884.8478 of doubly
charged parent ion: Mascot ion score = 38) peptides are shown. The fragment ions that
were detected by the Mascot search engine to identify the sequence are highlighted in red
or yellow; yellow denotes a neutral loss of 98 Da (H3PO4) from phosphorylated fragment
ions. y-ions and b-ions represent fragments containing the C-terminus and the N-terminus
respectively. The fragment ions that contain HPO3 (+79.9663) or show a neutral loss of
H3PO4 (- 97.9769; shown in yellow) are highlighted as red in the sequence cartoon and
the location of the phosphorylation is denoted by ”PH”. The ions that were used to
identify the site of phosphorylation are shown between the spectra from unmodified (A)
and phosphorylated (B).
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Figure 4.4: Peptides confirming the phosphorylation of YB-1 at S165 are present in
YB-1 from the cytoplasm from A549 and MDA-MB231 cells. A, extracted MS1 ion chro-
matogram plots showing the peak area under the curve of the monoisotopic (M), M+1,
and M+2 precursor ions for phosphorylated NYQQNYQNSESGEK from the YB-1 puri-
fied from the cytoplasm and nuclei of A549 and MDA-MB231 cells (replicates = Sample 1
or 2). The positive identification of the peptide from MS2 scans is indicated by ID above
the plots. B, plots showing the calculated peak area under the curve derived from the
extracted ion chromatograms shown in A. The isotope dot product (idotp) values indicate
how closely the ratio of the three precursor ions matches the expected ratio (idotp range
= 0 - 1; reliable identifications ≥ 0.90).
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N-terminal fragments, known as a-ions, ending with S165 (a++-9) and E166 (a++-10-
98) were also shifted to indicate the presence of HPO3 and a neutral loss of of H3PO4
respectively. Other peptides with this sequence were detected in the cytoplasm and
nucleus of A549 and MDA-MB231 cells. However, artificial or endogenous modifi-
cations (deamidations) inhibit high confidence in assigning the phosphorylation to
S165. The modifications also makes quantification using MS1 scans ineffective.
Phosphorylation of the peptide AADPPAENSSAPEAEQGGAE at S313 or S314
appears to be a common phosphorylation of YB-1 (Table 4.1). Peptides bearing this
modification were present on YB-1 from the cytoplasm of cells while phosphorylated
S314 was only detected on YB-1 from a single replicate for the nuclei of MDA-MB231
cells (Figures 4.6 - 4.6). Of the peptides detected, most lacked fragment ions to
precisely identify whether the phosphorylation was at S313 or S314. However, one
peptide containing a y-ion indicated that S314 was the site of phosphorylation (Y-11
in Figure 4.6). This mirrors the experience of previous work described in Woolley
et al. (2011) where phosphorylation was either localised to S314 or the spectra were
ambiguous. Therefore, YB-1 is phosphorylated at S314 and the phosphorylation
state of S313 is uncertain.
MS2 spectra also identified a peptide with the sequence NEGSESAPEGQAQQR
and a single phosphorylation (Figure 4.8.A). Two serine residues, S174 and S176,
lie within this peptide. The MS2 scan indicated that two peptides were present, one
was phosphorylated at S174 and the other was phosphorylated at S176 respectively
(Figure 4.8.B). The evidence for this came from the identification of two sets of
y-ions 10 and 11 that confirmed both phosphorylation sites. Therefore, YB-1 was
phosphorylated at S174 and at S176.
The other phosphopeptides lacked consistent detection or the exact site of phos-
phorylation was undetermined (Table 4.1). The purified YB-1 from the nuclear
samples produced a group of peptides with phosphorylation at either S165 or S167.
However, they are only observed in one replicate for immunoprecipitated YB-1 from
the nuclei from each cell line. These peptides appear to be a different population to
the S165 peptides.
In a single replicate from the cytoplasm of MDA-MB231 cells, a peptide with
an amino acid sequence matching Figure 4.5 (NYQQNYQNSESGEKNEGSESAP
EGQAQQR) was phosphorylated at two sites. Analysis of the fragments provided
evidence that one HPO3 was at either S165 or 167 and the other at either S174 or
S176. The mascot scores range from 33.8 - 37.3 depending on how the phosphoryla-
tion sites are arranged. Manual analysis of the raw data indicated that mass signals
108
Figure 4.5: Immmunopurified YB-1 from A549 and MDA-MB231 cells is phosphory-
lated at S165. MS2 spectra from NYQQNYQNSESGEKNEGSESAPEGQAQQR, a YB-1
peptide that spans serine 165 (red), S167, S174, and S176. MS2 spectra of representative
unmodified (monoisotopic mass of 3256.3889: m/z = 1086.4749 of triply charged parent
ion: Mascot ion score = 85, A) and phosphorylated (monoisotopic mass of 3336.3704:
m/z = 1113.1307 of triply charged parent ion: Mascot ion score = 64, B) peptides are
shown. The fragment ions that were detected by the Mascot search engine to identify the
sequence are highlighted in red or yellow; yellow denotes a neutral loss of 98 Da (H3PO4)
from phosphorylated fragment ions. y-ions and b-ions represent fragments containing the
C-terminus and the N-terminus respectively. The fragment ions that contain HPO3 (+
79.9663) or show a neutral loss of H3PO4 (- 97.9769; shown in yellow) are highlighted as
red in the sequence cartoon and the location of the phosphorylation is denoted by ”PH”.
The ions that were used to identify the site of phosphorylation are shown between the
spectra from unmodified (A) and phosphorylated (B).
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Figure 4.6: Immmunopurified YB-1 from A549 and MDA-MB231 cells is phosphorylated
at S314. MS2 spectra from AADPPAENSSAPEAEQGGAE a YB-1 peptide that spans
serine 313 and S314. MS2 spectra of representative unmodified (monoisotopic mass of
1896.7973: m/z = 949.4113 of doubly charged parent ion: Mascot ions score = 11, A)
and phosphorylated (monoisotopic mass of 1976.7636: m/z = 989.3947 of doubly charged
parent ion: Mascot ion score = 39, B) peptides are shown. The fragment ions that were
detected by the Mascot search engine to identify the sequence are highlighted in red or
yellow; yellow denotes a neutral loss of - 98 Da (H3PO4) from phosphorylated fragment
ions. y-ions and b-ions represent fragments containing the C-terminus and the N-terminus
respectively. The fragment ions that contain HPO3 (+ 79.9663) or show a neutral loss
of H3PO4 (- 97.9769; shown in yellow) are highlighted as red in the sequence cartoon
and the location of the phosphorylation is denoted by ”PH”. The ions that were used to
identify the site of phosphorylation are shown between the spectra from unmodified (A)
and phosphorylated (B).
110
Figure 4.7: Peptides confirming the phosphorylation of YB-1 at S314 are present in
YB-1 from the cytoplasm and nuclei of A549 and MDA-MB231 cells. A, extracted MS1
ion chromatogram plots showing the peak area under the curve of the monoisotopic (M),
M+1, and M+2 precursor ions for phosphorylated AADPPAENSSAPEAEQGGAE from
the YB-1 purified from the cytoplasm and nuclei of A549 and MDA-MB231 cells. The
positive identification of the peptide from MS2 scans is indicated by ID above the plots.
B, plots showing the calculated peak area under the curve derived from the extracted ion
chromatograms shown in A. The isotope dot product (idotp) values indicate how closely
the ratio of the three precursor ions matches the expected ratio (idotp range = 0 - 1;
reliable identifications ≥ 0.90).
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Figure 4.8: Immmunopurified YB-1 from A549 and MDA-MB231 cells is phosphorylated
at S174 and S176. MS2 spectra from NEGSESAPEGQAQQR indicates the presence of two
YB-1 peptides with a single HPO3 at either S174 or S176. A, MS
2 spectra of representative
phosphorylated peptides is shown (monoisotopic mass of 1666.6663: m/z = 834.3405 of
doubly charged parent ion: Mascot ion score = 59 [for assignment of HPO3 to S174]
or 54 [for assignment of HPO3 to S176]). The fragment ions that were detected by the
Mascot search engine to identify the sequence are highlighted in red or yellow; yellow
denotes a neutral loss of 98 Da (H3PO4) from phosphorylated fragment ions. y-ions and
b-ions represent fragments containing the C-terminus and the N-terminus respectively.
The fragment ions that contain HPO3 (+ 79.9663) or show a neutral loss of H3PO4 (-
97.9769; shown in yellow) are highlighted as red in the sequence cartoon. B, ions from
1025 - 1300 m/z of the spectrum that highlights the presence of y-ions that support the
presence of two peptides with a single HPO3 at either S174 (labels in red) or S176 (labels
in green).
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for the intact phosphorylated peptides were present in the other replicate IP from
the cytoplasm of MDA-MB231 cells as well as in one of the runs from MDA-MB231
nuclei. In both instances, no fragmentation information for the localisation of the
phosphorylation site was acquired as the precursors failed to reach the intensity
threshold that was required to trigger the acquisition of MS2 scans.
Chapter 3.2.4 highlighted the presence of YB-1 phosphorylated at S102 in
both A549 and MDA-MB231 cells. Information about the subcellular localisation of
YB-1 phosphorylated at S102 has been sought although peptides exhibiting phos-
phorylation at S102 are absent from the LC-MS/MS. Unphosphorylated peptides
including S102 are present in all samples showing that without modification this
peptide species ionises and fragments efficiently during LC-MS/MS. There are 5
arginine and lysine residues in the 10 amino acids that precede S102. Phospho-
rylation can interfere with trypsin cleavage at nearby lysine and arginine residues
(Benore-Parsons et al. 1989, Molina et al. 2007). To accommodate any localised
reduction in the efficiency of trypsin cleavage, the data were searched allowing up to
7 missed trypsin cleavage sites. This did not yield measurements from any peptides
with phosphorylated S102. Therefore, tryptic peptides that include phosphorylation
at S102 of YB-1 have poor compatibility with LC-MS/MS.
This work showed that the YB-1 in A549 and MDA-MB231 cells was phospho-
rylated at multiple sites (S165, S174, S176, and S314). Phosphorylation of S165 was
detected in all samples but was present at elevated levels in YB-1 from the cyto-
plasm. Phosphorylation at S314 appears to be present on YB-1 that is distributed
throughout A549 and MDA-MB231 cells. Other phosphorylated peptides did not
yield sufficient information to localise the HPO3 to a specific residue. These results
confirm that phosphorylation is not an event that is exclusive to YB-1 that resides
in the nucleus of cells.
4.2.3 The protein-protein interactions of YB-1
The PPI of YB-1 were hypothesised to change when YB-1 moves between the cyto-
plasm and nucleus of cultured cells. To study this hypothesis, the PPI of YB-1 that
was immunopurified from the cytoplasm and nuclei of A549 and MDA-MB231 cells
was surveyed. Immunoprecipitated YB-1 was separated on a 10% SDS-PAGE gel
(Figure 4.2.A; n = 2 for each cell line and sub-cellular compartment). The lanes
were cut from the gel, digested with trypsin, and the composition of the tryptic
peptides was analysed using LC-MS/MS (Chapter 2.13). LC-MS/MS was used to
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measure the proteins that had been co-precipitated with the YB-1 in each immuno-
precipitation sample. The results showed that the protein interactions of YB-1 in
the cytoplasm and nuclei of A549 and MDA-MB231 cells were extensive. 295 pro-
teins were identified in all LC-MS/MS runs using the strict filtering criteria and
significance thresholds described in Chapter 2.13 (For the full list see; Table B.1
and CD/Chapter_4/MS_subcell_sum_sht.xlsx).
The distribution of proteins across subcellular compartments and cell lines has
been assessed. Proteins were considered to be identified in the subcellular compart-
ment of a cell line if they satisfied either of the following rules;
Rule A = the protein was detected in both replicates for the subcellular com-
partment in that cell line.
OR
Rule B = the protein was detected in one replicate for the subcellular compart-
ment in that cell line and assigned to that subcellular compartent using Rule A in
the other cell line.
Using these rules, 267 of the 295 proteins that were identified have been assigned
to the cytoplasm and/or nucleus of each cell line. The YB-1 interacting proteins from
A549 and MDA-MB231 cells were very similar with ∼ 80% of proteins copurifying
with YB-1 from both cell lines (Figure 4.9.A; these proteins are listed in CD/
Chapter_4/MS_subcell_sum_sht.xlsx, rows 4 - 270). There were more unique
protein identifications made in the MDA-MB231 cell line (43 or 16.1% of proteins
identified). Of the 267 proteins that have been identified, more than one third were
detected in both the nucleus and the cytoplasm (94/36%) while 118 (44%) proteins
were uniquely identified in nuclear fractions.
The protein interactions that are shared between the two cell lines are likely
to contain PPI of YB-1 that are relevant in other biological contexts. There are
201 proteins that were present in the same subcellular locations in both cell lines
(Figure 4.9.B). From this initial group of 201 proteins, 85 (42.3%) were detected
in both the cytoplasm and the nucleus. In both cell lines, 29 proteins (14.4%)
were identified solely in the cytoplasm while 87 (43.3%) proteins were exclusively
detected interacting with YB-1 in the nucleus of both cell lines. The interactions
were consistent between the two cell lines. While YB-1 is in the nucleus it appears
to interact with a large number of proteins.
The similarity of the detected protein interactions of YB-1 was assessed by com-
paring them to previous publications. To do so, all of the first order protein interac-
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Figure 4.9: Venn diagrams showing the proteins that are detected in IP YB-1 from
the cytoplasm and nucleus of A549 and MDA-MB231 cells. A, the distribution of protein
identifications between A549 (pink) and MDA-MB231 (turquoise) cells. B, the distribution
of protein identifications between the cytoplasm (pink) and nucleus (turquoise). The
number of protein identifications are indicated in each quadrant.
tions of the identified proteins with one another were retrieved from the Experiments
and Databases fields in the String database (for details see Chapter 2.14). Forty-
two (24%) of the 178 first order protein interactions of YB-1 in String were also
detected in this experiment. Other known protein interactions of YB-1 were present
as homologous proteins. In this experiment, the polyadenylate-binding proteins were
resolved as polyadenylate-binding protein 1 (PABP1; P11940) and Polyadenylate-
binding protein 4 (Q13310). YB-1 was listed in the String database as interacting
with two other members of this protein family; Polyadenylate-binding protein 2
(Q86U42) and Polyadenylate-binding protein 3 (Q9H361). Insulin-like growth fac-
tor 2 mRNA-binding protein 1 (Q9NZI8) was also found in both this experiment
and the String database. This experiment also detected the presence of Insulin-like
growth factor 2 mRNA-binding protein 3 (O00425). Other proteins that YB-1 is
known to interact with, such as p53, AKT, and GSK3β, were not detected in this
experiment.
Ribosomal proteins, cytoskeletal proteins, keratins were detected but proteins
from these groups can be recovered due to non-specific interactions during immuno-
precipitation. YB-1 that is bound to RNA may interact with ribosomes and cy-
toskeletal proteins and these interactions are in keeping with YB-1 biology. Contam-
inating proteins that interact non-specifically with the beads should not be present
due to the specific recovery of YB-1 via competitive elution with the immunising
peptide (Figure 4.2 No antibody lane). However, there was no viable control for
proteins that interact transiently with YB-1, or its interaction partners, during the
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immunoprecipitation. Non-specific interactions may have a physiochemical speci-
ficity to YB-1 complexes under ex vivo conditions and thus may be reproducible.
The area of the top three peptides for each protein assignment were used to test
for concordance of the replicate LC-MS/MS runs for each cell line and subcellular
compartment. In spite of the low quality quantification, dendrograms supervise 6
of the immunoprecipitation samples into nuclear and cytoplasmic groupings and
then cell line groupings (Figure 4.10). The A549 cytoplasmic and nuclear fraction
that are not arranged with their replicates were processed separately from the other
samples. In the intervening months, the LC-MS/MS method had been optimised
and the levels of detergent in the immunoprecipitation buffers lowered. A group of
23 proteins with ubiquitous expression are grouped together and this group is likely
to represent contaminants. It includes keratins, cytoskeletal proteins (VIM, Plectin),
miscellaneous proteins (tRNA-splicing ligase RtcB homolog [Q9Y3I0], Complement
component 1 Q subcomponent-binding protein, mitochondrial [C1QBP; Q07021],
Eukaryotic initiation factor 4A-III [P38919], Ubiquitin-40S ribosomal protein S27a
[P62979], 60S ribosomal protein L27a [P46776]), YB-1 and the YB-1 homologue
DNA-binding protein A (DBPA; P16989). Due to its ubiquitous presence in each
sample, YB-1 was also assigned to this group along with most of the keratins in the
sample.
This work indicates that YB-1 interacts with a large number of proteins. The
use of two cell lines highlights that the PPI of YB-1 are consistent between A549
and MDA-MS231 cells. Furthermore, the PPI of YB-1 in the cytoplasm and nucleus
suggests that a number of proteins are likely to move between the two subcellular
compartments with YB-1.
4.2.4 Bioinformatic analyses of co-immunoprecipitating pro-
teins
The potential function of YB-1 in the two cell lines and in each subcellular compart-
ment can be inferred through the PPI of YB-1. The molecular functions of YB-1
are presumably represented by the functions and processes of the PPI of YB-1.
Bioinformatics was used to elucidate the range of functions that could be deduced
from the PPIs. To do this, the proteins that interacted with YB-1 were tested
for the enrichment of bioinformatic terms using DAVID (retrieved from v6.7 on
24.02.2014; Huang et al. 2009a, Huang et al. 2009b). DAVID contains the collated
data, such as gene ontology, KEGG, and protein functional domains, for genes and
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Figure 4.10: Heatmap showing binding partners of endogenous YB-1 in the cytoplasm
and nucleus of A549 and MDA-MB231 cells. Label-free quantification was log-transformed
for clustering and the colour was scaled across each row. Each row represents a protein
that was identified with a consistent subcellular localisation. Grey panels indicate that the
protein was not detected. Label-free quantifications from the top three peptides method
(Silva et al. 2006) are provided in CD/Chapter_4/MS_subcell_sum_Top3.xlsx.
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proteins from a wide variety of sources (terms). This approach assessed whether any
terms are overrepresented in the list of submitted proteins compared to a control,
or background, list; an enrichment score ≥ 1.3 was taken to indicate a significant
enrichment compared to the background (Huang et al. 2009a, Huang et al. 2009b).
The whole genome was used as the background list for this work. Similar terms
were clustered together, to remove the redundancy that is inherent in a database
like DAVID, which has been collated from many sources.
The results indicate that YB-1 participates in many processes (Table 4.2, All
identified; full results in CD/Chapter_4/DAVID_files/All_conserv_DAVID.txt).
RNA binding and processing are the most common processes attributed to the
proteins interacting with YB-1. The enrichment of terms associated with RNA
binding and the ribosome (Enrichment = 64.3) infers the involvement of YB-1 in
translation and possibly RNA stability in A549 and MDA-MB231 cells. A large
group of proteins interacting with YB-1 appears to be involved in RNA processing
and splicing (Enrichment = 33). Another small group of proteins is also involved
in RNA stability (Enrichment = 6.9). A group of nuclear encoded proteins that
localise to the mitochondrial matrix were also present (Enrichment = 2.9). Finally,
a smaller group of proteins with DNA-associated terms are enriched (Enrichment =
2).
Table 4.2: Enriched terms in YB-1 IP proteins from A549 and MDA-MB231 cells.
Cluster description All identified Cytoplasm Nuclear
ribosome:ribonucleoproteins:RNA binding 64.3 (23-145) 33.7 (13-73) 61.1 (28-121)
RNA processing:spliceosome 33.0 (28-82) 11.8 (13-32) 26.5 (24-67)
organelle lumen:nuclear lumen:nucleolus 28.2 (63-116) 6.2 (21-45) 28.7 (50-90)
DNA/RNA helicase activity 11.3 (30-31) 4.5 (5-15) 8.1 (9-22)
ubiquitin conjugation:isopeptide bond 8.7 (25-29) 6.7 (13 - 16) 7.9 (17-23)
mitochondrial matrix 2.9 (3-18) 0.35 (4-12) 3.6 (7-26)
regulation of mRNA stability 6.9 (8) 4.7 (5-13) 6.2 (6-7)
Translational initiation 5.9 (7-11) 8.2 (7-11) -
Protein-DNA complex:chromosome 2 (3-14) - 1.4 (3-10)
Data for Functional Annotation Clustering were retrieved from DAVID, v6.7 on 24.02.2014.
The columns provide the enrichment score for the clustered functional annotation from
amongst a total of 296 proteins for All identified column, 114 proteins in the Cytoplasm
column, and 214 proteins in the Nuclear column. Enrichment scores ≥ 1.3 are significant.
The bracketed numbers show the minimum and maximum number of proteins that were
associated with terms within the cluster.
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The terms associated with the detected proteins can also be used to test for the
specific enrichment of cytoplasmic and nuclear proteins in each fraction. The enrich-
ment of terms associated with translational initiation amongst the 112 proteins from
the cytoplasmic fraction was consistent with YB-1 being present in protein:RNA
complexes during the initiation of translation (Enrichment = 8.2; Table 4.2, Cyto-
plasm; full results in CD/Chapter_4/DAVID_files/unv_cyto_DAVID.txt). YB-1 is
known to participate in translation specifically at translational initiation (Chapter
1.8.3.2). Furthermore, the lack of proteins associated with translational initiation
confirmed that the nuclear fractions were only contaminated with cytoplasmic pro-
teins at very low levels. Information about the function of YB-1 in the nucleus
of A549 and MDA-MB231 cells came from terms associated with RNA process-
ing:spliceosome (Table 4.2, Nuclear; full results in CD/Chapter_4/DAVID_files/
unv_nuc_DAVID.txt). These terms were more enriched in the proteins that interact
with YB-1 in the nucleus (Enrichment = 26.5) than in the cytoplasm (Enrichment
= 11.8). The specific enrichment of proteins interacting with DNA and chromatin in
the nuclear fraction (Enrichment = 1.4) confirms that nuclear proteins were enriched
amongst the proteins recovered with YB-1 from nuclei.
The bioinformatics appear to confirm the predominance of the activities of bind-
ing or interacting with RNA in YB-1 biology. However, a small number of the
proteins recovered using immunoprecipitation of YB-1 indicate that YB-1 also in-
teracts with DNA. These results confirm the multifunctionality of YB-1.
The analysis of enriched terms provide an indication of the processes that the
detected proteins can participate in. However, most biochemical tasks, such as
splicing RNA, building a protein polypeptide, or transcribing DNA, require the
coordination of many processes. An in silico PPI network was built to gain further
insight into which proteins are likely to form functional units. The data sources
for building the in silico PPI differed from those used for the enrichment of terms
analysis. Therefore, this second approach provides independent evidence for the
protein groupings from the enrichment of terms. The interactions between the YB-
1 binding proteins with consistent subcellular localisation were retrieved from a
database of PPI (String, v9.1) and imported into Cytoscape (v3.1) for analysis
and visualisation. The in silico PPI network that resulted from this work was
highly connected with 3505 connections (edges) between the 265 proteins (nodes;
Figure 4.11). This was significantly more edges than the average of 850 edges
from 265 proteins that were randomly sampled from the human genome (p <0.001;
String v9.1). The connectivity of proteins that form complexes with one another
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should be greater than the connectivity of proteins with unrelated functions (Ge
et al. 2001, von Mering et al. 2002). In silico protein interaction networks were
also prepared using the proteins that were uniquely identified in the cytoplasm
(Supplementary figure C.1), proteins that were identified in the cytoplasm and
nucleus (Supplementary figure C.2), and those that were unique to the nucleus
of both cell lines (Supplementary figure C.3).
In an in silico PPI network, the proteins that reside together in MPCs should
form groups of proteins that are strongly connected to one another. These groups
of proteins are referred to as clusters. The presence of protein clusters in the net-
work was tested using decompositional clustering via the Markov Cluster Algorithm
(mcl-edge software Enright et al. 2002, Van Dongen 2012, Van Dongen 2000). The
Markov Cluster Algorithm separates sets of nodes that share a high density of edges
from one another (for more details see Van Dongen 2012). The clustering indi-
cated that there were 10 groups of connected proteins with 4 or more members
(Figure 4.11; full results in CD/Chapter_4/DAVID_files/DAVID_clusters). Six
of these 10 groups of proteins were enriched for some aspect of RNA biology. The
three largest clusters represent different aspects of RNA biology. The largest group-
ing (Cluster 1, red nodes) in the network included the translational machinery as
it was dominated by proteins involved in translation (61/67 proteins, translation
[GO:0006412]). The second largest group (Cluster 2, brown nodes) contains YB-
1 along with other RNA-binding proteins. Together these proteins include parts
of the spliceosome (37/62 proteins, RNA splicing [GO:0008380]). The proteins
in Cluster 3 (blue nodes) cover a wide range of functions associated with RNA
processing (17/36 proteins, RNA metabolic processes [GO:0016070]). Cluster 3
also included proteins that were likely to be involved in ribonucleoprotein complex
biogenesis (16/36 proteins, GO:0022613) and ribosomal or non-coding RNA pro-
cessing (7/36 proteins, rRNA processing [GO:0006364]; 8/36 proteins, non-coding
RNA processing [GO:0034660]). There was also a group of 6 helicases in Cluster
3 (Probable ATP-dependent RNA helicase DDX5 [P17844], ATP-dependent RNA
helicase DDX24 [Q9GZR7], Pre-mRNA-splicing factor ATP-dependent RNA heli-
case DHX15 [O43143], Probable ATP-dependent RNA helicase DDX17 [Q92841],
Putative ATP-dependent RNA helicase DHX30 [Q7L2E3], 5’-3’ exoribonuclease 2
[Q9H0D6]). Two groups of proteins contain cytoskeletal proteins and keratins (Clus-
ter 4, 14 proteins, light green nodes; Cluster 6, aqua blue nodes). The function of
the fifth group of proteins was unclear (Cluster 5, yellow nodes). This group in-
cluded Polyadenylate-binding protein 1 and other RNA-binding proteins that are
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Figure 4.11: Binding partners of endogenous YB-1 in the cytoplasm and nucleus of A549
and MDA-MB231 cells. A network of in silico interactions between the proteins that were
identified interacting with YB-1 (String, v9.1). Markov clustering has been applied and
the network was visualised in Cytoscape (v3.2). The network layout was performed using
the Allegro spring electric plugin. The nodes that were grouped together by the MCL
algorithm are coloured according to the key on the bottom left-hand side of the image.
This key also notes the primary function of the proteins in each cluster. The location of
YB-1 is highlighted by a red circle.
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involved in RNA processing (3/8 proteins, cytoplasmic mRNA processing body as-
sembly [GO:0033962]; 3/8 proteins, nuclear-transcribed mRNA catabolic process,
deadenylation-dependent decay [GO:0000288]) and the regulation of translation (4/8
proteins, regulation of translation [GO:0006417]). A small group of proteins (Clus-
ter 7, pink nodes) appeared to be involved in the negative regulation of translation
(3/5 proteins, GO:0017148) and another small group (Cluster 8, green nodes) were
most likely involved in mRNA splicing (2/3 proteins, RNA splicing [GO:0008380];
2/3 proteins, ribonucleoprotein complex assembly [GO:0022618]).
Two small groups of proteins were comprised of proteins that interact with DNA.
One of these groups (Cluster 9, pink nodes) contains proteins that were implicated
in DNA recombination (3/4 proteins, GO:0006310), histone deacetylation (2/4 pro-
teins, GO:0016575), DNA repair (3/4 proteins, GO:0006281), and also transcription
(4/4 proteins, Transcription DNA-templated [GO:0006351]). Three of these pro-
teins (Paraspeckle component 1 [Q8WXF1], Non-POU domain-containing octamer-
binding protein [Q15233], and Splicing factor, proline- and glutamine-rich [P23246])
can form a complex to influence transcription. However, while it is not included in
the gene ontology for these proteins, all 4 are also known to locate to paraspeckles
and participate in splicing (Fox et al. 2005, Marko et al. 2010). The final group of
proteins with 4 or more members (Cluster 10, purple nodes) consists of histone pro-
teins that are involved in chromatin structure (2/4 proteins, nucleosome positioning
[GO:0016584]; 4/4 proteins, chromatin organization [GO:0006325]).
The in silico PPI network revealed a number of the functions already reported
for YB-1. The principle functions of YB-1 were confirmed by the interaction of YB-1
with proteins that participate in RNA splicing (Clusters 2 and 8), RNA processing
(Cluster 3, 5), and translation (Clusters 1, 5, and 7). There were also protein groups
present that can interact with DNA to influence chromatin structure (Cluster 10)
and gene transcription (Cluster 9).
The connections (edges) within the network highlight groups of proteins that
are likely to act together (clusters; Figure 4.11). It was also hypothesised that
in addition to direct participation in these multiple processes, a critical function of
YB-1 was to regulate processes. To test this hypothesis, the flow of information
through the in silico PPI has been examined by calculating betweenness centrality
(Yan et al. 2010, Yu et al. 2007). Betweenness centrality assesses the likelihood that
a node regulates the flow of information to and from the groups of proteins in the
network. The shortest path that links every pair of nodes in the network is assessed
to calculate the betweenness centrality. For every protein a tally is then made for
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Figure 4.12: Betweenness centrality of the binding partners of endogenous YB-1 in the
cytoplasm and nucleus of A549 and MDA-MB231 cells. The betweenness centrality of
all protein pairs in the in silico PPI network was calculated using CytoNCA plugin in
Cytoscape. The betweenness centrality measurement for each protein in the network has
been graphed. The betweenness centrality measures have been graphed in intervals of 150
and the 10 proteins with the highest calculated betweenness centrality are highlighted in
the graph.
the number of times the protein is part of one of these shortest paths. By controlling
the flow of information between clusters, proteins with a high betweenness centrality
can regulate the behaviour of the network (Yan et al. 2010, Yu et al. 2007).
Betweenness centrality was calculated for all nodes in the in silico PPI network
(Tang et al. 2015). The results reveal that YB-1 has the highest betweenness cen-
trality of any protein in the network (Figure 4.12). This indicates that YB-1 has
the potential to link and regulate the multiple functional groups that are detected
interacting with YB-1.
Using bioinformatics to study the large number of proteins interacting with YB-1
revealed functions that were primarily related to the ability of YB-1 to bind to RNA.
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Groups of proteins with functions specific to every step in the lifecycle of RNA are
present. In the nucleus of both cell lines, YB-1 interacted with a small number of
proteins that influence chromatin. The placement of YB-1 within the in silico PPI
network indicates that YB-1 is well placed to control the activity of the functional
groupings contained within the network.
4.3 Discussion
The data presented in this chapter confirm that:
• The protein interactions of exogenous YB-1 are likely to differ from those of
endogenous YB-1;
• YB-1 is phosphorylated at S165, S174, S176, and S314 in MDA-MB231 and
A549 cells;
• The PPI of YB-1 indicate that YB-1 has similar functions in MDA-MB231
and A549 cells;
• The PPI of YB-1 in MDA-MB231 and A549 cells highlight the importance of
YB-1 in the regulation of RNA transcripts.
The work presented in this chapter characterises the phosphorylations of YB-1 in
the cytoplasm and nucleus of A549 and MDA-MB231 cells. It also analyses the PPI
of YB-1 that was purified using NYB1 in the cytoplasm and nucleus of A549 and
MDA-MB231 cells. RNA binding appears to be central to the molecular functions
of YB-1 in these two cell lines.
4.3.1 Over-expression of YB-1 and protein-protein interac-
tions
The forced expression of exogenous YB-1 in A549 cells shows that the mobility of
HA-tagged YB-1 in A549 cells on BN-PAGE differed from that of endogenous YB-1.
The differing mobility of YB-1 is likely to be caused by endogenous and exogenous
YB-1 having different PPI. These results prompted this study to rely solely on
endogenous YB-1 to assess the PPI of YB-1.
The mobility difference in BN-PAGE also highlights that recombinant proteins
differ from the molecules that they are supposed to mimick. The most obvious
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structural and biochemical differences are often the presence of a ‘tag’ protein
on the N-terminal or C-terminal of the studied protein. These tags commonly
have useful characteristics, such as the availability of high-affinity purification tools
(Glutathione-S-trasnferase; Moron et al. 1979, Smith & Johnson 1988) or the
ability to visualise the protein in live cells (Green-fluorescent protein; Morin &
Hastings 1971, Chalfie et al. 1994). However, tags can affect the tertiary structure
of proteins (Kapust & Waugh 1999, Smyth et al. 2003). The tertiary structure of
intrinsically disordered domains, such as that on either end of YB-1 (Selivanova
et al. 2010, Guryanov et al. 2012), may be influenced by tag proteins. Dahl et al.
(2009) demonstrated that a monoclonal antibody targeting YB-1 detected dena-
tured recombinant YB-1 but not endogenous YB-1 on immunoblots. The authors
proposed that the tag stabilised recombinant YB-1. This may be correct, however,
the ability to move between multiple structures is a functional feature of intriniscally
disordered protein domains.
There are other biochemical differences that distinguish recombinant proteins
from endogenous proteins. The RNA for recombinant proteins lack the process-
ing cues, 3’UTR, 5’UTR, and introns, that are present on endogenous RNA tran-
scripts. These elements influence the transport and translation of RNA transcripts
(Andreassi & Riccio 2009, Moore & Proudfoot 2009). Also potentially problematic
is the introduction of a recombinant protein without feedback mechanisms that slow
the rate of protein production into an otherwise regulated molecular environment.
In A549 cells the molecular functions of YB-1 were already performed by endoge-
nous YB-1. Overexpression of YB-1 has been shown to swamp regulatory signals
(Bader & Vogt 2008) and importantly, for an RNA binding protein like YB-1, other
studies have shown that mRNP function was greatly affected by the stoichiometry
of their constituents (Riley & Steitz 2013).
These experiments were performed to establish tools planned for use during this
PhD study. Exogenous YB-1 fused to tags has been used frequently to study the
functions of YB-1 (Toulany et al. 2011, Davies et al. 2011, Garand et al. 2011, Castel-
lana et al. 2015). The results presented here indicate that the PPI of exogenous and
endogenous YB-1 may differ. Therefore, over-expression of YB-1 is best suited as
a confirmatory method for the results gained from experiments using endogenous
protein.
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4.3.2 Phosphorylation of YB-1 in MDA-MB231 and A549
cells
Multiple phosphorylation sites were identified on the YB-1 that was purified from the
cytoplasm and nuclei of both A549 and MDA-MB231 cells. The phosphorylation of
YB-1 has been confirmed specifically at S165, S174, S176, and S314. This work also
shows that a single YB-1 molecule can be phosphorylated at two locations, once at
S165 or S167 and once at S174 or S176. The use of subcellular fractionation indicates
that the phosphorylation of YB-1 at S165 is more common in the cytoplasm of A549
and MDA-MB231 cells while phosphorylation of YB-1 at S314 occurs throughout
the cells. The other phosphorylation events (Table 4.1) require further work to
confirm their distribution through A549 and MDA-MB231 cells.
These phosphorylation events have been reported in high-throughput studies (see
Chapter 1.7.2.1). However, in the absence of manual curation of MS2 spectra as
was performed here, the results from the high-throughput studies are not definitive
about the location of the phosphorylated residue on peptides that include multiple
phosphorylation sites. The phosphorylation of YB-1 from the cytoplasm and nucleus
of A549 has also been studied by Al Jabry (2016) and the results were concordant
with those presented here.
The results presented in this thesis indicate that the phosphorylation of YB-1
at other sites is common in A549 and MDA-MB231 cells and highly likely to alter
the activity of YB-1. The phosphorylation of rabbit YB-1 at unspecified sites led
to its incorporation into free and polysomal mRNPs (Minich et al. 1993). Phos-
phorylation also impeded the ability of YB-1 to inhibit cap-dependant translation
(Evdokimova et al. 2006b). In this study, the PPI of YB-1 indicated that YB-1 was
interacting with RNA to influence splicing, RNA transport, and translation. The
identification of multiple phosphorylations highlights their potential to influence the
molecular function of YB-1. In HEK293 cells, the phosphorylation of YB-1 at S165
has been shown to occur following IL-1β exposure (Prabhu et al. 2015). This phos-
phorylation may promote the early stages of cancer development by contributing to
the activation of NF-κB (Prabhu et al. 2015). The means by which phosphorylation
alters the molecular function of YB-1 are still unclear and the work presented here
also shows that S165 can be phosphorylated in the absence of IL-1β exposure in
some cell types. Extensive work has been carried out to characterise the functional
implications of YB-1 being phosphorylated at S102. However, multiple molecular
functions, which are somewhat discordant, have been attributed to this phospho-
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rylation event (Chapter 1.7.2.1). The phosphorylation of another site on YB-1
alongside phosphorylation at S102 may explain the diverse functions that have been
attributed solely to YB-1 that is phosphorylated at S102.
The implications for the function of YB-1 have been not been confirmed for
these phosphorylation events. The initial plan for this experiment was to separate
purified YB-1 using BN-PAGE to describe the phosphorylation and PPI of YB-
1 for each MPC. However, purified YB-1 separates as a monomer in BN-PAGE
(Supplementary figure C.4). This meant that the phosphorylation of YB-1,
and the protein composition of the MPCs, was not determined. The PPI of YB-
1 did, however, provide some general insights into the function of YB-1 that is
phosphorylated at these residues.
4.3.3 Protein interactions of YB-1 in MDA-MB213 and A549
cells
The work reported here examined the PPI of YB-1 in two cancer cell lines. The
protein interactions of YB-1 were extensive and bioinformatic analyses indicated that
they were consistent with the known molecular functions of YB-1 (Chapter 1.8).
Furthermore, the identified proteins had specific functions that were appropriate for
their location in the cells. The high betweenness centrality of YB-1 within the in
silico network also indicates that YB-1 is well placed to control the function of the
proteins in the network.
The proteins that interact with endogenous YB-1 were consistent across the
two cell lines (∼ 80%). The in silico PPI network corroborated the results from
analysis of terms enrichment by showing that the reported multifunctionality of
YB-1 was reflected by specific groups of proteins within the network. Most research
effort into YB-1 necessarily focuses on a specific aspect of YB-1 function. This can
leave the impression that YB-1 neatly switches between functions in response to
stimuli. While this may be true for some of the processes that YB-1 participates
in, it is unlikely to be the case for many of the functions of YB-1. YB-1 is present
in stress granules where it interacts with Trinucleotide repeat-containing gene 6A
protein (GW182) and PABP1 (Kedersha & Anderson 2007). In this work, YB-1
was found to interact with PABP1 but not GW182. YB-1 and PABP1 are likely to
join mRNPs once a transcript has been processed to mRNA. GW182 is likely to be
recruited to mRNPs, and to interact with YB-1 and PABP1, upon stress activation
(Braun et al. 2013). Therefore, many protein interactions of YB-1 will not be
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present in these experiments as the experimental conditions were not conducive to
these interactions occurring.
More generally, the proteins that interact with YB-1 imply that in A549 and
MDA-MB231 cells rather than switching from one function to another, YB-1 partic-
ipates in a large number of processes concurrently at the cellular level. The central
importance of RNA binding in YB-1 biology is confirmed by the interaction of YB-1
primarily with RNA-binding proteins. However, there is also evidence that YB1
interacts with DNA-associated proteins. This is consistent with the observations
from IHC on breast cancer sections, and IF from MDA-MB231 cells, where YB-1 is
primarily in the cytoplasm but a small amount interacts with DNA (Chapter 3).
The molecular functions of YB-1 in mRNA transport and translation meant
that YB-1 was expected to interact with cytoskeletal proteins (Davies et al. 2011,
Hutchins et al. 2010, Maher-Laporte et al. 2010, Chernov et al. 2008b) and ribosomal
proteins (Chapter 1.8.3.2). Both of these groups of proteins are often considered
to be contaminants of immunoprecipitation experiments. IP will recover proteins
that interact non-specifically with protein complexes that contain YB-1. The use
of endogenous YB-1 precluded the use of tandem-affinity purifications which can
identify contaminants more effectively (Mellacheruvu et al. 2013).
The recovery of non-specific proteins was minimised in two ways. Eluting YB-
1 from the bead-NYB1 complex using competition with the NYB1 peptide should
avoid contamination of the samples by proteins that interact non-specifically with
the bead-NYB1 complex. Coommassie staining of the bead-only control confirmed
that negligible contamination came from the bead-NYB1 complex. However, pro-
teins that interact non-specifically with YB-1, or its interaction partners, will be
present in these samples. Keratins can accrue after IP and the keratins that were
detected are likely to be of no relevance to the function of YB-1. Subcellular frac-
tionation mitigated another source of non-specific contamination of immunoprecip-
itations; proteins that have a high affinity for one another but that never come into
contact due to their subcellular localisation (Mellacheruvu et al. 2013). However,
contaminating proteins will be present through non-specific interactions with YB-
1, or its binding partners, and these are difficult to identify. These contaminating
proteins may also behave like transient binding partners. However, the interaction
of YB-1 with ribosomes and cytoskeletal proteins was consistent with the known
functions of YB-1.
These observations are consistent with the findings that YB-1 adheres to newly
transcribed RNAs (Hartmuth et al. 2002, Wolf et al. 2009, Dutertre et al. 2010).
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Many of the proteins that are detected interacting with YB-1 are RNA-binding
proteins that will also adhere to RNAs at some point in their lifecycles (for more
discussion see Chapter 1.8.3). Therefore, many of the protein interactions may be
mediated by the shared interaction of a protein and YB-1 with another protein or
the same RNA transcript.
YB-1 that is binding to RNA in the nucleus should interact with the large number
of proteins that comprise the protein machinery that processes nascent RNA to
mRNA; spliceosomes are some of the biggest macromolecular complexes in the cell
(Chen & Manley 2009). Most of the PPI of YB-1 from nuclei appeared to reflect the
role of YB-1 in splicing and RNA processing. Many of these PPI were also found
in YB-1 from the cytoplasm, indicating the recovery of other RNA binding proteins
that remain with RNA transcripts throughout their lifecycle.
The components of the transcriptional machinery were not unambiguously iden-
tified, the presence of proteins that associate with chromatin (Table 4.2, Protein-
DNA complex:chromosome) confirmed the interaction of YB-1 with DNA. A small
amount of YB-1 was found in the nucleus of cancer cells where it appears to interact
with DNA as well as RNA (Figure 3.5). Therefore, these data do not necessarily
support the notion that YB-1 only influences cancer via RNA mechanisms.
There have been reports that YB-1 is capable of influencing chromatin struc-
ture (Davies et al. 2014). Two mechanisms have been proposed although both
require further validation. The first mechanism is that YB-1 stabilises the histone
acetyltransferase p300 through AKT that leads to chromatin remodelling (Davies
et al. 2014). Davies et al. (2014) also proposes that YB-1 can increase the chromatin
remodelling activity of p300 which in turn, allows YB-1 to function as a transcription
factor for target genes. p300 was not detected in this work.
Although DNA-associated proteins represented a small proportion of interacting
proteins, the small percentage of YB-1 that interacts with DNA could still have
a significant effect. YB-1 that is binding to DNA is expected to interact with far
fewer proteins as transcription can be initiated by <35 proteins (Murakami et al.
2013). An enrichment of annotations can provide insights into the function of protein
groups although it does not rank the biological importance of each functional group.
For YB-1, the processes that it participates in while binding to RNA (splicing,
translation) require the cooperation of many proteins.
Concentrating on the expression of a single gene can illustrate how the relatively
weak enrichment of annotations for chromatin, amongst the proteins that are de-
tected, could still be influential. As a transcription factor, YB-1 may bind to the
129
promoter of this gene to create many transcripts through its action as a dominant
transacting factor. As an RNA binding protein, many YB-1 molecules need to bind
to many RNA transcripts from this same gene to have a dominant transacting in-
fluence. Furthermore, it is likely that multiple YB-1 molecules per RNA transcript
are required.
4.3.4 Summary
The work outlined here supports the notion that YB-1 is a multifunctional protein
that is highly likely to participate in many processes in a single population of cells.
The majority of these processes are related to RNA metabolism and this is consistent
with the localisation of YB-1 in MDA-MB231 cells (Chapter 3.5). A small subset
of the proteins that copurified with YB-1 interact with DNA but they do not provide
strong evidence that YB-1 interacts with DNA as a transcription factor.
YB-1 has many functions in cancer (Chapter 1.4) and the subsequent research
in this thesis focuses on the function of YB-1 in drug resistance. Exposure to a
chemotherapuetic agent, where cells require YB-1 to survive the exposure, is hy-
pothesised to modulate the function of YB-1 to a process that promotes survival.
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Chapter 5
YB-1 confers resistance to
genotoxic stress treatment of
MDA-MB231 cancer cells
5.1 Introduction
The protein interactions of YB-1 in MDA-MB231 and A549 cells indicated that YB-1
was participating in a wide range of processes in dividing cancer cells (Chapter 4).
Notably, the protein interactions of the YB-1 in the nucleus of these cells indicated
that the critical function of YB-1 in the nucleus most likely relied on YB-1 binding
to RNA. The well documented role of YB-1 as a transcription factor (Chapter
1.8.2.1) did not receive direct support, as YB-1 only interacted with a small number
of proteins that were associated with DNA binding in the nucleus (Chapter 4).
This led to interest in the function of YB-1 during other events that were relevant
to cancer. Exposure to chemotherapeutic drugs was chosen as YB-1 can protect
cells during chemotherapy and this protection appears to require the interaction of
YB-1 with DNA (Chapter 1.4.3; discussed below). However, a wide range of drugs
and drug concentrations have been used to assess the functions of YB-1 during drug
exposure (Fujii et al. 1994, Chattopadhyay et al. 2008, Guay et al. 2008a, Garand
et al. 2011). Therefore, it was not clear how to select the appropriate drug and
exposure conditions to assess the molecular functions of YB-1 during drug exposure.
This chapter examined the importance of YB-1 to the survival of a TNBC cell
line, MDA-MB231, during exposure to a variety of chemotherapeutic agents. As
previously noted (Chapter 1.4.3), the biochemical activity of YB-1 in cancers dur-
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ing their exposure to chemotherapeutic agents is still unclear. However, the of YB-1
activity could functions as a transcription factor or a DNA repair protein. YB-
1 may directly interact with DNA to repair damage from DNA damaging agents.
Therefore, initially four common chemotherapeutic drugs with different mechanisms
of action were studied; paclitaxel, doxorubcin, camptothecin, and cisplatin. Pacli-
taxel is a microtubule-stabilizing agent (Blagosklonny & Fojo 1999) and members of
this drug family are used to treat TNBC. Doxorubicin is also used to treat TNBCs.
Doxorubicin can intercalculate with DNA to block DNA replication. The ability
of doxorubicin to kill cancer cells is thought to be mediated by its stabilisation of
DNA topoisomerase II on DNA which blocks DNA replication (Tacar et al. 2013).
Camptothecin inhibits the progression of cells through S-phase by stabilising DNA
topoisomerase I that is complexed with DNA (Liu et al. 2000). The stabilised
complex then has potential to collide with replication forks during S-phase. Camp-
tothecin is not currently used to treat TNBC but analogues are used for colon,
ovarian, cervical, and small cell lung cancers. Cisplatin interacts with DNA and can
cross-link DNA base-pairs to one another. The mode of action for cisplatin is not
fully understood. Cisplatin is not a common treatment for breast cancers but there
is renewed interest in using platinum-based therapies, cisplatin and carboplatin, to
treat TNBC (Byrski et al. 2014, Petrelli et al. 2014). TNBC appear to benefit
specifically from the inclusion of cisplatin in neoadjuvant therapy, as measured by
pathologic complete response (Petrelli et al. 2014). Recent work has highlighted
that cisplatin may be an effective treatment for drug-resistant TNBCs that carry
amplification of the BRCA1 gene (Byrski et al. 2014).
The work in this chapter aimed to confirm the importance of YB-1 to the drug
resistance of MDA-MB231 cells. The role of YB-1 in the drug resistance of MDA-
MB231 cells was tested using depletion of YBX1 mRNA and YB-1 followed by
exposure to chemotherapeutic drugs. The central motivation of this work was to
define drug exposure conditions in which MDA-MB231 cells could only survive when
YB-1 was present. These conditions would be ideal for a robust assessment of how
drug exposure alters the molecular functions of YB-1 by assessing the PPI of YB-1
during cisplatin exposure. Portions of this work are included in Lasham et al. (2016)
and were also presented at The DNA damage response in cell physiology and disease
(EMBO conference, October 2013, Greece).
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5.2 Results
5.2.1 Depleting YB-1 impairs the growth and survival of
MDA-MB231 cells
To assess the role of YB-1 in drug resistance YB-1 was depleted from MDA-MB231
cells prior to the addition of drugs. These experiments provided data about the
effects of depleting YB-1 on the growth and viability of MDA-MB231 cells. This
section focuses on these data. The design of the experiments in this chapter was
outlined in Chapter 2.9 and Figure 2.1. Briefly, MDA-MB231 cells were allowed
to settle for 24 hr in the presence of a non-targeting siRNA duplex (siCTRL) or one of
two siRNA duplexes directed against YB-1 (siYB1 1 and siYB1 2). The transfection
media were replaced with media containing 10% bovine foetal calf serum and the
confluence of each well was monitored every 2 - 3 hrs for 120 hrs using an Incucyte
FLR.
Immunoblotting confirmed that YB-1 was depleted 72 hrs after transfection with
siYB1 1 and siYB1 2 (Figure 5.1.A). The siRNA duplex siYB1 1 appeared to de-
plete YB-1 more efficiently than YB1 2, which was consistent with previous obser-
vations for these siRNA duplexes (A. Braithwaite, personal communication). Trans-
fecting MDA-MB231 cells with 5 nM siYB1 2 had a similar effect on YB-1 levels
as the transfection with 1 nM siYB1 1. Ponceau S staining of the membranes in-
dicated even loading of proteins. However, the resolution of the immunoblots did
not provide sufficient resolution to quantify the degree of YB-1 depletion from the
siRNA duplexes and the transfection efficiency was not confirmed.
The confluence of MDA-MB231 cells following transfection with siCTRL, or ei-
ther of the transfection controls (media-only and transfection reagent only), reached
plateaus after 55 - 96 hrs (representative plot showing cell confluence following trans-
fection with 5 nM siRNA duplexes is shown in Figure 5.1.B). Depleting YB-1 with
either siYB1 1 or siYB1 2 reduced the confluence of MDA-MB231 cells through-
out the 120 hrs of monitoring (representative plot showing cell confluence following
transfection with 5 nM siRNA duplexes is shown in Figure 5.1.B).
The maximal growth-rate of the MDA-MB231 cells was estimated using the
confluence data that was collected every 2 hours during the experiments (outlined
in Chapter 2.9). Using confluence data to derive the growth-rate means that
the growth-rate measurements represent the maximum rate of expansion of the
cell population. The maximal growth-rate may reflect changes in the rate of cell
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Figure 5.1: Depleting YB-1 reduces the growth-rate of MDA-MB231 cells. A, repre-
sentative immunoblot showing the depletion of YB-1 in MDA-MB231 cells 72 hrs after
the transfection with either of two siRNA duplexes directed against YB-1 (siYB1 1 and
YB1 2) but not when a scrambled siRNA duplex is used (siCTRL). B, plot showing the
change in confluence from the MDA-MB231 cells following transfection over 120 hrs (n
= 1). C, maximal growth-rates that were derived from the confluence data in C. D,
plot showing the maximal growth-rates from all experiments where YB-1 was depleted in
MDA-MB231 cells during experimental work for this thesis. The siRNA duplexes are non-
targeting or directed against YB-1 and used at a concentration ranging from 0.2 - 5nM
as indicated above each panel. One-tailed t-tests were used to compare the growth-rates
of MDA-MB231 cells following transfection with siCTRL and siYB1 each concentration
of siRNA duplex. The hypothesis used for the test was that depleting YB-1 reduced the
growth-rate of MDA-MB231 cells; * =p <0.05, ** = p <0.01, *** = p <0.001. Abbre-
viations; media = no transfection reagents, Trans ctrl = transfection reagent control,
siCTRL = scrambled siRNA duplex, siYB1 1 or 2 = two siRNA duplex directed against
YB-1.
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Table 5.1: Depleting YB-1 reduced the growth-rate of MDA-MB231 cells.
siRNA Concentration (nM) Reps Growth-rate ± S.E. p-value (t-value)
siCTRL 5 12 0.895 ± 0.063 -
siYB1 1 5 12 0.418 ± 0.085 0.0001142 (-4.4654)
siYB1 2 5 8 0.588 ± 0.096 0.04634 (-1.8407)
siCTRL 2 7 1.195 ± 0.053
siYB1 1 2 7 0.673 ± 0.077 <0.0001 (-5.5869)
siCTRL 1 15 0.958 ± 0.038
siYB1 1 1 15 0.762 ± 0.048 0.001842 (-3.1836)
siYB1 2 1 7 0.822 ± 0.072 0.1485 (-1.0936)
siCTRL 0.5 4 1.153 ± 0.051
siYB1 1 0.5 4 0.798 ± 0.062 0.002431 (-4.4171)
siCTRL 0.2 7 0.905 ± 0.026
siYB1 1 0.2 7 0.872 ± 0.066 0.3267 (-0.4667)
siYB1 2 0.2 7 0.943 ± 0.031 0.8178 (0.9439)
One-tailed t-tests, Welch Two Sample t-tests, were used to compare the growth-rate of
MDA-MB231 cells following the depletion of YB-1. The hypothesis used for the test was
that depleting YB-1 reduced the growth-rate of MDA-MB231 cells. Significant differences
are shown as bold text (p-value <0.05). Abbreviations; Reps = replication. S.E. =
standard error of the mean.
division, changes in cell survival, and/or changes in cell size. The images from
each experiment were carefully inspected to monitor for changes in cell morphology
and any apparent changes in the morphology of cells have been highlighted in the
results. The maximal growth-rates that are derived from the confluence data in
Figure 5.1.B show that depleting YB-1 appears to reduce the growth-rate of MDA-
MB231 cells (Figure 5.1.C). To confirm this observation the maximal growth-rates
from all of the experiments in this thesis were compared between non-targeting and
YB-1 siRNA duplexes (Figure 5.1.D. The results from statistical comparisons and
replication are shown in Table 5.1). The results show that depleting YB-1 using
siYB1 1 (0.5 - 5 nM) or siYB1 2 (5 nM) reduces the growth-rate of MDA-MB231
cells. Therefore, it was confirmed that depleting YB-1 does reduce the growth-rate
of MDA-MB231 cells.
The experiments described in Chapter 5.2.3 and Chapter 5.2.4 also moni-
tored the death of cells. This was carried out by including YOYO-1 Iodide in the
growth media and the acquisition of fluorescent images with an excitation of 470
nm max and emission of 515 nm every 3 hrs for 120 hrs. YOYO-1 Iodide is cell-
impermeant and produces fluorescence when it intercalculates with DNA from cells
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where the cell membrane is no longer intact (outlined in Chapter 2.9). The data
from YOYO-1 Iodide fluorescence are were normalised to produce a measure that is
termed death index (Death index is; log-transformed[(confluence of the fluorescent
signal / confluence of the cells)]; further details in Chapter 2.9).
Representative images show that depleting YB-1 appeared to increase the num-
ber of non-viable cells (green signal in Figure 5.2.A). The death index of MDA-
MB231 cells 120 hrs after transfection with siCTRL, siYB 1 or siYB 1 (0.2 - 5 nM)
was compared to confirm that depleting YB-1 increased the rate of cell-death. The
results show that the death index was increased in MDA-MB231 cells 120 hrs after
depleting YB-1 using either siYB1 1 or siYB1 2 at one or 5 nM (Figure 5.2.B).
Therefore, the results from these experiments show that depleting YB-1 increased
rates of cell death in MDA-MB231 cells.
Depleting YB-1 reduces the growth-rate of MDA-MB231 cells. Data from a fluo-
rescent marker of non-viable cells indicated that this reduction was in part explained
by increased levels of cell death, or reduced cell viability, following the depletion of
YB-1. The results in the following sections focus specifically how depleting YB-1
alters the response of MDA-MB231 cells to drug exposures.
5.2.2 Depleting YB-1 impairs the growth of MDA-MB231
cells during exposure to chemotherapeutic drugs
YB-1 has an affinity for modified DNA and has been reported to protect cells during
events that alter DNA (Ohga et al. 1996). In this thesis, YB-1 was hypothesised to
contribute to the resistance of MDA-MB231 cells to chemotherapeutic drugs that
modify DNA. The contribution of YB-1 to the tolerance of MDA-MB231 cells to
various drugs was tested by depleting YB-1 in MDA-MB231 cells prior to their
exposure to the drugs. The design of this experiment was outlined in Chapter 2.9
and Figure 2.1. Briefly, MDA-MB231 cells were allowed to settle for 24 hr in the
presence of a non-targeting siRNA duplex (siCTRL) or one of two siRNA duplexes
directed against YB-1 (siYB1 1 and siYB1 2). The transfection media were removed
and replaced with media containing drugs. Four drugs were added in dilution series;
cisplatin (7.5, 12.5, 25, 50, or 100 µM), camptothecin (0.1, 1, 2.5, 5, or 10 µM),
paclitaxel (0.1, 1, 10, 100 nM, 1, or 10 µM), and doxorubicin (0.1, 1, 5, 10, 20
µM). The confluence of each well was monitored every two hrs for 120 hrs using an
Incucyte FLR.
This experiment focussed on the importance of YB-1 to MDA-MB231 cells dur-
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Figure 5.2: YB-1 promotes the viability of MDA-MB231 cells. A, representative com-
posite images show phase-contrast and YOYO-1 Iodide fluorescence from MDA-MB231
cells 72 - 120 hrs after transfection with siRNA duplexes. B, the effects of transfection
with a scrambled siRNA duplex (siCTRL) or one of two siRNA duplexes directed against
YB-1 (siYB1 1 or siYB1 2) on the death index of MDA-MB231 cells (n = 7). Death
index = log-transformed[(confluence of the fluorescent signal / confluence of the cells)].
ANOVA was used to compare siCTRL to siYB1 1 or siYB1 2 at 120 hrs, Tukeys honestly
significant differences were used to compare the effects of changing the concentration of
siRNA duplexes on cell viability; NS = non-significant, * = p <0.05, *** = p <0.001.
Scale bar represents 200 µm.
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ing exposure to 4 drugs. The results from the drug exposures indicate that YB-1
participates in a process, or several processes, that protect MDA-MB231 cells from
all 4 chemotherapeutic drugs that were tested. To compensate for the reduction in
growth-rate that resulted from depleting YB-1 (Figure 5.1.C), the response of the
cells was calculated by normalising the maximal growth-rates for each transfection
(described in Chapter 2.9). Supplementary figures D.1 - D.4 provide plots showing
the change in confluence during the 120 hr monitoring period as well as response
plots showing how individual wells respond to drug exposure.
Depleting YB-1 sensitises MDA-MB231 cells to the microtubule-stabilizing agent
paclitaxel (Figure 5.3.A). The results highlight that at 0.1 µM paclitaxel, the low-
est concentration of paclitaxel used, depleting YB-1 with either siRNA duplex re-
duced the growth of MDA-MB231 cells below 50% response (0.55 ± 0.06 for siCTRL
compared to 0.02 ± 0.01 for siYB1 1 and 0.35 ± 0.01 for siYB1 2; Figure 5.3.A).
The absence of lower concentrations of paclitaxel in the experiment made the ED50
estimates from the log-logistic models unreliable.
The other drugs in this experiment derive their toxicity through their abil-
ity to inhibit DNA synthesis. Each drug achieves this via different mechanisms.
The results show that depleting YB-1 sensitises MDA-MB231 cells to camptothecin
(Figure 5.3.B). Depleting YB-1 reduced the growth-rate of MDA-MB231 cells in
the presence of as little as 0.1 µM camptothecin. This contrasts with the control
MDA-MB231 cells where the maximal growth-rate was unaffected by exposure to
0.1 µM camptothecin (Figure 5.3.B). However, after 72 hrs of exposure to 0.1 µM
camptothecin the confluence of the control cells ceased to increase before reducing,
possibly indicating cell death (Supplementary figure D.2.A siCTRL).
The results also indicate that depleting YB-1 sensitised MDA-MB231 cells to
the presence of cisplatin (Figure 5.3.C). The maximal growth-rate of the control
MDA-MB231 cells had a response of 0.58 ± 0.03 in the presence of 7.5 µM cisplatin.
Depleting YB-1 reduced the growth-rate of MDA-MB231 cells in all concentrations
of cisplatin, reducing to 0.05 ± 0.08 and 0.37 ± 0.02 for siYB1 1 and siYB1 2
respectively in the presence of 7.5 µM cisplatin. Therefore, YB-1 does play a role
in protecting MDA-MB231 cells from cisplatin.
The results from this experiment also showed that depleting YB-1 sensitised
MDA-MB231 cells to doxorubicin exposure (Figure 5.3.D). Exposure to 0.1 µM
doxorubicin reduced the response of siCTRL-transfected MDA-MB231 cells to 0.80
± 0.17. Depleting YB-1 reduced the response of these cells to 0.12 ± 0.07 and 0.35
± 0.02 for the siYB1 1 and siYB1 2 siRNA duplexes respectively.
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Figure 5.3: Depleting YB1 increases the sensitivity of MDA-MB231 cells to drugs with
a range of mechanisms of action. MDA-MB231 cells were transfected with a non-targeting
siRNA duplex (siCTRL) or one of two siRNA duplexes directed against YB-1 (siYB1 1
and siYB1 2; n = 1). The maximal growth-rate of the cells in paclitaxel (0.1, 1, 10,
100 nM, 1, 10 µM); A), camptothecin (0.1, 1, 2.5, 5, 10 µM; B), cisplatin (7.5, 12.5,
25, 50, or 100 µM; C), and doxorubicin (0.1, 1, 5, 10, 20 µM; D) was derived using the
confluence of the MDA-MB231 cells that were monitored for 120 hrs. The response to
drug was calculated as outlined in Chapter 2.9. Dotted horizontal lines indicates a 50%
reduction in relative growth-rate. Vertical lines show the drug concentration where this
50% reduction occurred.
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In summary, depleting YB-1 sensitises MDA-MB231 cells to all of the compounds
that were tested. Therefore, YB-1 appears to protect MDA-MB231 cells during ex-
posure to a range of toxic compounds despite each possessing a different mechanism
for killing cells. The ability of YB-1 to support cellular survival during exposure to
a range of threats does not appear to be consistent with the primary role of YB-1
during drug exposure being to participate in processes that repairing the damage
caused by drugs. It is more consistent with YB-1 having a regulatory role during
drug exposure. Of the chemotherapeutic drugs that were tested in this experiment,
doxorubicin and cisplatin were selected for further examination. Doxorubicin was
selected as it is a common chemotherapeutic for TNBC. Cisplatin was selected due
to the renewed evidence that it may be an effective treatment for a subset of TNBCs
in conjunction with previous reports that YB-1 promotes the survival of cells during
cisplatin exposure (Chapter 1.4.3).
5.2.3 Sensitivity of MDA-MB231 cells to doxorubicin
The preceding experiment led to the hypothesis that YB-1 helps to maintain the
viability of MDA-MB231 cells during doxorubicin exposure. The experiments used
to test this hypothesis was similar to those outlined in Chapter 5.2.2 but they
differed as each siRNA duplex (siCTRL, siYB1-1, and siYB1-2) was used at three
concentrations; 0.2 nM, 1 nM, and 5nM (outlined in Chapter 2.1). Doxorubicin
was included as a 1:1 dilution series starting at 10 µM and ending at 0.165 µM. Cell
death was monitored via the inclusion of YOYO-1 Iodide in the media.
These experiments assessed the importance of YB-1 to MDA-MB231 cells during
doxorubicin exposure. The response curves and confluence plots indicate that deplet-
ing YB-1 slows the growth-rate of MDA-MB231 cells in doxorubicin (Supplementary
figures D.5 - D.8). However, careful examination of the phase-contrast images
highlighted that the MDA-MB231 cells ceased to divide within the first 48 hrs
of exposure to ≥ 0.156 µM doxorubicin. Therefore, during doxorubicin exposure
the maximal growth-rate data represented the expansion of cells rather than cell-
division.
The increased confluence of MDA-MB231 cells in doxorubicin was caused by the
cells expanding, which began to occur after 48 hrs exposure to doxorubicin (Figure
5.4, media inset shows normal size of MDA-MB231 cells). For the final 72 hrs of
the experiments, the morphology of MDA-MB231 cells, which were transfected with
siCTRL siRNA duplex, remained enlarged (Figure 5.4). Furthermore, the lack of
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Figure 5.4: YB-1 contributes to the survival of MDA-MB231 cells during doxorubicin
exposure. Representative composite images show MDA-MB231 cells 72 - 120 hrs after
transfection with a scrambled siRNA duplex (siCTRL) or one of two siRNA duplexes
directed against YB-1 (siYB1 1) are grown in the presence of 0.156 µM doxorubicin. The
images are merged phase-contrast and fluorescence (excitation, 470 nm max; 450 - 490
nm/emission, 515 nm max; 500 - 530 nm) taken with a 10 × objective lens that are
representative of those from the three replicate experiments (n= 3). The insets, labelled
”media”, show the transfected cells grown in media at a matching magnification. Scale
bar represents 200 µm.
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fluorescent signal above most cells indicates that the majority of these cells had intact
membranes and were probably still viable. The absence of cell division, in addition
to the morphology and apparent viability of the cells in 0.165 µM doxorubicin,
suggested that these cells were senescent. However, the cells would need to progress
through the cell cycle in the presence of doxorubicin to enter a senescent state and
this was not confirmed.
The depletion of YB-1 did not stop MDA-MB231 cells from becoming larger while
in the presence of 0.156 µM doxorubicin (Figure 5.4, media inset shows normal
size of MDA-MB231 cells). However, depletion of YB-1 did lead to cells disappear-
ing after 72 hrs of exposure to 0.156 µM doxorubicin. Fluorescence from YOYO-1
Iodide above many of the cells highlighted that death was occurring (Figure 5.4).
The disparity between the size of the control and YB-1 depleted MDA-MB231 cells
precluded the reliable normalisation of the fluorescence data. Therefore, a qualita-
tive analysis was performed. Depleting YB-1 appears to cause most MDA-MB231
cells to die during doxorubicin exposure. The focus of further work in this thesis is
limited to the role of YB-1 during cisplatin exposure (see following section).
The concentration and duration of doxorubicin exposure meant that exposing
MDA-MB231 cells to doxorubicin caused them to cease dividing, although cell death
was relatively infrequent. Depleting YB-1 prior to doxorubicin exposure strongly re-
duced the viability of MDA-MB2331 cells. Therefore, YB-1 participates process(es)
that maintains the viability of the MDA-MB231 cells during exposure to doxoru-
bicin.
5.2.4 Sensitivity of MDA-MB231 cells to cisplatin
For these experiments, YB-1 was hypothesised to protect MDA-MB231 cells during
exposure to cisplatin. The use of cisplatin (0, 1.56, 3.125, 6.25, 12.5, 25, 50 µM),
rather than doxorubicin, is the only modification to the experimental protocol from
the previous section (Chapter 5.2.3).
It has already been noted that depleting YB-1 reduces the growth-rate of MDA-
MB231 cells (Figure 5.1.D and Figure 5.2). Plots of the confluence data highlight
the negative effects of YB-1 depletion and of cisplatin exposure on the growth of
MDA-MB231 cells (all growth plots in Supplementary figures D.9 - D.11).
The confluence data from experiment three highlighted that growth can be reduced
to almost zero when transfections are performed with 5 nM siYB1 1 and siYB1 2
(Figure D.9, experiment 3). In that experiment, the strong impairment of survival
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that accompanied transfection with 5 nM siYB1 1 or siYB1 2 meant that there were
no cells to assess the effects of cisplatin exposure. This reduced the replication to
two experiments for the 5 nM transfections. Therefore, statistical comparisons were
not made at the 5 nM level.
YB-1 was hypothesised to protect MDA-MB231 cells during cisplatin exposure.
To examine the effects of YB-1 depletion on the growth-rate of MDA-MB231 cells
in the presence of cisplatin, the change in growth-rate from the media only for that
siRNA duplex and siRNA duplex concentration was calculated (response). These
response curves were used to derive an estimate of the median effective dose (ED50),
an estimate of a concentration where 50% of the cells would die (for further details
see Chapter 2.9). The results show that depleting YB-1 reduces the ED50 estimates
for MDA-MB231 cells in cisplatin (Figure 5.5; statistics summarised in Table 5.2).
Included in this analysis are the results from a separate series of experiments where
YB-1 was depleted using 2 nM siYB1 1. This experiment included a narrower range
of cisplatin concentrations (1.56 - 12.5 µM cisplatin). The reduced range of cisplatin
concentrations lowered the ED50 estimates but the estimates were consistent within
the experiment. Depleting YB-1 with 2 nM siYB1 1 reduced the ED50 estimate for
MDA-MB231 cells in cisplatin by 1.85 ± 0.69 µM cisplatin (p-value, 0.0087; Table
5.2). Similarly, depleting YB-1 with 1 nM siYB1 1 reduced the ED50 estimate
to 1.81 ± 0.68 µM cisplatin (p-value, 0.0001; Table 5.2). The ED50 estimates
for cisplatin following the depletion of YB-1 with 1 nM or 0.2 nM siYB1 2 or 0.2
nM siYB 1, was significantly lower than the ED50 estimates for equivalent controls
(Table 5.2). These experiments show that depleting YB-1 inhibits the growth-rate
of MDA-MB231 cells during cisplatin exposure.
Representative images from these experiments highlight the negative effects of
depleting YB-1 in MDA-MB231 cells prior to cisplatin exposure. The MDA-MB231
cells that continued to divide in the presence of 1.56 µM cisplatin had a similar
phenotype and size to normal MDA-MB231 cells (Figure 5.6.A). Depleting YB-
1 prior to cisplatin exposure altered the phenotype of MDA-MB231 cells so that
many were shorter, with most cells showing signs of cell death. The size of MDA-
MB231 cells in cisplatin was similar irrespective of YB-1 depletion (Figure 5.6.A,
compared to insets).
The normalised data from YOYO-1 Iodide fluorescence, expressed as death in-
dex, were used to quantify the effects of YB-1 depletion on cell viability during
cisplatin exposure. Depleting YB-1 increased levels of cell death in MDA-MB231
cells (Figure 5.2). The plotted cell viability data appears to confirm that cisplatin
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Figure 5.5: Depleting YB-1 reduces the growth-rate of MDA-MB231 cells during cisplatin
exposure. The effects of varying concentrations of cisplatin (0, 1.56, 3.125, 6.25, 12.5, 25,
50 µM) on the growth-rate of MDA-MB231 cells with and without YB1 protein present.
YB-1 was depleted using two siRNA duplexes directed against YB-1 (siYB1 1 and YB1 2)
or the MDA-MB231 cells were transfected using a scrambled siRNA duplex (siCTRL).
The maximal growth-rate was calculated using the confluence data and for each siRNA
duplex, the response to drug is calculated as outlined in Chapter 2.9. See Table 5.2
for further explanation of the statistical analysis. Dotted horizontal lines indicates a 50%
reduction in relative growth-rate. Vertical lines show the drug concentration where this
50% reduction occurred. Replication; 5 nM, n= 2; 2 nM, n = 4; 1 nM and 0.2 nM n =
3. Abbreviations; ** = p <0.01, *** = p <0.001.
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Table 5.2: Depleting YB-1 reduced the growth-rate of MDA-MB231 cells during exposure
to cisplatin (0 - 50 µM).
siRNA Concentration Reps ED50 ± S.E. Delta ± S.E. p-value (t-value)
(µM) (µM)
siCTRL 5 2 8.30 ± 2.12 - -
siYB1 1 5 2 0.06 ± 0.21 - -
siYB1 2 5 2 2.91 ± 0.80 - -
siCTRL 2 4 2.73 ± 0.42 - -
siYB1 1 2 4 0.88 ± 0.55 -1.85 ± 0.69 0.0087 (2.690)
siCTRL 1 4 9.03 ± 1.50 - -
siYB1 1 1 3 1.81 ± 0.68 -7.22 ± 1.64 0.0001 (4.3986)
siYB1 2 1 3 6.39 ± 1.13 -2.64 ± 1.87 0.1640 (1.4107)
siCTRL 0.2 3 5.08 ± 1.47 - -
siYB1 1 0.2 3 5.30 ± 1.08 0.22 ± 1.82 0.9039 (0.1214)
siYB1 2 0.2 3 6.21 ± 1.19 1.13 ± 1.89 0.5506 (-0.6010)
The dose-response curves were fitted using log-logistic regression. Estimates are for effec-
tive doses where 50% of the cells were killed by cisplatin (ED50). T-tests were used to
compare the ED50 following the depletion of each protein to the ED50 of the siCTRL RNA
duplex, significant differences shown as bold text (p-value <0.05). 2 nM transfections
were from a separate set of experiments with a reduced range of doses (1.56 - 12.5 µM
cisplatin). Reps = replication. S.E. = standard error of the mean.
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Figure 5.6: Depleting YB-1 impairs the survival of MDA-MB231 cells during cisplatin
exposure. A, representative composite images show MDA-MB231 cells which have been
maintained in media that included 1.56 µM for up to 120 hrs after transfection with 1
nM scrambled siRNA duplex (siCTRL) and siYB1 1, one of two siRNA duplexes directed
against YB-1 (the other was siYB1 2). B, the change in the viability of MDA-MB231 cells
during cisplatin exposure relative to cells in media. Relative death index was calculated as
described in Chapter 2.9. The hypotheses that depleting YB-1 increased Relative death
index during cisplatin exposure was tested using two-way analysis of variance; model =
Relative death index ∼ siRNA.concentration + drug. The images shown are merged
phase-contrast and fluorescence (excitation, 470 nm max; 450 - 490 nm/emission, 515 nm
max; 500 - 530 nm) that are representative of those from the three replicate experiments
(n= 3 except for 5 nM siRNA duplexes where n = 2). The insets, labelled ”media”, show
the transfected cells grown in media at a matching magnification. Scale bar represents
200 µM. Abbreviations; * = p <0.05, ** = p <0.01.
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exposure further reduces the viability of MDA-MB231 cells (Supplementary fig-
ure D.12). There was a strong increase in the death index measurements following
transfection with siCTRL MDA-MB231 cells and 120 hrs of exposure to 25 - 50 µM
cisplatin. However, the growth-rate data indicates that depletion of YB-1 sensitises
MDA-MB231 cells to much lower concentrations of cisplitin (1.56 - 3.13 µM).
The effects of depleting YB-1 were examined in greater detail using the cell
viability measurements from cells that were exposed to the two lowest concentrations
of cisplatin (1.56 and 3.125 µM cisplatin) for 120 hrs. The levels of cell death were
assessed using Relative death index. This normalisation controls for the effects
of YB-1 depletion on death index to provide a measure of the cell death that was
induced by drug exposure (explained in detail in Chapter 2.9). The results confirm
that exposing cells to 3.125 µM cisplatin increases cell death compared to cells
exposed to 1.56 µM cisplatin (see rows siYB1 1; 1.56 vs 3.13 µM and siYB1 2;
1.56 vs 3.13 µM in Table 5.3; Figure 5.6.B). Depleting YB-1 also alters the
Relative death index measurements (see rows siYB1 1; transfections and siYB1 2;
transfections in Table 5.3; Figure 5.6.B).
The specific source of differences between the siRNA duplexes were examined
using Tukey’s honest significance tests. All possible combinations of the siRNA du-
plexes and concentrations were included in the post-hoc tests, but only the results
from control versus YB-1 depletion that match in concentration are presented here
(Table 5.3). Insufficient replication (n = 2) meant that post-hoc statistical com-
parisons were not made for 5 nM siRNA duplexes. Depleting YB-1, using either
siYB 1 or siYB1 2, prior to cisplatin exposure increased the Relative death index
measurements relative to siCTRL transfected cells (Table 5.3; Figure 5.6.B). The
Relative death index measurements were unaffected when YB-1 was depleted with
0.2 nM siYB 1 or siYB1 2 (Table 5.3; Figure 5.6.B). Therefore, depleting YB-1
further impairs the viability of MDA-MB231 cells during cisplatin exposure.
The data from YOYO-1 Iodide signal indicates that depleting YB-1 reduces the
viability of MDA-MB231 cells and that cisplatin exposure leads to further losses
in viability. The cell viability data, expressed as Relative death index, from these
experiments indicates that the reduced growth-rate that occurs following YB-1 de-
pletion and cisplatin exposure, can in part be explained by elevated levels of cell
death.
Another set of experiments were performed to assess how depleting YB-1 influ-
ences the survival of cells as they recover from a two hr exposure to cisplatin. This
brief exposure should limit the damage in each cell to a discrete point in the mitotic
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Table 5.3: Depletion of YB-1 increases Relative death index following 120 hrs exposure
to cisplatin (1.56 - 3.13 µM; n = 3).
Comparison Relative death index ± S.E. p-value (F/t-value)
siYB1 1; 1.56 vs 3.13 µM 0.0065 ± 0.0040 0.00247 (11.32)
siYB1 1; transfections - 0.000008 (11.52)
1 nM; siYB1 1 - siCTRL 0.0120 ± 0.0097 0.0096255
0.2 nM; siYB1 1 - siCTRL 0.0042 ± 0.0097 0.7667320
siYB1 2; 1.56 vs 3.13 µM 0.0039 ± 0.0008 <0.000001 (95.701)
siYB1 2; transfections - 0.000856 (6.034)
1 nM; siYB1 2 - siCTRL 0.0024 ± 0.0020 0.0120597
0.2 nM; siYB1 2 - siCTRL 0.0013 ± 0.0020 0.3976222
The hypotheses that depleting YB-1 increased Relative death index during cisplatin ex-
posure was tested using two-way analysis of variance; model = Relative death index ∼
siRNA.concentration + drug. Separate 2-way ANOVAs were performed for siYB 1 and
siCTRL and and YB 2 and siCTRL. The main effects from the 2-way ANOVAs are shown
in italics. Post-hoc tests were performed using Tukey multiple comparisons of means with
selected tests shown. Significant differences are shown as bold text. S.E. = standard
error of the mean.
cycle. Following the cisplatin exposure, the cells had the opportunity to recover
from cisplatin-induced damage in the absence of the added stress of new damage
occurring. For these experiments, YB-1 was depleted in MDA-MB231 cells (siRNA
duplexes at 0.5, 1, 2 nM). Forty-eight hrs later the cells were exposed to 3.125 - 25
µM cisplatin for 2 hrs. The confluence of each well was monitored for 96 hrs after
cisplatin exposure.
The results confirm that depleting YB-1 reduces the survival of MDA-MB231
cells following a two-hr exposure to cisplatin (n = 4; Figure 5.7; the statistical
analyses are summarised in Table 5.4). Irrespective of the concentration used for
the siRNA duplexes, depleting YB-1 reduced the ED50 estimates by half from ∼ 10
µM to ∼ 6 µM cisplatin (Table 5.4).
Together the data from these experiments supports the conclusion that loss of
YB-1 reduces the viability of MDA-MB231 cells during or after cisplatin exposure.
These experiments also indicated that 1.56 - 3.13 µM cisplatin is an appropriate
concentration range to assess the molecular function of YB-1 during cisplatin expo-
sure. Depletion of YB-1 with 0.2 nM siYB 1, or ≤1 nM siYB 2, did not sensitise
MDA-MB231 cells to cisplatin exposure. This indicates that a small amount of YB-1
could still improve the viability of MDA-MB231 cells during cisplatin exposure.
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Figure 5.7: Depleting YB-1 reduces the growth-rate of MDA-MB231 cells following a
two hr exposure to cisplatin (0, 3.125, 6.25, 12.5, 25 µM, n = 4). YB-1 was depleted
using siYB1 1 (0.5, 1, 2 nM) and 48 hrs later media that contained cisplatin was added
for two hrs. The confluence of the cells was then monitored for 96 hrs. The maximum
growth-rate was used to estimate the ED50 for each treatment during 120 hrs to cisplatin.
*** = p-value <0.001.
Table 5.4: Depleting YB-1 reduces the growth-rate of MDA-MB231 cells following two
hrs of exposure to cisplatin (0 - 25 µM; n = 4).
siRNA Concentration (nM) ED50 ± S.E. Delta ± S.E. p-value (t-value)
siCTRL 2 9.80 ± 0.73 - -
siYB1 1 2 5.55 ± 0.37 -4.26 ± 0.82 <0.0001 (5.169)
siCTRL 1 10.56 ± 0.87 - -
siYB1 1 1 5.72 ± 0.68 -4.84 ± 1.10 <0.0001 (4.394)
siCTRL 0.5 10.80 ± 0.78 - -
siYB1 1 0.5 6.66 ± 0.43 -4.14 ± 0.89 <0.0001 (4.634)
The dose-response curves were fitted using log-logistic regression. Estimates for the ef-
fective doses where 50 % of the cells were killed by cisplatin (ED50) are given. T-tests
were used to compare the ED50 following the depletion of each protein to the ED50 of the
siCTRL RNA duplex, significant differences shown as bold text. S.E. = standard error
of the mean.
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5.2.5 Cisplatin exposure alters the subcellular distribution
of YB-1
Challenging cells with various stressors has been shown to cause YB-1 to relocalise to
the nucleus (Koike et al. 1997, Stein et al. 2001, Fujita et al. 2005, Cohen et al. 2010).
It was hypothesised that YB-1 would translocate to the nucleus of MDA-MB231 cells
that were grown in media with 1.56 µM cisplatin. This translocation was hypothe-
sised to be prompted by the participation of YB-1 in either the repair of cisplatin
damage to DNA or the activity of YB-1 acting as a transcription factor for genes
that are involved in the cellular survival response to cisplatin exposure (reviewed
in Chapter 1.4.3). This hypothesis was tested using IF. MDA-MB231 cells were
grown on coverslips with or without 1.56 µM cisplatin for 48 hrs prior to fixation.
The subcellular localisation of YB-1 was analysed using confocal microscopy. The
distribution of YB-1 in the cells matched that discussed in Chapter 3.2.3 and
Figure 3.5. Briefly, most of the YB-1 was in the cytoplasm of the cells and many
cells had low levels of punctate signal from YB-1 in the nucleus (Figure 5.8.A,
overlapping YB-1 and DNA signals in profile plots for cells 1 - 3).
During cisplatin exposure, YB-1 was hypothesised to translocate to the nucleus
of MDA-MB231 cells. However, the results showed that YB-1 remained primarily
in the cytoplasm of all cells after 48 hrs of exposure to 1.56 µM cisplatin (Figure
5.8.B). Cisplatin exposure did lead to more intense YB-1 signal in the nucleus and
an accumulation of YB-1 signal at the perinuclear boundary in the cells (Figure
5.8.B, profile plots for cells 2 - 3). The alterations in the cellular distribution of
YB-1 that occurred following cisplatin exposure were consistent (comparing media
only; Figure 5.8.A and cisplatin exposure; Figure 5.8.B).
Experiments presented in this chapter also show that YB-1 promotes the survival
of MDA-MB231 cells following a short, two hr, exposure to cisplatin. YB-1 was
hypothesised to relocalise to the nucleus of cells following a two hr exposure to
cisplatin (Chapter 1.4.3). To test this hypothesis, ∼ 75% confluent MDA-MB231
cells, on glass coverslips, were exposed to 12.5 µM cisplatin for two hrs. The medium
was changed and, following a two hr recovery period, the cells were processed for
confocal microscopy. The results show an increase in the intensity of YB-1 signal
around the nucleus of MDA-MB231 cells (Figure 5.9.A - B). This signal partially
obscures the YB-1 signal in the nucleus of the cells.
The effect of cisplatin exposure on the residence of YB-1 in the nucleus was
tested using the extraction of cytoplasmic proteins and RNA from MDA-MB231
150
Figure 5.8: Cisplatin exposure increases the levels of YB-1 at the perinuclear boundary
in MDA-MB231 cells. IF signal from NYB1 in MDA-MB231 cells after in media (A) or
after 48 hrs of exposure to 1.56 µM cisplatin (B). Images are Z-projections of the maximal
signal from 3 Z-slices across the nuclei of MDA-MB231 cells. Profile plots show the signal
intensity from the line across each cell to the right of each graph. NYB1 is labelled using
AlexaFluor 488 and gray values are represented using the Green Hot LUT (ImageJ). DNA
labelled with Hoechst is represented as blue. Scale bar is 25 µM.
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Figure 5.9: Brief exposure of MDA-MB231 cells to 12.5 µM cisplatin increases the
intensity of YB-1 staining. A, confocal microscopy shows the signal from NYB1 in MDA-
MB231 cells (also shown in Figure 3.5.A). B, IF signal from NYB1 in MDA-MB231 cells
two hrs after a two hr exposure to 12.5 µM cisplatin. Images are Z-projections of the
maximal signal from 3 Z-slices across the nuclei of MDA-MB231 cells. Profile plots show
the signal intensity from the line across each cell to the right of each graph. NYB1 is
labelled with AlexaFluor 488 and gray values are represented using the Green Hot LUT
(ImageJ). DNA labelled with Hoechst is represented as blue. Scale bar is 25 µM.
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cells following two-hrs of exposure to 12.5 µM cisplatin and another two hr recovery
period (Chapter 2.10.1). The results from confocal microscopy showed that the
signal from YB-1 that was interacting with DNA formed foci which increased in
intensity following the brief exposure to cisplatin (Figure 5.10.A - B, profile plots
for intensity). Therefore, these experiments further confirm the presence of YB-1
in the nucleus. They also confirm that YB-1 interacts with DNA, or nuclear struc-
tures containing RNA that are refractory to RNase digestion, and this interaction
increases following a brief exposure to cisplatin.
The results from two sets of experiments show that during and following cis-
platin exposure, YB-1 is distributed throughout MDA-MB231 cells. Exposing MDA-
MB231 cells to cisplatin leads to YB-1 signal increasing at the periphery of the
nucleus. YB-1 levels also appear to increased in the nucleus during cisplatin expo-
sure. The results from IF following the extraction of cytoplasmic proteins and RNA
confirm that YB-1 interacts with DNA in the nucleus of MDA-MB231 cells.
5.3 Discussion
The results presented in this chapter show that:
• Loss of YB-1 reduces the growth-rate and increases the death index of MDA-
MB231 cells;
• Loss of YB-1 increases the sensitivity of MDA-MB231 cells to paclitaxel, camp-
tothecin, cisplatin, and doxorubicin;
• Loss of YB-1 increases a measure of cell death in MDA-MB231 cells during
exposure to cisplatin;
• Cisplatin exposure leads to the accumulation of YB-1 at the perinuclear bound-
ary;
• The interaction of YB-1 with the DNA of MDA-MB231 cells appears to in-
crease following cisplatin exposure.
5.3.1 Loss of YB-1 reduces the growth and viability of MDA-
MB231 cells
Depleting YB-1 in MDA-MB231 cells was a starting point for many of the experi-
ments that are presented in this chapter. The results indicate that depleting YB-1
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Figure 5.10: YB-1 interacts with DNA before and after a two hr exposure to 12.5 µM
cisplatin. A, IF signal from NYB1 in the nucleus of MDA-MB231 cells (also shown in
Figure 3.5.B). B, the signal from NYB1 in the nucleus of MDA-MB231 cells two hrs
after a two hr exposure to 12.5 µM cisplatin. Images are Z-projections of the maximal
signal from 3 Z-slices across the nuclei of cells. Profile plots show the signal intensity from
the line across each cell to the right of each graph. NYB1 is labelled with AlexaFluor 488
and gray values are represented using the Green Hot LUT (ImageJ). DNA labelled with
Hoechst is represented as blue. Scale bar is 25 µM.
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reduces the growth-rate of MDA-MB231 cells. Increased levels of death are also
shown to accompany the depletion of YB-1 from MDA-MB231 cells. Depleting YB-
1 with 5 nM siYB1 1 or siYB1 2 occasionally led to an almost complete inhibition
of cell growth.
The use of confluence data to estimate growth-rate meant that the relative con-
tribution of cell-division and death was not confirmed. However, others studies
indicate that YB-1 depletion may influence mitosis as depleting YB-1 can lead to an
accumulation of cells in the G1 phase of the mitotic cycle (Chapter 1.4.2). MDA-
MB231 cells accumulate in G1 following the depletion of YB-1 (Yu et al. 2010).
Therefore, the results from Yu et al. (2010) indicate that the reduced growth-rate
that accompanies the depletion of YB-1 from MDA-MB231 cells is likely to result
from the influence of YB-1 on both the cell-cycle and cell viability.
Robust depletion of YB-1 was required before the growth and viability of MDA-
MB231 cells was strongly reduced. Therefore, the results presented here indicate
that in MDA-MB231 cells low levels of YB-1 can promote cell survival. This appears
to contradict the findings from other studies which found that over-expression of YB-
1 promoted many of the functions of YB-1 in cancer, including increased cell division
(Chapter 1.3 - 1.4). Therefore, it appears likely that only a small amount of YB-1
is required to perform the tasks that maintain viability in MDA-MB231 cells. A post-
translationally modified form of YB-1 could also be responsible for the promotion
of the survival of MDA-MB231 cells. There are multiple phosphorylation sites on
YB-1 and many of these sites are phosphorylated in MDA-MB231 cells (Chapter
4.2.2, Toulany et al. 2011). Small amounts of specifically phosphorylated YB-1 may
be retained in MDA-MB231 cells where it can positively influence cell survival.
5.3.2 YB-1 supports cell survival during a range of stress
events
The results presented in this chapter confirm that depleting YB-1 decreases the
growth-rate of MDA-MB231 cells during exposure to a range of cytotoxic drugs
(paclitaxel, camptothecin, doxorubicin, cisplatin). These drugs kill cells via multiple
mechanisms. It is not currently clear if YB-1 has a single molecular function that
promotes cell survival during exposure to these agents.
These results indicate that depleting YB-1 sensitises cells to camptothecin. The
is potentially the first observation that indicates a protective role for YB-1 in MDA-
MB231 cells during camptothecin exposure. The breast cancer cell line, MCF-
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7, was also sensitised to camptothecin exposure by the depletion of YB-1 (Guay
et al. 2008b). However, the importance of YB-1 to cell survival during camptothecin
exposure appears to vary with cell type. Depleting YB-1 had no effect on the
sensitivity of epidermoid cancer (KB) cells to camptothecin (Ohga et al. 1996). In
prostate cancer cells (PC-3), which have mutant p53 (Isaacs et al. 1991, Carroll
et al. 1993), depleting YB-1 had the opposite effect to that observed in this study,
as it improved resistance to camptothecin (Wu et al. 2014). Therefore, YB-1 is only
important to camptothecin resistance in specific cellular contexts.
The results from the current work also confirm a number of studies which have
shown that YB-1 can protect cells from paclitaxel. YB-1 has been shown to improve
the survival of prostate, breast, and ovarian cancer cell lines during or following
paclitaxel exposure (Shiota et al. 2009, Shiota et al. 2011, Kang et al. 2013, Shiota
et al. 2014). Decreasing levels of YB-1 sensitised breast cancer cell lines, including
MDA-MB231 cells, to paclitaxel (Lee et al. 2008, To et al. 2010, Lasham et al. 2016).
However, as with camptothecin, YB-1 was not critical to paclitaxel resistance in
all breast cell lines as depleting YB-1 did not sensitise BT-549 cells to paclitaxel
(Lasham et al. 2016).
In this study doxorubicin exposure is shown to cause MDA-MB231 cells to en-
large and, it appears, to cease dividing (Chapter 5.2.3). The phenotype of these
cells could have indicated senescence. Depleting YB-1 altered the response of MDA-
MB231 cells to doxorubicin exposure so that the majority died. These observations
are consistent with a previous report which found that YB-1 inhibited the ability
of P53 to induce cell death without interfering with the ability of P53 to induce
cell cycle arrest via transactivation of the CDKN1A gene (Homer et al. 2005). The
efficiency of P53 at inducing cell death could explain how a small amount of cellular
YB-1 can inhibit cell-death during doxorubicin exposure. However, the p53 in MDA-
MB231 cells exhibits a gain-of-function mutation which can promote the survival
of MDA-MB231 cells during serum starvation (Hui et al. 2006). Previous research
has shown that following doxorubicin exposure, MDA-MB231 cells undergo delayed
apoptosis (Elmore et al. 2002). Due to the presence of functional p53, MCF-7 cells
became senescent following doxorubicin exposure (Elmore et al. 2002). Therefore,
it is unlikely that the phenotype of the MDA-MB231 cells during doxorubicin expo-
sure reflects senescence (Figure 5.4). Irrespective of this, depleting YB-1 strongly
reduces the viability of MDA-MB231 cells during doxorubicin exposure.
Other studies also indicate that YB-1 protects cells during doxorubicin expo-
sure. Doxorubicin resistance is accompanied by increased levels of YB-1 in HT1080
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fibrosarcoma cells (Levenson et al. 2000) and MCF-7 cells (Yang et al. 2010). Mul-
tiple myeloma cells with, elevated levels of YB-1, are highly proliferative and over-
expression of YB-1 conferred resistance to apoptosis following doxorubicin exposure
(Chatterjee et al. 2008). In bladder cancer cell lines, YB-1 promoted resistance to
doxorubicin (Shiota et al. 2010b). Kim et al. (2013) reported that ectopic expression
of YB-1 protects NIH3T3 fibroblasts during doxorubicin exposure. The ability of
YB-1 to promote resistance to doxorubicin may vary with cell type. Depleting YB-1
had no effect on the sensitivity of KB cells to doxorubicin (Ohga et al. 1996).
Therefore, the initial experiment in this chapter (Chapter 5.2.2) indicates that
YB-1 depletion sensitises MDA-MB231 cells to all four drugs that were tested. This
may indicate that in MDA-MB231 cells, YB-1 functions to generally promote cell
survival. This would also be consistent with the negative effect of depleting YB-1
on MDA-MB231 cell growth-rate and their survival in the absence of drug exposure.
Lasham et al. (2016) proposed that the ability of YB-1 to reduce levels of EGR-1 in
paclitaxel resistance could be a general mechanism for YB-1 to promote cell survival.
5.3.3 YB-1 supports cell survival during cisplatin exposure
The wide variation in the results from other studies was a significant factor that
prompted the experiments in this chapter. The central aim of this work was to
define drug exposure conditions where MDA-MB231 cells survived only when YB-1
was present. The results reported here confirm that depleting YB-1 sensitises MDA-
MB231 cells to cisplatin exposure between 1.56 - 3.13 µM. Furthermore, the drug
response curves utilise a derived response to cisplatin which separates the general
decreases MDA-MB231 cell survival following YB-1 depletion from the effects of
cisplatin exposure on survival. Therefore, the absolute reduction in survival that
accompanies YB-1 depletion and cisplatin exposure was cumulative, and it encom-
passes the reduced survival that was solely derived from depleting YB-1 in addition
to the effects of cisplatin exposure.
A number of previous studies have also focussed on the role of YB-1 in cisplatin
resistance but their exposure conditions, specifically the timing and concentrations
of cisplatin, varied greatly. This variation may reflect differences in the intrinsic
resistance of different cell lines to cisplatin. A cisplatin resistant KB cell line, KCP-
4, has an IC50 of 25 µM compared to 0.4 µM cisplatin in the parental KB cell line
(Fujii et al. 1994). However, some of the studies that focus on YB-1 have used
cisplatin at doses where cell survival is unlikely. For example, a study that showed
157
YB-1 interacting with the MDR-1 promoter to increase the levels of MDR-1 in the
colorectal cancer cell line, HCT-116, exposed the cells to 133 µM cisplatin for 6 hrs
(Chattopadhyay et al. 2008).
Two previous studies from the same research group are directly relevant to the
results presented in this chapter. They focused on the importance of YB-1 to the
survival of two breast cancer cell lines (MCF-7 and MDA-MB231) during cisplatin
exposure. The results are difficult to reconcile with one another and also with
those from this research. In one study, the EC50 for MDA-MB231 and MCF-7
cells following 96 hrs of cisplatin exposure was estimated to be 284 µM cisplatin
and 84 µM cisplatin respectively (Garand et al. 2011). These dosage ranges are
exceedingly high compared to those used in this chapter. However, the same lab
group also used a clonogenic assay where cells were exposed to cisplatin and then
seeded at a low density so that they formed colonies that could be counted (Guay
et al. 2008a). This clonogenic assay also demonstrated that depleting YB-1 impaired
the survival of MCF-7 and MDA-MB231 cells. However, both cell lines were very
sensitive to cisplatin. Eighteen hrs of exposure to 0.5 µM cisplatin reduced the
survival of MDA-MB231 cells by >90% (Guay et al. 2008a). The manner of cisplatin
exposure can alter the apparent sensitivity of cells to cisplatin but the variation in the
results from Garand et al. (2011) and Guay et al. (2008a) appear to be improbable.
The results from the current study provided robust evidence that, irrespective of
the duration of exposure, MDA-MB231 cells do not survive exposure to >25 µM
cisplatin. Furthermore, unlike previous studies, there is clear evidence that the
MDA-MB231 cells continued to divide in the presence of 1.56 - 3.13 µM cisplatin
while depleting YB-1 rendered many cells unviable.
Coarse changes in the localisation of a protein within the cell in response to drug
exposure are likely to indicate that the function of this protein has been altered
by the drug exposure. IF was performed to ensure that this low level of cisplatin
exposure, 1.56 µM cisplatin, had an effect on the subcellular localisation of YB-1.
However, cisplatin exposure did not lead to a strong redistribution of YB-1 in MDA-
MB231 cells. YB-1 did not translocate to provide diffuse signal in the nucleus as
Guay et al. (2008a) observed with ectopically expressed GFP-YB-1 during cisplatin
exposure. Instead, most of the YB-1 remained in the cytoplasm of MDA-MB231
cells during cisplatin exposure, with strong signal in the cytoplasm adjacent to the
nucleus. This perinuclear signal may come from the formation of stress granules
that contain YB-1 (Kedersha & Anderson 2007, Bounedjah et al. 2014, Anderson
et al. 2015). There was also an increase in the levels of YB-1 in the nucleus of MDA-
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MB231 cells following cisplatin exposure. The extraction of cytoplasmic proteins and
RNA provided, to the best of my knowledge, the first images of YB-1 interacting
with DNA within cultured cells in the absence of an interfering signal from YB-
1 interacting with RNA. The extraction of cytoplasmic and RNA bound proteins
prior to IF shows great promise for studying the interactions of YB-1 with DNA in
cultured cells.
5.3.4 Summary
The results presented in this chapter confirm that in MDA-MB231 cells, YB-1 pro-
motes survival during normal cell culture conditions and also during exposure to
a number of drugs. The finding that MDA-MB231 cells require YB-1 to survive
chronic exposure to 1.56 - 3.13 µM, satisfies the central aim of this chapter. YB-1
remained primarily in the cytoplasm of MDA-MB231 cells during exposure to 1.56
µM cisplatin. This cisplatin exposure lead to YB-1 accumulating at the perinu-
clear boundary and there was an increased intensity of YB-1 foci in the nucleus.
The molecular function of YB-1 in MDA-MB231 cells during exposure to 1.56 µM
cisplatin is unknown. The following chapter examined the PPI of YB-1 during cis-
platin exposure to gain further information about the molecular function of YB-1
in MDA-MB231 cells during exposure to 1.56 µM cisplatin.
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Chapter 6
Identification of YB-1 interacting
proteins during cisplatin exposure
6.1 Introduction
The ability of YB-1 to support the survival of MDA-MB231 cells during cisplatin
exposure (Chapter 5) is consistent with previous reports. These reports showed
that in a range of cells, YB-1 contributes to resistance to a variety of chemothera-
peutic agents (Chapter 5.3.3). However, YB-1 interacts with many proteins from
diverse biochemical pathways (Chapter 4).
Research highlights that YB-1 may contribute to the survival of cells during
genotoxic stress via any of the following pathways. YB-1 has been reported to
respond to cellular stress by binding RNA to influence splicing (Dutertre et al. 2010),
by forming stress granules (Onishi et al. 2008, Chernov et al. 2009, Wehner et al.
2010, Salleron et al. 2014, Tanaka et al. 2014, Somasekharan et al. 2015), and by
translation via the promotion of the internal ribosome entry pathway (Evdokimova
et al. 2006b, King et al. 2014, Bisio et al. 2015). YB-1 can also bind to DNA at which
point it may induce or inhibit transcription. Furthermore, by binding to modified
DNA, YB-1 may influence the cellular response to DNA damage (Chapter 1.4.3).
The results of the previous chapter indicate that YB-1 increases its interaction with
DNA during and following cisplatin exposure (Chapter 5.2.5).
When cells are exposed to cisplatin, the activity of YB-1 as a transcription
factor appears to be important. Specifically, YB-1 has been shown to protect a
variety of cancer cells by driving transcription from the MDR-1 gene (Ohga et al.
1996, Ohga et al. 1998, Sengupta et al. 2011, Chattopadhyay et al. 2008). The
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transcriptional activation of MDR-1 has been shown to rely on YB-1 binding to
an inverted CCAAT-box in the MDR-1 gene promoter (Ohga et al. 1996, Ohga
et al. 1998, Sengupta et al. 2011). However, other reports show that YB-1 does not
alter the levels of MDR-1 mRNA or protein (Kaszubiak et al. 2007). Recently, it
has been postulated that YB-1 does not bind to the inverted CCAAT-box in vivo
(Dolfini & Mantovani 2013a, Dolfini & Mantovani 2013b).
Other research into the function of YB-1 during cisplatin exposure centres around
YB-1 binding to double-stranded DNA that is modified by cisplatin (Ise et al. 1999,
Izumi et al. 2001, Gaudreault et al. 2004). The functional outcome of this binding
has not been confirmed, but the research to date has provided support for two sce-
narios. Firstly, YB-1 may be part of the DNA damage sensing and repair machinery.
YB-1 appears to be directly involved in DNA-strand separation in preparation for its
repair by the base excision repair pathway (Gaudreault et al. 2004). YB-1 interacts
with the DNA repair protein complementing XP-C cells (XPC) - UV excision repair
protein RAD23 homolog B (HR23B) complex (Fomina et al. 2015). This complex
is a damage sensing component of the nucleotide excision repair pathway and the
interaction of YB-1 has a synergistic effect on the binding of both to bulky DNA
lesions (Fomina et al. 2015). YB-1 has also been shown to participate in nucleotide
excision repair via an interaction with human endonuclease III (Guay et al. 2008b).
The second scenario is that YB-1 allows DNA synthesis to continue in the presence
of DNA damage by interacting with PCNA to facilitate the initiation of a DNA
damage tolerant synthesis pathway (Ise et al. 1999).
The work presented in this chapter is based around the hypothesis that a cohort
of the proteins that interact with YB-1 in MDA-MB231 cells will be modulated dur-
ing exposure to cisplatin. This cohort of proteins should highlight the biochemical
process via which YB-1 contributes to the resistance of MDA-MB2331 cells during
cisplatin exposure.
An alternative YB-1 purification strategy was used to test this hypothesis. Pro-
teins have been cross-linked in vivo prior to the immunoprecipitation of YB-1 and
LC-MS/MS analyses. Portions of the work in this chapter have been presented at




6.2.1 Optimising strategies for cross-linking YB-1 complexes
To study the PPI of YB-1 during cisplatin exposure, MDA-MB231 cells were cross-
linked to stabilise PPI in situ prior to IP (Chapter 2.13.5). Cross-linking sta-
bilises many transient and weak PPI in cells while also creating adducts between
polypeptide sequences that are proximal (Figure 2.2). These adducts remain when
reduction and alkylation are omitted from the tryptic digestion, ensuring that pairs
of linked peptides are present in the tryptic digestion. LC-MS/MS can be used to
gain information about the peptides that are linked by the cross-links.
The suitability of two cross-linking agents were assessed in this thesis using
formaldehyde (in the form of paraformaldehyde) and dithiobis[succinimidyl propi-
onate] (DSP). Formaldehyde favours reaction with primary amines (R-NH2) but it
may also react with secondary amines (R-NH2-R; reviewed variously in Sutherland
et al. 2008, Klockenbusch & Kast 2010, Leitner et al. 2010). DSP has greater
specificity for the primary amines on lysines or the N-termini of proteins. The
cross-linkers were tested at various concentrations, temperatures, and on adherent
cells or cell suspensions. Following cross-linking, the lysates were separated using
non-reducing SDS-PAGE. The criteria for assessing the efficacy of the cross-linkers
was their ability to slow the migration of YB-1 on non-reducing SDS-PAGE gels.
The results from immunoblotting confirm that both DSP and formaldehyde
cross-links alter the migration of YB-1 in non-reducing SDS-PAGE (Figure 6.1).
In the absence of cross-linking, the YB-1 from MDA-MB231 cells had identical mi-
gration irrespective of whether they had been reduced with DTT (Figure 6.1, lanes
1 - 2). Therefore, the absence of reduction prior to SDS-PAGE did not alter the mi-
gration of YB-1. Cross-linking MDA-MB231 cells using DSP shifted the migration
of some YB-1 signal so that it ranged between ∼ 90 kDa and the top of the gel. DSP
caused this mass shift irrespective of concentration (1 mM or 2 mM) and tempera-
ture (4oC or room temperature). Reducing and heating aliquots of lysates that were
cross-linked with 2 mM DSP caused most YB-1 to migrate as a monomer (slightly
below 50 kDa Figure 6.1, DSP = lane 9). The loss of mass-shifted YB-1 that ac-
companied the reduction and breaking of the di-sulfide bond on DSP confirmed that
DSP cross-links caused the observed mass-shifts in YB-1 signal on immunoblots.
Cross-linking MDA-MB231 cells with paraformaldehyde also altered the migra-
tion of YB-1. When paraformaldehyde was used as a cross-linker, the maximal
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Figure 6.1: The mobility of YB-1 on non-reducing SDS-PAGE alters following the ex-
posure of MDA-MB231 cells to cross-linking agents. Paraformaldehyde and DSP were
used to cross-link the proteins in MDA-MB231 cells to one another prior to their ly-
sis. Immunoblotting was performed using NYB1. Abbreviations; DSP = dithiobis-
succinimidylpropionate (concentration = mM); PFA = paraformaldehyde (concentration
= %); RT = room-termperature; L = molecular ladder.
mass-shifted signal migrated between 90 and 120 kDa (Figure 6.1, lanes 10 - 14).
Cross-linking MDA-MB231 cells with paraformaldehyde between 0.4 and 0.6% at
4oC produced the most consistent alterations in the migration of YB-1. Heating
paraformaldehyde samples breaks the paraformaldehyde cross-links (Jackson 1999).
Heating an aliquot of lysates from MDA-MB231 cells that were cross-linked with
2% paraformaldehyde at 4oC removed most of the mass-shifted YB-1 signal (Figure
6.1, paraformaldehyde = lane 15). The negative effects of formaldehyde on protein
solubility are likely to explain these observations. The absence of mass-shifted YB-1
following reduction with DTT confirmed that formaldehyde cross-links caused the
mass-shift.
Both of the cross-linking agents that were tested successfully cross-link YB-1.
DSP produced the widest range of mass-shifted YB-1. Furthermore, DSP offered
the advantage of creating adducts with consistent masses when intact (Figure 2.2)
and also following reduction and alkylation (Figure 2.3). Information from reduced
and alkylated peptides is critical to searching for cross-linked peptide pairs with LC-
MS/MS. The linking distance of formaldehyde is ∼ 2Å compared to 12 Å for DSP.
However, paraformaldehyde contains polymers of formaldehyde that retain cross-
linking activity at either end; this means that the cross-linking distance can vary.
Therefore, DSP was used as the cross-linker in subsequent experiments.
The immunoblots of lysates from DSP cross-linked MDA-MB231 cells revealed
the presence of monomeric YB-1 (Figure 6.1, migrating slightly below 50 kDa).
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Figure 6.2: Cross-linked YB-1 from MDA-MB231 cells cannot be separated from
monomeric YB-1 prior to its separation by non-reducing SDS-PAGE. A, lysates from
cross-linked MDA-MB231 cells were passed through a 100 kDa molecular weight cut-off
spin filter (MWCO). A 10% non-reducing SDS-PAGE was used to separate the proteins
from the upper (upper) and lower (lower) chambers of the MWCO filter and half of the
gel stained with colloidal commassie G250. B, the other half of the gel in A was used
for immunoblotting with NYB1. Size exclusion chromatography was performed on lysates
from cross-linked MDA-MB231 cells and the fractions collected. The fractions were sepa-
rated using non-reducing 10% SDS-PAGE. The gels were stained with colloidal coomassie
G-250 (C) or blotted to a nylon membrane and YB-1 detected using NYB1 (D).
This monomeric YB-1 could not be cross-linked to YB-1 interaction partners. Dur-
ing IP, the monomeric YB-1 competes with YB-1 that is cross-linked to its inter-
action partners to bind the antibody against YB-1. As the monomeric YB-1 would
reduce the recovery of YB-1 that was cross-linked to its interaction partners, at-
tempts were made to remove it from the cross-linked lysates.
To remove monomeric YB-1, the cross-linked MDA-MB231 cell lysates were
passed through a 100 kDa molecular weight cutoff filter. These lysates were then
separated using non-reducing SDS-PAGE. Coommassie staining and immunoblot-
ting of the 100 kDa flow-through fraction (lower chamber with molecules <100 kDa)
revealed the absence of monomeric YB-1 (Figure 6.2 A - B). Therefore, YB-1 does
not pass through 100kDa molecular cut-off filters.
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Size exclusion chromatography was used as an alternative strategy to separate
monomeric YB-1 from the YB-1 protein complexes in cross-linked MDA-MB231
cell lysates. Coommassie staining of non-reducing SDS-PAGE from size exclusion
chromatography confirmed that the fractions were sorted by size (Figure 6.2 C).
However, the immunoblot from these samples confirmed the presence of monomeric
YB-1 in all fractions that contain YB-1 (Figure 6.2 D). Therefore, monomeric
YB-1 was still observed on non-reducing SDS-PAGE following size exclusion chro-
matography.
These results led to the conclusion that most of the monomeric YB-1 that was
observed on non-reducing SDS-PAGE was absent before and during size exclusion
chromatography. It was hypothesised that the SDS in the SDS-PAGE buffers re-
leases YB-1 from larger molecular assemblages whereupon the released YB-1 mi-
grates as monomeric YB-1. No further attempts were made to purify solely YB-1
that exhibited a mass shift on non-reducing SDS-PAGE.
6.2.2 The mobility of cross-linked YB-1 following cisplatin
and doxorubicin exposure
The distribution of YB-1 in MDA-MB2331 cells was altered following 48 hrs of
cisplatin exposure (Figure 5.8). Changes in the cellular distribution of YB-1 are
likely to indicate changes to the function of YB-1 and also its PPI. However, the
point(s) when YB-1 begins to protect MDA-MB231 cells during cisplatin exposure
remain unknown. It was important to purify YB-1 at the point when it was involved
in protecting MDA-MB231 cells from the effects of cisplatin. Therefore, coarse
temporal information about the response of YB-1 to cisplatin may be used to inform
decisions about when to assess the PPI of YB-1.
It was hypothesised that exposing MDA-MB231 cells to cisplatin and to doxoru-
bicin would alter the mobility of cross-linked YB-1 on non-reducing SDS-PAGE. To
test this hypothesis, MDA-MB231 cells at ∼30% confluence were cultured in media
containing cisplatin (1.56, 3.125, or 6.25 µM) or doxorubicin (0.156 or 0.3125 µM)
for up to 120 hrs (Figure 6.3, n = 3). These data highlighted that exposure to
neither cisplatin nor doxorubicin disrupted the signals from cross-linked YB-1 at a
coarse level. Exposure of MDA-MB231 cells for 4 or 24 hrs did not induce reliable
alterations to the migration of YB-1 (Figure 6.3, lanes 1 - 12). However, following
48 hrs of exposure to cisplatin and doxorubicin there was an increase in YB-1 signal
from ∼ 200 kDa to the top of the gel (Figure 6.3, lanes 13 - 24). This increase
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Figure 6.3: Exposure to cisplatin and doxorubicin does not cause large disruptions to the
mobility of YB-1 from MDA-MB231 cells that are cross-linked using DSP. Representative
immunoblots showing NYB1 signal from MDA-MB231 cells that were incubated with 1.56
- 6.125 µM cisplatin or 0.156 - 0.313 µM doxorubicin for 4 - 120 hrs (n = 3). Lysates were
prepared from DSP cross-linked MDA-MB231 cells and separated using non-reducing 6%
SDS-PAGE gel. Abbreviations; cisplatin (cisp); + = 1.56, ++, 3.13, +++ = 3.25 µM;
doxorubicin (dox); + = 0.156, ++ = 0.313 µM.
was attenuated in the lysates from MDA-MB231 cells exposed to 1.56 µM cisplatin
(Figure 6.3, lanes 14 and 20).
These results indicate that the PPI of YB-1 are most likely to be modulated
following 48 - 120 hrs of cisplatin exposure. There is no evidence that the mobility
of cross-linked YB-1 alters following 4 or 24 hrs of cisplatin exposure. These results,
in conjunction with those from IF (Figure 5.8), led to the decision to collect IP
YB-1 data following 48 and 120 hrs of cisplatin exposure.
6.2.3 Immunoprecipitation of cross-linked YB-1
The work in this chapter utilised a new preparation of affinity purified polyclonal
antibody raised in sheep against the same sequence as NYB1 (NYB1sheep). The abil-
ity of NYB1sheep to purify YB-1 from DSP cross-linked MDA-MB231 lysates was
tested. The binding capacity of the protein-G beads was also tested by using the
protein G beads at 1 × (+) or 2 × (++) the manufacturers capacity for bind-
ing human immunoglobulin G. The results showed that using 50 µg of NYB1sheep
for every mL of lysate at 10 000 cells per µL provided optimal recovery of YB-1
from DSP cross-linked MDA-MB231 cells (Figure 6.4). Using twice the volume of
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Figure 6.4: Optimising the IP of YB-1 using a sheep anti-N-terminal YB-1 (NYB1sheep).
YB-1 was immunoprecipitated using NYB1sheep from lysates prepared from 1 × 106 MDA-
MB231 cells that were cross-linked using DSP. NYB1sheep was used at concentrations
ranging from 10 - 50 µg. The proteins that had bound to NYB1sheep were recovered
using protein G beads at 1 × (+) or 2 × (++) the manufacturers capacity for binding
human immunoglobulin G (2.6 µg igg/µL of storage solution). The recovered proteins
were separated using non-reducing 6% SDS-PAGE and YB-1 detected by immunoblotting
using NYB1.
protein-G beads further improved the recovery of YB-1 from the cell lysates. This
experiment also confirmed that both monomeric YB-1 and cross-linked YB-1 were
recovered using IP. Therefore, 50 µg of NYB1sheep per mL of cross-linked cell lysate
and twice the volume of protein-G beads recommended by the manufacturer was
used for subsequent immunoprecipitations of YB-1.
The next set of experiments optimised the detection of DSP cross-links and
reduced and alkylated DSP adducts on peptides using LC-MS/MS. This step was
important, as detecting cross-linked peptide pairs is challenging and data analysis
relies on knowledge of the peptide sequences that are being searched. YB-1 was
precipitated from 4 × 107 DSP cross-linked MDA-MB231 cells. The purified YB-1
was separated using non-reducing SDS-PAGE and fractions were cut from above
150 kDa. Tryptic peptides were generated from these fractions, but to preserve
intra- and inter-peptide cross-links the reduction and alkylation steps were omitted
(Chapter 2.3). The similarity of intact cross-linked peptides and the reduced and
alkylated peptides was maintained by splitting the peptide pool after over-night
digestion. Aliquots of the peptide samples were reduced, alkylated, and analysed
on LC-MS/MS. These experiments confirmed that DSP modified the peptides and
also that tryptic digestion still occurred in the absence of reduction and alkylation.
These experiments were also used to optimise LC-MS/MS conditions and the
data analysis of cross-linked peptide pairs. Over two experiments, various condi-
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tions were tested, including collision induced disassociation (CID) and higher-energy
collisional dissociation (HCD). Sites of cross-linking were not identified when search-
ing the LC-MS/MS datasets against sequence databases containing all possible DSP
cross-linked peptide pairs (Figure 2.2 B) of the expected YB-1 interaction partners
using the xComb software (Panchaud et al. 2010).
The optimisation experiments confirmed that reduced and alkylated DSP adducts
were readily detected using LC-MS/MS. Intact cross-linked peptide pairs were not
detected. This failure was attributed to the low concentration of the samples. There-
fore, the following experiments utilised more starting material to boost the concen-
tration of peptides that were used for LC-MS/MS.
6.2.4 The purification of cross-linked YB-1 from MDA-MB231
cells during cisplatin exposure
It was hypothesised that the PPI of YB-1 would change while YB-1 promoted the
survival of MDA-MB231 cells during cisplatin exposure. To examine this, YB-1 was
purified from MDA-MB231 cells that were exposed to 1.56 µM cisplatin for 0, 48,
or 96 hrs. This experiment aimed to survey the PPI of YB-1 in MDA-MB231 cells
during cisplatin exposure. It also aimed to gain information about which proteins
interacted directly with YB-1 by analysing cross-linked peptide pairs.
MDA-MB231 cells were grown in 1.56 µM cisplatin for 48 and 96 hrs. The
cells were collected and the cross-linking reaction was performed on these intact
suspension MDA-MB231 cells using 2 mM DSP. For each experimental condition
250 µg of NYB1sheep was used to purify YB-1 from 5 × 107 MDA-MB231 cells.
A control YB-1 IP came from MDA-MB231 cells that were seeded alongside the
cisplatin-treated cells, grown in normal media for 48 hrs, and processed concurrently
with the 48 hr cisplatin sample. It was intended that MDA-MB231 cells would be
harvested following 48 and 120 hrs of cisplatin exposure. However, after 96 hrs of
cisplatin exposure the cells that were intended to be harvested at 120 hrs were ∼ 85
- 95 confluent. The PPI of YB-1 could be affected by the division of cells slowing or
ceasing in response to confluence and these changes would constitute a confounding
effect. Therefore, the cells were harvested 24 hrs early, following 96 hrs of cisplatin
exposure.
The proteins that purified with YB-1 from the cross-linked MDA-MB231 cells
using NYB1sheep were separated by non-reducing SDS-PAGE. The polyacrylamide
gels were fixed and stained using colloidal coomassie G250. Scans of these gels
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Figure 6.5: Coomassie stained non-reducing SDS-PAGE gels showing the proteins that
were recovered by the IP of YB-1 from MDA-MB231 cells following 0, 48, or 96 hrs of
exposure to 1.56 µM cisplatin. The regions of each gel where monomeric YB-1 migrates is
referred to as B1 and the region of the gel where cross-linked YB-1 migrated is referred to
as F1. The region F2 was also cut for LC-MS/MS. Pooled refers to data analyses that
were performed using all fractions from each sample.
showed the recovery of proteins with a higher molecular weight than YB-1 (Figure
6.5). The main protein bands migrate with similar masses to the immunoblots that
were performed using NYB1 (Figure. 6.4). This indicated that the majority of
proteins and protein complexes that were recovered were likely to be in complex
with YB-1. However, the poor resolution of these gels prompted the pooling of the
region of the gel where cross-linked YB-1 migrates (Figure 6.5, >90 kDa; F1). The
monomeric YB-1 band at the base of the gel (B1) was cut separately and the gel
region between B1 and F1 was also cut as a fraction (Figure 6.5, F2). Analyses
that incorporate LC-MS/MS data from all fractions (F1, F2, and B1) are referred
to as pooled (Figure 6.5, pooled).
Information about the direct interaction partners of YB-1 was to be obtained
using MS/MS spectra from cross-linked peptide pairs that included YB-1 and a di-
rect interaction partner that were joined by an inter-protein cross-link (Chapter
2.13.5). Successful identification of these cross-linked peptide pairs required knowl-
edge of the peptide sequences that were likely to be linked to one another. The
pilot studies were deemed to have failed to resolve cross-linked peptide pairs in part
because of insufficient starting material. The signal on the coomassie stained gels
indicated that there was still insufficient material to reliably detect cross-linked pep-
tides. Therefore, each peptide sample was reduced, alkylated, and then injected in
triplicate for LC-MS/MS. The aim of the new approach was to collect quantitative
data about the peptides to allow more accurate estimation of the protein quantities
from each fraction.
The ability of DSP to cross-link YB-1 was confirmed by searching the LC-MS/MS
data with the monoisotopic mass of a reduced and alkylated DSP adduct (145.0197
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u; Figure 2.3) included as a variable modification to lysine residues. The results
show that of the 22 unique peptide sequences that aligned to YB-1, 14 include either
the reduced or alkylated DSP adduct. Of the 14 peptide sequences with evidence
of cross-linking, 9 were only ever observed with the modification corresponding to
a reduced and alkylated DSP adduct. The remaining 5 peptide sequences were
detected with and without DSP adducts. YB-1 peptides with DSP adducts were
detected in LC-MS/MS runs from B1 as well as from F1.
The DSP adducts from the YB-1 that migrated as a monomer, in B1, were
extensive. The YB-1 in this region did not show a mass shift compared to reduced
YB-1, indicating that these adducts were most likely to be the result of DSP reacting
with two lysines on a single YB-1 molecule (intra-protein cross-links). The results
confirmed that the DSP cross-linking reaction was highly efficient in these MDA-
MB231 cells and that YB-1 was cross-linked by DSP.
6.2.5 The PPI of cross-linked YB-1 from MDA-MB231 cells
during cisplatin exposure.
To gain information about the proteins that purify with YB-1, all LC-MS/MS
data (pooled) from this experiment were searched against the human UniProtKB
database. Pooling the searches from all runs and filtering the search data, as
outlined in Chapter 4.2.3, resulted in the identification of 461 unique proteins
(see CD/Chapter_6/All_crosslinked_protein_ID.xlsx for full results including
Uniprot identifiers). Of these 461 proteins, 307 (67%) were observed in all three sam-
ples (Figure 6.6.A; protein groups shown in CD/Chapter_6/euler_xlink_all_
cisplatin.csv). The euler diagram also highlighted that the protein identifica-
tions varied in response to cisplatin exposure without being strongly disrupted.
The altered IP protocol incorporated cross-linking and a new antibody, and this
would have influenced the proteins that were recovered with YB-1. To test the
consistency of the PPI of YB-1, the proteins that copurified with cross-linked YB-1
were compared to the protein identifications from previous purifications of YB-1
(Chapter 4.2.3). This comparison highlighted that 55% of the proteins from the
MDA-MB231 cells in the subcellular experiments were shared with identifications
from the cross-linked MDA-MB231 cells (140 out of 254 proteins; Figure 6.6.B;
protein groups shown in CD/Chapter_6/euler_xlink_all_Mcyt_Mnuc.csv). The
proteins that copurified with YB-1 from both the cytoplasm and nuclei of MDA-
MB231 cells had the best coverage with 59 out of 89 proteins identified in the YB-1
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Figure 6.6: Euler diagrams showing all proteins (pool) that copurify with YB-1 from
cross-linked MDA-MB231 cells and in the cytoplasm and nucleus of MDA-MB231 cells. A,
the distribution of pooled protein identifications between media (red), 48 hrs of cisplatin
exposure (turquoise), and 96 hrs of cisplatin exposure (pale yellow). B, the distribution
of all protein identifications from cross-linked MDA-MB231 cells (red) and the cytoplasm
(turquoise) and nucleus (pale yellow) of MDA-MB231 cells in Chapter 4.2.3. The number
of protein identifications are indicated in each quadrant.
immunoprecipiations from cross-linked MDA-MB231 cells (69%). Of the proteins
that were identified exclusively in the cytoplasm or nucleus of MDA-MB231 cells,
40% of the cytoplasmic (16 out of 40 proteins) and 50% of the nuclear proteins (65
out of 128 proteins) were also identified in this experiment.
The PPI of YB-1 from the cytoplasmic fractions were expected to exhibit the
strongest concordance with the protein list from the cross-linked IP. This is because
the protein lysates were loaded to the YB-1 IP with an input ratio of 1:1 with
these cross-linked immunoprecipiations. The results from the nuclear fractions were
expected to include PPI that were too rare to detect, as the nuclei to cell number
was 10:1 for the nuclear proteins. However, the results showed that ∼ 60% of the
protein identifications from nuclear fractions of MDA-MB231 cells overlapped with
those from YB-1 that was purified from cross-linked MDA-MB231 cells (124 out of
214 proteins; Figure 6.6.B; protein groups shown in CD/Chapter_6/euler_xlink_
all_Mcyt_Mnuc.csv). Therefore, this experiment provided confirmatory evidence of
an interaction with YB-1 for ∼ 60% of the proteins that were identified in Chapter
4.2.3.
Many of the proteins identified in this experiment were absent in cytoplasmic or
nuclear fractions from MDA-MB231 cells (322 out of 461 proteins; Chapter 4.2.3).
These protein level identifications may have been the result of weak and transient
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Figure 6.7: Euler diagrams showing the proteins detected in fraction 1 (F1) from im-
munopurified YB-1 from cross-linked MDA-MB231 cells and in the cytoplasm and nucleus
of MDA-MB231 cells. A, the distribution of protein identifications in F1 between media
(red), 48 hrs of cisplatin exposure (turqoise), and 96 hrs of cisplatin exposure (yellow). B,
the distribution of the pooled protein identifications in F1 from cross-linked MDA-MB231
cells (red) and the cytoplasm (turquoise) and nucleus (pale yellow) of MDA-MB231 cellsin
Chapter 4.2.3. The number of protein identifications are indicated in each quadrant.
interactions being stabilised by DSP. Alternatively, the addition of 2.5 fold more
antibody may have resulted in an increased yield of YB-1 and a concomitant increase
in the amount of copurified proteins.
The region of the gel that contained mass-shifted YB-1 (F1) was hypothesised to
be enriched for the direct interaction partners of YB-1. In total, 272 proteins were
identified in F1 (see; Table E.1 and CD/Chapter_6/F1_crosslinked_protein_ID.
xlsx for full results). The presence of cross-linked proteins in F1 was supported by
a predominance of proteins with a molecular weight below 80 kDa, despite F1 being
cut from above 90 kDa on the gels (77%; 209 of 272 proteins; Figure 6.5). Sixty-
seven percent of the protein identifications were present in all three samples (182
out of 272 proteins; Figure 6.7.A; protein groups shown in CD/Chapter_6/euler_
xlink_F1_drugs.csv). The protein identifications from F1 of the media-only IP
overlapped entirely with those from F1 of the 48 hrs cisplatin exposure YB-1 IP.
Twenty percent of the protein identifications in F1 were unique to the samples that
were exposed to cisplatin (56 out of 272 proteins; Figure 6.7.A). Cisplatin exposure
altered a cohort the PPI of YB-1 in MDA-MB231 cells.
The protein identifications from F1 were also compared to those from the sub-
cellular localisation experiments (Chapter 4.2.3). The direct interaction partners
of YB-1 were hypothesised to be enriched in F1. The presence of these direct inter-
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action partners meant that the identifications that overlapped with the subcellular
experiments were likely to be genuine YB-1 interaction partners. The results show
that 44% of the proteins identified in F1 were also observed in the subcellular frac-
tionation experiments (119 out of 272 proteins; Figure 6.7.B; protein groups shown
in CD/Chapter_6/euler_xlink_F1_Mcyt_Mnuc.csv). Therefore, a greater propor-
tion of the proteins that were identified in F1, the region of the gels that contained
cross-linked YB-1, overlapped with the proteins that were identified in Chapter
4.2.3 when compared to the pooled protein identifications from this experiment
(30% or 139 out of 461; Figure 6.6.B).
Purifying YB-1 from MDA-MB231 cells that were cross-linked using DSP recov-
ered cross-linked YB-1. The detection of peptides with reduced or alkylated DSP
adducts at lysine residues confirmed that the cross-linking was successful. These
adducts were detected on YB-1 peptides from B1 and F1, indicating that intra-
protein and inter-protein DSP cross-links were present on YB-1. Approximately
60% of the protein identifications from Chapter 4 were also observed copurifying
with cross-linked YB-1. However, ∼ 70% of the protein identifications were unique
to this experiment.
6.2.6 Bioinformatic analyses of PPI of cross-linked YB-1
during cisplatin exposure
The potential function(s) of YB-1 in MDA-MB231 cells during cisplatin exposure
were examined by analysing the functions that were attributed to the identified
proteins. These analyses were carried out using DAVID. The results from DAVID for
all protein identifications are provided in CD/Chapter_6/DAVID_files/xlink_all_
DAVID_FAC_20151125.txt. However, the proteins identifications from F1, which
include quantitative data, were the basis for the analyses that follow.
The enrichment analysis presented here was performed using the 272 proteins
that were identified in F1. The results from DAVID provide further support for
the multifunctional nature of YB-1 (summarised in Table 6.1; full results in CD/
Chapter_6/DAVID_files/xlink_F1_DAVID_FAC_20151125.txt). The proteins that
coimmunoprecipitated with mass-shifted YB-1 in F1 were enriched for annotations
relating to interaction with RNA, including those for ribosomal proteins (Enrichment
= 55.35), RNA splicing (Enrichment = 8.63), and RNA stabilisation (Enrichment
= 5.86). Other annotations, which were also observed in the previous experiments,
were associated with the chromosome (Enrichment = 2.22), ubiquitin conjugation
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Table 6.1: Enriched terms in the proteins that interact with cross-linked YB-1 (F1).
Cluster description All identified Up or down
ribosome:ribonucleoproteins:RNA binding 55.35 (54 - 93) -
transit peptide:mitochondrion 12.7 (30 - 54) -
ubiquitin conjugation:isopeptide bond 9.98 (21 - 29) -
RNA processing:spliceosome 8.63 (15 - 60) -
glycolysis 7.81 (12 - 26) -
mRNA stabilization 5.86 (6 - 20) -
Citrate cycle (TCA cycle) 4.83 (7 - 14) -
Reg. of apoptosis:negative reg. of apoptosis 3.74 (17 - 34) -
Internal ribosome entry pathway 2.49 (3 - 7) -
14-3-3 proteins:protein targeting 2.36 (4 - 10) -
chromatin assembly and organisation 2.22 (3 - 20) 1.71 (3 - 24)
DNA:double-stranded DNA binding - 1.90 (4 - 8)
The All identified column includes the 272 proteins that were identified in F1. The Up
or down column includes enrichment analysis from 64 proteins that increased by a ratio
of ≥ 2 or decreased by ≤ 0.5 following either 48 or 96 hrs of exposure to 1.56 µM cisplatin.
All 772 proteins that were identified as copurifying with YB-1 were used as a background
for enrichment analysis of the Up or down column.
(Enrichment = 9.98), and also with mitochondrial localisation (Enrichment = 12.7).
There were groups of enriched terms that were unique to this experiment. Specif-
ically, those associated with glycolysis, the cell cycle (via the 14-3-3 proteins; En-
richment = 2.36), internal ribosome entry pathway (Enrichment = 2.49), and the
citrate cycle (TCA cycle; Enrichment = 4.83) . Therefore, the functions of the
proteins identified in F1 overlapped with the functionality of proteins identified in
Chapter 4.2.4. Additional functional groupings of proteins that interact with RNA
were detected via an enrichment for proteins that were involved in internal ribosome
entry.
The potential function of the proteins that were detected in F1 was further exam-
ined by building an in silico PPI network comprised of all the protein identifications
from F1 using String (v10). This network was highly enriched for edges indicat-
ing a high degree of PPI. There were 4957 edges (PPI) amongst the 268 proteins
that were mapped using the String database (Figure 6.8). The level of PPI that
would be expected from a random sample of 268 proteins from any location in the
genome was 132 edges (Enrichment, protein-protein interaction, P-value = 0; String
v10). Decompositional clustering using markov clustering produced two groups of
proteins that incorporated 78% of the network; cluster 1 (120 proteins) and cluster
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2 (91 proteins) (Figure 6.8; cluster 1 and 2). The in silico network showed that
the proteins in F1 were strongly connected to one another.
More specific details about the effect of cisplatin exposure on the PPI of YB-
1 were gained via label-free quantification of each protein identification from F1.
The label-free quantification used the average peak area of the three most abundant
peptides for each protein identified in F1 (top three peptides method described in
Silva et al. 2006). These data were used to compare the levels of YB-1 in F1 from
each treatment. The levels of YB-1 in the F1 from each cisplatin treatment were
calculated as a ratio of the amount of YB-1 in the control sample. The ratios
from the quantitative data indicated that there was less YB-1 in F1 from the 48 hrs
cisplatin exposure sample (0.82-fold of media) than there was in F1 from media only
cells. There was no difference in the amount of YB-1 in F1 from media MDA-MB231
cells and those following 96 hrs of cisplatin exposure (1.02-fold of media loading).
The quantification of YB-1 was confirmed using the peak area of each precursor
for the YB-1 peptides that were identified in F1 (outlined in Chapter 2.13.4,
Skyline). The results from this more detailed screen of peptide precursor areas
appeared to confirm that there was less YB-1 in F1 following 48 hrs of cisplatin
exposure, with the YB-1 peptide ratio dropping by 0.83± 0.39 relative to media-only
MDA-MB231 cells. Cisplatin exposure for 96 hrs elevated the YB-1 peptides by 1.10
± 0.23 relative to F1 from media. However, the individual peptide quantifications
varied, which was highlighted by the standard errors and also the plot of individual
peptide identifications (Figure 6.9, YBX1). Given the variance in the YB-1 peptide
quantifications, the quantitative values for the proteins identified in F1 were not
normalised to YB-1 loading.
From the 272 proteins that were identified in F1, the abundance of 65 pro-
teins changed following 48 or 96 hrs of cisplatin exposure (by > 2-fold or < 0.5-
fold; full list in CD/Chapter_6/F1_UP_DOWN.xlsx). An analysis of the terms that
were enriched was performed on these 65 proteins, and also YB-1, using DAVID.
A stringent background was used for detecting which terms were enriched amongst
these 65 proteins. This background was the list of all proteins that were identi-
fied in LC-MS/MS from all purifications of YB-1 in thesis (772 proteins; full list in
CD/Chapter_6/DAVID_files/All_proteinIDs_forDAVIDbackground.xlsx). The
results showed that the enriched terms amongst the proteins that had their abun-
dance in F1 modulated by cisplatin exposure, were associated with chromatin as-
sembly and organisation (Enrichment = 1.71) and also double-stranded DNA bind-
ing (Enrichment = 1.90 ; Table 6.1; full results in CD/Chapter_6/DAVID_files/
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Figure 6.8: An in silico network of proteins that copurify with cross-linked YB-1 from
cisplatin-treated MDA-MB231 cells. The predicted interactions of the proteins that were
identified in F1 cross-linked YB-1 (String, v10). Markov clustering was applied and the
network visualised in Cytoscape (v3.2). The network layout was performed using the Al-
legro spring electric plugin. The nodes that were grouped together by the MCL algorithm
have been coloured according to the key on the bottom left-hand side of the image. This
key also notes the primary function of the proteins in each cluster. The location of YB-1
is highlighted by a black circle.
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Figure 6.9: Quantitative changes in a subset of peptides for the proteins that interact
with YB-1 during cisplatin exposure. These proteins were also detected in the cytoplasm
or nuclei of MDA-MB231 cells in Chapter 4.2.3 and the peptide quantification was
performed using MS1 filtering in Skyline. The y-axis was plotted in log2 and the major
y-axis lines indicate a doubling (2) or halving (0.5) of the peptide quantification relative to
no cisplatin exposure. The minor y-axis lines indicate successive doubling or halving of the
quantifications. The mean inferred protein-level fold changes for each treatment are shown
as black lines and the coloured lines linking the treatments lead to peptide-level means.
The colour of the data points indicates which of the triplicate injection each peptide
was detected in (R1 - R3). Abbreviations; YBOX = YB-1, F120A = Constitutive
coactivator of PPAR-gamma-like protein 1, DDX21 = Nucleolar RNA helicase 2, H12 =
Histone H1.2, ODO2 = Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial, ODP2 = Dihydrolipoyllysine-residue
acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, RS27
= 40S ribosomal protein S27, NPM = nucleophosmin, DHX9 = ATP-dependent RNA
helicase A.
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xlink_F1_updown_2to0,5_FAC_allIPbckgrnd_20151125.txt). These results ap-
peared to indicate that during cisplatin exposure, a subset of cellular YB-1 became
more involved in influencing transcription and/or chromatin structure. Thirty of
the 65 (46%) modulated proteins included these enriched terms. The function of
the other 35 proteins is highlighted in the following section.
To gain a better understanding of the relationship between the proteins that
were modulated by cisplatin exposure, an in silico PPI network was built from the
cisplatin modulated proteins. The in silico PPI network of the 62 proteins that
String could map was enriched for edges (150 edges observed; 5.1 edges expected,
P-value = 0, Enrichment, protein-protein interaction, String v10; Figure 6.10).
Nine of the proteins lacked edges that connected them to the rest of the network.
The markov clustering algorithm was used to group the proteins in F1 that
were altered in abundance by cisplatin exposure. The largest group of proteins
that was modulated by cisplatin exposure were the ribosomal proteins, involved in
translation (Cluster 1; 11 of 14 proteins, translation; GO:0006412; Figure 6.10).
The second largest group included many proteins that were unique to this experi-
ment. These proteins were involved in energy metabolism, specifically, the oxida-
tion of carbohydrates and fatty acids (6 of 11 proteins, KEGG pathway; Citrate
cycle [TCA cycle]). Other proteins from this group were mitochondrial (7 out of
11, mitochondrion; GO:0005739). Cluster 4 included proteins that were associated
with the proteasome (5 of 7 proteins, proteolysis; GO:0006508, 4 of 7 associated
with ubiquitin-dependent protein catabolic process; GO:0006511) while cluster 6
was dominated by cytoskeletal proteins (5 of 6 proteins, cytoskeleton; GO:0005856).
The functional annotations for proteins in these clusters were not specifically en-
riched amongst the proteins that were modulated by cisplatin exposure (Table 6.1,
the specific enrichments are summarised in column Up or down).
The proteins in the remaining groups, cluster 3 and cluster 5, included func-
tional annotations that were specifically enriched amongst cisplatin modulated pro-
teins (Table 6.1; chromatin and DNA binding). Cluster 3 was diverse. It in-
cluded proteins that can shuttle between the cytoplasm and nucleus and also form
mRNPs (HNRNPA2B1, ALYREF, YBX1, ILF3, NPM1, ribonucleoprotein complex;
O:0030529). Proteins in this cluster, including YB-1, may also regulate transcrip-
tion (YBX1, ILF3, TRIM28, NPM1; GO:0030528) and transcriptional repression
(YBX1, ILF3, TRIM28; GO:0016564). Cluster 5 was connected to cluster 3 by 4
proteins (NPM1, ILF3, NAP1L1, and NAP1L4). Three of these proteins shared an
annotation for nucleosome assembly (NAP1L1, NAP1L4, NPM1) with 5 of the 7
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Figure 6.10: A network of proteins that copurify with cross-linked YB-1 and change
their abundance in F1 in response to cisplatin exposure (by ≥ 2-fold or ≤ 0.5-fold by top
3 quantification). The predicted in silico interactions of the proteins that were identified
interacting with cross-linked YB-1 (String, v10). Markov clustering was applied and the
network visualised in Cytoscape (v3.2). Nodes that were grouped by the MCL algorithm
have been coloured. The key shows the colour for each node alongside a summary of the
functional annotations for proteins in the cluster. The location of YB-1 is highlighted by
a red circle. The shape of the nodes indicates whether a protein was detected interacting
with YB-1 in a subcellular compartment of MDA=MB231 (Chapter 4.2.4); Square nodes
= not detected in subcellular samples, rhomboid nodes = cytoplasm, diamond nodes =
cytoplasm, and nucleus, arrow = nucleus.
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proteins in cluster 5 (GO:0034728). In addition to the association with nucleosome
assembly, all 7 proteins in cluster 5 were associated with chromosome organization
(GO:0051276).
The network analyses highlighted that two clusters in the in silico network in-
cluded proteins associated with chromatin and DNA binding. These terms appeared
to co-operate with YB-1 to protect MDA-MB231 cells during cisplatin exposure. To
continue studying the process(es) by which YB-1 protects MDA-MB231 cells dur-
ing cisplatin exposure, proteins needed to be selected from those that were detected
interacting with YB-1. The following criteria were used to guide the selection of pro-
teins that had the potential to be important interactions for YB-1 during cisplatin
exposure;
• Proteins whose association with YB-1 was altered by cisplatin exposure;
• Proteins with terms that were enriched specifically in the cisplatin modulated
group (chromatin assembly and organisation; DNA:double-stranded DNA bind-
ing);
• Proteins that functioned as effectors; proteins with enzymatic and/or regula-
tory functions;
• Proteins that were detected in the nucleus of MDA-MB231 cells in Chapter
4.
These guidelines directed research into the 65 proteins that were modulated
following cisplatin exposure. As cisplatin creates DNA damage, effector molecules
involved in DNA repair were of particular interest. Three proteins involved in DNA
repair fit the above criteria; X-ray repair cross-complementing protein 5 [also known
as Ku80] (XRCC5), X-ray repair cross-complementing protein 6 [also known as
Ku70] (XRCC6), and Transcription intermediary factor 1-beta [also known as TIF1B
or KAP1] (TRIM28).
XRCC5 and XRCC6 form a dimer with one another to repair double-strand
breaks via non-homologous end joining (Davis & Chen 2013). Nucleotide excision
repair, rather than non-homologous end joining, is the canonical pathway for the
repair of DNA damage caused by cisplatin. However, cisplatin adducts that have
not been repaired prior to S-phase may then give rise to double-strand breaks (Bosco
et al. 2004, Huang et al. 2004b, Kaminski et al. 2008). XRCC6 was only detected in
the cytoplasm of MDA-MB231 cells in Chapter 4 while XRCC5 was only detected
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following 48 hrs of cisplatin exposure. An increase in the association of YB-1 and
DNA repair proteins was consistent with the recruitment of YB-1 to DNA repair
machinery. However, the association of XRCC6 with YB-1 was unchanged following
48 hrs cisplatin exposure and then it reduces to 0.20-fold after 96 hrs. Therefore, the
quantitative data were inconsistent with YB-1, XRCC5, and XRCC6 interacting to
promote the repair of DNA damage from cisplatin via non-homologous end joining.
TRIM28 was the other DNA repair protein that was regulated by cisplatin expo-
sure. TRIM28 can act as an effector molecule during the repair of double-stranded
DNA (reviewed in Lemaitre & Soutoglou 2014). In addition to this, TRIM28 can
influence transcription (Friedman et al. 1996, Wang et al. 2007). TRIM28 regulates
both pathways through the ability to influence the formation of heterochromatin
(reviewed in Lemaitre & Soutoglou 2014). Following 48 hrs of cisplatin exposure,
TRIM28 was elevated 3.05-fold and remained slightly elevated after 96 hrs (1.38-
fold). In Chapter 4, TRIM28 was detected in the nucleus of MDA-MB231 cells.
These observations were consistent with the interaction of YB-1 and TRIM28 to in-
fluence transcription or DNA repair during cisplatin exposure. TRIM28 was chosen
as a representative of the DNA interacting proteins.
The results from functional enrichment analysis indicated that proteins involved
in chromatin formation (cluster 5) were important to the function of YB-1 during
cisplatin exposure. However, the peptides that were identified for the proteins in
cluster 5 provided poorly resolved protein identifications. For example, the peptides
that provided identification of histone 1.2 were equally likely to come from histone
1.4. This low resolution was partly due to the strong sequence homology of the
histone proteins. Furthermore, the histone proteins are small, which reduces their
potential to produce proteotypic peptides that are appropriate for detection using
LC-MS/MS. Including the mass adducts of common histone modifications, such as
acetylation, in searches of the LC-MS/MS data provided no further information
about the effects of cisplatin on the histone proteins that interacted with YB-1
during cisplatin exposure.
The proteins that linked cluster 3, which included YB-1, to the chromosomal
proteins in cluster 5 could regulate the function of the latter group in the in silico
network. Four proteins, Interleukin enhancer-binding factor 3 (ILF3), Nucleophos-
min (NPM1), Nucleosome assembly protein 1-like 1 (NAP1L1), and Nucleosome
assembly protein 1-like 4 (NAP1L4), linked these two clusters of proteins. Edges
connected ILF3 to 4 out of the 8 proteins in cluster 3 (Figure 6.10). ILF3 was
also detected in the nucleus of MDA-MB231 cells (Chapter 4). During cisplatin
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exposure, the interaction of ILF3 with YB-1 appeared to weaken. The levels of
ILF3 reducing in F1 by 48% following 48 hrs of cisplatin exposure and by 56% fol-
lowing 96 hrs. Furthermore, ILF3 has similar multifunctionality to YB-1, as it can
bind to DNA and RNA to influence transcription, splicing, and translation (Castella
et al. 2015). This made the functional significance of this interaction unclear.
NAP1L1 and NAP1L4 are involved in the formation of chromatin via roles as
chaperones for histone proteins. They were reduced 0.47-fold and 0.49-fold respec-
tively, following 96 hrs of cisplatin exposure. Neither protein was detected in Chap-
ter 4. The abundance of NPM1 in F1 reduced 0.29-fold after 48 hrs and 0.44-fold
after 96 hrs of cisplatin exposure. However, more accurate analysis, using Skyline,
indicated that interference in one of the peptides used for quantification artificially
elevated the quantification in the media samples. Without any clear candidates from
this group of four proteins, or from directly within cluster 5, TRIM28 was chosen
as the sole representative of the chromatin assembly proteins.
Inspection of the quantitative data also highlighted other proteins of interest. Of
these, Constitutive coactivator of PPAR-gamma-like protein 1 [also known as OSSA]
(FAM120A) was reliably detected in all samples. It was also detected in the nucleus
of MDA-MB231 cells (Chapter 4.2.4). The levels of FAM120A in F1 were elevated
following cisplatin exposure, increasing 1.95-fold following 48 hrs and 2.96 fold fol-
lowing 96 hrs of cisplatin exposure. Since its annotation in 2001 the function(s) of
FAM120A have remained largely unknown. In the mouse, FAM120A appeared to
be an RNA-binding protein (Kobayashi et al. 2008). A manual query of a screen
of RNA-binding proteins (Baltz et al. 2012) confirmed that human FAM120A also
appeared to bind RNA. FAM120A may also be an effector molecule with the ability
to regulate the activity of Src kinases to protect cells from oxidative stress-induced
apoptosis (Tanaka et al. 2009). As an RNA-binding protein, FAM120A could provide
insight into the detection of YB-1 function during cisplatin exposure via a pathway
that TRIM28 was unlikely to be part of. Therefore, FAM120A was selected for
further research.
6.3 Discussion
The results from the work that was presented here revealed that:
• Cross-linking alters the migration of YB-1 on non-reducing SDS-PAGE gels;
• The PPI reveals the interaction of YB-1 with clusters of functionally distinct
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proteins that are consistent with the known molecular functions of YB-1;
• Cisplatin exposure leads to distinct but not global changes to the PPI of YB-1;
• Quantitative LC-MS/MS reveals that proteins associated with chromatin as-
sembly and organisation, and DNA binding are disproportionately altered by
cisplatin exposure.
6.3.1 Cross-linking YB-1
The results confirm that cross-linking YB-1 with DSP shifts YB-1 signals on im-
munoblots. This indicates the successful cross-linking of YB-1 with both formalde-
hyde and DSP. Furthermore, multiple DSP cross-linking sites are identified on YB-1
peptides using LC-MS/MS.
Following cross-linking, some of the YB-1 from lysates that were separated us-
ing non-reducing SDS-PAGE migrated as monomers. Attempts to remove this
monomeric YB-1 from the immunoblots were unsuccessful. It was hypothesised
that the monomeric YB-1 on non-reducing SDS-PAGE was in complex with other
proteins prior to their preparation for non-reducing SDS-PAGE. Previously, the
structural arrangement of YB-1 in situ was postulated to explain the differences in
the sensitivity of NYB1 and YB1C as prognostic markers (Chapter 3.3; Woolley
et al. 2011). The physical occlusion of some regions of multimerised YB-1 would also
stop DSP from forming inter-molecular cross-links on lysine residues in these regions
of YB-1. Furthermore, the model of YB-1 homo-multimerisation presented by Sk-
abkin et al. (2004) allows monomeric YB-1 (B1) to be cross-linked variously at the
N-terminus or C-terminus depending on the level of YB-1 saturation on individual
RNA transcripts.
More information about the intra- and inter-molecular cross-links would have
allowed further analysis of this model. However, rather than collecting cross-linked
peptide data, quantitative data was obtained using F1 from gels of YB-1 that was
purified from cisplatin-treated MDA-MB231 cells. This quantitative data provides
critical insights into the effects of cisplatin exposure on the PPI of YB-1.
6.3.2 Protein interactions of YB-1 during cisplatin exposure
The functional enrichment and in silico network analyses are concordant with the
results in Chapter 4. Amongst the proteins that copurified with YB-1, there
are proteins that interact with RNA transcripts as they are transcribed through
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to their translation. In both sets of experiments, there are groups of proteins that
interact with DNA and also those which have functional annotations associated with
mitochondria. The discussion here focuses on the effects of cisplatin exposure on
the PPI of YB-1.
The data presented in this chapter indicate that YB-1 continues to participate
in most functions irrespective of cisplatin exposure. Exposing MDA-MB231 cells to
up to 6.125 µM cisplatin had little effect on the migration of cross-linked YB-1 on
immunoblots. Analyses using LC-MS/MS show that 1.56 µM cisplatin exposure for
up to 96 hrs also leads to subtle alterations to a subset of the PPI of YB-1. Therefore,
this work conflicts with reports linking cisplatin resistance with almost exclusive
localisation of YB-1 to the nucleus (Yahata et al. 2002, Gaudreault et al. 2004).
However, the results are consistent with the localisation of YB-1 in MDA-MB231
cells during exposure to 1.56 µM cisplatin (Chapter 5.2.5). Specifically, IF shows
that YB-1 remains in the cytoplasm during cisplatin exposure. This appears to
be confirmed by the continued interaction of YB-1 with proteins with molecular
functions in the cytoplasm. The increased intensity of YB-1 signal in the nucleus,
and on the DNA, of MDA-MB231 cells that was observed using IF is consistent with
the altered interaction of YB-1 with a subset of proteins associated with chromatin
binding during cisplatin exposure.
In order to survive cisplatin exposure, cells need to decrease the amount of cis-
platin that can modify DNA or become resistant to the effects of cisplatin modifying
DNA (Kelland 2007). Reducing the amount of cisplatin that enters cells appears
to be the primary mechanism by which cisplatin resistant cancer cells reduce the
amount of cisplatin that reaches DNA (reviewed in Gately & Howell 1993). YB-1
has been reported to protect cells from cisplatin exposure via the transcriptional
activation of the MDR-1 gene.
Transcription factors have diverse protein interactions and these alter when the
transcription factors associate with chromatin (Mohammed et al. 2013, Li et al.
2015). The PPI of YB-1 from MDA-MB231 cells during cisplatin exposure did
not provide strong support for the hypothesis that positive regulation of transcrip-
tion was central to the role of YB-1 during cisplatin exposure. Only 12 of the 272
proteins that are identified in F1 were annotated with transcription factor binding
(GO:0008134; SND1, PURA, DRG1, CSDA, ENO1, YAP1, YWHAB, RPS3, PURB,
TRIM28, NPM1, YWHAZ). There is evidence that FAM120A interacts with two
transcription factors (FOXK2 and FOXQ1) but not when either protein is bind-
ing to chromatin (Li et al. 2015). Importantly, transcriptional proteins that have
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been shown to interact with YB-1 previously, P300 and RNA polymerases (Chansky
et al. 2001, Sengupta et al. 2011), were not detected in the current work. Finally, de-
spite previous work linking YB-1, cisplatin exposure, and MDR-1 expression during
cisplatin exposure, the predominant drug efflux pathways associated with cisplatin
resistance appear to involve copper binding pathways rather than members of the
ABC-transporter family, of which MDR-1 is a member (Larson et al. 2009, Samimi
et al. 2003, Katano et al. 2002). In summary, the proteins that copurify with YB-1
from MDA-MB231 cells exposed to cisplatin provide little evidence that the YB-
1 in MDA-MB231 cells positively influences transcription in response to cisplatin
exposure.
The bioinformatic analyses indicates that the interactions of YB-1 with proteins
that influence chromatin structure were disproportionately affected when MDA-
MB231 cells are exposed to cisplatin. YB-1 has been linked to a repressive chromatin
complex that includes H1.2 (Kim et al. 2008). H1.2 was identified in F1 from all
three samples. Besides YB-1, only one of the other 7 proteins that have been shown
to interact directly with H1.2, was also detected in F1; Transcriptional activator
protein Pur-alpha (PUR-α). Notably, it is these three proteins together, H1.2,
YB-1, and PUR-α, that can repress P53 driven transcription of the BAX gene
by binding specifically with P53 that is bound to the BAX gene promoter (Kim
et al. 2008). Other researchers have also found that PUR-α can promote cisplatin
resistance (Kaminski et al. 2008).
TRIM28 can also repress the transcription of genes, specifically those that are
targets of the E2F- family members, through its ability to promote the formation of
heterochromatin (Wang et al. 2007). By repressing the transcription of E2F1 target
genes in concert with TRIM28, YB-1 could slow cell division and provide more time
for cisplatin damaged DNA to be repaired before S-phase. However, in order to
function as a transcriptional repressor, TRIM28 needs to interact with a Kruppel-
associated box zinc finger protein (Wolf et al. 2015). Kruppel-associated box zinc
finger proteins were not detected in the current work. Changes in chromatin struc-
ture, such as the ability of TRIM28 to promote the formation of heterochromatin,
can influence processes besides transcriptional repression (reviewed in Lemaitre &
Soutoglou 2014).
In addition to altering gene transcription during cisplatin exposure, YB-1 may
protect cells due to its interaction with cisplatin damaged DNA and participation in
the repair of cisplatin damage to DNA (Chapter 1.4.3). Cisplatin causes multiple
DNA adducts and legions which can be repaired by multiple repair mechanisms (re-
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viewed in Siddik 2003). Nucleotide excision repair is thought to be the main DNA re-
pair pathway that removes intra-strand cisplatin-DNA adducts (Siddik 2003). Base
excision repair may also protect cells from cisplatin damage by rapidly removing
cisplatin adducts before an inter-strand cross-link can form (Caiola et al. 2015). Fi-
nally, double-strand breaks in the DNA are a secondary form of cisplatin induced
DNA damage. These result from the incorrect repair of cisplatin adducts (Huang
et al. 2004b) or the presence of inter-strand cross-links during DNA replication
(Bosco et al. 2004, Frankenberg-Schwager et al. 2005, Brozovic et al. 2009). The
inter-strand cross-links and double-strand breaks have a significant effect on cell
death following cisplatin exposure (Brozovic et al. 2009).
YB-1 may remove cisplatin adducts via nucleotide excision repair or base excision
repair. YB-1 interacts preferentially with damaged DNA, and this binding may
promote the repair of cisplatin adducts. Some of the chromatin proteins that were
modulated by cisplatin exposure have the potential to participate in DNA repair.
However, few of the DNA repair proteins that are known to interact with YB-1
were detected in this work. Gaudreault et al. (2004) links YB-1 with base excision
repair and mis-match repair mechanisms through the interactions of YB-1 with
MSH2, DNA polymerase delta, XRCC5, and WRN. However, in this study, only
XRCC5 was detected. Furthermore, nucleotide excision repair, rather than base
excision repair, is the primary repair pathway for intra-strand cisplatin-DNA adducts
(Kothandapani et al. 2011). None of the nucleotide excision repair proteins, XPC,
HR23B, or NEIL, that have been shown to interact with recombinant YB-1 (Das
et al. 2007, Fomina et al. 2015) were detected in the current work. Other researchers
also failed to recover NEIL when they purify either endogenous or exogenous YB-
1 (Pestryakov et al. 2012). PCNA, which has crucial roles in DNA synthesis as
well as in DNA repair, has previously been shown to interact with YB-1 (Ise et al.
1999). PCNA was identified in F1 in the current work, but cisplatin exposure has
no effect on the levels of PCNA that copurify with YB-1. YB-1 may already be
interacting with PCNA to promote an error tolerant DNA synthesis pathway in
MDA-MB231 cells, as MDA-MB231 cells are aneuploid with 57 ± 5 chromosomes
(Satya-Prakash et al. 1981). Therefore, the evidence to support the participation of
YB-1 in nucleotide excision repair in MDA-MB231 cells during cisplatin exposure is
equivocal.
The potential for YB-1 to participate in the repair of double-strand breaks in
the DNA was studied. Three proteins that are involved in repairing double-strand
breaks in DNA have been identified in F1; TRIM28, XRCC5, and XRCC6 (discussed
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in Chapter 6.2.6). The subcellular localisation and quantification of XRCC5 and
XRCC6 are inconsistent with an interaction with YB-1 promoting increased DNA
repair during cisplatin exposure. TRIM28 is known to participate in the repair
of double-stranded DNA breaks in regions of heterochromatin, where repair rates
are slower (reviewed in Lemaitre & Soutoglou 2014). Through an interaction with
these proteins, YB-1 may participate in the repair of double-stranded DNA breaks
in heterochromatin. Chapter 5 indicates that following the depletion of YB-1,
MDA-MB231 cells begin to die after 2 - 3 days in 1.56 µM cisplatin. This timing is
consistent with YB-1 having a role in the repair of double-stranded DNA breaks in
regions of heterochromatin.
6.3.3 Differences from other studies
The discrepancies between the PPI detected in this work and by other researchers
have already been noted. Various factors are likely to explain these discrepancies.
The YB-1 molecules that have been studied here differ from the YB-1 that were
previously used to study the PPI of YB-1. The current work used YB-1 from MDA-
MB231 cells. With the exception of Pestryakov et al. (2012), the other studies used
ectopically expressed YB-1 to research the PPI of YB-1 (Ise et al. 1999, Chansky
et al. 2001, Gaudreault et al. 2004, Das et al. 2007, Guay et al. 2008a, Kim et al. 2008,
Garand et al. 2011, Tsofack et al. 2011, Fomina et al. 2015). The poor suitability
of ectopically expressed YB-1 for studying PPI was highlighted (Chapter 4.2.1).
Therefore, the use of endogenous YB-1 may explain some discrepancies in the PPI
observed here and those observed previously.
Phosphorylation of YB-1 is likely to differ with cellular context. Previous studies
utilised a wide range of cell types. The YB-1 in MDA-MB231 cells was phosphory-
lated at multiple sites (Table.4.1; Toulany et al. 2011). Phosphorylation to YB-1 at
atleast one of these sites, serine 102, modulates the function of YB-1. There is little
information available regarding the functional consequences of phosphorylation at
other amino acids in YB-1. Therefore, the PPI of YB-1 are likely to be altered by
the multiple phosphorylations to YB-1 in MDA-MB231 cells (Table 4.1).
The proteins that are available to interact with YB-1 also vary with the cellular
context. The significance of the presence of wild-type P53 has already been discussed
(Chapter 5.3.2). Gaudreault et al. (2004) used a cell line with wild-type P53 that is
expressed at very low levels, HEK 293, to detect NONO and RALY interacting with
exogenously expressed, calmodulin and streptavidin tagged, YB-1 during oxaliplatin
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exposure (Tsofack et al. 2011). NONO and RALY were identified in the nucleus
of MDA-MB231 cells but neither protein copurified with cross-linked YB-1. The
failure to detect NONO or RALY in IP from cross-linked cells also highlights that
the conditions of the purification impact on the identification of PPI.
The final, and potentially critical, reason that the results from the current study
may differ from previous results relates to the manner of cisplatin exposure. Other
studies exposed cells to cisplatin for different durations and at different concentra-
tions. The cisplatin exposure used in this work is tolerated by the cells when YB-1
is present. However, the cisplatin exposures used by other studies, appear to be
likely to cause cell death (discussed in Chapter 5.3.3). It is difficult to assess the
significance of the PPI of YB-1 during a lethal exposure of cisplatin.
6.3.4 Summary
The work in this chapter indicated that many of the functions of YB-1 in MDA-
MB231 cells were unaffected by cisplatin exposure. This is consistent with the results
from IF (Chapter 5.2.5) that show cisplatin exposure causing consistent, but sub-
tle, alterations to the localisation of YB-1. In the absence of gross perturbations to
the PPI of YB-1, the quantitative LC-MS/MS data were used to investigate which
YB-1 functions were altered and likely to be important to the survival of MDA-
MB231 cells during cisplatin exposure. The interaction of YB-1 with chromatin
proteins appeared to be important. Previous publications indicated that the ability
of YB-1 to promote a transcriptional response is central to its role during cisplatin
exposure. However, the results presented here highlight that the PPI of YB-1 pro-
vide little evidence that this occurs in MDA-MB231 cells during cisplatin exposure.
Two proteins, FAM120A and TRIM28, were selected for further analysis. TRIM28
was chosen to represent the molecular function of YB-1 in nucleus, specifically tran-
scriptional repression and the repair of DNA damage. The molecular function of
FAM120A is less clear but cisplatin exposure lead to increased levels of FAM120A
copurifying with YB-1 and it may be an RNA protein.
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Chapter 7




Four-hundred and sixty-one proteins copurified with cross-linked YB-1 from MDA-
MB231 cells (Chapter 6). The levels of 65 of these proteins altered in response to
cisplatin exposure. A disproportionate number of these 64 proteins had functions
relating to chromatin formation and double-strand DNA binding (Chapter 6).
Two of these proteins, TRIM28 and FAM120A, were selected for further analyses.
Both proteins were hypothesised to co-operate with YB-1 to help MDA-MB231 cells
to survive cisplatin exposure. However, the functions of FAM120A and TRIM28
differ (discussed below). Therefore, separate hypotheses were required to explain
the interaction of each protein with YB-1 in MDA-MB231 cells during cisplatin
exposure.
Two hypotheses were generated to explain how the interaction of YB-1 and
TRIM28 may promote the survival of MDA-MB231 cells during cisplatin expo-
sure. The first hypothesis was that by interacting with one another, YB-1 and
TRIM28 facilitate the repair of double-strand DNA breaks in regions of heterochro-
matin. TRIM28 has been shown to repair double-strand breaks in heterochromatic,
or compacted, DNA. These DNA lesions are repaired more slowly than other double-
strand breaks (Goodarzi et al. 2008, Goodarzi et al. 2009, Noon et al. 2010, Goodarzi
et al. 2010). The second hypothesis was that the interaction of YB-1 and TRIM28
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down-regulates transcription of E2F-family gene targets to slow the division of
MDA-MB231 cells during cisplatin exposure. This hypothesis was inconsistent with
the ability of YB-1 to positively regulate E2F1 gene targets (Lasham et al. 2012).
However, increased interaction with TRIM28 during cisplatin exposure, which is
known repress transcription from E2F-family gene targets (Wang et al. 2007, Hu
et al. 2012, Chen et al. 2012), may lead to YB-1 functioning as a repressor E2F1
gene targets.
Although the function of FAM120A is poorly characterised it is thought that
FAM120A is likely to bind to RNA (Kobayashi et al. 2008, Tanaka et al. 2009).
Furthermore, FAM120A can influence cell survival in response to oxidative stress
(Tanaka et al. 2009, Woźniak et al. 2014). The mechanisms that explains the ability
of FAM120A to promote cell survival is poorly characterised. Tanaka et al. (2009)
proposes that FAM120A protects cells from oxidative stress-induced apoptosis by
regulating the activity of Src kinases. The same study suggests that this molecular
function of FAM120A is due to its ability to act as a scaffold for kinases (Tanaka et al.
2009). The IL13 receptor subunit α-2 (IL13Rα2) required FAM120A to activate the
Focal adhesion kinase 1 and PI3K pathways (Bartolome et al. 2015). At the cellular
level, the interaction of FAM120A and the IL13Rα2 also promotes the survival of two
colon carcinoma cell lines. Therefore, FAM120A and YB-1 appear to be unlikely to
participate in a DNA repair pathway during cisplatin exposure. Instead, FAM120A
and YB-1 were hypothesised to promote the survival of MDA-MB231 cells via either
the regulation of kinase activity or the ability to influence gene expression by binding
to RNA (splicing, translation, or protecting RNA from degradation).
YB-1 also interacts with nuclear-encoded mitochondrial proteins. These inter-
actions did not appear to vary during cisplatin exposure (Chapter 6) but mito-
chondria play an important role in cell survival (Sena & Chandel 2012). During
cisplatin exposure the mitochondria of a prostate cancer cell line, DU-145, promote
cell death by producing reactive oxygen species (Marullo et al. 2013). C1QBP was
chosen to represent the group of mitochondrial proteins that copurified with YB-
1. C1QBP has been shown to participate in pre-mRNA splicing (Petersen-Mahrt
et al. 1999, Zheng et al. 2003, Heyd et al. 2008), to interact with the immune system
(reviewed in Peerschke & Ghebrehiwet 2014) and it is also a mitochondrial protein
(Muta et al. 1997, Dedio et al. 1998, Hu et al. 2013).
C1QBP was identified in all IP samples in Chapter 6 but cisplatin exposure
did not alter the levels of C1QBP (1.45-fold at 48 hrs and 1.29-fold after 96 hrs).
However, elevated levels of C1QBP can promote cell death (Meenakshi et al. 2003,
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Sunayama et al. 2004, Reef et al. 2007). Furthermore, cisplatin exposure led to
elevated levels of C1QBP in rat and HeLa cells (Meenakshi et al. 2003, Kamal &
Datta 2006). There are conflicting reports regarding the effects of depleting C1CBP
on the survival of HeLa cells following cisplatin exposure. One report showed that
depleting C1QBP in HeLa cells increased the levels of cell death in response to
cisplatin exposure (Hu et al. 2013). Another found that cell death was reduced
(Kamal & Datta 2006). Given the number of studies that show increased levels
of C1QBP leading to cell death, it was hypothesised that depleting C1QBP would
protect MDA-MB231 cells during cisplatin exposure.
In this chapter, the presence and subcellular localisation of TRIM28, FAM120A,
and C1QBP in MDA-MB231 cells were confirmed. Following this, the effects of
depleting all three proteins in MDA-MB231 cells on the sensitivity to cisplatin was
tested. Finally, the effects of depleting YB-1 on γH2AX foci formation during
cisplatin exposure was used to study the role of YB-1 in repairing double-strand
DNA breaks.
7.2 Results
7.2.1 The depletion and detection of FAM120A, TRIM28,
and C1QBP
The specificity of the antibodies against TRIM28, FAM120A, C1QBP was tested.
To do this, MDA-MB231 cells were allowed to settle in the presence of transfection-
ready siRNA duplexes directed against TRIM28, FAM120A, C1QBP, and YB-1
at concentrations ranging from 2 - 10 nM. Lysates were collected after 48 and 96
hrs. The signal on immunoblots for each primary antibody corresponded with the
expected mass of each protein (Figure 7.1.A - C; TRIM28 = 89 kDa, FAM120A
= 122 kDa, C1QBP = 31 kDa). Furthermore, in each instance the siRNA duplexes
effectively deplete this signal. Figure 7.1.D shows the depletion of YB-1 by 2
nM siYB1 1 and the stable levels of YB-1 following the depletion of FAM120A and
TRIM28.
These results confirmed that each antibody could bind specifically to its target
protein. They also confirmed that the siRNA duplexes depleted their target proteins.
Therefore, the specificity of the tools for depleting and detected FAM120A, TRIM28,
and C1QBP has been confirmed.
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Figure 7.1: Validation of siRNA duplexes and antibodies to FAM120A, TRIM28, and
C1QBP. MDA-MB231 cells were transfected with siRNA duplexes against FAM120A,
TRIM28, and C1QBP at a range of concentrations (2 - 10 nM). The cells were harvested
following 48 or 96 hrs and lysates prepared. Immunoblots were performed for cells trans-
fected with each siRNA duplex and detected against the proteins that were targeted for
depletion (TRIM28, A; FAM120A, B; C1QBP, C; NYB1, D). Even loading is confirmed
using anti-β-actin (shown below each blot).
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Figure 7.2: The levels of TRIM28 and FAM120A increase in MDA-MB231 cells following
cisplatin exposure. MDA-MB231 cells were exposed to 1.56 µM cisplatin for 24 - 96 hrs.
The lysates were separated on 6% SDS-PAGE gels prior to immunoblotting with antibodies
against TRIM28 and FAM120A.
7.2.2 The effects of cisplatin exposure on TRIM28, FAM120A,
and C1QBP in MDA-MB231 cells
TRIM28, FAM120A, and C1QBP copurify with YB-1 from MDA-MB231 cells dur-
ing cisplatin exposure (Chapter 6.2.5). Cisplatin exposure did not alter the levels
of C1QBP that copurified with YB-1 (Chapter 6.2.5). However, the levels of
TRIM28 and FAM120A that copurified with YB-1 did increase in response to cis-
platin exposure. Therefore, the effects of exposing MDA-MB231 cells to 1.56 µM
cisplatin on the levels of TRIM28 and FAM120A were assessed. Lysates were col-
lected from MDA-MB231 cells following 24, 48, and 96 hrs of exposure to 1.56
µM cisplatin. Immunoblots indicated that cisplatin exposure increased the amount
of TRIM28 and FAM120A in MDA-MB231 cells (Figure 7.2). The signal from
FAM120A highlighted that the protein may migrate as two separate bands but
the resolution of the 10% SDS-PAGE was too low to confirm this (Figure 7.1).
Lowering the acrylamide percentage of the gel to 6% should have provided better
separation of FAM120A, however, the resolution was still insufficient to confirm
the presence of two bands in the immunoblot of FAM120A (Figure 7.2). There-
fore, these immunoblots indicated that cisplatin exposure may increase the levels of
TRIM28 and FAM120A in MDA-MB231 cells.
TRIM28, FAM120A, and C1QBP were all excised from the region of gels that
contained mass-shifted YB-1 that was purified from cross-linked MDA-MB231 cells
(Figure 6.5, F1). However, TRIM28 and FAM120A migrated in the same region of
the gel as mass-shifted YB-1 in the absence of cross-linking (Figure 7.2). Therefore,
it was possible that TRIM28 and FAM120A were detected in F1 without being
cross-linked to YB-1. If either protein was cross-linked to YB-1, its migration on
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non-reducing SDS-PAGE will be further slowed following cross-linking.
The ability of cross-linking to alter the mobility of each protein was tested.
Aliquots of MDA-MB231 cells were cross-linked using DSP and separated by non-
reducing 6% SDS-PAGE. The results show that cross-linking slows the migration of
FAM120A, TRIM28, and C1QBP (Figure 7.3). Cross-linking abolished monomeric
TRIM28 from the immunoblot. FAM120A was similar, with the strongest signal
migrating above the 220 kDa molecular weight marker. The presence or absence of
monomeric C1QBP was unconfirmed as the mass of C1QBP was below the resolving
limit of the 6% SDS-PAGE. However, the strong signal from C1QBP exhibited a
mass-shift that was consistent with cross-linking. The immunoblots for all three
proteins highlighted the presence of mass-shifted signal above 220 kDa (shown as
bars in Figure 7.3). This was a region where mass-shifted YB-1 also appeared
following cross-linking.
DNA and RNA were removed from aliquots of the cross-linked samples to con-
firm the primary importance of DSP adducts in altering the migration of YB-1,
FAM120A, TRIM28, and C1QBP. Removing DNA and RNA had no effect on the
migration of YB-1, TRIM28, FAM120A, or C1QBP (Figure 7.3). However, the
removal of DNA and RNA increased the signal intensity. The improved solubility of
proteins that were bound to DNA, which can precipitate with cellular debris when
lysates are centrifuged, may account for these increases.
Cross-linking MDA-MB231 cells using DSP slowed the migration of FAM120A,
TRIM28, and C1QBP. This signal was present in areas of gels where cross-linked
YB-1 also migrated. Only a fraction of the mass-shifted FAM120A and C1QBP
signals overlapped with those from YB-1, but all of the TRIM28 migrated in the
same area of the gel as mass-shifted YB-1.
7.2.3 The distribution of C1QBP, TRIM28, and FAM120A
in MDA-MB231 cells before and during exposure to
cisplatin
In order to bind to one another, C1QBP, TRIM28, or FAM120A need to be present
in the same area of MDA-MB231 cells as YB-1. IF was used to assess the distribution
of each protein in MDA-MB231 cells. For this experiment, MDA-MB231 cells, grown
on glass coverslips, were exposed to 1.56 µM cisplatin for 72 hrs. Following this, the
cells were fixed and IF performed.
The literature indicated that C1QBP can localise to the mitochondria and nu-
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Figure 7.3: Cross-linking MDA-MB231 cells alters the migration of TRIM28, FAM120A,
and C1QBP. MDA-MB231 cells were exposed to 1.56 µM cisplatin for 0 - 96 hrs prior to be-
ing cross-linked using DSP. The cross-linked lysates were separated using non-reducing 6%
SDS-PAGE. Immunoblotting was performed using antibodies against TRIM28, FAM120A,
C1QBP, and YB-1. The cells that were cross-linked come from an aliquot of the cells shown
in Figure 7.2. Benzonase was used to remove RNA and DNA from aliquots of the cross-
linked cells. The black bars that are adjacent to the TRIM28 and FAM120A immunoblots
indicate regions where there were signals from cross-linked YB-1.
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Figure 7.4: C1QBP and YB-1 in MDA-MB231 cells. IF signals from NYB1 (green) and
anti-C1QBP1 (magenta) in MDA-MB231 cells in media (A) or after 72 hrs of exposure to
1.56 µM cisplatin (B) were assessed using confocal microscopy. Images are Z-projections
of the maximal signal from 3 Z-slices across the nuclei of MDA-MB231 cells. NYB1 was
labelled with AlexaFluor 488 and gray values are represented using the Green Hot LUT
(ImageJ). C1QBP1 was labelled with AlexaFluor 568 and gray values were represented
using the Magenta Hot LUT. DNA labelled with Hoechst is represented as blue. Scale bar
is 25 µM.
cleus (Chapter 7.1). The results from IF indicated that most C1QBP localised in
the cytoplasm close to the nuclear membrane, an area where it was most likely in
mitochondria (Figure 7.4.A). Cisplatin exposure did not appear to alter the dis-
tribution of C1QBP in MDA-MB231 cells (Figure 7.4.B). There was signal from
NYB1 in the same locations as that from C1QBP (Figure 7.4.A - B). Therefore,
the interaction of YB-1 and C1QBP was most likely to occur in the mitochondria
of MDA-MB231 cells.
The primary antibody preparations for TRIM28 and FAM120A were raised
in rabbit and purchased with the aim of co-localising them with the signal from
NYB1sheep. However, the fluorescent signals from
NYB1sheep, and also an antibody
against YB-1 that was raised in mouse (Table 2.3; YB-1 [59-Q]), were weak and
diffuse. These signals were comparable to those from control cells that received
no primary antibody for each secondary antibody. Therefore, the co-localisation of
TRIM28 or FAM120A with YB-1 YB-1 was not confirmed.
The distribution of TRIM28 in MDA-MB231 cells was assessed. YB-1 was hy-
pothesised to interact with TRIM28 in the nucleus. The signal from γH2AX is
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Figure 7.5: TRIM28 is distributed throughout MDA-MB231 cells and cisplatin exposure
led to stronger TRIM28 signal in the nucleus. IF signal from TRIM28 (green) and anti-
γH2AX (magenta) in MDA-MB231 cells in media (A) or after 72 hrs of exposure to 1.56
µM cisplatin (B) was assessed using confocal microscopy. Images are Z-projections of
the maximal signal from 3 Z-slices across the nuclei of MDA-MB231 cells. TRIM28 was
labelled with AlexaFluor 488 and gray values are represented using the Green Hot LUT
(ImageJ). γH2AX was labelled with AlexaFluor 568 and gray values are represented using
the Magenta Hot LUT. DNA labelled with Hoechst is represented as blue. Scale bar is 25
µM.
shown, as TRIM28 and YB-1 were hypothesised to interact during the repair of
double-strand DNA breaks in regions of heterochromatin. γH2AX foci form around
these breaks as they repair. The IF signal from TRIM28 showed that TRIM28 was
distributed throughout MDA-MB231 cells (Figure 7.5). In many cells, the signal
from TRIM28 was slightly stronger in the nucleus than the cytoplasm, and large
foci were apparent in the nuclei of many cells. Following 72 hrs of exposure to cis-
platin, the TRIM28 in some MDA-MB231 cells increased (Figure 7.5.B). Cisplatin
exposure also led to a general brightening of the TRIM28 in the nuclei of many cells
with more, and stronger, foci also evident in the nucleus.
The function of FAM120A is poorly characterised. Analysis of the IF signal from
FAM120A highlighted that FAM120A was distributed throughout MDA-MB231
cells (Figure 7.6.A). The signal from FAM120A was predominantly in the cy-
toplasm and punctate FAM120A signal was observed in the nuclei of most cells.
Seventy-two hrs of exposure to 1.56 µM cisplatin did not appear to alter the distri-
bution of FAM120A signal in MDA-MB231 cells (Figure 7.6.B). The distribution
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Figure 7.6: FAM120A is distributed throughout MDA-MB231 cells. IF signal from
FAM120A (green) and anti-γH2AX (magenta) in MDA-MB231 cells in media (A) or after
72 hrs of exposure to 1.56 µM cisplatin (B) was assessed using confocal microscopy. Images
are Z-projections of the maximal signal from 3 Z-slices across the nuclei of MDA-MB231
cells. FAM120A was labelled with AlexaFluor 488 and gray values are represented using
the Green Hot LUT (ImageJ). γH2AX was labelled with AlexaFluor 568 and gray values
were represented using the Magenta Hot LUT. DNA labelled with Hoechst is represented
as blue. Scale bar is 25 µm.
of FAM120A in MDA-MB231 cells was similar to the distribution of YB-1 (Figure
7.4.A - B).
The distribution of two of the three proteins, C1QBP and TRIM28, in MDA-
MB231 cells indicated that the function of each protein was only likely to overlap
with discrete subsets of the functions of YB-1. These two proteins appeared to
be associating with YB-1 via separate functional pathways. The distribution of
FAM120A throughout MDA-MB231 cells indicated that YB-1 and FAM120A appear
to be unlikely to interact at the cell-membrane as part of a kinase signal transduction
network (Bartolome et al. 2015). Instead, the similarities between the distribution
of signal from FAM120A and YB-1 in MDA-MB231 cells were more consistent with
the hypothesis that FAM120A and YB-1 interacted with one another while binding
to RNA.
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7.2.4 FAM120A contributes to the survival of MDA-MB231
cells during cisplatin exposure
To examine the importance of each protein to MDA-MB231 cells during cisplatin
exposure, each protein was depleted using siRNA duplexes (validated in Chap-
ter 7.2.1) prior to a drug sensitivity assay being performed (the same design as
Chapter 5.2.4). The strong reductions to cell viability that resulted from trans-
fections using 5 nM siYB1 1 (Figure D.9) prompted a reduction to the maximum
concentration of the siRNA duplexes from 5 nM to 2 nM. These experiments were
designed to assess the functional links between YB-1 and the interacting proteins
via analysis of the effect of each siRNA duplex on the growth-rates and morphology
of MDA-MB231 cells. The effects of depleting a binding partner that is essential to
the function of YB-1 should be similar to the effect of depleting YB-1 from the cells.
Depleting YB-1 was shown to reduce the growth-rate of MDA-MB231 cells
(Figure 5.1.D). In these experiments, depleting YB-1 reduced the growth-rate
of MDA-MB231 cells by 0.48 ± 0.40 compared to the siCTRL-treated cells (Figure
7.7.A - B; t = 5.1437, df = 2, p-value = 0.03578). The potential for the loss of
FAM120A, TRIM28, or C1QBP to reduce the growth-rate of MDA-MB231 cells was
assessed. The results show that depleting FAM120A, TRIM28, or C1QBP did not
change the growth-rate of MDA-MB231 cells (Figure 7.7.A - B; for all t-tests,
df=2, p-value >0.50; complete plots Supplementary figures F.1 - F.5). There-
fore, the three proteins did not appear to be important to the function of YB-1 that
leads to reduced growth in MDA-MB231 cells following YB-1 depletion.
The phase-contrast images from this experiment were used to assess how de-
pleting each protein altered the morphology of MDA-MB231 cells. MDA-MB231
cells retained their normal morphology following transfection with the non-target
siRNA duplex (siCTRL; Figure 7.7.C). Depleting YB-1 using 2 nM siYB1 1 led
to increased numbers of cells with poor attachment while other cells also appeared
to be unhealthy (siYB1 1; Figure 7.7.C).
The morphological changes of MDA-MB231 cells following the depletion of FAM120A,
TRIM28, or C1QBP were also assessed. Depleting TRIM28 or C1QBP had no dis-
cernible effect on the morphology of MDA-MB231 cells (Figure 7.7.C, siTRIM28
and siC1Q 2). In contrast, depleting FAM120A did appear to alter the morphology
of MDA-MB231 cells. Following the depletion of FAM120A, MDA-MB231 cells be-
came less polarised and more cuboidal (Figure 7.7.C). Depleting FAM120A also
appeared to increase the size of MDA-MB231 cells but this increase was not quan-
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Figure 7.7: Depleting FAM120A, TRIM28, and C1QBP does not alter the growth-rate
of MDA-MB231 cells. YB-1, FAM120A, TRIM28, and C1QBP have been depleted using
2 nM siRNA duplexes for 24 hrs, the media changed, and the confluence of the cells mon-
itored using the Incucyte FLR. A, the confluence of each treatment from a representative
experiment (Experiment 1). B, the maximum growth-rate that was derived from the
confluence data for each experiment. C, representative images from Experiment 1 high-
lighted the morphology of MDA-MB231 cells following the depletion of YB-1, FAM120A,
TRIM28, and C1QBP. A p-value of <0.05 from paired t-tests of the growth-rates of MDA-
MB231 cells following transfection of siCTRL and each protein target is indicated by *.
siRNA = siRNA duplexes against the indicated transcripts. Exp = experiment identifier.
Scale bar is 100 µm.
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tified as the margins of cells that touched one another were poorly defined. In
conclusion, the results appear to show that the morphology of MDA-MB231 cells is
altered following the depletion of YB-1 and FAM120A.
The varied effects that depleting FAM120A, TRIM28, or C1QBP had on the
morphology of MDA-MB231 cells further highlighted that the functions of the three
proteins were not entirely shared by YB-1. However, these proteins were selected
due to their potential to interact with YB-1 in MDA-MB231 cells during cisplatin
exposure. It was hypothesised that depleting TRIM28, FAM120A, or C1QBP would
sensitise MDA-MB231 cells to cisplatin. The ED50 for cisplatin in each treatment
was calculated (shown in Table 7.1). The results from these experiments confirm
the importance of YB-1 to the survival of MDA-MB231 cells during cisplatin expo-
sure. Compared to the 2 nM non-targeting siRNA duplex, depleting YB-1 using 2
nM siYB1 1 reduced the ED50 of MDA-MB231 cells from 2.73 ± 0.42 µM cisplatin in
2 nM siCTRL to 0.88 ± 0.55 µM cisplatin (p-value, 0.0087; Table 7.1 and Figure
7.8.A).
The results from these experiments, summarised in Table 7.1 and Figure
7.8.A, highlight that the estimated ED50 for cisplatin did not decrease when TRIM28
or C1QBP were depleted from MDA-MB231 cells. Depleting TRIM28 had no ef-
fect on the ED50 estimates for cisplatin. The ED50 estimates for cisplatin were also
unchanged following the depletion of C1QBP with either siRNA duplex, with one
exception. Depleting C1QBP using 1 nM siC1Q 2 elevated the ED50 for cisplatin in
MDA-MB231 cells by 0.99 ± 0.29 µM cisplatin compared to a curve fitted to all 1
nM siRNA measurements (p-value, 0.0010; Table 7.1; Figure 7.8.A). The reasons
for the discrepancy between the two siRNA duplexes against C1QBP are unknown.
The results show that depleting FAM120A reduces the ED50 for cisplatin in
MDA-MB231 cells (Table 7.1; Figure 7.8.A). This was true when the mix of
siRNA duplexes against FAM120A were used at either 2 or 1 nM. The reduction of
the ED50 for cisplatin in MDA-MB231 cells was inversely correlated with the concen-
tration of siFAM120A. Transfecting MDA-MB231 cells with 2 nM siFAM120A re-
duced the ED50 by 1.57 ± 0.38 µM cisplatin relative to the control (p-value, 0.0068;
Figure 7.8.A). Compared to the ED50 of all 1 nM siRNA duplex transfections,
using 1 nM siFAM120A reduced the ED50 estimate by 0.62 ± 0.29 µM cisplatin
(p-value, 0.0324; Table 7.1; Figure 7.8.A). Therefore, the results from these ex-
periments indicate that depleting either YB-1 or FAM120A reduces growth-rate of
MDA-MB231 cells during cisplatin exposure.
The morphology of MDA-MB231 cells that were transfected with 2 nM siCTRL
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Table 7.1: Depleting YB-1 or FAM120A reduces the ED50 for cisplatin in MDA-MB231
cells (0 - 12.5 µM; n = 3).
siRNA Concentration ED50 ± S.E. Delta ± S.E. p-value (t-value)
siCTRL 2 µM 2.73 ± 0.42 - -
siYB1 1 2 µM 0.88 ± 0.55 -1.85 ± 0.69 0.0087 (2.690)
siFAM120A 2 µM 1.16 ± 0.38 -1.57 ± 0.56 0.0068 (2.781)
siTRIM28 2 µM 1.85 ± 0.24 -0.88 ± 0.48 0.0714 (1.828)
siC1Q 2 2 µM 2.28 ± 0.29 -0.45 ± 0.51 0.3789 (-0.885)
siC1Q 3 2 µM 3.34 ± 0.36 0.61 ± 0.55 0.2699 (1.111)
all siRNA 1 µM 2.62 ± 0.14 - -
siFAM120A 1 µM 1.99 ± 0.25 -0.62 ± 0.29 0.0324 (-2.166)*
siTRIM28 1 µM 2.54 ± -0.30 -0.08 ± 0.32 0.8145 (-0.235)*
siC1Q 2 1 µM 2.39 ± 0.22 -0.23 ± 0.26 0.3806 (-0.880)*
siC1Q 3 1 µM 3.61 ± 0.26 0.99 ± 0.29 0.0010 (3.375)*
all siRNA 0.2 µM 2.87 ± 0.24 - -
siFAM120A 0.2 µM 2.31 ± 0.35 -0.57 ± 0.45 0.1813 (-1.345)*
siTRIM28 0.2 µM 4.07 ± 0.73 1.18 ± 0.76 0.1258 (1.542)*
siC1Q 2 0.2 µM 2.97 ± 0.41 0.08 ± 0.55 0.8527 (0.186)*
siC1Q 3 0.2 µM 2.65 ± 0.46 -0.24 ± 0.52 0.6493 (-0.456)*
The dose-response curves were fitted using log-logistic regression. Estimates for the ef-
fective doses, the dose where 50% of the cells were killed by cisplatin (ED50), are given.
T-tests were used to compare the ED50 of MDA-MB231 cells to cisplatin following the
depletion of each protein to the ED50 of the siCTRL RNA duplex, significant differences
are shown as bold text. siCTRL and siYB1 1 were only used at 2 nM so for the 1 nM and
0.2 nM siRNA duplexes, the effects of depleting FAM120A, TRIM28 and C1QBP were
compared to the ED50 that was calculated by fitting a log-logistic model to the pooled
growth-rate data from all measurements where siRNA duplexes were used at that concen-
tration (”all siRNA”). A ”*” in the ”p-value (t-value)” column indicates that comparing
the ED50 estimate to the ED50 estimate from 2 nM siCTRL provided the same result
(p-value <0.05). S.E. = standard error of the mean.
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Figure 7.8: Depleting YB-1 or FAM120A reduces the growth-rate of MDA-MB231 cells
during cisplatin exposure (1.56 - 12.5 µM; n = 3). YB-1, FAM120A, TRIM28, and C1QBP
were depleted using siRNA duplexes at 0.2, 1, or 2 nM and the growth of the cells mon-
itored using the Incucyte FLR. A, survival curves were generated from the maximum
growth-rate of MDA-MB231 cells that were cultured in the presence of varying concen-
trations of cisplatin. B, images from Experiment 1 highlight the effects of 2 nM siRNA
duplexes on the morphology of MDA-MB231 cells in 1.56 µM cisplatin. siRNA = siRNA
duplexes against the indicated transcripts. These data were generated in the same ex-
periments as those shown in Figure 7.7. * =p <0.05, ** = p <0.01. Scale bar is 100
µm.
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appeared normal during exposure to 1.56 µM cisplatin (Figure 7.8.B). Following
the depletion of YB-1 using 2 nM siYB1 1, the few MDA-MB231 cells remaining
after 120 hrs of exposure to 1.56 µM cisplatin were enlarged (Figure 7.8.B). De-
pleting TRIM28 did not alter the morphology of MDA-MB231 cells during exposure
to 1.56 µM cisplatin (siCTRL compared to siTRIM28, Figure 7.8.B). However, ex-
posure to 1.56 µM cisplatin may result in a small increase in the prevalence of poorly
attached cells following their transfection with 2 nM siC1Q 2 (Figure 7.8.B). The
morphology of MDA-MB231 cells following the depletion of FAM120A using 2 nM
siRNA duplexes appeared to be further altered during cisplatin exposure. Following
72 and 120 hrs of exposure to cisplatin, many cells appeared to increase in size and
they also possessed enlarged nuclei (Figure 7.8.B).
In summary, the growth-rates and morphology of MDA-MB231 cells following
the depletion of C1QBP, TRIM28, or FAM120A highlights that the functions of
each of the three proteins were not entirely equivalent to the functions of YB-1 in
MDA-MB231 cells. Unlike YB-1, depletion of any of these three proteins was not
accompanied by a reduction in growth-rate. However, depleting FAM120A increased
the sensitivity of MDA-MB231 cells to cisplatin. These data were consistent with the
hypothesis that FAM120A and YB-1 interact co-operatively to promote the survival
of MDA-MB231 cells during cisplatin exposure.
Further experiments were carried out to assess the interaction between YB-1
and each of FAM120A, TRIM28, and C1QBP. For these experiments, up to two
proteins were depleted concurrently. Each transfection included either of 1 nM
siCTRL or 1nM siYB1 1 (level 1). Each transfection also included one of 1 nM
siCTRL, 1 nM siYB1 1, 1 nM siFAM120A, 1 nM siTRIM28, or 1 nM siC1Q 3 (level
2). Cisplatin, at concentrations ranging from 0 - 3.125 µM, was added 24 hrs after
the commencement of the transfection and the confluence of the cells monitored for
120 hrs. The aim of these experiments was to highlight interactions between YB-1
and the selected proteins. One potential interaction was synthetic lethality, where
the effect of depleting either protein in isolation is recoverable but depleting both
together is irrecoverable.
The effects of depleting YB-1, in combination with the other proteins, on the
growth-rate of MDA-MB231 cells were assessed. The results show that depleting
YB-1 reduces the growth-rate of MDA-MB231 cells (level 1, two-way ANOVA, df, 1,
f-value, 17.243, p-value, 0.000358; Figure 7.9.A). Consistent with previous results
(Figure 7.7.A - B), the growth-rates of MDA-MB231 cells were unaffected by the
depletion of any of the other proteins, irrespective of siCTRL or siYB1 1 treatment
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(level 2, two-way ANOVA, df, 3, f-value, 2.58, p-value, 0.855).
The relationship between the growth-rate of MDA-MB231 cells and YB-1, FAM120A,
TRIM28, and C1QBP1 was also examined in finer detail using pairwise comparisons.
The comparisons were limited to a total of 10 as the growth-rates of FAM120A,
TRIM28, and C1QBP1 depletions were not compared to one another (summarised
in Table 7.2). The comparisons revealed that depleting TRIM28 and YB-1 together
reduced the growth-rate of MDA-MB231 cells in a similar manner to that observed
when YB-1 was depleted alone (Table 7.2, rows 3 - 4). Depleting FAM120A or
C1QBP, in addition to YB-1, appeared to attenuate the reduction in growth-rate
that was normally observed during cisplatin exposure (Figure 7.7.A). Pairwise
comparisons revealed that the growth-rate was somewhere between that observed
for depletion of C1QBP or FAM120A alone and that of MDA-MB231 cells where
only YB-1 was depleted (Table 7.2, rows 6 - 7 and 9 - 10). Therefore, depleting
FAM120A or C1QBP appeared to lessen the negative effects that depleting YB-1
had on the growth-rate of MDA-MB231 cells. However, depleting FAM120A or
C1QBP did not completely abrogate the negative effects of depleting YB-1 on the
growth-rate of MDA-MB231 cells. The morphology of the MDA-MB231 cells, where
YB-1 was depleted alongside FAM120A, TRIM28, or C1QBP, was similar (Figure
7.7.A). Therefore, there is no evidence of synthetic lethality occurring when YB-1
is depleted alongside any of FAM120A, TRIM28, or C1QBP.
These experiments also included an analysis of the survival of MDA-MB231 cells
during cisplatin exposure. The previous experiments provided knowledge about
the critical cisplatin dose range for MDA-MB231 cells, allowing a restricted range of
cisplatin doses to be used for these experiments (0 - 3.125 µM). Consistency of ED50
estimation was maintained by using the log-logisitic model settings from the previous
work. However, the scaling was altered as some MDA-MB231 cells remained alive
following 120 hrs of exposure to the maximum cisplatin dose (3.125 µM). Therefore,
it was inappropriate to scale the growth-rates in each treatment to the maximum
growth-rates from cells that were exposed to 3.125 µM cisplatin. Instead, each
treatment was scaled to the 0 µM cisplatin measurement. The similarity of the
ED50 estimate for 2 nM siCTRL of 2.85 ± 0.35 µM cisplatin with that from previous
experiments, 2.73± 0.42 (Table 7.1), indicated that the results were consistent with
the previous experiment. Furthermore, the experiments are internally consistent.
The results from these experiments show that depleting YB-1 sensitises MDA-
MB231 cells to cisplatin (Table 7.3 and Figure 7.10.A). The previous experiment
indicates that depleting FAM120A reduced the growth-rate of MDA-MB231 cells
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Figure 7.9: Depleting FAM120A and C1QBP counteracts the negative effects of depleting
YB-1 on the growth-rate of MDA-MB231 cells (n = 4). Two levels of siRNA duplex were
used in these experiments. Level 1 included 1 nM siCTRL or 1nM siYB1 1 and level 2
included 1nM siYB1 1, 1nM siFAM120A, 1nM siTRIM28, or 1nM siC1QBP (see Table
7.3 for siRNA duplex combinations). Following transfections, the growth of the cells was
monitored using the Incucyte FLR. A, the maximum growth-rate for each transfection was
derived from the confluence data. The bar colour above the plot indicates significant main
effects in a 2-way ANOVA while capital to lower case letters indicate significant differences
in post-hoc t-tests. B, images from a single experiment show how the morphology of
MDA-MB231 cells was affected by transfection with 1 nM siYB1 1 combined with siRNA
duplexes against one of FAM120A, TRIM28, and C1QBP. Scale bar is 100 µm.
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Table 7.2: The effects of depleting the interaction partners of YB-1 and YB-1 together
on the growth-rate of MDA-MB231 cells (n = 4).
Depletion #1 Depletion #2 p-value
siCTRL + siCTRL siYB1 1 +siCTRL 0.0324
siCTRL + siCTRL siCTRL + siTRIM28 0.4588
siYB1 1 + siCTRL siYB1 1 + siTRIM28 0.5280
siCTRL + siTRIM28 siYB1 1 + siTRIM28 0.0012
siCTRL + siCTRL siCTRL + siFAM120A 0.8946
siCTRL + siFAM120A siYB1 1 + siFAM120A 0.3569
siYB1 1 + siCTRL siYB1 1 + siFAM120A 0.2429
siCTRL + siCTRL siCTRL + siC1Q 3 0.9618
siCTRL + siC1Q 2 siYB1 1 + siC1Q 2 0.1652
siYB1 1 + siCTRL siYB1 1 + siC1Q 2 0.4370
The hypotheses that depleting YB-1 and the interaction partners of YB-1 together al-
tered the growth-rate of MDA-MB231 cells was tested using two-way analysis of variance;
model = Growth-rate siRNA #1 (siCTRL, siYB1 1) + siRNA #2 (siCTRL, siTRIM28,
siFAM120A, siC1Q 3. Post-hoc tests were performed as pairwise comparisons using t-
tests with pooled standard deviation with selected tests shown. Significant differences are
shown as bold text. S.E. = standard error of the mean.
Table 7.3: Depleting the interaction partners of YB-1 and YB-1 together further reduces
the survival of MDA-MB231 cells during cisplatin exposure (0 - 3.125 µM; n = 4).
siRNA #1 siRNA #2 ED50 ± S.E. Delta ± S.E. p-value (t-value)
siCTRL siCTRL 2.85 ± 0.35 - -
siCTRL siFAM120A 2.09 ± 0.21 -0.76 ± 0.41 0.0634 (1.871)
siCTRL siTRIM28 2.10 ± 0.17 -0.75 ± 0.38 0.0542 (1.941)
siCTRL siC1q 3 2.34 ± 0.30 -0.51 ± 0.46 0.2681 (1.112)
siCTRL siYB1 1 1.83 ± 0.19 -1.02 ± 0.40 0.0110 (2.575)
siYB1 1 siFAM120A 1.16 ± 0.13 -0.66 ± 0.23 0.0038 (2.944)
siYB1 1 siTRIM28 1.32 ± 0.13 -0.52 ± 0.23 0.0253 (2.261)
siYB1 1 siC1q 3 1.28 ± 0.13 -0.55 ± 0.23 0.0177 (2.399)
The dose-response curves have been fitted using log-logistic regression. Estimates for the
effective doses where 50% of the cells were killed by cisplatin (ED50) are given. T-tests
were used to compare the ED50 estimates. All ED50 estimates that include 1 nM siCTRL
in ”siRNA #1” were compared to the ED50 estimate for 2 nM siCTRL (row #1). The
ED50 estimates that included siYB1 1 in ”siRNA #1” were compared to the ED50 estimate
for 1 nM siCTRL + 1 nM siYB1 1 (row #5). Significant differences are shown as bold
text. S.E. = standard error of the mean.
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during cisplatin exposure (Table 7.1). The trend in the current experiment is
consistent with this, as depleting FAM120A reduces the ED50 estimate for cisplatin
compared to the siCTRL samples, but the reduction is not significant (p,value,
0.0634; Table 7.3).
Depleting any of FAM120A, TRIM28, or C1QBP alongside YB-1 results in fur-
ther reductions in the ED50 estimates for MDA-MB231 cells in cisplatin compared
to MDA-MB231 cells where only YB-1 is depleted (statistical analysis summarised
in Table 7.3; Figure 7.10.A). The lowest ED50 estimate came from MDA-MB231
cells where YB-1 and FAM120A were both depleted (1.16 ± 0.13 µM cisplatin,
t-value, 2.944, p-value, 0.0038). The results from these experiments confirm the im-
portance of YB-1 to the survival of MDA-MB231 cells during exposure to cisplatin.
Depleting FAM120A, TRIM28, or C1QBP, alongside YB-1 further sensitises
MDA-MB231 cells to cisplatin. Furthermore, depleting either C1QBP or FAM120A
mitigated some of the negative growth effects that resulted from depleting YB-1
(Figure 7.7.A). The apparent need that FAM120A, and likely C1QBP, be present
for the depletion of YB-1 to have a significant effect on reducing the growth-rate
of MDA-MB231 cells infers that these two proteins lie down-stream to YB-1 in a
signalling pathway that is perturbed by the depletion of YB-1. From these results,
it could also be inferred that the biochemical pathways underpinning the effects of
YB-1 depletion on the growth-rates may be different, and possibly separate, to those
promote the role of YB-1 in cisplatin sensitivity. FAM120A appears to be involved
in both pathways but, in the growth pathway, FAM120A would lies downstream
of YB-1. In the cisplatin pathway, FAM120A appears to be more likely to have a
function that is equivalent to that of YB-1.
The effects of depleting FAM120A, C1QBP, or TRIM28 on the survival of MDA-
MB231 cells following a 2 hr exposure to cisplatin were examined. Data from the
siCTRL and siYB1 1 treatments are also presented in Table 5.4 and Figure 5.7,
although these results are not discussed further here. For these experiments, YB-1,
FAM120A, TRIM28, or C1QBP were depleted in MDA-MB231 cells using reverse
transfections (siRNA duplexes at 0.5, 1, 2 nM). To provide sufficient time for the
proteins to be depleted, the cells were exposed to 3.125 - 25 µM cisplatin for 2 hrs
48 hrs after the commencement of the transfections. Following the two hr exposure,
the media was replaced and the confluence of the cells monitored for 96 hrs.
The results from this experiment show that YB-1 depletion reduces the sur-
vival of MDA-MB231 cells following a 2 hr exposure (summarised in Table 7.4 and
Figure 7.11). Depleting C1QBP has no effect on estimates of the ED50 for cis-
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Figure 7.10: Depleting FAM120A, TRIM28, or C1QBP in conjunction with YB-1 further
reduces the growth-rate of MDA-MB231 cells during cisplatin exposure (0 - 3.125 µM; n =
4). YB-1, FAM120A, TRIM28, and C1QBP were depleted using 1 nM siRNA duplexes and
the growth of the cells was monitored using the Incucyte FLR (see Table 7.3 for siRNA
duplex combinations). A, the ED50 for cisplatin was estimated by fitting the maximum
growth-rates using log-logistic regression. B, representative images from Experiment 1
highlighted how transfection altered the morphology of MDA-MB231 cells that were grown
in 1.56 µM cisplatin. siRNA = siRNA duplexes against the indicated transcripts. These
data were generated in the same experiments as those shown in Figure 7.9. * = p <0.05,
** = p <0.01. Scale bar is 100 µm.
209
Table 7.4: Depleting YB-1 or FAM120A reduces the growth-rate of MDA-MB231 cells
following 2 hrs of exposure to cisplatin (0 - 25 µM; n = 4).
siRNA Concentration ED50 ± S.E. Delta ± S.E. p-value (t-value)
siCTRL 2 9.80 ± 0.73 - -
siYB1 1 2 5.55 ± 0.37 -4.26 ± 0.82 0.0000 (5.169)
siFAM120A 2 7.36 ± 0.64 -2.44 ± 0.97 0.0139 (2.510)
siTRIM28 2 10.94 ± 0.72 1.13 ± 1.03 0.2744 (-1.100)
siC1Q 3 2 9.57 ± 0.77 -0.24 ± 1.06 0.8239 (-0.22322)
siCTRL 1 10.56 ± 0.87 - -
siYB1 1 1 5.72 ± 0.68 -4.84 ± 1.10 0.0000 (4.394)
siFAM120A 1 8.96 ± -0.88 -1.61 ± 1.23 0.1963 (1.301)
siTRIM28 1 10.95 ± 1.02 0.39 ± 1.34 0.7743 (-0.288)
siC1Q 3 1 11.78 ± -1.19 1.22 ± 1.47 0.4106 (0.827)
siCTRL 0.5 10.80 ± 0.78 - -
siYB1 1 0.5 6.66 ± 0.43 -4.14 ± 0.89 0.0000 (4.634)
siFAM120A 0.5 10.11 ± 0.73 -0.69 ± 1.07 0.5222 (0.643)
siTRIM28 0.5 13.75 ± 1.11 2.95 ± 1.36 0.0327 (-2.169)
siC1Q 3 0.5 10.01 ± 0.81 0.78 ± 1.13 0.4885 (-0.696)
The dose-response curves were fitted using log-logistic reggression. Estimates for the
effective doses, where 50% of the cells were killed by cisplatin (ED50), are given. T-tests
were used to compare the ED50 following the depletion of each protein to the ED50 of the
siCTRL RNA duplex, significant differences are shown as bold text. S.E. = standard
error of the mean.
platin in MDA-MB231 cells (summarised in Table 7.4.A). The effects of depleting
TRIM28 are more complex. Depleting TRIM28 using siTRIM28 at 2 or 1 nM has
no effect on the sensitivity of MDA-MB-231 cells to cisplatin. However, transfect-
ing MDA-MB231 cells using 0.5 nM siTRIM28 appears to decrease the sensitivity
of MDA-MB231 cells to cisplatin, as the estimated ED50 increased by 2.95 ± 1.36
µM cisplatin compared to the ED50 estimate from 0.5 nM siCTRL-treated cells
(Table 7.4.A; t-value= -2.169,p-value = 0.0327). Finally, FAM120A also appears
to support the survival of MDA-MB231 cells following cisplatin exposure. Depleting
FAM120A using 2 nM, reduces the ED50 of cisplatin by 2.44 ± 0.97 compared to
the 2 nM siCTRL-treated cells (p-value, 0.0139). The sensitivity of MDA-MB231
cells to cisplatin was unaltered when less siFAM120A duplex was used (Table 7.4
and Figure 7.11.A).
The morphology of MDA-MB231 cells following two hrs of exposure to 6.25
µM cisplatin was also examined. MDA-MB231 cells that were transfected with 2
nM siCTRL, siTRIM28, or siC1Q 2 displayed similar morphologies to one another,
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Figure 7.11: Depleting YB-1 or FAM120A reduces the survival of MDA-MB231 cells
following a 2 hr exposure to cisplatin (3.125 - 25 µM, n = 4). YB-1, FAM120A, TRIM28,
and C1QBP were depleted using siRNA duplexes (0.5, 1, 2 nM) and 48 hrs later media
that contained cisplatin was added for two hrs. The confluence of the cells was monitored
for 96 hrs. A, response curves were prepared from the maximum growth-rates to estimate
the ED50 for each treatment. B, representative phase-contrast images of MDA-MB231
cells 24 and 72 hrs after a 2 hr exposure to 6.25 µM cisplatin. Abbreviations; * =
p-value <0.05, *** = p-value <0.001. < = bi-nucleate cell. Scale bar is 100 µm.
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24 and 72 hrs after two hrs of exposure to 6.25 µM cisplatin (Figure 7.11.B).
Corresponding to the reductions in the ED50 estimates resulting from the YB-1
depletion, the cells that remained after 24 and 72 hrs using 2 nM siYB1 1 and two hrs
of exposure to 6.25 µM cisplatin exhibited poor attachment (Figure 7.11.B, YB-
1). Depleting FAM120A with 2 nM siRNA duplex resulted in some cells appearing
to be enlarged 72 hrs after cisplatin exposure (Figure 7.11.B, FAM120A). Loss of
control of mitosis following the depletion of YB-1 or FAM120A, and a brief cisplatin
exposure, was also indicated by the presence of what appeared to be cells with two
nuclei (Figure 7.11.B, <). Therefore, the effects of depleting YB-1 and FAM120A
on the morphology of MDA-MB231 cells, following a 2 hr exposure to 6.25 µM
cisplatin, are consistent with the two proteins supporting the viability of MDA-
MB231 cells.
The results from these experiments highlight three primary points. Firstly, they
further illustrate the importance of YB-1 to the survival of MDA-MB231 cells during
and following cisplatin exposure. Secondly, of the three proteins that were studied,
only FAM120A consistently shows the potential to interact with YB-1 to influence
the survival of MDA-MB231 cells during, and following, cisplatin exposure. The final
point involves the partial abrogation of the negative effects on the growth of MDA-
MB231 cells that was observed following concurrent depletion of YB-1 and FAM120A
or C1QBP. These observations raise the possibility that the pathway leading to
reduced growth following YB-1 depletion may act in part through FAM120A and
C1QBP. However, further experiments that explicitly enumerate cell division are
needed to confirm this final point.
7.2.5 The repair of double-strand DNA breaks is not central
to YB-1 function during cisplatin exposure
YB-1 is known to interact with DNA repair proteins that act via the nucleotide ex-
cision and base excision repair pathways (reviewed in Chapter 1.8.1; Gaudreault
et al. 2004, Das et al. 2007, Chattopadhyay et al. 2008, Sengupta et al. 2011, Fomina
et al. 2015). However, the YB-1 in MDA-MB231 cells did not appear to interact
with proteins that were exclusively linked to either pathway during cisplatin ex-
posure (Chapter 6). Instead, YB-1 interacted with proteins that participate in
the repair of double-strand DNA breaks (TRIM28, XRCC5, and XRCC6; Chapter
6). Double-strand DNA breaks form as secondary lesions during cisplatin exposure
(discussed in Chapter 6.3.2 and Chapter 7.1). TRIM28 is known to have an
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important role in the repair of double-strand breaks in regions of heterochromatin
which get repaired slowly (Goodarzi et al. 2008, Noon et al. 2010, White et al. 2012).
Therefore, the late onset of death in MDA-MB231 cells during cisplatin exposure
(>72 hrs), and the increased levels of TRIM28 that copurified with YB-1 from cells
that were exposed to cisplatin, prompted these experiments that focus on the repair
of double-strand DNA breaks.
Histone H2AX (H2AX) with phosphorylation to serine 139 forms foci (γH2AX
foci) around double-strand DNA breaks. It then facilitates the recruitment of DNA
repair factors (Paull et al. 2000, Lowndes & Toh 2005, Löbrich et al. 2010). YB-1
was hypothesised to participate in the repair of the sub-population of double-strand
DNA breaks that occur in heterochromatin during cisplatin exposure. Therefore,
the number of γH2AX foci in each cell was used to indicate that double-strand
DNA breaks were being repaired, including those double-strand breaks in regions of
heterochromatin.
These experiments utilised 5 nM siRNA duplexes (siCTRL or siYB1 1) to deplete
YB-1 in MDA-MB231 cells, grown on poly-L-lysine coated coverslips in 24-well
plates, prior to 48 hrs of 1.56 µM cisplatin exposure. The cells were fixed using 2%
paraformaldehyde in PBS and IF performed using anti-γH2AX. A 40 × objective
lens was used to image the coverslips and multiple fields of view were selected using
the signal from DNA (Hoechst). The γH2AX foci in the nuclei of a minimum of 200
cells were counted for each treatment (see Chapter 2.10.2).
The IF indicated that the nuclei of MDA-MB231 cells enlarged following 48 hrs
of cisplatin exposure (Figure 7.12.A). The steps for counting γH2AX foci included
the creation of a mask around all nuclei in each image. The data from these masks
were used to examine how cisplatin exposure and YB-1 depletion altered the size
of MDA-MB231 cell nuclei. Following 48 hrs of cisplatin exposure, the average size
of nuclei increased from 2954 ± 148 nm2 in the control media to 4037 ± 212 nm2
in nuclei that were incubated in 1.56 µM cisplatin (Figure 7.12.B; Df = 1,F-value
= 23.371, p-value = 0.00022). The average size of the nuclei of MDA-MB231 cells
was consistent irrespective of the presence or absence of YB-1 (Df = 1, F-value -=
0.077, p-value = 0.785). Experimental variation was noticed during data analyses,
so the experiment was included in the 2-way ANOVA model as a covariate. This
revealed that the average size of the nuclei varied between the experiments (Df =
1, F-value = 7.468, p-value = 0.01541). The reasons for increases in nuclear size
were not clear. However, chromatin dynamics can affect nuclear size (Jevtić &
Levy 2014, Gasser 2002). The repair of double-strand DNA breaks in regions of
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heterochromatin would constitute a disruption to chromatin dynamics.
The results from counting γH2AX foci showed that following 48 hrs of cisplatin
exposure, the average number of γH2AX foci in the nuclei of MDA-MB231 cells
increased from 1.45 ± 0.33 γH2AX foci per nucleus to 4.92 ± 0.87 γH2AX foci per
nucleus (Figure 7.12.A and C; DF = 1, F-value = 15.677, P-value = 0.00126).
However, depleting YB-1 had no effect on the number of γH2AX foci that were
observed (Figure 7.12.C; Df = 1, F-value = 0.944, P-value = 0.34657). The
experiment identifiers were also included in the 2-way ANOVA as covariates but no
significant effect was detected (DF = 1, F-value = 0.06038,P-value=0.06038).
YB-1 depletion has no effect on the number of γH2AX foci that are present in
MDA-MB231 cells during cisplatin exposure. Furthermore, the preceding section
highlights that TRIM28 plays no role in the survival of MDA-MB231 cells during
cisplatin exposure (Chapter 7.2.4). The function of TRIM28 is central to the
hypothesis that YB-1 participates in the repair of double-strand DNA breaks in
regions of heterochromatin during cisplatin exposure. The finding that TRIM28 has
no effect on the survival of MDA-MB231 cells during cisplatin exposure (Chapter
7.2.4) and, that the number γH2AX foci in MDA-MB231 cells are not altered
following the depletion of YB-1, means that there was no support for the hypothesis
that YB-1 participates in the repair of double-strand DNA breaks in regions of
heterochromatin during cisplatin exposure.
7.3 Discussion
Three proteins, C1QBP, FAM120A, and TRIM28, were hypothesised to co-operate
with YB-1 to improve the survival of MDA-MB231 cells during cisplatin exposure.
TRIM28 was also hypothesised to co-operate with YB-1 to influence the repair
of double-strand DNA breaks or to repress the transcription of E2F- gene targets.
Finally, FAM120A and C1QBP were hypothesised to co-operate with YB-1 to trans-
duce survival signals as was C1QBP. The results that were presented in this chapter
show that:
• Of the three proteins studied, the subcellular distribution of FAM120A was
most similar to the distribution of YB-1 in MDA-MB231 cells;
• Depleting FAM120A increases the sensitivity of MDA-MB231 cells to cisplatin;
• Depleting FAM120A or C1QBP in conjunction with YB-1 may attenuate the
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Figure 7.12: Depleting YB-1 has no effect on the size of MDA-MB231 nuclei or the
number γH2AX foci during cisplatin exposure. MDA-MB231 cells were fixed with 2%
paraformaldehyde and IF performed (n = 5). A, representative images from IF of MDA-
MB231 cells where anti-γH2AX was labelled with AlexaFluor 488 and DNA labelled with
Hoechst is represented as blue. B, the average size of the nuclei of MDA-MB231 cells
following 48 hrs of media or 1.56 µM cisplatin in media. C, the average number of γH2AX
foci per MDA-MB231 cell with and without YB1 protein present. Two-way ANOVA was
used to assess how siRNA duplex, cisplatin, and experiment (covariate) alter the number
of γH2AX foci per MDA-MB231 cell. ** = p <0.005, *** = p <0.001.
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growth reduction that normally accompanies the depletion of YB-1 in MDA-
MB231 cells;
• There was no support for the hypothesis that YB-1 participates in the repair
of double-strand DNA breaks during cisplatin exposure.
7.3.1 The interaction of YB-1 and TRIM28 or C1QBP is
unlikely to positively influence cell survival
The experiments provided no support for the involvement of either TRIM28 or
C1QBP in the cisplatin resistance of MDA-MB231 cells. C1QBP was selected due
to its reported function as a survival factor during cisplatin exposure rather than in-
creased levels of C1QBP copurifying with YB-1 during cisplatin exposure (reviewed
in Chapter 7.1). The results presented here contradict another study that showed
depleting C1QBP in MDA-MB231 cells reduced cell proliferation and cell migration
(McGee et al. 2011).
Prior to the commencement of this work TRIM28 appeared to be the strongest
candidate (Chapter 6) as it is well connected to functions that would be appro-
priate for YB-1; repairing DNA damage and the repression of transcription. One
hypothesis stated that the interaction of the two proteins facilitated a transcriptional
response to cisplatin exposure; most likely as a down-regulation of E2F-family gene
targets (Wang et al. 2007, Hu et al. 2012, Chen et al. 2012). The second hypothesis
held that YB-1 and TRIM28 interact to repair double-strand DNA breaks in regions
of heterochromatin. The results from the experiments in this chapter showed that
depleting TRIM28 has no effect on the survival of MDA-MB231 cells during cisplatin
exposure. Depleting TRIM28 failed to render MDA-MB231 cells more sensitive to
chronic cisplatin exposure or, to reduce their survival following a 2 hr exposure to
cisplatin. This is sufficient evidence to reject both hypotheses relating to the func-
tional significance of TRIM28 and YB-1 interactions in MDA-MB231 cells during
cisplatin exposure.
Indirect support for rejecting the latter hypothesis came from the quantification
of γH2AX foci in MDA-MB231 cells. Depleting YB-1 had no effect on the number of
γH2AX foci in MDA-MB231 cells. Therefore, YB-1 does not appear to be involved
in the repair of double-strand DNA breaks during cisplatin exposure, irrespective of
any interaction with TRIM28. Variation between experiments was evident for the
γH2AX foci quantifications. This may be explained by variations in the number of
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γH2AX foci during the cell cycle as the number of γH2AX foci is elevated during
the later stage of cell division (Löbrich et al. 2010). Therefore, variations in the
cell cycle profile may explain some of the variation. The intensity of the signal
from nuclei can be used to identify cells that are yet to begin S-phase. However,
plotting the intensity of individual nuclei did not provide sufficient resolution to
separate cells that were yet to begin S-phase of the mitotic cycle. There is also
a further reason why these experiments may have missed a real alteration to the
number of γH2AX foci following the depletion of YB-1. The hypothesised targets for
these experiments, double-strand DNA breaks in regions of heterochromatin, were
outnumbered by the predominance of double-strand DNA breaks in euchromatin
which comprise ∼ 75% of double-strand DNA breaks in primary human fibroblasts
(Goodarzi et al. 2008). Furthermore, γH2AX foci can provide reliable estimates of
double-strand DNA breaks but deregulated DNA repair mechanisms may lead to
γH2AX foci failing to accurately represent these breaks and their repair (Löbrich
et al. 2010).
An alternative approach is to accept the null hypothesis for the γH2AX exper-
iments, that is, the ability of YB-1 to promote the survival of MDA-MB231 cells
during cisplatin exposure is unrelated to the repair of double-strand DNA breaks.
Double-strand DNA break repair proteins, besides TRIM28, were detected in LC-
MS/MS of cross-linked YB-1. XRCC5 and XRCC6 participate in the repair of
double-strand breaks. However, both proteins appear to interact with RNA in addi-
tion to roles in DNA repair (Britton et al. 2013). Therefore, their presence in IP of
YB-1 may be explained via RNA binding rather than DNA binding. Furthermore,
quantification of XRCC6 in Chapter 6.2.6 indicates that its interaction with YB-1
was unaffected or reduced during cisplatin exposure and this is inconsistent with
increased rates of DNA repair.
Further indirect evidence against the importance of double-strand DNA breaks
comes via the observation that YB-1 is important to the survival of MDA-MB231
cells following a brief exposure to cisplatin. The shorter period of exposure should
reduce the potential for double-strand DNA breaks to occur following the cisplatin
exposure. Many of the cells that in the growth phase of mitosis when the cisplatin
is added will have more time to remove cisplatin adducts before double-strand DNA
breaks are introduced during S-phase. However, the sensitisation that is elicited by
depleting YB-1 remains strong despite the reduction in the potential for double-
strand DNA breaks to be produced. Therefore, the null hypothesis that YB-1 pro-
motes the survival of MDA-MB231 cells during cisplatin exposure, without relying
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on the repair of double-strand DNA breaks, is accepted.
Double-strand DNA breaks are not the primary form of DNA damage from
cisplatin exposure and γH2AX foci are not general markers of DNA damage or
repair. The repair pathways that can remove platinum adducts and cross-links from
DNA do not necessarily lead to γH2AX foci (Revet et al. 2011).
The question of whether YB-1 participates in DNA repair remains interesting.
During cisplatin exposure, YB-1 increased its interaction with DNA in the nuclei
of MDA-MB231 cells (Chapter 5.2.5). The ability of YB-1 to preferentially bind
to cisplatin-modified DNA, and participate in the main repair pathways for re-
moving cisplatin adducts, still have potential to be relevant to YB-1 function dur-
ing cisplatin exposure (reviewed in Chapter 1.8.1; Gaudreault et al. 2004, Das
et al. 2007, Chattopadhyay et al. 2008, Sengupta et al. 2011, Fomina et al. 2015).
Further experiments could be designed to use methods that detect cisplatin on DNA.
Direct quantification of DNA-cisplatin could confirm whether a continued focus on
DNA repair mechanisms is justified. Enzyme linked immunosorbent assays, using
antibody preparations directed against cisplatin-DNA, can quantify the amount of
cisplatin in purified DNA (Liedert et al. 2006). However, direct assessment of the
cisplatin content of DNA using MS, specifically inductively coupled plasma MS,
would be the ideal assay for the sensitive quantification of the platinum content of
DNA (Bonetti et al. 1996, Brouwers et al. 2006, Hermann et al. 2013).
The work performed here was sufficient to discount the interaction of YB-1 and
C1QBP or TRIM28 as a critical component of the function of YB-1 during cisplatin
exposure. Furthermore, the interaction of TRIM28 and YB-1 to repair double-strand
DNA breaks does not appear to be a central mechanism by which YB-1 promotes
the survival of MDA-MB231 cells during cisplatin exposure.
7.3.2 YB-1 and FAM120A during cisplatin exposure
At the beginning of this chapter, FAM120A was hypothesised to promote the survival
of MDA-MB231 cells. Formulating a hypothesis about the potential function of any
interaction between YB-1 and FAM120A was difficult due to a lack of research into
the function of FAM120A. However, the two known functions, the regulation of
kinase activity or the ability to influence gene expression by binding to RNA, were
both consistent with YB-1 biology. Recent work from Bartolome et al. (2015) has
provided further support for the importance of the former function of FAM120A in
cell survival.
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In MDA-MB231 cells, FAM120A appears to be similar to YB-1 in a number of
ways. The subcellular distribution of YB-1 and FAM120A in MDA-MB231 cells is
almost indistinguishable. Information about the distribution of FAM120A is scarce.
Bartolome et al. (2015) has performed IHC on colorectal tissue samples and IF
in a colon carcinoma cell line (KM12SM). The distribution of FAM120A diverged
between the IHC and IF. The IHC indicated that FAM120A was present at elevated
levels in the cytoplasm of cells in sections from colorectal cancers. The IF signal
from FAM120A in KM12SM cells showed that FAM120A was primarily localised
to the cell membrane where the authors proposed FAM120A interacted with the
IL13 receptor subunit α-2 (IL13Rα2). The results presented in this chapter, show
that FAM120A is found throughout MDA-MB231 cells with the majority of signal
in the cytoplasm (Figure 7.6). Therefore, it is possible that YB-1 and FAM120A
interact at the cell membrane. However, the only function that has been attributed
to YB-1 at the cell membrane relates to cell movement (Lovett et al. 2010) rather
than cell survival. Like YB-1, the subcellular distribution of FAM120A was generally
consistent with RNA binding and FAM120A has been shown to associate with PUR-
α-containing mRNPs in mouse neuronal tissue (Kobayashi et al. 2008). Human
YB-1 also interacts with PUR-α (Chapter 4, Chapter 6, Kim et al. 2008, Lasham
et al. 2000, Chen et al. 1995). Further experiments should focus on the accurate co-
localisation of YB-1 and FAM120A. Proximity ligation assays, an imaging technique
that only produces signal when two antibodies are adjacent to one another (Gullberg
et al. 2003, Söderberg et al. 2008), is ideally suited to this work.
A key finding from this chapter is that depleting FAM120A and YB-1 impairs
the survival of MDA-MB231 cells during cisplatin exposure. This is the first report
that FAM120A supports cell survival during cisplatin exposure. FAM120A and YB-
1 were hypothesised to promote the survival of MDA-MB231 cells via the ability
of FAM120A to regulate kinase activity. Tanaka et al. (2009) found that following
oxidative stress, the association of FAM120A with Src family kinases led to phos-
phorylation to tyrosine(s) on FAM120A. The phosphorylated FAM120A was then
able to interact with PI3-kinase and Src family kinases to activate the Akt-mediated
antiapoptotic pathway. Tanaka et al. (2009) hypothesised that the RNA binding and
antiapoptotic activities of FAM120A were separate functions of FAM120A. A recent
study from a clinical trial of an AKT inhibitor (GSK2141795) found that AKT in-
hibition reduced the growth-rate of cells from tumour biopsies while re-sensitising
them to cisplatin (Cheraghchi-Bashi et al. 2015). Intruigingly, Cheraghchi-Bashi
et al. (2015) also found that biopsies from ovarian cancer patients that received
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GSK2141795 had greater levels of YB-1.
Finally, depleting FAM120A, or C1QBP, in conjunction with YB-1 highlighted
that FAM120A may have a dual role in MDA-MB231 cells. This observation re-
quires further validation using experiments that directly assess cell division and the
cell-cycle. The requirement for MDA-MB231 cells to have FAM120A or C1QBP
present, in order for YB-1 depletion to strongly inhibit cell growth, is consistent
with the function of C1QBP, which is known to negatively influence cell survival
(Meenakshi et al. 2003, Sunayama et al. 2004, Reef et al. 2007). There is currently
no research indicating that FAM120A can modulate signals that inhibit cell survival
or growth. However, it is possible that when YB-1 is not present in MDA-MB231
cells, FAM120A ceases to be activated, possibly by phosphorylation of tyrosines
(Tanaka et al. 2009),
7.3.3 Summary
Two of the three proteins that were the focus of this chapter, TRIM28 and C1QBP,
do not appear to have functions that are critical to the survival of MDA-MB231 cells
during cisplatin exposure. The results from the experiments that were presented in
this chapter, are consistent with FAM120A having a function that supports the
survival of MDA-MB231 cells during cisplatin exposure. FAM120A appears to be
able to influence kinase signalling (see above). However, whether the effects observed
involve kinase signalling has yet to be confirmed. Therefore, future work should focus
on the interaction of YB-1 and FAM120A and the involvement of kinase signalling.
Another proposition requiring further research is if the RNA binding function that
both proteins share is important to the ability of YB-1 and FAM120A to support
cell survival during cisplatin exposure.
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Chapter 8
Overall summary and conclusions
8.1 Key findings
A number of conclusions can be reached from the research that is outlined in this
thesis.
1. Elevated levels of YB-1 in the cytoplasm of breast cancer cells are correlated
with high histological grade and ER-ve/PR-ve breast cancers.
2. The binding of antibodies against YB-1 appears to be affected by the tertiary
structure or PPI of YB-1.
3. YB-1 from the cytoplasm or nucleus of two cancer cell lines is phosphorylated
at multiple sites.
4. Depleting YB-1 impairs the survival of MDA-MB231 cells.
5. Depleting FAM120A or C1QBP, in conjunction with YB-1, counteracts the
growth reduction that accompanies YB-1 depletion.
6. Depleting YB-1 impairs the survival of MDA-MB231 cells during cisplatin
exposure.
7. The PPI of YB-1 in two cancer cell lines indicates that YB-1 binds to DNA
but the molecular function of YB-1 in these cells appears to rely on the ability
of YB-1 to bind to RNA.
8. Cisplatin exposure modulates a subset of the PPI of YB-1 that are associated
with chromatin assembly.
9. FAM120A is likely to cooperate with YB-1 during cisplatin exposure.
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8.2 Introduction
Early research identified the ability of YB-1 to bind to the promoters of known
oncogenes; EGFR, ERBB2, and ABCB1 (Sakura et al. 1988, Ozer et al. 1990,
Asakuno et al. 1994, Kohno et al. 1994). Following this, the levels of YB-1 in breast
cancers were positively correlated with ABCB1 expression (Bargou et al. 1997) and
a number of studies have confirmed that YB-1 is elevated in a range of cancers,
including breast cancer (reviewed in Chapter 1.3). However, the work that has
followed Bargou et al. (1997) has also revealed that the role of YB-1 in cancer is
more complex than solely promoting drug resistance by acting as a transcription
factor for the ABCB1 gene. Instead, it appears that YB-1 has four main functions
in cancer. These functions explain the elevated levels of YB-1 in cancers (Chapter
1.4):
• Promoting the early stages of cancer development;
• Having a positive role on mitosis;
• Promoting drug resistance;
• Facilitating an invasive phenotype.
The involvement of YB-1 in these four functions appears to rely on the multifunc-
tionality of YB-1 at the molecular level (Chapter 1.8). YB-1 can bind to both DNA
and RNA. The ability to bind to DNA allows YB-1 to act as a transcription factor
and to participate in DNA repair (Chapter 1.8.2). While binding to RNA, YB-1
can modulate the inclusion or exclusion of exons during splicing, stabilise RNA, and
either promote or inhibit translation of mRNA transcripts (Chapter 1.8.3).
The aim of this thesis was to study the functions of YB-1 in cancer and the
mechanisms of drug resistance. IHC was used to examine the levels of YB-1 in
breast tumours (Chapter 3.2.2). The phosphorylation and PPI of YB-1 from the
cytoplasm and nuclei of two cancer cell lines were analysed (Chapter 4). The role
of YB-1 during cisplatin exposure was also studied (Chapter 5). Additionally,
this thesis examined the PPI of YB-1 in MDA-MB231 cells during cisplatin expo-
sure. The roles of three proteins that copurify with YB-1 during cisplatin were also
assessed.
222
8.3 YB-1 as a clinical biomarker
IHC was used to reconfirm that YB-1 is elevated in aggressive breast cancers (Chapter
3.2.2; Bargou et al. 1997, Lee et al. 2008, Woolley et al. 2011, Stratford et al.
2012, Reipas et al. 2013). The direct comparison of the signals from two antibodies
against YB-1, NYB1 and YB1C , in the same breast tumours was unique. Both anti-
body preparations have similar affinities for reduced YB-1 (Chapter 3.2.4; Cohen
et al. 2010) but their sensitivity as prognostic markers differs (Chapter 3.2.2;
Woolley et al. 2011). The tertiary structure or protein interactions of YB-1 appear
to explain the differences in YB-1 detection between NYB1 and YB1C in IHC and
BN-PAGE. The PPI of YB-1 as it binds to RNA, including interactions between
two YB-1 molecules, are likely to be the primary initiators of change in epitope
availability. These changes are hypothesised to rely on the multimerisation of YB-1
particles that have bound densely to an RNA transcript. This multimerisation is
likely to occlude the C-terminus of the YB-1 particles (Izumi et al. 2001, Skabkin
et al. 2004, Woolley et al. 2011).
A number of researchers have concluded that YB-1 has potential as a biomarker
as well as being a therapeutic target (Habibi et al. 2008, Basaki et al. 2010, Davies
et al. 2011, Wang et al. 2015, Lasham et al. 2016). However, the results presented
here indicate that there are significant hurdles to overcome before YB-1 can be
used in a clinical setting as a biomarker. A biomarker that is useful in the clinic
needs to provide reproducible results that also lead to clear clinical outcomes (Taube
et al. 2005, Matos et al. 2010). The results presented here highlight that YB-1 is
present in almost all tissues and that the levels of YB-1 in normal breast tissue vary
greatly between individuals (Chapter 4). This variation in subcellular localisation
between different studies is another barrier to making a clear assessment of the
elevations of YB-1 in cancer (reviewed in Chapter 3.3). The results indicate that
the signal from antibodies against YB-1 are influenced by factors other than the
levels of YB-1, namely the tertiary structure or PPI of YB-1. The importance of
this effect is yet to be determined.
If IHC cannot reliably provide the levels of YB-1 in tissues, then YBX1 mRNA
levels may supply a more accurate assessment (Lasham et al. 2012). However, impor-
tant information which may be relevant to clinical decisions about YB-1 protein char-
acteristics, such as teriary structure, PTM, and subcellular localisation, would be
unavailable. Finally, the translation of YBX1 mRNA appears to be highly regulated
by both YB-1 (Chapter 1.7.1) and the mTOR pathway (Ilic et al. 2011, Lehmann
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et al. 2011, Huober et al. 2013, Vicier et al. 2014, Basho et al. 2016) and both
are elevated or activated in some breast cancers. Therefore, it is unclear whether
YBX1 mRNA levels provide an accurate representation of YB-1 levels in all breast
tumours.
The usefulness of YB-1 as a clinical biomarker is currently unclear. However, the
result that elevated levels of YB-1 are present in aggressive breast cancers is clear
and it is supported by multiple studies (Chapter 3.2.2; Bargou et al. 1997, Lee
et al. 2008, Woolley et al. 2011, Stratford et al. 2012, Reipas et al. 2013). The
functional significance of this elevation is less clear.
8.4 Phosphorylation of YB-1
The YB-1 that was purified from the cytoplasm and nuclei of MDA-MB231 and
A549 cells was phosphorylated at multiple sites (Chapter 4.2.2). YB-1 was phos-
phorylated at S165, S174, S176, and S314. S167 was also identified as a possible
site. Of these phosphorylation sites, only the effect of phosphorylation of YB-1 at
S165 has been studied. In this work, phosphorylation of YB-1 at S165 appeared to
be associated with YB-1 that is in the cytoplasm (Chapter 4.2.2). A single paper
has shown that phosphorylation of YB-1 at S165 is necessary for NF-κB activation
and it may also be significant to the development of colon cancers (discussed in
Chapter 1.7.2.1).
YB-1 peptides with phosphorylation at S102 were not identified in this work
despite being a known PTM to YB-1 in MDA-MB231 cells (Toulany et al. 2011).
This modification appears to be difficult to detect using LC-MS/MS.
The effects of phosphorylation on the molecular function of YB-1 at the other
residues (S165, S167, S174, S176, and S314) are yet to be characterised. Further
study to examine the importance and function of these phosphorylations is war-
ranted. However, currently the cost of developing antibodies against each phospho-
rylation site would be prohibitive. The LC-MS/MS analyses that were performed
here were optimised to identify phosphorylated peptides without consideration for
quantification or the consistent detection of specific peptides. However, the data
from this study can be used to establish a quantitative assay that targets the iden-
tified peptides (discussed in Chapter 6.3.2; Picotti & Aebersold 2012). Using
isotopcally labelled peptides, with and without phosphorylation, would provide ac-
curate estimates of the proportion of YB-1 that has each phosphorylation. This
assay could be established for all the phosphorylation sites that have been identified
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here at a similar price to commercially producing a single phosphorylation specific
monoclonal antibody. Refinements to the liquid chromatography and disassociation
for MS2 would also improve the sensitivity of the assay to allow meaningful measure-
ments to be made from less starting material. It would also allow the identification
of fragments that can be used to quantify a single phosphorylation in MS2 spectra
that are comprised of two separate peptides; each with a phosphorylation at a dif-
ferent site (an example of this is shown in Figure 4.8.B). A quantitative assay for
phosphorylated YB-1 peptides would have a number of uses.
The presence and potential importance of these phosphorylation sites may be
confirmed by gaining information about their occurrence in other cells. The mutated
K-ras gene in MDA-MB231 cells leads to constitutive phosphorylation of YB-1 at
S102 (Toulany et al. 2011). YB-1 from HEK293 cells was only phosphorylated at
S165 following IL-1β exposure while the YB-1 from A549 and MDA-MB231 cells was
phosphorylated at S165 with no requirement for external stimulation. Therefore,
additional phosphorylation sites may be constitutively active in A549 and MDA-
MB231 cells. The phosphorylation state of the YB-1 from cell lines representing
normal breast tissue and the subtypes of breast cancer could be assessed using
a quantitative LC-MS/MS assay that targets phosphorylated YB-1 peptides (an
appropriate list of breast cell lines is shown in Table 1 of Holliday & Speirs 2011).
Research to date has identified that a function of YB-1 is to support the growth
and viability of cancer cells (Chapter 1.4.2). The findings in this thesis also support
this observation. Depleting YB-1 was seen to reduce the viability of asynchronously
dividing MDA-MB231 cells (Chapter 5). A LC-MS/MS assay that targets the
phosphorylated peptides could also be used to study whether YB-1 phosphorylation
changes with the cell cycle. Breast cancer cell lines, including MDA-MB231, could
be synchronised to G1/S-phase using a double thymidine block (Bootsma et al. 1964,
Bostock et al. 1971) and the phosphorylation of YB-1 monitored as the cells move
through the cell cycle.
8.5 Function of YB-1
The multifunctionality of YB-1 has been extensively reviewed in Chapter 1. YB-
1 can act as a transcription factor (Chapter 1.8.2), modulate the inclusion or
exclusion of exons during splicing, stabilise RNA, and promote or inhibit translation
of mRNA transcripts (Chapter 1.8.3). These functions were generally supported
by the results from analysing the proteins that copurified with YB-1 from MDA-
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MB231 and A549 cells (Chapter 4 and Chapter 6). Furthermore, the results
from Chapter 4 indicate that most of the YB-1 in the nucleus of these cells was
also likely to bind to RNA. Therefore, the results from this thesis imply that the
molecular functions of YB-1 that is binding to RNA are important in cancer cells.
YB-1 can bind to RNA and participate in the many steps that separate freshly
transcribed pre-mRNA transcripts from the point where a protein is translated
(Chapter 3.2.3). The PPI of YB-1 are consistent with the literature regarding
the interaction of YB-1 with RNA and the biochemical functions that stem from it.
The function of the YB-1 that is binding to DNA in MDA-MB231 cells remains less
clear (Chapter 3.2.3 - 3.2.4).
The ability of YB-1 to act as a transcription factor is well documented (re-
viewed in Chapter 1.8.2.1). In this thesis, YB-1 was shown to interact with DNA
(Figure 3.7 and Figure 5.10) and this was consistent with YB-1 participating in
transcription. Therefore, prior to performing the immunoprecipitation of YB-1 from
the nuclei of two cell lines (reported in Chapter 4), the literature and observations
from IF and DNA affinity proteins led to an expectation that nuclear YB-1 was act-
ing as a transcription factor. The PPI of YB-1 indicated that, while in the nucleus,
YB-1 was binding to both DNA and RNA. The proteins that were associated with
RNA binding are consistent with YB-1 influencing RNA splicing, transport, and
maturation in the nucleus. However, a subset of the proteins that copurified with
YB-1 from the nuclei of the two cancer cell lines, provided further evidence for YB-
1 interacting with DNA as proteins that are associated with chromatin, including
histones 1 - 3 and TRIM28 among others. However, there was no clear evidence
linking this chromatin association with transcriptional machinery.
Studies have highlighted the ability of YB-1 to repress the transcription of genes,
including CD95, MMP2, and GM-CSF (see Table 1.2). Some of the proteins
that copurified with YB-1 are known to repress transcription. TRIM28 has been
identified as one of these proteins and it copurified with YB-1 from the nuclei of
both MDA-MB231 and A549 cells. However, in addition to the ability to repress
transcription of E2F- family target genes, TRIM28 can also participate in DNA
repair (Iyengar & Farnham 2011, Neo et al. 2015). Therefore, the function of the
interaction between YB-1 and TRIM28 is unclear. The Transcriptional activator
protein Pur-alpha (PURA) is another protein that copurifies with YB-1 which can
repress transcription (reviewed in Gallia et al. 2000). PURA has been shown to
interact with YB-1 to repress the transcription of CD95 and TP53 (Lasham et al.
2000, Kim et al. 2008). However, PURA also interacts with RNA to influence
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translation (Gallia et al. 2000). In the current study, PURA copurified with YB-1
from the cytoplasm and the nuclei. This is consistent with the interaction of PURA
and YB-1 occurring while both proteins are binding to RNA. This study confirms
that YB-1 interacts with proteins that associate with chromosomes although the
significance of this to the function of YB-1 is yet to be fully defined.
The inferred functions of YB-1 were consistent with the molecular processes in
which YB-1 participates (Chapter 1.8). However, the significance of some PPI of
YB-1 remains less clear. The present work was unable to confirm the importance of
the inferred interactions to the molecular functions of YB-1 in the cell lines.
YB-1 is capable of influencing most levels of gene expression. Future work should
confirm the molecular functions of YB-1 in these cell lines by testing the effects of
depleting YB-1 on all levels of gene expression. To do so, YB-1 can be depleted
prior to pulse labelling newly transcribed RNA and proteins in conjunction with se-
quencing and LC-MS/MS. This protocol, following the approach in Schwanhäusser
et al. (2011), provides a model of the rates of mRNA production, mRNA degrada-
tion, translation, and protein degradation. Previous research indicates that YB-1
can influence all of these processes except protein degradation (Chapter 1.8). This
method could confirm whether the molecular functions of YB-1 in A549 and MDA-
MB231 cells matches the functions that were strongly inferred by the PPI of YB-1.
Specfically, that YB-1 primarily regulates gene expression in A549 and MDA-MB231
cells through post-transcriptional regulation of RNA transcripts and translation.
8.6 YB-1 during cisplatin exposure
The work presented here provides further confirmation that YB-1 can support resis-
tance to a range of drugs (Chapter 5; Ohga et al. 1996, Ohga et al. 1998, Shibahara
et al. 2004, Shibahara et al. 2004). The conditions used in this thesis ensured that
the cisplatin exposure received by MDA-MB231 cells was tolerated. It is not clear
that this is true of other papers that explore the role of YB-1 in cisplatin resistance
(discussed in Chapter 5.3; Guay et al. 2008a, Garand et al. 2011).
The work outlined shows that a subset of proteins interacting with YB-1 in-
creased or decreased in abundance following cisplatin exposure and, that these
proteins appeared to have functions in chromatin organisation and DNA binding.
Therefore, the modulation of two known functions of YB-1, the repair of DNA dam-
age or a transcriptional response, would be consistent with the protein interactions
of YB-1 during cisplatin exposure. The evidence for proteins that are involved in
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transcription has been discussed in the preceding chapter. A number of studies have
indicated that during cisplatin exposure YB-1 can participate in the repair of DNA
(Chapter 1.8.2.2 and Chapter 6.3.2). Proteins from the nucleotide excision re-
pair pathway and the base excision repair pathway, the two DNA repair pathways
that YB-1 is known to participate in, did not copurify with YB-1. Instead, more
TRIM28 copurified with YB-1 following cisplatin exposure and this interaction was
hypothesised to be related to the repair of DNA double strand breaks. However,
depleting YB-1 had no effect on the formation of γH2AX foci. Depleting TRIM28
prior to cisplatin exposure did not alter the response of MDA-MB231 cells to the
exposure. Therefore, DNA repair via the repair of double strand DNA breaks does
not appear to be central to the reduced survival of MDA-MB231 cells accompanying
YB-1 depletion. The significance of the interaction between TRIM28 and YB-1 is
unknown.
During cisplatin exposure, FAM120A and YB-1 increased their association and
depleting FAM120A reduced the growth rate of MDA-MB231 cells. The subcellular
distributions of YB-1 and FAM120A were very similar. However, the function of
FAM120A is currently poorly defined. The work detailed here is consistent with
two previous reports that FAM120A can promote cell survival during stress (Tanaka
et al. 2009, Woźniak et al. 2014). This is the first report to show that the presence
of FAM120A can improve the growth rate of cells during cisplatin exposure.
One of the novel findings from this thesis is that there is an interaction be-
tween YB-1 and FAM120A in A549 and MDA-MB231 cells. This interaction has
the potential to promote the survival of cells during cisplatin exposure. Further
work is required to confirm the interplay between the two proteins and define the
nature of the interaction. However, two alternative models may predict how the
proteins interact. The first model pedicts that FAM120A can inhibit cell division
but YB-1 represses this function (Figure 8.1.A). This is consistent with the deple-
tion of FAM120A rescuing the negative effects of YB-1 depletion on cell division.
This model also predicts that FAM120A and YB-1 interact directly to influence cell
survival during cisplatin exposure.
The second hypothetical model for the interaction of YB-1 and FAM120A pre-
dicts that the two proteins interact to promote the survival of MDA-MB231 cells
during stress (Figure 8.1.B). In this model, both the depletion of YB-1 and also
exposure to cisplatin lead to cell stress and the interaction of YB-1 and FAM120A
to promote survival. This second model is the most consistent with reports that
FAM120A can promote cell survival (Tanaka et al. 2009, Woźniak et al. 2014).
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Figure 8.1: Hypothetical models for the interaction of YB-1 and FAM120A. A, a model
that predicts the interaction of YB-1 and FAM120A. B, an alternative model that predicts
the interaction of YB-1 and FAM120A.
The molecular function of the interaction between YB-1 and FAM120A was not
confirmed in this thesis. However, the work outlined here shows that the association
of YB-1 and FAM120A is unlikely to be at the cell membrane. IF indicated that
FAM120A was distributed throughout MDA-MB231 cells. FAM120A copurified
with YB-1 from the cytoplasm and from the nucleus of MDA-MB231 and A549
cells. Given that both FAM120A and YB-1 can bind to RNA, it appears that
these two proteins interact while associating with RNA. However, as was noted in
Chapter 7.3.2, a proximity ligation assay that tests the colocalisation of YB-1 and
FAM120A could confirm where YB-1 and FAM120A interact within cells and how
cisplatin exposure influences this interaction. Proximity ligation assays also provide
an alternative technique to IP to confirm the interactions of proteins (Gullberg
et al. 2003, Söderberg et al. 2008).
On of the assays that was suggested in the preceding sections of this chapter could
also be useful to study the role of YB-1 during cisplatin exposure. Phosphorylation
has the potential to modulate the molecular function of YB-1. The quantitative
assay of YB-1 phosphorylation described in Chapter 8.4 may also provide useful
information about the effects of cisplatin exposure on the phosphorylation of YB-1.
FAM120A can influence kinase function, possibly by acting as a scaffold (Tanaka
et al. 2009, Bartolome et al. 2015). Therefore, it is possible that the role of FAM120A
during cisplatin exposure is to alter the phosphorylation of YB-1. The quantitative
assay of YB-1 phosphorylation could also assess whether depleting FAM120A alters
the phosphorylation of YB-1 during cisplatin exposure.
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8.7 Final remarks
The work presented here indicates that the contribution of different molecular func-
tions of YB-1 may differ from those described in previous reports. It is important
to gain an understanding of the relative contribution of the molecular functions of
YB-1. The work in this thesis highlights that the role of YB-1 as an RNA binding
protein requires greater attention. Many studies that attribute a transcriptional
effect to YB-1 may be measuring the effects of YB-1 as an RNA binding protein.
The ability of YB-1 to stabilise mRNA transcripts is one mechanism that may lead
to increased levels of an mRNA transcript (reviewed in Chapter 1.8.3.3). YB-1
may also appear to promote the transcription of a gene via its role as an exonic
splicing enhancer during pre-mRNA splicing. Disrupting the interaction of YB-1
with MDM2 pre-mRNA by camptothecin exposure or depleting YB-1 leads to co-
transcriptional exon skipping (Dutertre et al. 2010). Without the intricate assays
that were presented by Dutertre et al. (2010), this effect could appear to be a loss
of YB-1 transcriptional promotion.
The dominance of proteins that are involved in RNA amongst those that copurify
with YB-1 was consistent with the results from IHC and IF. However, the function
of YB-1 while it is binding to DNA remains an interesting focus, particularly if this
focus confirms that the DNA binding functions of YB-1 are of secondary importance
to the RNA binding functions. As noted above this question should receive further
attention.
Phosphorylation of YB-1 was more extensive than expected. Given the poten-
tial for these phosphorylations to partition the molecular function of YB-1 they also
warrant further study. Finally, FAM120A appears to be an important binding part-
ner for YB-1. The handful of papers highlight important functions of its own. It is
difficult to study because of the small amount that is currently known about it but
this is also a strength of its identification.
Finally, FAM120A appears to be an important binding partner for YB-1. It is
currently challenging to study FAM120A as there is a limited body of work charac-
terising this protein. The potential to contribute knowledge regarding the function of
both proteins by further defining the interaction of YB-1 and FAM120A, highlights
that this should be a focus for future research.
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Morkel, M., Fritzmann, J., Schlag, P. M., Birchmeier, W., Krueger, T., Sper-
ling, S., Sers, C., Royer, H.-D., Herzel, H. & Schäfer, R. (2010). Identification of
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mechanisms of mammalian DNA repair and the DNA damage checkpoints,
Annu Rev Biochem 73: 39–85.
Satya-Prakash, K. L., Pathak, S., Hsu, T. C., Olivé, M. & Cailleau, R. (1981).
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Wehner, K. A., Schütz, S. & Sarnow, P. (2010). OGFOD1, a novel modulator of
eukaryotic translation initiation factor 2alpha phosphorylation and the cellular
response to stress, Mol Cell Biol 30(8): 2006–16.
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of stress-associated Src activator/Homo sapiens chromosome 9 open reading
frame 10 protein following photodynamic therapy, Photodiagnosis Photodyn
Ther 11(1): 27–33.
Wu, J., Lee, C., Yokom, D., Jiang, H., Cheang, M. C. U., Yorida, E., Turbin,
D., Berquin, I. M., Mertens, P. R., Iftner, T., Gilks, C. B. & Dunn, S. E.
(2006). Disruption of the Y-box binding protein-1 results in suppression of the
epidermal growth factor receptor and HER-2, Cancer Res 66(9): 4872–9.
Wu, Y., Wang, K.-y., Li, Z., Liu, Y.-p., Izumi, H., Uramoto, H., Nakayama, Y., Ito,
K.-i. & Kohno, K. (2014). Y-box binding protein 1 enhances DNA topoiso-
merase 1 activity and sensitivity to camptothecin via direct interaction, J Exp
Clin Cancer Res 33(1): 112.
Wu, Y., Yamada, S., Izumi, H., Li, Z., Shimajiri, S., Wang, K.-Y., Liu, Y.-P., Kohno,
K. & Sasaguri, Y. (2012). Strong YB-1 expression is associated with liver
metastasis progression and predicts shorter disease-free survival in advanced
gastric cancer, J Surg Oncol 105(7): 724–30.
Xu, W., Zhou, L., Qin, R., Tang, H. & Shen, H. (2009). Nuclear expression of YB-1
in diffuse large B-cell lymphoma: correlation with disease activity and patient
outcome, Eur J Haematol 83(4): 313–9.
273
Yahata, H., Kobayashi, H., Kamura, T., Amada, S., Hirakawa, T., Kohno, K.,
Kuwano, M. & Nakano, H. (2002). Increased nuclear localization of transcrip-
tion factor YB-1 in acquired cisplatin-resistant ovarian cancer, J Cancer Res
Clin Oncol 128(11): 621–6.
Yan, K.-K., Fang, G., Bhardwaj, N., Alexander, R. P. & Gerstein, M. (2010).
Comparing genomes to computer operating systems in terms of the topology
and evolution of their regulatory control networks, Proc Natl Acad Sci U S A
107(20): 9186–91.
Yan, X.-B., Zhu, Q.-C., Chen, H.-Q., Peng, J.-Y., Chao, H.-L., Du, H.-X., Wang,
Z.-G. & Jin, Z.-M. (2014). Knockdown of Y-box-binding protein-1 inhibits the
malignant progression of HT-29 colorectal adenocarcinoma cells by reversing
epithelial-mesenchymal transition, Mol Med Rep 10(5): 2720–8.
Yang, J. Y., Ha, S.-A., Yang, Y.-S. & Kim, J. W. (2010). p-Glycoprotein ABCB5
and YB-1 expression plays a role in increased heterogeneity of breast cancer
cells: correlations with cell fusion and doxorubicin resistance, BMC Cancer
10: 388.
Yang, W.-H. & Bloch, D. B. (2007). Probing the mRNA processing body using
protein macroarrays and ”autoantigenomics”, RNA 13(5): 704–12.
Yokoyama, H., Harigae, H., Takahashi, S., Takahashi, S., Furuyama, K., Kaku, M.,
Yamamoto, M. & Sasaki, T. (2003). Regulation of YB-1 gene expression by
GATA transcription factors, Biochem Biophys Res Commun 303(1): 140–5.
Yoon, J. S. (2015). AllegroLayout (v2.2.2), AllegoViva.
Yu, H., Kim, P. M., Sprecher, E., Trifonov, V. & Gerstein, M. (2007). The impor-
tance of bottlenecks in protein networks: correlation with gene essentiality and
expression dynamics, PLoS Comput Biol 3(4): e59.
Yu, Y.-N., Yip, G. W.-C., Tan, P.-H., Thike, A. A., Matsumoto, K., Tsujimoto,
M. & Bay, B.-H. (2010). Y-box binding protein 1 is up-regulated in prolifer-
ative breast cancer and its inhibition deregulates the cell cycle, Int J Oncol
37(2): 483–92.
Yuan, L., Xiao, Y., Zhou, Q., Yuan, D., Wu, B., Chen, G. & Zhou, J. (2014).
Proteomic analysis reveals that MAEL, a component of nuage, interacts with
stress granule proteins in cancer cells, Oncol Rep 31(1): 342–50.
Zaccara, S., Tebaldi, T., Pederiva, C., Ciribilli, Y., Bisio, A. & Inga, A. (2014).
p53-directed translational control can shape and expand the universe of p53
target genes, Cell Death Differ 21(10): 1522–34.
Zaidi, S., Blanchard, M., Shim, K., Ilett, E., Rajani, K., Parrish, C., Boisgerault,
N., Kottke, T., Thompson, J., Celis, E., Pulido, J., Selby, P., Pandha, H.,
Melcher, A., Harrington, K. & Vile, R. (2015). Mutated BRAF emerges as a
major effector of recurrence in a murine melanoma model after treatment with
immunomodulatory agents, Mol Ther 23(5): 845–56.
274
Zasedateleva, O. A., Krylov, A. S., Prokopenko, D. V., Skabkin, M. A., Ovchinnikov,
L. P., Kolchinsky, A. & Mirzabekov, A. D. (2002). Specificity of mammalian
Y-box binding protein p50 in interaction with ss and ds DNA analyzed with
generic oligonucleotide microchip, J Mol Biol 324(1): 73–87.
Zhang, Y. F., Homer, C., Edwards, S. J., Hananeia, L., Lasham, A., Royds, J.,
Sheard, P. & Braithwaite, A. W. (2003). Nuclear localization of Y-box factor
YB1 requires wild-type p53, Oncogene 22(18): 2782–94.
Zheng, Y.-H., Yu, H.-F. & Peterlin, B. M. (2003). Human p32 protein relieves
a post-transcriptional block to HIV replication in murine cells, Nat Cell Biol
5(7): 611–8.
Znojek, P. J. (2012). Investigation of the role of poly (ADP-ribose) polymerase
inhibition in topoisomerase I poison-induced cytotoxicity, PhD thesis, Northern
Institute for Cancer Research.
Zou, Y. & Chien, K. R. (1995). EFIA/YB-1 is a component of cardiac HF-1A binding
activity and positively regulates transcription of the myosin light-chain 2v gene,





Analysing peptides using mass
spectrometry
A.1 Mass spectrometry; shotgun sequencing
A brief overview of a typical LC-MS/MS experiment is required to better understand
the results from LC-MS/MS. Liquid chromatography is used to separate peptides
from one another based on alterations to their interaction with the column material
as the mobile solvent phase is changed (Figure A.1.A). During chromatography,
the mass spectrometer cycles between two types of scan. The first is a survey scan
(MS1) of all positively-charged ions that are entering the mass spectrometer at that
time. The second type are MS/MS scans (MS2) that provide information about
the structure, or sequence, of the selected precursor. The MS1 scans measure the
mass over charge (m/z) and intensity of all detectable ions that are entering the
mass spectrometer at that time (Figure A.1.B). The ions detected in the MS1
scan are referred to as parent or precursor ions. Following the MS1 scan, MS2 frag-
ment spectra are generated from the most intense parent ions that were detected in
the MS1 scan (annotated in Figure A.1.B). LC-MS/MS programs usually exclude
precursors from further MS2 scans for a short time once 1 - 2 MS2 scans have been
made. The machine uses these rules to collect multiple MS/MS fragment spectra
between each MS1 scan throughout the run. During shotgun mass spectrometry,
the machine setup aims produce high quality MS2 scans of the maximum number
of peptides during each run.
The MS1 scans record the intensity of precursor ions during the LC-MS/MS
run. A plot of the intensity of a precursor over sequential MS1 scans is known
ii
Figure A.1: The basic principles of shotgun sequencing using LC-MS/MS. A, a chro-
matogram showing the material that elutes of a C18 column during an LC-MS/MS run.
B, MS1 survey scans provide information about the peptide ions, and other ions, entering
the mass spectrometer at a given point in the LC-MS/MS run. C, the plotted intensity
of the MS1 survey scans for a peptide (854.39 m/z in the MS1 scan in B). The peak area
under the curve (annotated) provides quantitative information for the plotted peptide ion.
D, MS2 collision-induced disassociation (CID) spectrum of 854.39 m/z precursor showing
the specific fragment ions which reveal amino acid sequence information.
iii
Figure A.2: The isotope peaks in a MS1 survey scan can be used to gain information
about the charge state of ions. A, MS1 survey scans provide information about the peptide
ions, and other ions, entering the mass spectrometer at a given point in the LC-MS/MS
run. B, the isotopic envelope of a peptide (854.39 m/z) from the MS1 scan (A).
as an extracted ion chromatogram (XIC) (Figure A.1.C). The area under the
elution peak of a precursor in a XIC plot reflects the quantity of the precursor ion.
Where an MS2 spectrum has been attributed to a peptide sequence, the peak area
measurements from the corresponding XIC can be assigned to that peptide. The
average peak area of the three most abundant peptides assigned to a protein can be
used to estimate the amount of a protein that is present (Silva et al. 2006).
Peptides include heavy stable isotopes of the elements, such as C13m N15, O17,
and S34, at a rate that reflects the natural abundance of the isotopes. The presence
of heavy isotopes in peptides means that precursor ions exist as a monoisotopic peak
(M) with no heavy elements followed by other peaks at +1 Da intervals (Figure
A.2.B). The first peak that follows the monoisotopic peak is the population of
peptides with 1 heavy isotope, referred to as M+1. The second peak, referred to as
M+2, is comprised of peptides that include 2 heavy isotopes. Thus larger molecules
contain more and stronger isotope peaks because there is a higher probability that
they contain stable heavy isotopes compared to smaller molecules with less atoms.
The intensity of each isotope peak (M, M+1, M+2, ....M+n) can be predicted from
the elemental structure of the precursor and the rate at which heavy isotopes occur
in nature.
To create the fragment ions, or peptide fragments, that comprise MS2 spectra,
the parent ion is fragmented using collision-induced dissociation (CID). The frag-
ment spectra reveal sequence information for peptide identification. During CID,
peptides tend to fragment at amide bonds. Only the fragments that retain the charge
can be measured. Peptide fragments that retain the charge on their N-terminus are
referred to as b-ions. B-ion fragments are numbered starting at the first amino acid
iv
at the N-terminus (b-1). Peptide fragments that have retained the charge on their
C-terminus are known as y-ions and the numbering for y-ion fragments starts at the
first amino acid at the C-terminus (the full notation is outlined in Biemann 1990).
A.1.1 Analysis of phosphorylated peptides, neutral losses
The detection of phosphorylated peptides during LC-MS/MS relies on the 80 Da
increase in mass that the addition of HPO3 confers to parent and fragment ions.
However, analysis of phosphorylation using LC-MS/MS is complicated by the ten-
dency of the phosphate group to be lost (fragmented) from some parent ions and
ion fragments during mass analysis. This process is referred to as neutral loss. Neu-
tral loss from phosphorylated ions have a mass of -80 Da when HPO3 is lost, or
-97.9769 Da when H3PO4 is lost. Ions that have lost HPO3 are problematic as their
mass then matches a peptide fragment with no phosphorylation. The neutral loss of
H3PO4 can be detected as a loss of 97.9769 Da from phosphorylated ions. Following
a neutral loss of H3PO4, the mass of phosphorylated peptide fragments is shifted by
-18.0106 Da relative to unmodified peptide fragments. This leaves a dehydro amino
acid at the site of phosphorylation.
v
Appendix B
Protein interactions of YB-1 in
A549 and MDA-MB231 cells.
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Table B.1: Proteins that interact with YB-1 in A549 and MDA-MB231 cells.









































P67809 YBX1 Nuclease-sensitive element-binding protein 1 1 2350 1 1 1 1
P04264 KRT1 Keratin, type II cytoskeletal 1 1 4678 1 1 1 1
P11940 PABPC1 Polyadenylate-binding protein 1 2 4059 1 1 1 1
P13645 KRT10 Keratin, type I cytoskeletal 10 1 3119 1 1 1 1
P35527 KRT9 Keratin, type I cytoskeletal 9 1 2623 1 1 1 1
P35908 KRT2 Keratin, type II cytoskeletal 2 epidermal 1 2620 1 1 1 1
Q13310 PABPC4 Isoform 2 of Polyadenylate-binding protein 4 3 2591 1 1 1 1
Q92900 UPF1 Isoform 2 of Regulator of nonsense transcripts 1 4 1380 1 1 1 1
P60709 ACTB Actin, cytoplasmic 1 2 1101 1 1 1 1
P02533 KRT14 Keratin, type I cytoskeletal 14 1 1090 1 1 1 1
P08779 KRT16 Keratin, type I cytoskeletal 16 1 1067 1 1 1 1
P13647 KRT5 Keratin, type II cytoskeletal 5 1 1056 1 1 1 1
P23396 RPS3 40S ribosomal protein S3 1 1033 1 1 1 1
O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 1 1011 1 1 1 1
Q6PKG0 LARP1 La-related protein 1 2 997 1 1 1 1
P11142 HSPA8 Heat shock cognate 71 kDa protein 2 853 1 1 1 1
P04259 KRT6B Keratin, type II cytoskeletal 6B 1 820 1 1 1 1
Q13501 SQSTM1 Sequestosome-1 1 801 1 1 1 1
O60506 SYNCRIP Isoform 3 of Heterogeneous nuclear ribonucleoprotein Q 5 796 1 1 1 1
P61247 RPS3A 40S ribosomal protein S3a 1 670 1 1 1 1
Q9HCE1 MOV10 Putative helicase MOV-10 1 663 1 1 1 1
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protein 1 3 643 1 1 1 1
v
ii
P08670 VIM Vimentin 1 612 1 1 1 1
P68363 TUBA1B Tubulin alpha-1B chain 3 605 1 1 1 1
P07437 TUBB Tubulin beta chain 1 604 1 1 1 1
O00571 DDX3X Isoform 2 of ATP-dependent RNA helicase DDX3X 2 590 1 1 1 1
P46781 RPS9 40S ribosomal protein S9 1 567 1 1 1 1
Q15149 PLEC Plectin 9 547 1 1 1 1
P15880 RPS2 40S ribosomal protein S2 1 538 1 1 1 1
P05787 KRT8 Keratin, type II cytoskeletal 8 1 534 1 1 1 1
P62701 RPS4X 40S ribosomal protein S4, X isoform 1 528 1 1 1 1
P39023 RPL3 60S ribosomal protein L3 2 509 1 1 1 1
P07910 HNRNPC Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 3 502 1 1 1 1
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 1 482 1 1 1 1
P62249 RPS16 40S ribosomal protein S16 1 475 1 1 1 1
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 3 468 1 1 1 1
P62979 RPS27A Ubiquitin-40S ribosomal protein S27a 4 463 1 1 1 1
P62753 RPS6 40S ribosomal protein S6 1 447 1 1 1 1
P62241 RPS8 40S ribosomal protein S8 1 412 1 1 1 1
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M 2 394 1 1 1 1
Q00577 PURA Transcriptional activator protein Pur-alpha 1 389 1 1 1 1
Q15717 ELAVL1 ELAV-like protein 1 1 356 1 1 1 1
Q7L2E3 DHX30 Isoform 3 of Putative ATP-dependent RNA helicase DHX30 3 355 1 1 1 1
P31943 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 1 353 1 1 1 1
P43243 MATR3 Matrin-3 1 348 1 1 1 1
P08729 KRT7 Keratin, type II cytoskeletal 7 1 343 1 1 1 1
Q13283 G3BP1 Ras GTPase-activating protein-binding protein 1 1 341 1 1 1 1
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 1 340 1 1 1 1
P08865 RPSA 40S ribosomal protein SA 1 326 1 1 1 1
P46782 RPS5 40S ribosomal protein S5 1 322 1 1 1 1
P11021 HSPA5 78 kDa glucose-regulated protein 1 319 1 1 1 1
v
iii
P26373 RPL13 60S ribosomal protein L13 1 312 1 1 1 1
P05388 RPLP0 60S acidic ribosomal protein P0 2 308 1 1 1 1
P27635 RPL10 60S ribosomal protein L10 1 296 1 1 1 1
P51114 FXR1 Fragile X mental retardation syndrome-related protein 1 2 291 1 1 1 1
P26196 DDX6 Probable ATP-dependent RNA helicase DDX6 1 277 1 1 1 1
P62917 RPL8 60S ribosomal protein L8 1 274 1 1 1 1
P46777 RPL5 60S ribosomal protein L5 1 274 1 1 1 1
P02768 ALB Serum albumin 2 272 1 1 1 1
P18124 RPL7 60S ribosomal protein L7 1 261 1 1 1 1
P05783 KRT18 Keratin, type I cytoskeletal 18 1 206 1 1 1 1
Q8WWM7 ATXN2L Ataxin-2-like protein 6 205 1 1 1 1
P38919 EIF4A3 Eukaryotic initiation factor 4A-III 1 202 1 1 1 1
P62280 RPS11 40S ribosomal protein S11 1 183 1 1 1 1
Q15366 PCBP2 Isoform 4 of Poly(rC)-binding protein 2 5 181 1 1 1 1
Q07020 RPL18 60S ribosomal protein L18 1 180 1 1 1 1
P18621 RPL17 60S ribosomal protein L17 1 172 1 1 1 1
Q9UKM9 RALY Isoform 1 of RNA-binding protein Raly 3 165 1 1 1 1
Q9H2U1 DHX36 Isoform 2 of Probable ATP-dependent RNA helicase DHX36 3 162 1 1 1 1
Q09161 NCBP1 Nuclear cap-binding protein subunit 1 1 149 1 1 1 1
P46778 RPL21 60S ribosomal protein L21 1 141 1 1 1 1
Q96QR8 PURB Transcriptional activator protein Pur-beta 1 138 1 1 1 1
P51116 FXR2 Fragile X mental retardation syndrome-related protein 2 1 137 1 1 1 1
Q9NUL3 STAU2 Isoform 2 of Double-stranded RNA-binding protein Staufen homolog 2 4 134 1 1 1 1
Q7Z417 NUFIP2 Nuclear fragile X mental retardation-interacting protein 2 1 132 1 1 1 1
Q71RC2 LARP4 La-related protein 4 3 118 1 1 1 1
Q7Z2W4 ZC3HAV1 Zinc finger CCCH-type antiviral protein 1 2 89 1 1 1 1
P30050 RPL12 60S ribosomal protein L12 1 76 1 1 1 1
P62913 RPL11 Isoform 2 of 60S ribosomal protein L11 2 67 1 1 1 1
O43143 DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 1 61 1 1 1 1
ix
Q9NUD5 ZCCHC3 Zinc finger CCHC domain-containing protein 3 1 61 1 1 1 1
Q99700 ATXN2 Isoform 2 of Ataxin-2 3 50 1 1 1 1
Q9NX05 FAM120C Constitutive coactivator of PPAR-gamma-like protein 2 1 48 1 1 1 1
Q6P2E9 EDC4 Enhancer of mRNA-decapping protein 4 2 42 1 1 1 1
Q14671 PUM1 Isoform 2 of Pumilio homolog 1 2 38 1 1 1 1
P46783 RPS10 40S ribosomal protein S10 1 177 1 1 1
P16989 CSDA DNA-binding protein A 2 789 1 1
P16989 CSDA Isoform 2 of DNA-binding protein A 1 436 1 1
P68371 TUBB4B Tubulin beta-4B chain 2 435 1 1
P68104 EEF1A1 Elongation factor 1-alpha 1 3 336 1 1
P10155 TROVE2 60 kDa SS-A/Ro ribonucleoprotein 1 124 1 1
Q92615 LARP4B La-related protein 4B 1 119 1 1
P48200 IREB2 Iron-responsive element-binding protein 2 1 102 1 1
P52597 HNRNPF Heterogeneous nuclear ribonucleoprotein F 1 101 1 1
Q86YZ3 HRNR Hornerin 1 94 1 1
P55884 EIF3B Eukaryotic translation initiation factor 3 subunit B 2 91 1 1
Q04637 EIF4G1 Isoform E of Eukaryotic translation initiation factor 4 gamma 1 5 88 1 1
Q14152 EIF3A Eukaryotic translation initiation factor 3 subunit A 1 81 1 1
P57678 GEMIN4 Gem-associated protein 4 1 79 1 1
Q9Y262 EIF3L Eukaryotic translation initiation factor 3 subunit L 1 71 1 1
P04183 TK1 Thymidine kinase, cytosolic 1 64 1 1
Q06787 FMR1 Isoform 8 of Fragile X mental retardation protein 1 8 58 1 1
Q96I24 FUBP3 Far upstream element-binding protein 3 1 57 1 1
Q9UKV8 EIF2C2 Isoform 2 of Protein argonaute-2 2 53 1 1
Q9NSB4 KRT82 Keratin, type II cuticular Hb2 1 43 1 1
O75534 CSDE1 Isoform Short of Cold shock domain-containing protein E1 2 41 1 1
Q9Y5A9 YTHDF2 Isoform 2 of YTH domain family protein 2 2 40 1 1
Q9UHI6 DDX20 Probable ATP-dependent RNA helicase DDX20 1 37 1 1
Q99613 EIF3C Eukaryotic translation initiation factor 3 subunit C 1 37 1 1
x
Q9BRZ2 TRIM56 E3 ubiquitin-protein ligase TRIM56 1 33 1 1
O15234 CASC3 Protein CASC3 1 33 1 1
Q9H6S0 YTHDC2 Probable ATP-dependent RNA helicase YTHDC2 1 28 1 1
O15371 EIF3D Eukaryotic translation initiation factor 3 subunit D 1 26 1 1
Q8IXB1 DNAJC10 Isoform 2 of DnaJ homolog subfamily C member 10 2 25 1 1
Q9Y5S9 RBM8A Isoform 2 of RNA-binding protein 8A 2 16 1 1
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 1 117 1
Q15365 PCBP1 Poly(rC)-binding protein 1 1 104 1
Q9Y520 PRRC2C Isoform 3 of Protein PRRC2C 7 63 1
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit I 1 36 1
Q8TEQ6 GEMIN5 Gem-associated protein 5 1 34 1
Q9BYK8 PRIC285 Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein 1 33 1
P48634 PRRC2A Isoform 2 of Protein PRRC2A 4 26 1
Q14258 TRIM25 E3 ubiquitin/ISG15 ligase TRIM25 1 23 1
Q9Y3F4 STRAP Serine-threonine kinase receptor-associated protein 1 16 1
P54136 RARS Isoform Monomeric of Arginine–tRNA ligase, cytoplasmic 2 15 1
P54687 BCAT1 Isoform 4 of Branched-chain-amino-acid aminotransferase, cytosolic 4 10 1
Q9H0J9 PARP12 Poly [ADP-ribose] polymerase 12 1 8 1
Q07021 C1QBP Complement component 1 Q subcomponent-binding protein, mitochondrial 1 510 1 1 1
Q92841 DDX17 Probable ATP-dependent RNA helicase DDX17 4 277 1 1 1
P62906 RPL10A 60S ribosomal protein L10a 1 179 1 1 1
P84098 RPL19 60S ribosomal protein L19 1 147 1 1 1
P05091 ALDH2 Aldehyde dehydrogenase, mitochondrial 1 136 1 1 1
P61254 RPL26 60S ribosomal protein L26 2 117 1 1 1
P36957 DLST Dihydrolipoyllysine-residue succinyltransferase component 1 62 1 1 1
of 2-oxoglutarate dehydrogenase complex, mitochondrial
P49406 MRPL19 39S ribosomal protein L19, mitochondrial 1 45 1 1 1
Q9NYK5 MRPL39 39S ribosomal protein L39, mitochondrial 2 56 1 1
Q9Y3D9 MRPS23 28S ribosomal protein S23, mitochondrial 1 54 1 1
x
i
Q9NZI8 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 1 958 1
P48668 KRT6C Keratin, type II cytoskeletal 6C 1 644 1
Q04695 KRT17 Keratin, type I cytoskeletal 17 1 276 1
P14618 PKM2 Pyruvate kinase isozymes M1/M2 3 208 1
P08107 HSPA1A Heat shock 70 kDa protein 1A/1B 1 148 1
P14923 JUP Junction plakoglobin 1 98 1
Q9BPW8 NIPSNAP1 Protein NipSnap homolog 1 1 69 1
O75323 GBAS Protein NipSnap homolog 2 1 62 1
Q13162 PRDX4 Peroxiredoxin-4 1 46 1
Q8ND56 LSM14A Protein LSM14 homolog A 2 30 1
P04792 HSPB1 Heat shock protein beta-1 1 23 1
P32969 RPL9 60S ribosomal protein L9 1 16 1
Q9NR30 DDX21 Nucleolar RNA helicase 2 2 702 1 1
Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U 2 624 1 1
P16403 HIST1H1C Histone H1.2 1 613 1 1
P19338 NCL Nucleolin 1 546 1 1
P10412 HIST1H1E Histone H1.4 2 485 1 1
Q6P2Q9 PRPF8 Pre-mRNA-processing-splicing factor 8 1 476 1 1
Q9BUJ2 HNRNPUL1 Isoform 2 of Heterogeneous nuclear ribonucleoprotein U-like protein 1 4 422 1 1
Q02878 RPL6 60S ribosomal protein L6 1 405 1 1
P62269 RPS18 40S ribosomal protein S18 1 397 1 1
P36578 RPL4 60S ribosomal protein L4 1 382 1 1
P38646 HSPA9 Stress-70 protein, mitochondrial 1 355 1 1
P26599 PTBP1 Polypyrimidine tract-binding protein 1 9 335 1 1
O43390 HNRNPR Heterogeneous nuclear ribonucleoprotein R 2 318 1 1
O75643 SNRNP200 U5 small nuclear ribonucleoprotein 200 kDa helicase 1 304 1 1
Q14444 CAPRIN1 Isoform 2 of Caprin-1 2 284 1 1
P14866 HNRNPL Heterogeneous nuclear ribonucleoprotein L 1 267 1 1
Q15029 EFTUD2 116 kDa U5 small nuclear ribonucleoprotein component 1 260 1 1
x
ii
Q08211 DHX9 ATP-dependent RNA helicase A 1 253 1 1
P62424 RPL7A 60S ribosomal protein L7a 1 241 1 1
P07355 ANXA2 Annexin A2 2 240 1 1
Q8NC51 SERBP1 Isoform 3 of Plasminogen activator inhibitor 1 RNA-binding protein 4 220 1 1
P62277 RPS13 40S ribosomal protein S13 1 219 1 1
O76021 RSL1D1 Ribosomal L1 domain-containing protein 1 1 200 1 1
Q12905 ILF2 Interleukin enhancer-binding factor 2 1 178 1 1
P62266 RPS23 40S ribosomal protein S23 1 177 1 1
P60866 RPS20 40S ribosomal protein S20 2 174 1 1
P06748 NPM1 Nucleophosmin 3 173 1 1
P62851 RPS25 40S ribosomal protein S25 1 167 1 1
P61313 RPL15 60S ribosomal protein L15 1 167 1 1
Q9BQG0 MYBBP1A Myb-binding protein 1A 2 165 1 1
P23246 SFPQ Splicing factor, proline- and glutamine-rich 1 160 1 1
P83731 RPL24 60S ribosomal protein L24 1 154 1 1
P46776 RPL27A 60S ribosomal protein L27a 1 150 1 1
P40429 RPL13A 60S ribosomal protein L13a 2 124 1 1
P58876 HIST1H2BD Histone H2B type 1-D 11 122 1 1
Q02543 RPL18A 60S ribosomal protein L18a 1 120 1 1
Q15233 NONO Non-POU domain-containing octamer-binding protein 1 119 1 1
P84103 SRSF3 Serine/arginine-rich splicing factor 3 1 117 1 1
P51991 HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 2 111 1 1
P0CW22 RPS17L 40S ribosomal protein S17-like 1 107 1 1
Q9BZE4 GTPBP4 Nucleolar GTP-binding protein 1 1 104 1 1
Q9BQ39 DDX50 ATP-dependent RNA helicase DDX50 1 103 1 1
P50914 RPL14 60S ribosomal protein L14 1 101 1 1
P22087 FBL rRNA 2’-O-methyltransferase fibrillarin 1 100 1 1
P68431 HIST1H3A Histone H3.1 5 97 1 1
Q07955 SRSF1 Serine/arginine-rich splicing factor 1 3 87 1 1
x
iii
Q3MHD2 LSM12 Protein LSM12 homolog 2 80 1 1
P62841 RPS15 40S ribosomal protein S15 1 78 1 1
P61353 RPL27 60S ribosomal protein L27 1 78 1 1
Q12906 ILF3 Interleukin enhancer-binding factor 3 6 78 1 1
Q9P015 MRPL15 39S ribosomal protein L15, mitochondrial 1 74 1 1
Q9GZR7 DDX24 ATP-dependent RNA helicase DDX24 1 70 1 1
Q96KR1 ZFR Zinc finger RNA-binding protein 1 66 1 1
Q9UN86 G3BP2 Isoform B of Ras GTPase-activating protein-binding protein 2 2 64 1 1
Q07666 KHDRBS1 KH domain-containing, RNA-binding, signal transduction-associated protein 1 2 64 1 1
Q9BVP2 GNL3 Isoform 2 of Guanine nucleotide-binding protein-like 3 2 64 1 1
P46779 RPL28 60S ribosomal protein L28 2 62 1 1
Q9BUQ8 DDX23 Probable ATP-dependent RNA helicase DDX23 1 61 1 1
P04114 APOB Apolipoprotein B-100 1 60 1 1
O94906 PRPF6 Isoform 2 of Pre-mRNA-processing factor 6 2 60 1 1
P23527 HIST1H2BO Histone H2B type 1-O 5 58 1 1
Q9H0D6 XRN2 5’-3’ exoribonuclease 2 2 57 1 1
Q13247 SRSF6 Isoform SRP55-3 of Serine/arginine-rich splicing factor 6 3 51 1 1
Q14690 PDCD11 Protein RRP5 homolog 1 51 1 1
Q9UHX1 PUF60 Isoform 4 of Poly(U)-binding-splicing factor PUF60 6 50 1 1
Q9UMS4 PRPF19 Pre-mRNA-processing factor 19 1 50 1 1
P46087 NOP2 Isoform 2 of Putative ribosomal RNA methyltransferase NOP2 2 46 1 1
P10515 DLAT Dihydrolipoyllysine-residue acetyltransferase component 1 45 1 1
of pyruvate dehydrogenase complex, mitochondrial
P51398 DAP3 Isoform 2 of 28S ribosomal protein S29, mitochondrial 2 43 1 1
Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog 1 42 1 1
Q96PK6 RBM14 RNA-binding protein 14 1 39 1 1
Q9H6R4 NOL6 Isoform 4 of Nucleolar protein 6 2 36 1 1
Q15393 SF3B3 Splicing factor 3B subunit 3 1 35 1 1
Q9H0A0 NAT10 N-acetyltransferase 10 1 34 1 1
x
iv
Q9BXP5 SRRT Isoform 5 of Serrate RNA effector molecule homolog 5 32 1 1
Q8TDN6 BRIX1 Ribosome biogenesis protein BRX1 homolog 1 32 1 1
Q1KMD3 HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-like protein 2 1 29 1 1
Q13263 TRIM28 Isoform 2 of Transcription intermediary factor 1-beta 2 27 1 1
P14678 SNRPB Isoform SM-B of Small nuclear ribonucleoprotein-associated proteins B and B’ 4 26 1 1
Q8N163 KIAA1967 DBIRD complex subunit KIAA1967 2 25 1 1
Q99873 PRMT1 Isoform 3 of Protein arginine N-methyltransferase 1 3 21 1 1
Q9NY93 DDX56 Probable ATP-dependent RNA helicase DDX56 1 21 1 1
Q13148 TARDBP TAR DNA-binding protein 43 2 19 1 1
Q96DV4 MRPL38 39S ribosomal protein L38, mitochondrial 1 19 1 1
Q9BZE1 MRPL37 39S ribosomal protein L37, mitochondrial 1 19 1 1
Q99575 POP1 Ribonucleases P/MRP protein subunit POP1 1 17 1 1
Q8NHQ9 DDX55 ATP-dependent RNA helicase DDX55 1 13 1 1
P39019 RPS19 40S ribosomal protein S19 1 170 1
P62263 RPS14 40S ribosomal protein S14 1 136 1
P62854 RPS26 40S ribosomal protein S26 2 131 1
P62847 RPS24 40S ribosomal protein S24 3 94 1
P49207 RPL34 60S ribosomal protein L34 1 53 1
P62888 RPL30 60S ribosomal protein L30 1 48 1
Q92552 MRPS27 28S ribosomal protein S27, mitochondrial 1 46 1
Q9BYD3 MRPL4 Isoform 2 of 39S ribosomal protein L4, mitochondrial 2 44 1
Q96HS1 PGAM5 Serine/threonine-protein phosphatase PGAM5, mitochondrial 2 41 1
Q99848 EBNA1BP2 Probable rRNA-processing protein EBP2 1 38 1
P05141 SLC25A5 ADP/ATP translocase 2 1 36 1
Q96DI7 SNRNP40 U5 small nuclear ribonucleoprotein 40 kDa protein 1 32 1
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 5 31 1
Q8N983 MRPL43 Isoform 4 of 39S ribosomal protein L43, mitochondrial 1 27 1
P82650 MRPS22 28S ribosomal protein S22, mitochondrial 1 25 1
Q9H9J2 MRPL44 39S ribosomal protein L44, mitochondrial 1 21 1
x
v
O00148 DDX39A ATP-dependent RNA helicase DDX39A 3 20 1
P33992 MCM5 DNA replication licensing factor MCM5 1 19 1
Q9Y2Q9 MRPS28 28S ribosomal protein S28, mitochondrial 1 19 1
P62318 SNRPD3 Small nuclear ribonucleoprotein Sm D3 1 17 1
Q9Y265 RUVBL1 RuvB-like 1 1 17 1
Q8IUX4 APOBEC3F DNA dC→dU-editing enzyme APOBEC-3F 1 17 1
P02545 LMNA Isoform C of Prelamin-A/C 3 15 1
P52815 MRPL12 39S ribosomal protein L12, mitochondrial 1 14 1
Q15269 PWP2 Periodic tryptophan protein 2 homolog 1 13 1
Q8WXF1 PSPC1 Isoform 2 of Paraspeckle component 1 2 12 1
P45880 VDAC2 Isoform 2 of Voltage-dependent anion-selective channel protein 2 3 11 1
O95400 CD2BP2 CD2 antigen cytoplasmic tail-binding protein 2 1 11 1
P42285 SKIV2L2 Superkiller viralicidic activity 2-like 2 1 11 1
Q9Y3B2 EXOSC1 Exosome complex component CSL4 1 9 1
Q9BW19 KIFC1 Kinesin-like protein KIFC1 1 8 1
Q00341 HDLBP Vigilin 1 717
P02538 KRT6A Keratin, type II cytoskeletal 6A 1 350
P62081 RPS7 40S ribosomal protein S7 1 135
P22626 HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 2 119
Q14764 MVP Major vault protein 1 96
Q9NUL7 DDX28 Probable ATP-dependent RNA helicase DDX28 1 88
Q96KK5 HIST1H2AH Histone H2A type 1-H 7 80
P68871 HBB Hemoglobin subunit beta 1 72
P62750 RPL23A 60S ribosomal protein L23a 1 69
P38159 RBMX RNA-binding motif protein, X chromosome 1 69
P21589 NT5E 5’-nucleotidase 2 65
O75127 PTCD1 Pentatricopeptide repeat-containing protein 1 1 63
P04908 HIST1H2AB Histone H2A type 1-B/E 3 61




P69892 HBG2 Hemoglobin subunit gamma-2 2 46
P04196 HRG Histidine-rich glycoprotein 1 45
Q14694 USP10 Ubiquitin carboxyl-terminal hydrolase 10 3 44
Q9NX00 TMEM160 Transmembrane protein 160 1 38
P69905 HBA1 Hemoglobin subunit alpha 1 38
Q9NVP1 DDX18 ATP-dependent RNA helicase DDX18 1 27
P33993 MCM7 DNA replication licensing factor MCM7 2 27
Q9Y3B7 MRPL11 39S ribosomal protein L11, mitochondrial 2 24
P42694 HELZ Probable helicase with zinc finger domain 1 21
P15924 DSP Isoform DPII of Desmoplakin 2 20
P31942 HNRNPH3 Isoform 3 of Heterogeneous nuclear ribonucleoprotein H3 3 20
P25205 MCM3 DNA replication licensing factor MCM3 1 19
P18077 RPL35A 60S ribosomal protein L35a 1 12
Q8TDD1 DDX54 ATP-dependent RNA helicase DDX54 2 10





Further in silico networks
xviii
Figure C.1: The binding partners of endogenous YB-1 in the cytoplasm of A549 and
MDA-MB231 cells. A, a network of in silico interactions between the proteins that were
identified interacting with YB-1 in the cytoplasm (String, v9.1). Markov clustering (MCL)
was applied to the network and the nodes are coloured based on their groupings from the
MCL. The terms that summarise the proteins in each cluster are provided in the legend.
B, enriched terms from gene ontology.
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Figure C.2: The binding partners of endogenous YB-1 in the cytoplasm and nucleus of
A549 and MDA-MB231 cells. A, a network of in silico interactions between the proteins
that were identified interacting with YB-1 in the cytoplasm and nucleus (String, v9.1).
Markov clustering (MCL) was applied to the network and the nodes are coloured based
on their groupings from the MCL. The terms that summarise the proteins in each cluster
are provided in the legend. B, enriched terms from gene ontology.
xx
Figure C.3: The binding partners of endogenous YB-1 in the nucleus of A549 and
MDA-MB231 cells. A, a network of in silico interactions between the proteins that were
identified interacting with YB-1 in the nucleus (String, v9.1). Markov clustering (MCL)
was applied to the network and the nodes are coloured based on their groupings from the
MCL. The terms that summarise the proteins in each cluster are provided in the legend.
B, enriched terms from gene ontology.
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Figure C.4: Purified YB-1 fails to separate on BN-PAGE. Immunopurified YB-1 from
5 × 107 A549 cells was separated using BN-PAGE (IP-YB-1). A549 indicates a lane
where a lysate from A549 cells (input) were run. The dark areas on the gel come from
coommassie G-250 that could not be destained from the gel. Over-exposed provides the
clearest image that could be obtained to highlight the presence of purified YB-1 running
as a monomer on BN-PAGE (IP YB1>).
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Appendix D
Growth plots from drug sensitivity
experiments
xxiii
Figure D.1: Depleting YB-1 sensitised MDA-MB231 cells to paclitaxel. MDA-MB231
cells were transfected with a non-targeting siRNA duplex (siCTRL) or one of two siRNA
duplexes directed against YB-1 (siYB1 1 and siYB1 2). A, media containing paclitaxel
(0.1,1,10,100nM, 1, or 10µM) was added and the confluence of the MDA-MB231 cells
monitored for 120 hours. B, the maximal growth rate (µ) was calculated using the con-
fluence data and for each siRNA duplex, the response to drug was calculated as outlined
in Chapter 2.9.
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Figure D.2: Depleting YB-1 sensitised MDA-MB231 cells to camptothecin. MDA-
MB231 cells were transfected with a non-targeting siRNA duplex (siCTRL) or one of
two siRNA duplexes directed against YB-1 (siYB1 1 and siYB1 2). A, media contain-
ing camptothecin (0.1 - 10 µM) was added and the confluence of the MDA-MB231 cells
monitored for 120 hours. The variable measurements of confluence in wells that received
siCTRL after 72 hours of exposure to 0.1 µM camptothecin was the result of failed image
masking by the confluence algorithm (v1.5). B, the maximal growth rate (µ) was cal-
culated using the confluence data and for each siRNA duplex, the response to drug was
calculated as outlined in Chapter 2.9.
xxv
Figure D.3: Depletion of YB-1 sensitised MDA-MB231 cells to cisplatin. MDA-MB231
cells were transfected with a non-targeting siRNA duplex (siCTRL) or one of two siRNA
duplexes directed against YB-1 (siYB1 1 and siYB1 2). A, media containing cisplatin
(7.5 - 100 µM) was added and the confluence of the MDA-MB231 cells monitored for 120
hours. B, the maximal growth rate (µ) was calculated using the confluence data and for
each siRNA duplex, the response to drug was calculated as outlined in Chapter 2.9.
xxvi
Figure D.4: Depletion of YB-1 sensitised MDA-MB231 cells to doxorubicin. MDA-
MB231 cells were transfected with a non-targeting siRNA duplex (siCTRL) or one of two
siRNA duplexes directed against YB-1 (siYB1 1 and siYB1 2). A, media containing dox-
orubicin (0.1 - 20 µM) was added and the confluence of the MDA-MB231 cells monitored
for 120 hours. B, the maximal growth rate (µ) was calculated using the confluence data
and for each siRNA duplex, the response to drug was calculated as outlined in Chapter
2.9.
xxvii
Figure D.5: Depleting YB-1 reduced the confluence of MDA-MB231 cells that are ex-
posed to doxorubicin. The confluence of MDA-MB231 cells in the presence of varying
ranges of doxorubicin (0.156 - 10 µM) was monitored for 120 hours. MDA-MB231 cells
were transfected with a non-targeting siRNA duplex (siCTRL) or one of two siRNA du-
plexes directed against YB-1 (siYB1 1 or siYB1 2; A). The maximum growth rate for
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure D.12: The viability of MDA-MB231 cells in cisplatin was reduced following the
depletion of YB-1. MDA-MB231 cells were transfected with non-targeting siRNA duplex
(siCTRL) or one of two siRNA duplexes directed against YB-1 (siYB1 1 or siYB1 2) at
0.2, 1, and 5 nM. The cells were then cultured in media containing 0 - 50 µM cisplatin and
YOYO-1 Iodide. The presence of non-viable cells is shown as Death index (see Chapter
2.9 for details about calculations).
xxxv
Appendix E
Proteins that interact with
crosslinked YB-1 in MDA-MB231
cells.
xxxvi
Table E.1: Proteins that interact with crosslinked YB-1 in MDA-MB231 cells.






















Q92734 TFG Protein TFG 1 1.15 0.82
P67809 YBX1 Nuclease-sensitive element-binding protein 1 1 0.82 1.02
P04264 KRT1 Keratin, type II cytoskeletal 1 1 0.75 1.93
P35908 KRT2 Keratin, type II cytoskeletal 2 epidermal 1 0.74 1.77
Q01813 PFKP 6-phosphofructokinase type C 1 0.99 0.63
P11940 PABPC1 Polyadenylate-binding protein 1 1 1.22 0.97
P62241 RPS8 40S ribosomal protein S8 1 1.03 0.78
Q04637 EIF4G1 Isoform E of Eukaryotic translation initiation factor 4 gamma 1 5 0.92 0.9
P23396 RPS3 40S ribosomal protein S3 1 1.17 0.79
P13645 KRT10 Keratin, type I cytoskeletal 10 1 0.83 1.18
Q13310 PABPC4 Isoform 2 of Polyadenylate-binding protein 4 3 1.28 1.02
P35527 KRT9 Keratin, type I cytoskeletal 9 1 0.9 2.43
P15880 RPS2 40S ribosomal protein S2 1 1.26 0.74
Q14444 CAPRIN1 Isoform 2 of Caprin-1 2 1.07 0.75
P16989 CSDA Isoform 3 of DNA-binding protein A 3 1.01 3.23
P68363 TUBA1B Tubulin alpha-1B chain 1 1.24 0.73
P62249 RPS16 40S ribosomal protein S16 1 1.11 0.61
P60709 ACTB Actin, cytoplasmic 1 2 1.04 1.09
O60506 SYNCRIP Isoform 3 of Heterogeneous nuclear ribonucleoprotein Q 1 1.22 1.02
P17858 PFKL 6-phosphofructokinase, liver type 1 0.84 0.52
Q07021 C1QBP Complement component 1 Q 1 1.45 1.29
subcomponent-binding protein, mitochondrial






P68104 EEF1A1 Elongation factor 1-alpha 1 2 1.08 0.56
P07900 HSP90AA1 Heat shock protein HSP 90-alpha 2 0.9 0.73
P55209 NAP1L1 Nucleosome assembly protein 1-like 1 1 0.99 0.47
P61247 RPS3A 40S ribosomal protein S3a 1 1.42 0.75
P46781 RPS9 40S ribosomal protein S9 1 0.98 0.59
O43390 HNRNPR Heterogeneous nuclear ribonucleoprotein R 1 0.99 0.7
P62851 RPS25 40S ribosomal protein S25 1 1.07 0.61
P11142 HSPA8 Heat shock cognate 71 kDa protein 1 0.95 0.67
P36578 RPL4 60S ribosomal protein L4 1 1.31 0.74
P18621 RPL17 60S ribosomal protein L17 1 1.02 0.42
Q12931 TRAP1 Heat shock protein 75 kDa, mitochondrial 1 1.83 0.62
Q00341 HDLBP Vigilin 1 1.28 1.13
P10809 HSPD1 60 kDa heat shock protein, mitochondrial 1 1.22 1.33
P19338 NCL Nucleolin 1 1.34 0.81
P06733 ENO1 Alpha-enolase 1 0.95 0.86
Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U 2 1.65 1.1
P13646 KRT13 Isoform 2 of Keratin, type I cytoskeletal 13 3 0.68 1.4
Q13283 G3BP1 Ras GTPase-activating protein-binding protein 1 1 1.19 0.73
P06576 ATP5B ATP synthase subunit beta, mitochondrial 1 1.11 0.98
P25705 ATP5A1 ATP synthase subunit alpha, mitochondrial 1 1 0.86
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 3 1.24 0.88
P62701 RPS4X 40S ribosomal protein S4, X isoform 1 1.2 0.61
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 1 1.1 0.67
P62753 RPS6 40S ribosomal protein S6 1 1.09 1.31
P08237 PFKM 6-phosphofructokinase, muscle type 2 0.87 0.57
P62913 RPL11 Isoform 2 of 60S ribosomal protein L11 2 0.56 0.65
P83731 RPL24 60S ribosomal protein L24 1 1.08 0.61
P62979 RPS27A Ubiquitin-40S ribosomal protein S27a 1 1.98 1.44






Q8NC51 SERBP1 Isoform 3 of Plasminogen activator 4 1.2 0.68
inhibitor 1 RNA-binding protein
P07437 TUBB Tubulin beta chain 1 1.54 0.82
Q00577 PURA Transcriptional activator protein Pur-alpha 1 1.14 0.89
P34931 HSPA1L Heat shock 70 kDa protein 1-like 1 1.54 0.79
P48668 KRT6C Keratin, type II cytoskeletal 6C 1 0.85 1.79
P13647 KRT5 Keratin, type II cytoskeletal 5 1 0.85 1.79
P02533 KRT14 Keratin, type I cytoskeletal 14 1 0.33 0.66
P08779 KRT16 Keratin, type I cytoskeletal 16 1 0.31 0.56
Q96KG9 SCYL1 Isoform 5 of N-terminal kinase-like protein 6 1.17 0.71
P62854 RPS26 40S ribosomal protein S26 1 1.04 0.73
P14618 PKM2 Pyruvate kinase isozymes M1/M2 1 0.67 0.82
P62263 RPS14 40S ribosomal protein S14 1 0.71 0
P46776 RPL27A 60S ribosomal protein L27a 1 1.07 0.71
P38646 HSPA9 Stress-70 protein, mitochondrial 1 1.17 1.27
Q6PKG0 LARP1 La-related protein 1 1 1.34 1.3
P50914 RPL14 60S ribosomal protein L14 1 0.87 0.47
Q96PU5 NEDD4L Isoform 3 of E3 ubiquitin-protein ligase NEDD4-like 7 0.93 0.79
P62269 RPS18 40S ribosomal protein S18 1 0.97 0.5
P68371 TUBB4B Tubulin beta-4B chain 1 1.7 0.88
P62280 RPS11 40S ribosomal protein S11 1 1.34 0.78
P46934 NEDD4 Isoform 4 of E3 ubiquitin-protein ligase NEDD4 1 0.94 0.72
Q16555 DPYSL2 Dihydropyrimidinase-related protein 2 1 1.3 1.29
P46782 RPS5 40S ribosomal protein S5 1 1.02 0.51
P16403 HIST1H1C Histone H1.2 3 0.63 3.52
P62266 RPS23 40S ribosomal protein S23 1 1.12 0.53
P46937 YAP1 Isoform 3 of Yorkie homolog 3 0.8 0.72
P30048 PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial 1 0.98 1.19





P60866 RPS20 40S ribosomal protein S20 2 0.96 0.38
P39023 RPL3 60S ribosomal protein L3 1 1.28 0.45
P62277 RPS13 40S ribosomal protein S13 1 1.04 0.6
P63104 YWHAZ 14-3-3 protein zeta/delta 1 0.82 0.8
P34897 SHMT2 Serine hydroxymethyltransferase, mitochondrial 1 0.95 0.57
O75521 ECI2 Isoform 2 of Enoyl-CoA delta isomerase 2, mitochondrial 2 1.53 1.23
Q99733 NAP1L4 Nucleosome assembly protein 1-like 4 1 0.9 0.49
O43707 ACTN4 Alpha-actinin-4 1 1.03 1.33
P40926 MDH2 Malate dehydrogenase, mitochondrial 1 1.45 1.38
P08865 RPSA 40S ribosomal protein SA 1 0.99 0.7
P11021 HSPA5 78 kDa glucose-regulated protein 1 1.1 1.04
P62258 YWHAE Isoform SV of 14-3-3 protein epsilon 2 0.9 0.83
Q02543 RPL18A 60S ribosomal protein L18a 1 1.16 0.51
P12814 ACTN1 Isoform 2 of Alpha-actinin-1 3 1.06 1.31
P00367 GLUD1 Glutamate dehydrogenase 1, mitochondrial 1 1.36 1.64
P26641 EEF1G Elongation factor 1-gamma 1 1.01 0.56
P46783 RPS10 40S ribosomal protein S10 1 1.11 0.7
P62424 RPL7A 60S ribosomal protein L7a 1 1.14 0.89
P25398 RPS12 40S ribosomal protein S12 1 1.05 0.54
P14625 HSP90B1 Endoplasmin 1 0.73 0.8
P27348 YWHAQ 14-3-3 protein theta 1 0.82 0.76
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 1 1.02 0.95
Q15366 PCBP2 Isoform 4 of Poly(rC)-binding protein 2 5 1.1 0.67
P19013 KRT4 Keratin, type II cytoskeletal 4 1 0.68 1.6
P84103 SRSF3 Serine/arginine-rich splicing factor 3 1 1.12 0.93
O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 1 1.51 1.66
P21980 TGM2 Protein-glutamine gamma-glutamyltransferase 2 1 0.83 1.15
P29401 TKT Transketolase 1 0.86 0.98
P27635 RPL10 60S ribosomal protein L10 1 1.43 0.76
x
l
P07355 ANXA2 Annexin A2 2 0.95 0.87
P26373 RPL13 60S ribosomal protein L13 1 0.89 0.66
Q02878 RPL6 60S ribosomal protein L6 1 1.31 1.12
Q92598 HSPH1 Isoform Beta of Heat shock protein 105 kDa 3 1.22 0.61
P31946 YWHAB Isoform Short of 14-3-3 protein beta/alpha 2 1.32 0.96
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 1 0.96 0.94
P46778 RPL21 60S ribosomal protein L21 1 1.85 0.78
Q15365 PCBP1 Poly(rC)-binding protein 1 1 0.88 0.66
Q92900 UPF1 Isoform 2 of Regulator of nonsense transcripts 1 2 1.32 1.16
P10155 TROVE2 60 kDa SS-A/Ro ribonucleoprotein 1 0.99 0.23
Q7KZF4 SND1 Staphylococcal nuclease domain-containing protein 1 1 1.03 0.62
Q13765 NACA Nascent polypeptide-associated complex subunit alpha 1 0.65 0
Q07020 RPL18 60S ribosomal protein L18 1 0.99 1.37
Q9HCE1 MOV10 Putative helicase MOV-10 1 1.43 1.15
Q9BUJ2 HNRNPUL1 Isoform 4 of Heterogeneous nuclear 4 1.49 0.94
ribonucleoprotein U-like protein 1
P05388 RPLP0 60S acidic ribosomal protein P0 1 1.04 1.63
P62829 RPL23 60S ribosomal protein L23 1 1.09 0.74
P07954 FH Isoform Cytoplasmic of Fumarate hydratase, mitochondrial 2 0.55 0.54
P62847 RPS24 Isoform 2 of 40S ribosomal protein S24 3 1.69 0.71
P27824 CANX Calnexin 1 0.49 0
Q13011 ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 1 1.21 0.88
P06748 NPM1 Isoform 2 of Nucleophosmin 2 0.29 0.44
P84098 RPL19 60S ribosomal protein L19 1 1.64 1.22
P61604 HSPE1 10 kDa heat shock protein, mitochondrial 1 1.04 1.02
P09651 HNRNPA1 Isoform 2 of Heterogeneous nuclear ribonucleoprotein A1 4 1.26 0.53
P22314 UBA1 Ubiquitin-like modifier-activating enzyme 1 1 1.03 0.69
Q96QR8 PURB Transcriptional activator protein Pur-beta 1 1.16 1.23
Q96HN2 AHCYL2 Isoform 2 of Putative adenosylhomocysteinase 3 5 1.04 0.9
x
li
P42766 RPL35 60S ribosomal protein L35 1 0.63 0.56
P62081 RPS7 40S ribosomal protein S7 1 1.02 0.54
P13639 EEF2 Elongation factor 2 1 1.02 0.57
P22626 HNRNPA2B1 Isoform A2 of Heterogeneous nuclear ribonucleoproteins A2/B1 2 1.27 0.39
P55072 VCP Transitional endoplasmic reticulum ATPase 1 0.68 0.5
P61313 RPL15 60S ribosomal protein L15 1 1.08 1.04
Q2M2I8 AAK1 Isoform 2 of AP2-associated protein kinase 1 2 0.61 1
P62917 RPL8 60S ribosomal protein L8 1 1.17 1.31
P23528 CFL1 Cofilin-1 1 1.3 1.33
Q99729 HNRNPAB Isoform 3 of Heterogeneous nuclear ribonucleoprotein A/B 2 1.09 0.74
P62899 RPL31 Isoform 3 of 60S ribosomal protein L31 3 1.39 0.93
P49207 RPL34 60S ribosomal protein L34 1 0.69 0.89
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 1 0.99 0.58
P00505 GOT2 Aspartate aminotransferase, mitochondrial 1 0.92 1.08
P29692 EEF1D Elongation factor 1-delta 2 0.93 0.83
Q14103 HNRNPD Isoform 4 of Heterogeneous nuclear ribonucleoprotein D0 4 1.05 0.9
Q06830 PRDX1 Peroxiredoxin-1 1 0.85 0.74
Q14697 GANAB Neutral alpha-glucosidase AB 2 0.96 1.12
P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial 1 1.01 1.3
P26038 MSN Moesin 1 1.2 0.7
Q9ULV4 CORO1C Coronin-1C 1 1.36 1
Q9Y262 EIF3L Eukaryotic translation initiation factor 3 subunit L 1 1.28 1.13
P42704 LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial 1 1.38 1.14
P31943 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 1 1.49 1.08
P41091 EIF2S3 Eukaryotic translation initiation factor 2 subunit 3 1 1.18 1.48
P55884 EIF3B Eukaryotic translation initiation factor 3 subunit B 2 1.82 1.6
Q86V81 ALYREF THO complex subunit 4 1 0.77 0
P30050 RPL12 60S ribosomal protein L12 1 1.15 0.93
P26599 PTBP1 Polypyrimidine tract-binding protein 1 3 1.44 1.43
x
lii
P18206 VCL Isoform 1 of Vinculin 3 0.88 0.45
Q99623 PHB2 Prohibitin-2 1 1.06 0.61
P50552 VASP Vasodilator-stimulated phosphoprotein 1 1.1 0.81
P05141 SLC25A5 ADP/ATP translocase 2 2 1.06 0.97
P61254 RPL26 60S ribosomal protein L26 2 1.2 0.82
P11177 PDHB Isoform 2 of Pyruvate dehydrogenase E1 3 1.03 0.94
component subunit beta, mitochondrial
P0CW22 RPS17L 40S ribosomal protein S17-like 1 1.07 0.9
P46379 BAG6 Isoform 2 of Large proline-rich protein BAG6 3 1.75 0.97
P40429 RPL13A 60S ribosomal protein L13a 2 1.21 0.63
P62750 RPL23A 60S ribosomal protein L23a 1 0.6 0.7
Q13243 SRSF5 Isoform SRP40-4 of Serine/arginine-rich splicing factor 5 2 1.74 1.03
Q9NZB2 FAM120A Isoform D of Constitutive coactivator of PPAR-gamma-like protein 1 3 1.92 2.96
Q14974 KPNB1 Importin subunit beta-1 1 1.21 0.95
Q8IVD9 NUDCD3 NudC domain-containing protein 3 1 1.09 0.93
O75369 FLNB Isoform 6 of Filamin-B 6 0.93 0.56
P34932 HSPA4 Heat shock 70 kDa protein 4 1 1.03 0.7
Q9UN86 G3BP2 Isoform B of Ras GTPase-activating protein-binding protein 2 2 1.47 1.11
Q96RD7 PANX1 Isoform 2 of Pannexin-1 2 0.89 1.38
O14874 BCKDK [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial 1 1.69 1.2
Q14694 USP10 Ubiquitin carboxyl-terminal hydrolase 10 3 1.02 0.83
P19474 TRIM21 E3 ubiquitin-protein ligase TRIM21 1 1.75 1.1
P22234 PAICS Multifunctional protein ADE2 2 0.89 0
P20810 CAST Isoform 3 of Calpastatin 7 0.76 0.72
P52597 HNRNPF Heterogeneous nuclear ribonucleoprotein F 1 1.75 1.22
Q08211 DHX9 ATP-dependent RNA helicase A 1 1.7 0.69
Q13263 TRIM28 Isoform 2 of Transcription intermediary factor 1-beta 2 3.05 1.38
P09622 DLD Dihydrolipoyl dehydrogenase, mitochondrial 1 1.04 0.91
P07910 HNRNPC Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 3 1.91 1.07
x
liii
P12956 XRCC6 X-ray repair cross-complementing protein 6 1 1.17 0.2
P22681 CBL E3 ubiquitin-protein ligase CBL 1 2.19 0
Q9P015 MRPL15 39S ribosomal protein L15, mitochondrial 1 1.26 1.15
P49411 TUFM Elongation factor Tu, mitochondrial 1 1.37 1.39
P04181 OAT Ornithine aminotransferase, mitochondrial 1 1.41 0.98
P48047 ATP5O ATP synthase subunit O, mitochondrial 1 0.49 1.06
P26196 DDX6 Probable ATP-dependent RNA helicase DDX6 1 1.78 1.31
P46779 RPL28 60S ribosomal protein L28 2 1.95 1.12
Q92615 LARP4B La-related protein 4B 1 1.38 1.73
Q12906 ILF3 Isoform 5 of Interleukin enhancer-binding factor 3 6 0.48 0.56
P06744 GPI Glucose-6-phosphate isomerase 2 1.37 0.89
O00571 DDX3X Isoform 2 of ATP-dependent RNA helicase DDX3X 2 1.17 0.85
P04075 ALDOA Fructose-bisphosphate aldolase A 1 0 0
P18124 RPL7 60S ribosomal protein L7 1 0.52 0.65
P51398 DAP3 Isoform 2 of 28S ribosomal protein S29, mitochondrial 2 1.15 1.14
P05091 ALDH2 Aldehyde dehydrogenase, mitochondrial 1 1.55 1.85
P35232 PHB Prohibitin 1 1.15 1.03
P01024 C3 Complement C3 1 0.73 0.52
P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic 1 1.12 0
Q9Y295 DRG1 Developmentally-regulated GTP-binding protein 1 1 1.25 0.67
Q96KK5 HIST1H2AH Histone H2A type 1-H 10 0.97 3.2
P62841 RPS15 40S ribosomal protein S15 1 3.24 0.23
Q9C0C9 UBE2O Ubiquitin-conjugating enzyme E2 O 1 1.57 0.74
P78371 CCT2 T-complex protein 1 subunit beta 1 0.52 0.58
Q14315 FLNC Isoform 2 of Filamin-C 2 0.76 0.73
P05455 SSB Lupus La protein 1 1.39 0.66
P30101 PDIA3 Protein disulfide-isomerase A3 1 1.08 0.67
Q04837 SSBP1 Single-stranded DNA-binding protein, mitochondrial 1 1.38 1.9
P40939 HADHA Trifunctional enzyme subunit alpha, mitochondrial 1 0 1.34
x
liv
P48382 RFX5 DNA-binding protein RFX5 1 1.35 2.41
Q6NYC8 PPP1R18 Phostensin 2 0 2.66
P04083 ANXA1 Annexin A1 1 1.44 1
Q9BSJ8 ESYT1 Extended synaptotagmin-1 2 1.43 0.96
O95793 STAU1 Isoform Short of Double-stranded RNA-binding protein Staufen homolog 1 3 1.37 0.87
P21399 ACO1 Cytoplasmic aconitate hydratase 1 0.77 0
P30837 ALDH1B1 Aldehyde dehydrogenase X, mitochondrial 1 1.13 1.39
P61289 PSME3 Proteasome activator complex subunit 3 2 1.48 1.49
P00338 LDHA Isoform 5 of L-lactate dehydrogenase A chain 5 0.77 0.83
Q92552 MRPS27 28S ribosomal protein S27, mitochondrial 1 1.56 1.16
P41250 GARS Glycine–tRNA ligase 1 1.63 1.27
P42677 RPS27 40S ribosomal protein S27 1 0.45 0
Q29960 HLA-C Isoform 2 of HLA class I histocompatibility antigen, Cw-16 alpha chain 25 0 3.05
P23588 EIF4B Eukaryotic translation initiation factor 4B 1 0.94 2.28
P31040 SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 1 1.1 1.07
Q71RC2 LARP4 Isoform 3 of La-related protein 4 3 1.37 1.78
Q9Y305 ACOT9 Isoform 3 of Acyl-coenzyme A thioesterase 9, mitochondrial 4 0 0
Q02218 OGDH Isoform 2 of 2-oxoglutarate dehydrogenase, mitochondrial 2 0.96 2.23
P49406 MRPL19 39S ribosomal protein L19, mitochondrial 1 0.96 0
P22102 GART Trifunctional purine biosynthetic protein adenosine-3 1 1.77 0.85
P36957 DLST Dihydrolipoyllysine-residue succinyltransferase component 1 0 3.67
of 2-oxoglutarate dehydrogenase complex, mitochondrial
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 1 0.9 0
P48200 IREB2 Iron-responsive element-binding protein 2 1 0.85 0.84
P08133 ANXA6 Annexin A6 1 0 1.36
Q8N5N7 MRPL50 39S ribosomal protein L50, mitochondrial 1 2.72 1.76
P48643 CCT5 T-complex protein 1 subunit epsilon 1 1.74 0.96
Q9NR30 DDX21 Isoform 2 of Nucleolar RNA helicase 2 2 1.65 0
Q14152 EIF3A Eukaryotic translation initiation factor 3 subunit A 1 1.46 2.67
x
lv
O00116 AGPS Alkyldihydroxyacetonephosphate synthase, peroxisomal 1 1.12 0.97
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 5 1.85 1.41
O43242 PSMD3 26S proteasome non-ATPase regulatory subunit 3 1 1.48 1.24
Q8NE71 ABCF1 Isoform 2 of ATP-binding cassette sub-family F member 1 2 0 0
P25787 PSMA2 Proteasome subunit alpha type-2 1 2.44 1.31
O75390 CS Citrate synthase, mitochondrial 1 1.35 0.95
Q00610 CLTC Isoform 2 of Clathrin heavy chain 1 2 0.88 1.26
Q9HC35 EML4 Echinoderm microtubule-associated protein-like 4 1 2514734.53 2814552.93
P10515 DLAT Dihydrolipoyllysine-residue acetyltransferase component 1 1906005.72 2684224.72
of pyruvate dehydrogenase complex, mitochondrial 1
Q8TAA3 PSMA8 Isoform 2 of Proteasome subunit alpha type-7-like 4 1667597.05 1
P49720 PSMB3 Proteasome subunit beta type-3 1 1179805.13 1420907.99
Q6YN16 HSDL2 Hydroxysteroid dehydrogenase-like protein 2 1 1080817.55 1356826.78
P13010 XRCC5 X-ray repair cross-complementing protein 5 1 1041194.36 1
Q07065 CKAP4 Cytoskeleton-associated protein 4 1 918132.09 2320006.64
Q08999 RBL2 Retinoblastoma-like protein 2 1 592091.66 1677832.42
P07305 H1F0 Isoform 2 of Histone H1.0 2 1 3267102.48
Q92522 H1FX Histone H1x 1 1 3064126.7
O60814 HIST1H2BK Histone H2B type 1-K 15 1 3052111.41
P35579 MYH9 Myosin-9 1 1 2523520.26
Q7Z6Z7 HUWE1 Isoform 2 of E3 ubiquitin-protein ligase HUWE1 3 1 1859035.7
Q99798 ACO2 Aconitate hydratase, mitochondrial 1 1 1661822.24
P53396 ACLY Isoform 2 of ATP-citrate synthase 2 1 638738.84





FAM120A and TRIM28 and their
importance to the survival of
MDA-MB231 cells during cisplatin
exposure.
xlvii
Figure F.1: The maximal growth rates from MDA-MB231 cells during 120 hours of
exposure to cisplatin (1.56 - 25 µM; n = 3). MDA-MB231 cells were transfected with
siCTRL, siYB1 1, siFAM120A, siTRIM28, siC1Q 1,and siC1Q 2 (0.2 - 5 nM) for 24 hours















































































































































































































































































































































































































































































































































































































































































































































































































































Cyclin dependent kinase inhibitor 2A (also known as CDKN2A) (p16INK4A)
ABCB1
BCL2 associated X, apoptosis regulator (BAX )
chicken YB-1 homologue (Chk-YB-1b)
epidermal growth factor receptor [ also known as HER-1 or Receptor tyrosine-protein kinase erbB-1] (EGFR)
GTPase KRas, isoform 1 (KRAS4A)
GTPase KRas, isoform 2 (KRAS4B)
Cellular tumor antigen p53 (TP53)
Vascular endothelial growth factor (VEGF)
β-actin (β-actin)
Histone H2AX phosphorylated on S140 (γH2AX)
eukaryotic translation initiation factor 4E-binding protein (4E-BP)
RAC-alpha serine/threonine-protein kinase (AKT)
THO complex subunit 4 (ALYREF)
Transcription factor AP-2-alpha (AP2A) apurinic/apyrimidinic (AP) endonuclease 1 (APE1) Breast cancer type 1 susceptibility
protein (BRCA1) Complement component 1 Q subcomponent-binding protein, mitochondria (C1QBP) CC motif chemokine 5 [also
known as regulated upon activation, normal T cell expressed and secreted [RANTES]] (CCL5) cyclin D1 (CCND1) Tumor necro-
sis factor receptor superfamily member 6 [also known as the fas receptor] (CD95) DNA-binding protein A [also known as YBX3
and CSDA] (DBPA) Probable ATP-dependent RNA helicase DDX6 (DDX6) ATP-dependent RNA helicase A (DHX9) DNA ligase
3 (DNLI3) DNA polymerase subunit δ-1 (DPOD1) DNA polymerase subunit γ-1 (DPOG1) DNA polymerase β (DPOLB) Eukary-
otic initiation factor 2 (eIF2) Eukaryotic translation initiation factor 4B (eIF4B) Eukaryotic translation initiation factor 4E (eIF4E)
Eukaryotic translation initiation factor 4F complex (eIF4F complex) Eukaryotic translation initiation factor 4H (eIF4H) Alpha-
enolase (ENO1) Histone acetyltransferase p300 (EP300) Receptor tyrosine-protein kinase erbB-2 [also known as HER-2] (ERBB2)
extracellular signal-regulated kinase (ERK) Ewings Sarcoma proto-oncoprotein (EWS) Enhancer of Zeste Homolog 2 (EZH2) Focal
adhesion kinase 1 (FAC) FAM120A F-box only protein 33 (FBX33) Forkhead box protein K2 (FOXK2) Forkhead box protein Q1
(FOXQ1) follicle stimulating hormone (FSH) Ras GTPase-activating protein-binding protein 1 (G3BP1) Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) Erythroid transcription factor (GATA1) Granulocyte-Macrophage Colony-Stimulating factor (GM-CSF)
Glycogen synthase kinase-3 beta (GSK3β) Human leukocyte antigen [also known as Major Histocompatibility complex] (HLA) Het-
erogeneous nuclear ribonucleoprotein A1 (hnRNP-A1) Heterogeneous nuclear ribonucleoproteins C1/C2 (hnRNP-C) Heterogeneous
nuclear ribonucleoprotein K (hnRNP-K) Heterogeneous nuclear ribonucleoprotein L (hnRNP-L) Heterogeneous nuclear ribonucle-
oproteins A2/B1 (HNRNPA2B1) Heterogeneous nuclear ribonucleoprotein U (HNRNPU) Heterogeneous nuclear ribonucleoprotein
Q [also known as Synaptotagmin-binding, cytoplasmic RNA-interacting protein] (HNRPQ) human endonuclease III (hNTH1) UV
excision repair protein RAD23 homolog B (HR23B) GTPase HRas (HRAS) Eukaryotic initiation factor 4A-III [P38919] (IF4A3)
Insulin-like growth factor 2 mRNA-binding protein 1 [Q9NZI8] (IGF2BP1) Insulin-like growth factor 2 mRNA-binding protein 3
[O00425] (IGF2BP3) Interleukin-1 beta (IL-1β) IL13 receptor subunit-2 (IL13R) Interleukin-2 (IL2) interleukin 6 (IL6) Interleukin
enhancer-binding factor 3 (ILF3) Mitogen-activated protein kinase 1 [also known as ERK2] (MAPK1) Protein max (MAX) Ras-
Raf-mitogen-activated and extracellular-signal regulated kinase (MEK) 72 kDa type IV collagenase (also known as gelatinase A)
(MMP2) DNA mismatch repair protein Msh2 (MSH2) Membrane type 1 matrix metalloproteinase (MT1-MMP) mammalian tar-
get of rapamycin (mTOR) mTOR complex 1 (mTORC1) MDR-1 MYC (Myc proto-oncogene) Nucleosome assembly protein 1-like
1 (NAP1L1) Nucleosome assembly protein 1-like 4 (NAP1L4) Neurogenic differentiation 6 [also known as MATH2] (NDF6) Protein
NDRG1 (NDRG1) Endonuclease 8-like 1 (NEIL1) Endonuclease 8-like 2 (NEIL2) Nuclear factor NF-κ-B (NF-κB) Neurofibromin (NF1)
Non-POU domain-containing octamer-binding protein (NONO) Nucleophosmin (NPM1) GTPase NRas (NRAS) Endonuclease III-like
protein 1 (NTH) 2-oxoglutarate and Fe(II)-dependent oxygenase domain containing 1 (OGFOD) Cyclin-dependent kinase inhibitor 1
(p21(Cip1)) p53 tumor suppressor (p53) polyadenylate-binding protein (PABP) polyadenylate-binding protein 1 [P11940] (PABP1)
polyadenylate-binding protein 2 [Q86U42] (PABP2) polyadenylate-binding protein 3 [Q9H361] (PABP3) polyadenylate-binding pro-
tein 4 [Q13310] (PABP4) poly(ADP-ribose)polymerase 1 (PARP1) proliferating cell nuclear antigen (PCNA) programmed cell death
protein 4 (PDCD) phosphatidylinositol 3-kinase (PI3K) Phosphatidylinositol 4,5-bisphosphate 3-kinase (PIK3CA) Plectin (PLEC)
polypyrimidine tract binding protein (PTB) Pur-α (PURA) Pur-β (PURB) RNA-binding protein Raly (RALY) Retinoblastoma-
associated protein (RB) retinoblastoma binding protein 6 (RBBP6) 60S ribosomal protein L27a [P46776] (RL27A) Ubiquitin-40S
ribosomal protein S27a [P62979] (RS27A) 40S ribosomal protein S3 (RS3) p90 ribosomal S6 kinase (RSK) tRNA-splicing ligase RtcB
homolog [Q9Y3I0] (RTCB) Sodium-coupled neutral amino acid transporter 1 (SNAT1) Staphylococcal nuclease domain-containing
protein 1 (SND1) Splicing regulatory glutamine/lysine-rich protein 1 (SREK1) Serine/arginine-rich splicing factor 9 (SRSF9) Signal
transducer and activator of transcription 3 (STAT3) Transforming growth factor beta-1 (TGF-β) translocation liposarcoma pro-
tein (TLS) DNA topoisomerase II (TOP2A) tumor protein 73 (TP73) TRIM28 Twist homolog 1 (TWIST) Vimentin (VIM) Werner
syndrome ATP-dependent helicase (WRN) DNA repair protein complementing XP-C cells (XPC) XRCC5 XRCC6 Transcriptional
coactivator YAP1 [Yes-associated protein 1] (YAP1) Transcriptional coactivator YAP1 [Yes-associated protein 1] (YWHAB) 14-3-3
protein zeta/delta (YWHAZ)
liii
